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HIV	   infection	   is	   characterized	   by	   generalized	   high	   levels	   of	   systemic	   immune	  
activation	   that	  plays	  an	   important	  role	   in	  accelerating	   the	  depletion	  of	  CD4+	  T-­‐
cells.	   Levels	   of	   immune	   activation	   are	   higher	   at	   mucosal	   sites	   like	   the	   female	  
genital	   tract	   than	   blood	   during	   HIV	   infection.	  While	   initiation	   of	   highly	   active	  
antiretroviral	   therapy	   (HAART)	  during	  HIV	   infection	   reduces	  plasma	  viral	   load	  
and	   partially	   restores	   CD4+	   T-­‐cell	   numbers,	   individuals	   on	   HAART	   retain	   an	  
activated	   phenotype	   in	   blood	   that	   is	   significantly	   higher	   than	   uninfected	  
individuals.	   The	   precise	   mechanisms	   leading	   to	   recruitment	   and	   activation	   of	  
immune	  cells	  into	  the	  female	  genital	  tract	  during	  HIV	  infection	  and	  the	  influence	  
of	  HAART	  on	  activation	  are	  not	  clear.	  The	  aim	  of	  this	  study	  was	  to	  investigate	  the	  
impact	   of	   HAART	   on	   the	   levels	   of	   inflammatory	   cytokines	   and	   immune	  
reconstitution	  (measured	  by	  immune	  activation,	  proliferation	  and	  exhaustion	  of	  
T-­‐cells)	  in	  the	  female	  genital	  tract	  compared	  to	  blood.	  	  
Peripheral	   blood	   mononuclear	   cells	   and	   cervical	   cytobrush-­‐derived	   cells	   from	  
the	  genital	  tract	  of	  26	  HIV-­‐infected	  women	  were	  included	  in	  this	  study.	  Of	  these,	  
15/26	  had	  been	  HAART	  for	  a	  long	  period	  of	  time	  (~7	  years)	  while	  11/26	  were	  
enrolled	   as	   they	  were	   about	   to	   start	   HAART	   and	   followed	   until	   1	  month	   after	  
initiating	  HAART.	  A	  10-­‐colour	  flow	  cytometry	  panel	  was	  designed	  and	  optimized	  
to	  measure	  expression	  of	  phenotypic	  and	  memory	  markers	  on	  T-­‐cells	  (CD3,	  CD4,	  
CD8,	   CCR7,	   and	   CD45RO).	   In	   addition,	   activation	   (CD38	   and	   HLA-­‐DR),	  
proliferation	   (Ki67)	   and	   senescence	   (CD57)	   of	   T-­‐cells	   were	   evaluated.	   The	  
concentration	  of	  IL-­‐1β,	  IL-­‐6,	  IL-­‐8,	  IP-­‐10,	  MIP-­‐1α,	  MIP-­‐1β,	  TNF-­‐	  α,	  IL-­‐7,	  G-­‐CSF	  and	  
IL-­‐10	  in	  plasma	  and	  genital	  secretions	  were	  assessed	  using	  Luminex.	  
The	  majority	  of	  T-­‐cells	  in	  the	  genital	  tract	  were	  found	  to	  be	  effector	  memory	  T-­‐
cells	   (TEM),	   while	   the	   majority	   of	   T-­‐cells	   in	   blood	   were	   naïve	   and	   effector	  
memory	  CD4+	  T-­‐cells	  and	  terminally-­‐differentiated	  CD8+	  T-­‐cells.	  HAART	  did	  not	  
influence	   the	   predominance	   of	   TEM	   cells	   in	   the	   genital	   tract,	   although	   the	  
frequency	  of	  the	  central	  memory	  T-­‐cell	  (TCM)	  population	  within	  the	  genital	  tract	  




genital	  tract	  were	  activated	  (measured	  by	  expression	  of	  CD38	  and	  HLA-­‐DR)	  than	  
those	   in	   blood	   from	   HIV-­‐infected	   women	   on	   HAART.	   Initiation	   of	   HAART	  
resulted	  in	  a	  significant	  reduction	  in	  the	  level	  of	  T-­‐cell	  activation	  in	  blood	  but	  not	  
in	  the	  genital	  tract,	  where	  activation	  levels	  were	  slightly	  increased	  compared	  to	  
before	  initiation	  of	  HAART.	  T-­‐cells	  collected	  from	  the	  genital	  tract	  of	  women	  on	  
HAART	   were	   significantly	   more	   exhausted	   than	   those	   in	   blood	   (measured	   by	  
CD57	  expression);	  and	  1	  month	  on	  HAART	  resulted	  in	  an	  increased	  population	  of	  
exhausted	   T-­‐cells	   in	   the	   genital	   tract,	   particularly	   for	   TCM	   and	   TEM	   subsets.	  
CD4:CD8	   ratios	   in	   blood	   of	   HIV-­‐infected	   women	   on	   long-­‐term	   HAART	   (1:1.4)	  
showed	   evidence	   of	   partial	   CD4	   immune	   reconstitution	   compared	   to	   other	  
studies,	   although	   genital	   tract	   CD4:CD8	   ratios	   (1:0.8)	  were	   significantly	   lower.	  
While	  complete	  viral	   suppression	   in	  both	  plasma	  and	   in	  genital	   secretions	  was	  
evident	   as	   early	   as	   1	   month	   following	   initiation	   of	   HAART,	   immune	  
reconstitution	  (measured	  by	  CD4:CD8	  ratios)	  was	  not	  significantly	  higher.	  Lastly,	  
cytokine	  concentrations	  in	  the	  genital	  tract	  were	  generally	  higher	  than	  those	  in	  
blood.	  Viral	   suppression	  seen	  early	  after	  HAART	   initiation	  was	  associated	  with	  
significantly	   lower	   IP-­‐10	   concentrations	   in	   plasma	   as	   well	   as	   the	   level	   of	  
activation	  of	  T-­‐cells	  in	  blood.	  In	  contrast,	  inflammatory	  cytokine	  concentrations	  
in	  genital	  secretions	  were	  largely	  unchanged	  after	  initiation	  of	  HAART	  although	  
the	   anti-­‐inflammatory	   cytokine	   IL-­‐10	   was	   detected	   at	   significantly	   lower	  
concentrations.	  	  
In	  conclusion,	  initiation	  of	  HAART	  during	  HIV	  infection	  had	  a	  more	  pronounced	  
impact	   on	   T-­‐cell	   activation	   and	   inflammation	   in	   blood	   than	   in	   the	   genital	  
compartment,	  which	   remained	   inflamed	  and	  highly	  activated.	  Being	  on	  HAART	  
for	  longer	  periods	  of	  time	  was	  still	  accompanied	  by	  higher	  levels	  of	  genital	  T-­‐cell	  
activation	  and	  inflammation	  in	  genital	  tract	  than	  blood,	  despite	  the	  fact	  that	  most	  
women	  had	  fully	  suppressed	  blood	  viral	  loads.	  Since	  several	  studies	  have	  shown	  
that	  women	  on	  HAART	  continue	  to	  shed	  HIV	  in	  their	  genital	  secretions	  (despite	  
being	   fully	   virologically	   suppressed	   in	   blood),	   understanding	   local	  
immunological	  factors	  leading	  to	  on-­‐going	  inflammation	  in	  the	  genital	  tract	  and	  
local	   immune	   activation	   during	   HAART	   is	   very	   important	   as	   this	   would	  
potentially	  place	  women	  at	   increased	  risk	   for	  HIV	  genital	   shedding	  despite	   full	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  Antiretroviral	  Therapy	  	  




HLA	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  Antigen	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IFN	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MFI	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MIP	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  protein	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   Non-­‐Nucleoside	  Reverse	  Transcriptase	  Inhibitor	  
NRTI	   Nucleoside	  Reverse	  Transcriptase	  Inhibitor	  
NSAID	   Non-­‐Steroidal	  Anti-­‐Inflammatory	  Drug	  
NtRTI	   Nucleotide	  Reverse	  Transcriptase	  Inhibitor	  
PBMC	  	   Peripheral	  Blood	  Mononuclear	  Cell	  
PBS	  	   Phosphate	  Buffered	  Saline	  	  
PCR	   Polymerase	  Chain	  Reaction	  
PD-­‐1	   Programmed	  Cell	  Death-­‐1	  
PE	  	   Phycoerythrin	  	  
PerCP	  Cy5.5	  	   Peridininchlorophyll	  protein	  Cy5.5	  	  
PI	   Protease	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Qdot	  	   Quantum	  Dot	  	  
RANTES	   Regulated	  on	  Activation	  Normal	  T-­‐cell	  Expressed	  and	  
Secreted	  
RNA	   RiboNucleic	  Acid	  
SIV	   Simian	  Immunodeficiency	  Disease	  
SSC	  	   Side	  Scatter	  	  
STD	   Sexually	  transmitted	  disease	  
STI	   Sexually	  transmitted	  infection	  
TCM	   Central	  memory	  T-­‐cell	  
TCR	  	   T-­‐cell	  Receptor	  	  
TD	   Terminally	  differentiated	  T-­‐cell	  
TDF	   Tenofovir	  
TEM	   Effector	  memory	  T-­‐cell	  
Tfh	   Follicular	  helper	  T-­‐cell	  
Th1	   T-­‐helper	  1	  
TNF	   Tumor	  Necrosis	  Factor	  
Vivid	  	   Violet	  Fluorescent	  Reactive	  Dye	  	  
μl	   Microlitres	  	  
ZDV	   Zidovudine	  
3TC	   Lamivudine	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Chapter	  1.	  Literature	  Review	  
	  
1.1. Introduction	  
Thirty	  years	  have	  elapsed	  since	   the	  Human	  Immunodeficiency	  Virus	  (HIV)	  was	  
first	   described	   in	   1983	   and	   the	   heterosexual	   epidemic	   in	  Africa	  was	   identified	  
(Merson	  et	  al.,	  2008).	  According	  to	  the	  2013	  UNAIDS	  report,	  it	  is	  estimated	  that	  
there	  were	  about	  35.3	  million	  adults	  and	  children	  living	  with	  HIV	  worldwide.	  For	  
the	   first	   time	  since	   the	   first	   identification	  of	  HIV,	   the	  UNAIDS	  report	  details	  an	  
overall	  decrease	   in	  HIV	   incidence,	  with	  2.3	  million	  new	  people	  getting	   infected	  
with	  HIV	  in	  2012	  compared	  to	  3.4	  million	  in	  2001.	  Despite	  this	  33%	  decrease	  in	  
the	   number	   of	   new	   HIV	   cases,	   the	   UNAIDS	   report	   clearly	   shows	   an	   overall	  
increase	  in	  the	  total	  number	  of	  HIV-­‐infected	  individuals	  worldwide,	  which	  could	  
be	   attributed	   to	   the	   fact	   that	   more	   and	   more	   HIV-­‐infected	   people	   now	   have	  
access	   to	   antiretroviral	   therapy	   (ART)	   and	  death	   rates	   are	  declining.	  Of	   all	   the	  
countries	   affected	   by	   HIV,	   sub-­‐Saharan	   Africa	   is	   the	   most	   severely	   affected	  
region	   of	   the	   world,	   with	   about	   70%	   of	   the	   global	   total	   of	   HIV-­‐infected	  
individuals	   living	   in	   this	   region	   (Figure	   1.1,	   UNAIDS,	   2013).	   With	   an	   HIV	  
prevalence	  of	  17.9%,	  South	  Africa	  has	  the	  highest	  number	  of	  cases	  of	  HIV	  in	  the	  
world.	  Internationally,	  it	  is	  also	  the	  country	  with	  the	  highest	  number	  of	  women	  




Figure	   1.1.	  Total	  number	  of	  people	  estimated	   to	  be	   living	  with	  HIV	   in	  2012	  (taken	  by	  
UNAIDS,	  2013).	  	  
	  
1.2. HIV	  replication	  and	  cell	  tropism	  
HIV-­‐1	   is	   a	   retrovirus	   of	   the	   lentivirus	   family	   derived	   from	   the	   simian	  
immunodeficiency	   virus	   (SIV)	   of	   chimpanzees	   (SIVcpz)	   (Chahroudi	   et	   al.,	   2012;	  
Hahn,	   2000).	   Like	   other	   lentiviruses,	   HIV	   infection	   develops	   into	   a	   chronic	  
disease,	   with	   a	   relatively	   long	   period	   of	   clinical	   latency	   and	   persistent	   viral	  
replication.	  HIV	  infects	  CD4+	  immune	  cells,	  predominantly	  of	  the	  lymphocyte	  and	  
mononuclear	   phagocytic	   lineages	   (Rosenberg	   &	   Fauci,	   1991;	   reviewed	   by	  
Swanstrom	  et	   al.,	   2012).	   It	   has	   an	  RNA	  genome,	  which	   consists	  mainly	   of	   nine	  
open	   reading	   frames	   that	   can	   produce	   fifteen	   proteins	   (Frankel	   and	   Young,	  
1998).	   Using	   reverse	   transcriptase,	   it	   converts	   its	   ribonucleic	   acid	   (RNA)	   to	  
double-­‐stranded	  deoxyribonucleic	  acid	  (DNA),	  which	  can	  be	  integrated	  into	  the	  
genome	  of	   the	   infected	  cell.	  The	  virus	  depends	  mostly	  on	   the	   three	  genes,	  gag,	  
pol	   and	   env,	   for	   successful	   replication.	   Gag	   and	   env	   genes	   code	   for	   the	   virus	  
nucleocapsid	   and	   the	   membrane	   glycoproteins	   while	   the	   pol	   gene	   codes	   for	  
reverse	   transcriptase	   and	   other	   enzymes	   (Frankel	   and	   Young,	   1998).	   The	  
genome	   also	   consists	   of	   six	   smaller	   genes	   encoding	   for	   various	   accessory	   (vif,	  
vpu,	  vpr	  and	  nef)	  and	  regulatory	  (tat	  and	  rev)	  proteins	  (Tang	  et	  al.,1999).	  These	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genes	   control	   processes	   such	   transcription,	   intracellular	   transport	   and	  
translation	  of	  the	  viral	  RNA	  into	  the	  provirus	  (as	  reviewed	  by	  Lever,	  2005).	  	  
	  
The	   first	   step	   in	   the	  replication	  of	  HIV	  within	  CD4+	  host	  cells	   is	   the	   interaction	  
between	  the	  virus	  envelope	  glycoprotein,	  gp120	  and	  the	  cell	  membrane	  receptor	  
CD4	  (Myszka	  et	  al.,	  2000).	  However,	  the	  virus	  also	  needs	  to	  bind	  to	  an	  obligatory	  
chemokine	   receptor	   for	   successful	   entry.	   Binding	   of	   gp120	   to	   CD4	   causes	   a	  
conformational	  change,	  enabling	  the	  virus	  to	  then	  bind	  to	  either	  C-­‐C	  chemokine	  
receptor	   type	   5	   (CCR5)	   or	   C-­‐X-­‐C	   chemokine	   receptor	   type	   4	   (CXCR4),	   two	  
chemokine	   receptors	   found	   on	   the	   host	   cell	   membrane,	   leading	   to	   membrane	  
fusion	  (Myszka	  et	  al.,	  2000).	  The	  virus	  capsid	  is	  released	  into	  the	  cell	  cytoplasm	  
where	  reverse	  transcriptase	  starts	  the	  transcription	  of	  the	  viral	  RNA	  to	  double-­‐
stranded	   DNA.	   Using	   p17,	   the	   integrase	   enzyme	   and	   vpr,	   the	   genome	   is	   then	  
transported	   to	   the	   cell	   nucleus	  where	   it	   integrates	   the	   chromosome	  of	   the	   cell	  
(Melikyan,	   2008).	   The	   integrated	   provirus	   is	   able	   to	   generate	   new	   viral	  
messenger	   RNA	   transcripts	   using	   the	   host	   cellular	   RNA	   polymerase	   II.	  
Transcription	   produces	   more	   copies	   of	   the	   RNA	   genome,	   which	   is	   then	  
translated	   to	   proteins	   in	   the	   cytoplasm.	   These	   proteins	   return	   to	   the	   nucleus	  
where	  tat	  causes	  the	  amplification	  of	  viral	  RNA	  production	  and	  rev	  interacts	  with	  
the	  nuclear	  pore	  proteins,	  allowing	  the	  RNA	  molecules	  to	  be	  transported	  to	  the	  
cytoplasm	  (reviewed	  by	  Lever,	  2005).	  In	  the	  cytoplasm,	  the	  translated	  envelope	  
glycoprotein	   and	   gag	   proteins	   are	   transported	   to	   the	   cell	   surface.	   A	   capsid	  
structure	   forms,	  which	  expresses	   the	  glycoproteins	  on	   its	   surface	  and	  encloses	  
two	   RNA	  molecules,	   the	   replicative	   enzymes	   and	   the	   structural	   and	   accessory	  
proteins	  (reviewed	  by	  Lever,	  2005).	  	  
	  
The	  chemokine	   receptors	  CCR5	  and	  CXCR4	  are	   the	   two	  main	  co-­‐receptors	   that	  
HIV	  uses	  to	  gain	  entry	  into	  cells	  (reviewed	  by	  Alkhatib,	  2010).	  Generally,	  HIV	  are	  
either	  T-­‐tropic	  (which	  infect	  mainly	  blood	  CD4+	  T-­‐cells)	  or	  M-­‐tropic	  (which	  are	  
able	  to	  infect	  CD4+	  T-­‐cells,	  monocytes	  and	  macrophages)	  (reviewed	  by	  Alkhatib,	  
2010).	  In	  addition	  to	  being	  dependent	  of	  the	  availability	  of	  the	  CD4	  receptor,	  T-­‐
tropic	   viruses	   need	   CXCR4	   to	   enter	   the	   cell	   (X4	   viruses)	   while	   the	   M-­‐tropic	  
viruses	   use	   CCR5	   (R5	   viruses).	   Several	   studies	   have	   shown	   that	   HIV	   that	   is	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transmitted	  sexually	  across	  genital	  mucosal	  surfaces	  are	  mostly	  M-­‐tropic	  and	  use	  
CCR5	  (Deng	  et	  al.,	  1996;	  Dragic	  et	  al.,	  1996;	  reviewed	  by	  Lever,	  2005).	  	  
	  
1.3. The	  natural	  course	  of	  HIV	  infection	  
Three	   main	   stages	   of	   HIV	   infection	   in	   humans	   have	   been	   defined:	   the	   acute	  
phase,	  the	  asymptomatic	  chronic	  phase	  and	  the	  onset	  of	  AIDS	  (reviewed	  by	  An	  &	  
Winkler,	   2010)	   as	   shown	   in	   figure	   1.2.	   The	   infection	   starts	   with	   a	   severe	  
symptomatic	  illness	  which	  is	  associated	  with	  a	  high	  viraemia,	  a	  drastic	  decrease	  
in	  blood	  CD4+	  T-­‐cell	  counts,	  the	  formation	  of	  a	  reservoir	  of	  latently-­‐infected	  CD4+	  
T-­‐cells,	   and	   the	   development	   of	  HIV-­‐1	   specific	   immune	   responses	   (Clark	   et	   al.,	  
1991;	  Schacker	  et	  al.,	  1998;	  Freel	  et	  al.,	  2011).	  Following	  this	  is	  a	  100-­‐1000	  fold	  
decrease	  in	  viral	  load,	  a	  fractional	  increase	  in	  blood	  CD4+	  T-­‐cell	  counts	  (although	  
these	   rarely	   reach	   pre-­‐infection	   numbers	   or	   proportions)	   and	   then	   the	  
asymptomatic	  phase	  of	   chronic	  HIV	   infection,	  which	   is	   characterised	  by	  a	   slow	  
decrease	   in	  CD4+	  T-­‐cell	   counts	  and	  an	   incremental	   increase	   in	  viraemia.	  At	   the	  
time	  of	   seroconversion,	   the	   level	   of	  HIV-­‐RNA	  would	  have	  decreased	   to	  <1%	  of	  
the	  original	  viral	  load	  and	  remains	  at	  a	  relatively	  constant	  level	  for	  a	  number	  of	  
years.	  This	   is	  called	  the	  viral	  set	  point	  and	  several	  studies	  have	  shown	  that	  the	  
higher	  the	  viral	  set	  point,	  the	  faster	  the	  decrease	  in	  CD4+	  T-­‐cell	  counts	  during	  the	  
chronic	   phase	   (reviewed	   by	   Fanales-­‐Belasio	   et	   al.,	   2010).	   Viral	   set	   point	   is	  
dependent	  on	  a	  variety	  of	  host-­‐specific	  and	  viral	  factors	  such	  as	  human	  leukocyte	  
antigen	   (HLA)-­‐type	   or	   chemokine	   receptor	   mutations,	   cytotoxic	   T-­‐lymphocyte	  
(CTL)	  responses,	  amongst	  others	  (reviewed	  by	  Simon	  &	  Ho,	  2003).	  The	  immune	  
system	  gradually	   deteriorates	   as	   the	   numbers	   of	   CD4+	  T-­‐cells	   (providing	   help)	  
decline	   and	   other	   cells	   become	   dysfunctional.	   This	   leads	   to	   increased	  
susceptibility	   to	   opportunistic	   diseases	   and	   the	   eventual	   development	   of	  
acquired	   immunodeficiency	   syndrome	   (AIDS).	   If	   left	   untreated,	   an	   individual	  
infected	   with	   HIV	   will	   succumb	   to	   opportunistic	   AIDS-­‐defining	   illnesses	   as	   a	  
result	   of	   a	   compromised	   immune	   system	   at	   a	   median	   of	   8-­‐10	   years	   after	  
infection.	   These	   illnesses,	   rather	   than	   the	   HIV	   infection	   itself,	   will	   eventually	  
result	  in	  the	  death	  of	  the	  individual	  (Hoffman	  and	  Rockstroh,	  2013).	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Figure	  1.2.	  The	  natural	  history	  of	  an	  HIV	  infection,	  according	  to	  two	  clinical	  markers	  of	  
disease	   progression	   -­‐	   plasma	   viraemia	   (red	   line)	   and	   blood	   CD4+	   T-­‐cell	   counts	   (blue	  
line).	  The	  acute	  phase	  of	  HIV	  infection	  is	  accompanied	  by	  a	  rise	  in	  viral	  load	  and	  a	  sharp	  
drop	   in	   CD4+	   T-­‐cell	   count	   and	   is	   associated	   with	   clinical	   symptoms.	   After	   the	   first	  
months,	   plasma	   viraemia	   stabilises	   (set	   point)	   and	   the	   CD4+	   T-­‐cell	   numbers	   become	  
normalised.	   The	   chronic	   phase	   is	   asymptomatic	   despite	   the	   fact	   that	  HIV-­‐1	   carries	   on	  
replicating.	   AIDS	   is	   defined	   by	   the	   occurrence	   of	   opportunistic	   infections,	   the	   risk	   of	  
which	   increase	   as	   the	   CD4	   T-­‐cell	   counts	   fall	   below	   200	   cells/ml	   (taken	   from	   An	   &	  
Winkler,	  2010)	  
	  
1.3.1. CD4+	  T-­‐cell	  depletion	  in	  HIV	  infection	  
HIV	   infection	   is	   characterised	   by	   a	   gradual	   decrease	   in	   CD4+	   T-­‐cell	   numbers,	  
which	  eventually	  leads	  to	  AIDS	  (Mehandru	  et	  al.,	  2004).	  This	  CD4+	  T-­‐cell	  decline	  
has	  been	  described	  in	  mucosal	  tissues,	  within	  the	  first	  weeks	  of	  infection	  and	  is	  
more	  severe	  than	  depletion	  measurable	  in	  blood	  (Mehandru	  et	  al.,	  2004).	  More	  
than	   60%	   of	   the	   total	   CD4+	   T-­‐lymphocyte	   population	   are	   found	   within	   the	  
gastrointestinal	  mucosa	  and	  other	  secondary	  lymphoid	  organs,	  and	  as	  a	  result,	  a	  
greater	  depletion	  of	  CD4+	  T-­‐cell	  happens	  at	   these	  sites	  compared	   to	  peripheral	  
blood	  (Brenchley	  et	  al.,	  2004).	  Early	  during	  HIV	  infection,	  this	  destruction	  of	  cells	  
is	   countered	   by	   CD4+	   memory	   T-­‐cell	   regeneration	   which	   allows	   the	   immune	  
system	  to	  maintain	  CD4+	  T-­‐cell	  count	  above	  the	  threshold	  for	  immunodeficiency	  
(Gorochov	  et	  al.,	  1998).	  However,	  as	  the	  chronic	  phase	  of	  infection	  is	  established	  
and	   immune	   dysregulation	   becomes	   more	   pronounced,	   memory	   T-­‐cell	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homeostasis	   fails	   and	   the	   effector	   CD4+	   T-­‐cell	   populations	   fall	   below	   the	  
minimum	   levels	  needed	   to	  protect	  against	  opportunistic	  diseases	   (Okoye	  et	  al.,	  
2007).	  	  
	  
Several	  mechanisms	  have	   been	   suggested	   to	   explain	  HIV-­‐mediated	  CD4+	  T-­‐cell	  
depletion.	   One	   proposed	   mechanism	   relates	   to	   the	   direct	   viral	   elimination	   of	  
HIV-­‐infected	  cells,	  such	  as	  the	  infection-­‐mediated	  death	  of	  progenitor	  cells	  or	  the	  
destruction	   of	   the	   supporting	   stromal	   network	   required	   for	   lineage-­‐restricted	  
haematopoiesis	   (Zeng	   et	   al.,	   2012).	   Alternatively,	   CD4+	   T-­‐cell	   depletion	   during	  
HIV	   infection	   could	   be	   due	   to	   immune	   responses	   to	   the	   infection,	   for	   example	  
cytokine	  dysfunction,	  HIV-­‐induced	  apoptosis	  of	  bystander	  cells	  or	  opportunistic	  
infections	  of	  the	  bone	  marrow	  by	  cytomegalovirus	  (CMV),	  which	  would	  end	  up	  in	  
the	  depletion	  of	  uninfected	  cells	  (reviewed	  by	  McCune,	  2001	  and	  Okoye	  &	  Picker,	  
2013).	  	  
	  
1.3.2. Immune	  responses	  to	  HIV	  
Both	   innate	   and	   adaptive	   immune	   responses	   are	   mounted	   following	   infection	  
with	   HIV	   (figure	   1.3).	   The	   innate	   immune	   response	   is	   immediate	   and	   non-­‐
specific	  while	  the	  adaptive	  response	  occurs	  later	  in	  the	  primary	  infection	  via	  the	  
activation,	  proliferation	  and	  differentiation	  of	  B-­‐	  and	  T-­‐lymphocytes.	  	  
	  
	  
Figure	  1.3.	  Temporal	  emergence	  of	  different	  arms	  of	   the	   innate	  and	  adaptive	   immune	  
responses	   to	   appear	   following	   the	   acute	   phase	   of	   an	   HIV	   infection	   (adapted	   from	  

















































The	  innate	   immune	  system	  is	  the	  body’s	   first	   line	  of	  defence	  against	  pathogens	  
and	   is	   especially	   important	   in	   fighting	   off	   viral	   infections	   at	   the	   mucosal	   cell	  
surface.	  It	  involves	  both	  soluble	  components	  (cytokines,	  complements,	  defensins,	  
etc)	  and	  cells	  [including	  macrophages,	  neutrophils,	  natural	  killer	  (NK)	  cells,	  CD8+	  
T-­‐cells	  with	  noncytotoxic	  antiviral	  activity	  (CNAR),	  γδ	  T-­‐cells	  and	  dendritic	  cells	  
(DCs)]	   (figure	   1.3;	   reviewed	   by	   Levy,	   2001).	   Cytokines	   involved	   in	   innate	  
responses	   determine	   whether	   a	   T-­‐helper	   (Th)-­‐1	   or	   a	   Th2	   immune	   response	   is	  
mounted.	   Tumor-­‐necrosis	   factor	   (TNF)-­‐α	   and	   interferons	   (IFNs)	   also	   help	   in	  
controlling	   the	   degree	   of	   HIV	   replication.	   Chemokines	   are	   involved	   in	   the	  
recruitment	  of	  NK	  cells,	  T-­‐cells	  and	  macrophages	  to	  the	  site	  of	  infection.	  Cytokine	  
production	   by	   the	   innate	   immune	   system	   induces	   both	   innate	   and	   adaptive	  
cellular	   responses	   to	   HIV	   infection	   (Graziosi	   et	   al.,	   1996;	   Biron	   et	   al.,	   1999;	  
reviewed	  by	  Levy,	  2001).	  	  
	  
Adaptive	   immune	   responses	   against	   HIV	   take	   longer	   to	   mount	   than	   innate	  
responses	  and	  consists	  of	  different	  phases,	  including	  recognition	  of	  the	  antigen,	  
activation	  of	  lymphocytes	  and	  the	  effector	  phase	  where	  the	  antigen	  is	  eliminated	  
(figure	   1.3).	   Eventually,	  memory	   immune	   cells	   are	   formed,	  with	   the	   B-­‐	   and	   T-­‐
lymphocytes	  considered	  to	  be	  the	  principle	  effector	  cells	  of	  the	  antigen-­‐specific	  
immune	   response.	   B-­‐	   and	   T-­‐cells	   work	   in	   tandem	   to	   provide	   protective	  
immunity;	   with	   CD8+	  T-­‐cells	   being	   necessary	   to	   control	   viral	   replication	  while	  
antibodies	  block	  viral	  entry	  into	  host	  cells.	  Since	  this	  dissertation	  focuses	  on	  T-­‐
cell	  responses,	   this	  review	  will	   focus	  on	  CD8+	  and	  CD4+	  T-­‐cell	   immunity	  to	  HIV	  
infection.	  
	  
1.3.2.1. CD8+	  T-­‐cell	  responses	  to	  HIV	  	  
Virus-­‐specific	  CD8+	  T-­‐cells	  are	  detected	  relatively	  early	  after	  HIV	  infection	  within	  
2	  weeks;	   and	   are	   responsible	   for	   the	   decrease	   in	   viral	   load	   and	   the	   control	   of	  
viral	   replication	  observed	  during	  acute	   infection	   (Walker	  et	   al.,	   1987).	  CD8+	  T-­‐
cell	  responses	  occur	  before	  the	  appearance	  of	  neutralizing	  antibodies	  (Fiebig	  et	  
al.,	  2003).	  HIV-­‐specific	  CTL	  are	  able	   to	  eliminate	   infected	  CD4+	  T-­‐cells	  and	  also	  
produce	   cytokines	   and	   chemokines	   on	   recognition	   of	   HIV	   antigen	   fragments	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expressed	   on	   the	   target	   cell	   surface	   (peptide:	   MHC	   class	   I	   complex).	   The	   β-­‐
chemokines	   [including	   macrophage	   inflammatory	   proteins	   (MIP)-­‐1α,	   MIP-­‐1β	  
and	   regulated-­‐on-­‐activation,	   normal	   T-­‐cell-­‐expressed	   and	   secreted	   (RANTES)]	  
produced	  by	  the	  CTLs	  act	  to	  suppress	  viral	  replication	  and	  entry	  into	  target	  CD4+	  
T-­‐cells	  (reviewed	  by	  Alfano	  &	  Poli,	  2005).	  	  
	  
The	  initial	  decrease	  in	  viraemia	  during	  acute	  HIV	  infection	  is	  associated	  with	  the	  
emergence	  of	  HIV-­‐specific	  CTLs	  (Borrow	  et	  al.,	  1994).	  They	  are	  able	  to	  recognise	  
and	   eliminate	   HIV-­‐infected	   cells	   and	   are	   essential	   for	   the	   control	   of	   viral	  
replication	   (Kaul	   et	   al.,	   2001b).	   The	   crucial	   role	   played	   by	   CD8+	  T-­‐cells	   during	  
HIV	   infection	   was	   confirmed	   in	   primate	   studies	   where	   CD8+	   T-­‐cells	   were	  
depleted	  using	  in	  vivo	  administration	  of	  anti-­‐CD8	  monoclonal	  antibodies	  in	  SIV-­‐
infected	  macaques,	  which	  resulted	   in	  a	  marked	  rise	   in	  viraemia	  (Schmitz	  et	  al.,	  
1999).	   In	   these	   experiments,	   viral	   RNA	   levels	   subsequently	   decreased	   as	   SIV-­‐
specific	   CD8+	   T-­‐cell	   numbers	   were	   restored,	   suggesting	   that	   these	   cells	   were	  
important	  in	  controlling	  the	  progression	  of	  infection	  (Jin	  et	  al.,	  1999;	  Schmitz	  et	  
al.,	   1999).	   Many	   studies	   have	   also	   shown	   that	   CTL	   escape	   mutants	   appear	  
regularly	  in	  many	  HIV-­‐infected	  individuals,	  both	  during	  acute	  and	  chronic	  stages	  
of	   infection,	   indicating	   that	   CTLs	   play	   an	   active	   role	   in	   the	   immune	   response	  
against	  HIV	   and	   that	   the	  CTL-­‐mediated	  pressure	   leads	   to	   the	   formation	  of	  HIV	  
mutants	   (Friedrich	   et	   al.,	   2004;	   Jones	   et	   al.,	   2004).	   Although	  most	  HIV-­‐specific	  
CD8+	  T-­‐cells	  are	  able	  to	  kill	  infected	  target	  cells,	  they	  also	  exhibit	  other	  effector	  
functions	   such	   as	   the	   ability	   to	   produce	   cytokines,	   including	   IFN-­‐γ,	   interleukin	  
(IL)-­‐2,	  MIP-­‐1α,	  MIP-­‐1β	  and	  RANTES	  (Betts	  et	  al.,	  2006;	  Streeck	  et	  al.,	  2008).	  	  
	  
The	  differentiation	  status	  of	  CD8+	  T-­‐cells	  has	  been	  shown	  to	  influence	  the	  kind	  of	  
functions	  these	  cells	  exhibit	  (Surh	  and	  Sprent,	  2008).	  Naïve	  CD8+	  T-­‐cells,	  which	  
have	  never	  been	  exposed	  to	  their	  cognate	  antigen	  before,	  require	  several	  days	  of	  
antigenic	   stimulation	   before	   becoming	   activated	   to	   produce	   cytokines.	   In	  
contrast,	  memory	  CD8+	  T-­‐cells	  respond	  faster	  and	  produce	  IFN-­‐γ	  after	  only	  a	  few	  
hours	  of	   antigenic	   stimulation	   (Veiga-­‐Fernandes	  et	   al.,	   2000).	  Effector	  memory	  
T-­‐cells	   are	   known	   to	   release	   perforin	   and	   granzymes	   within	   minutes	   of	  
encountering	  the	  antigen	  (Lalvani	  et	  al.,	  1997).	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1.3.2.2. CD4+	  T-­‐cell	  responses	  to	  HIV	  
CD4+	  T-­‐cells	  are	  the	  known	  targets	  for	  HIV	  infection	  but	  can	  also	  recognise	  and	  
respond	  to	  HIV	  antigens.	  In	  fact,	  of	  all	  CD4+	  T-­‐cell	  specificities	  and	  subsets,	  HIV-­‐
specific	  CD4+	  T-­‐cells	  have	  been	  shown	  to	  be	  preferentially	  infected	  and	  depleted	  
by	   HIV	   (reviewed	   by	   Okoye	   &	   Picker,	   2013).	   The	   proliferative	   capacity	   and	  
ability	  of	  these	  HIV	  target	  cells	  to	  produce	  cytokines	  is	  lost	  early	  during	  infection	  
but	   they	   preserve	   the	   capacity	   to	   produce	   IFN-­‐γ	   during	   the	   chronic	   phase	   of	  
infection	   (Harari	   et	   al.,	   2006).	   In	   addition	   to	  directly	   recognizing	  HIV	  antigens,	  
cytokine	   production	   by	   CD4+	   T-­‐cells	   is	   known	   to	   provide	   crucial	   help	   for	   the	  
maturation	  of	  B-­‐	  and	  CD8+	  T-­‐cell	  memory	  (Mascola	  and	  Montefiori,	  2010).	  
	  
During	   the	   acute	   phase	   of	   HIV	   infection,	   memory	   CD4+	   T-­‐cells	   are	   drastically	  
depleted	  from	  the	  lymphoid	  system,	  especially	  the	  gut,	  both	  directly	  by	  the	  virus	  
and	   indirectly	   via	   bystander	   activation-­‐induced	   cell	   death.	   This	   happens	   to	   all	  
memory	  CD4+	  T-­‐cells	  in	  general	  but	  HIV-­‐specific	  cells	  are	  preferentially	  depleted	  
(Douek	   et	   al.,	   2009;	   Mattapallil	   et	   al.,	   2005).	   HIV-­‐infected	   individuals	   who	  
progress	  slowly	  to	  AIDS	  without	  treatment	  (termed	  slow	  progressors)	  have	  been	  
shown	  to	  have	  stronger	  CD4+	  T-­‐cell	  responses	  than	  normal	  or	  rapid	  progressors,	  
and	   their	   delayed	   progression	   correlated	  with	   the	   rate	   of	   disease	   progression	  
(Rosenberg	  and	  Billingsley,	  1997).	  Furthermore,	  others	  have	  reported	  a	  positive	  
relationship	  between	  the	  strength	  of	  an	  infected	  individuals	  HIV-­‐specific	  CD4+	  T-­‐
cell	  responses	  and	  an	  effective	  CD8+	  T-­‐cell	  response	  (Kalams	  et	  al.,	  1999).	  Two	  
independent	   studies	   have	   shown	   that	   IL-­‐21-­‐producing	   CD4+	   T-­‐cells	   have	   an	  
important	   role	   to	   play	   in	  maintain	   effective	   CD8+	   T-­‐cell	   responses.	   These	   cells	  
have	   been	   found	   in	   higher	   numbers	   in	   elite	   controllers	   (individuals	   with	  
undetectable	   plasma	   viral	   loads	   and	   high	   CD4+	   T-­‐cell	   counts	   in	   the	   absence	   of	  
HAART	  for	  longer	  than	  10	  years;	  Cao	  et	  al.,	  1995)	  who	  are	  able	  to	  control	  their	  
infection	  (Chevalier	  et	  al.,	  2011;	  Williams	  et	  al.,	  2011).	  	  
	  
1.4. Memory	  T-­‐cell	  subsets	  
Heterogeneity	   within	   the	   memory	   T-­‐cells	   was	   first	   characterised	   using	   the	  
homing	   receptor	  C-­‐C	   chemokine	   receptor	   type	  7	   (CCR7)	   (Sallusto	   et	   al.,	   1999).	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CCR7	  interacts	  with	  its	  ligand	  CCL21	  expressed	  by	  endothelial	  cells	  (Gunn	  et	  al.,	  
1998)	  and	  this	  interaction	  causes	  the	  adhesion	  and	  transmigration	  of	  T-­‐cells	  into	  
the	   lymph	  node	   (Campbell	   et	   al.,	   1998).	  On	   the	   other	   hand,	   cells	   lacking	   CCR7	  
migrate	  mostly	  through	  peripheral	  tissues	  and	  are	  controlled	  by	  a	  different	  set	  of	  
integrins	  and	  chemokine	  receptors	  (Mackay	  et	  al.,	  1990).	  CCR7+	  memory	  T-­‐cells	  
were	  considered	  to	  be	  TCM	  because	  of	  their	  capacity	  to	  home	  to	  the	  secondary	  
lymphoid	   tissues.	   CCR7-­‐	   memory	   T-­‐cells	   are	   considered	   as	   TEM	   due	   to	   their	  
potential	   to	   home	   to	   peripheral	   lymphoid	   tissue	   and	   also	   due	   to	   their	   rapid	  
effector	   function	   ex-­‐vivo.	   TEM	   have	   downregulated	   CCR7,	   allowing	   them	   to	  
circulate	  through	  the	  periphery,	  and	  are	  able	  to	  immediately	  produce	  cytokines	  
after	  antigen	  recognition	  (Unsoeld	  et	  al.,	  2002;	  reviewed	  by	  Mahnke	  et	  al.,	  2013).	  	  
	  
Immune	   memory	   leads	   to	   a	   faster	   and	   more	   sensitive	   secondary	   immune	  
response	   than	   naïve	   cells	   (reviewed	   by	   Mahnke	   et	   al.,	   2013	   &	   Jameson	   &	  
Masopust,	   2009).	   The	   CD45RO+	   memory	   T-­‐cell	   population	   can	   be	   further	  
subdivided	  into	  three	  subsets,	  including	  effector	  memory	  (TEM),	  central	  memory	  
(TCM)	   and	   tissue-­‐resident	   memory	   T-­‐cells	   (Shin	   and	   Iwasaki,	   2013).	   For	   the	  
purpose	  of	  this	  study,	  the	  circulating	  memory	  T-­‐cell	  populations	  -­‐	  TEM	  and	  TCM	  
-­‐	  will	  be	  discussed	  in	  detail.	  	  
	  
T-­‐cells	   can	   be	   classified	   into	   four	   idealised	   basic	   subsets	   based	   on	  markers	   of	  
their	   respective	   longevity	   and	   proliferative	   capacity:	   naïve,	   TCM,	   TEM	   and	  
terminally	   differentiated	   (TD)	   T-­‐cells	   (Jameson	   and	  Masopust,	   2009).	   Naïve	   T-­‐
cells	  (CD45RO-­‐CCR7+)	  are	  long-­‐lived	  and	  have	  not	  encountered	  any	  antigen	  yet.	  
Their	  longevity	  viability	  relies	  on	  certain	  exogenous	  signals	  such	  as	  the	  presence	  
of	   the	   cytokine	   IL-­‐7	   or	   contact	   with	   self-­‐peptide/MHC	   ligands	   (Appay	   &	  
Rowland-­‐Jones,	  2004;	  Ma	  et	  al.,	  2006).	  Memory	  T-­‐cells	  respond	  more	  rapidly	  to	  
antigens.	  TCM	  cells	  (CD45RO+CCR7+)	  are	  long-­‐lived	  cells	  that	  have	  little	  effector	  
function.	  They	  respond	  to	  antigen	  exposure	  by	  dividing	  and	  differentiating	  into	  
TD/effector	  cells.	  On	  the	  other	  hand,	  TEM	  (CD45RO+CCR7-­‐)	  are	  short-­‐lived	  and	  
respond	  to	  antigen	  with	  more	  rapid	  effector	  functions	  than	  TCM.	  They	  also	  have	  
a	  lower	  ability	  to	  proliferate	  and	  express	  pro-­‐apoptotic	  genes	  (Day	  and	  Walker,	  
2003;	  Kassiotis	   and	  Stockinger,	   2004;	  Riou	  et	   al.,	   2007).	   It	   has	  been	   suggested	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that	   TCM	   can	   maintain	   longer	   telomeres	   (which	   means	   they	   have	   a	   longer	  
lifetime	  and	  can	  go	  through	  more	  cycles	  of	  cell	  division	  and	  differentiation;	  Roth	  
et	  al.,	  2003)	  than	  TEM	  cells	  and	  are	  able	  to	  generate	  TEM	  cells,	  but	  not	  vice-­‐versa	  
(Sallusto	  et	  al.,	  1999).	  TD	  (CD45RO-­‐CCR7-­‐)	  are	  the	  most	  differentiated	  subset	  of	  
T-­‐cells	  and	  most	  of	  them	  die	  upon	  restimulation	  (Jameson	  and	  Masopust,	  2009).	  	  
	  
The	  pathway	  followed	  during	  differentiation	  of	  memory	  T-­‐cells	  is	  still	  not	  clearly	  
understood.	   Chang	   et	   al.	   (2007)	   showed	   that	   naïve	   T-­‐cells	   follow	   a	   divergent	  
pathway	  where	  progeny	  of	  a	  single	  naïve	  T-­‐cell	  could	  develop	  into	  either	  effector	  
or	   memory	   T-­‐cells	   (figure	   1.4A).	   This	   means	   that	   memory	   T-­‐cells	   are	   formed	  
directly	   from	  naïve	  T-­‐cells	  without	   first	  becoming	  effector	  T-­‐cells	   (Chang	  et	  al.,	  
2007).	   An	   alternative	   model	   explaining	   the	   formation	   of	   memory	   T-­‐cells	   was	  
proposed	   by	   Hu	   et	   al.	   (2001)	   (figure	   1.4B).	   Hu	   et	   al.	   (2001)	   showed,	   in	   an	  
adoptive	  transfer	  experiment	   in	  mice,	   that	  effector	  T-­‐cells	  have	  the	  potential	  to	  
become	  memory	  T-­‐cells	   directly,	  without	   further	  division,	   thus	   suggesting	   that	  
the	   development	   of	   memory	   T-­‐cells	   follows	   a	   linear	   pathway	   from	   naïve	   to	  
memory	   cells.	   Other	   studies	   have	   shown	   that	  memory	   T-­‐cells	   are	   formed	   in	   a	  
non-­‐linear	   fashion	   and	   this	   depends	  on	   certain	  priming	   conditions	   such	   as	   the	  
duration	  of	  antigenic	  stimulation	  or	  the	  type	  of	  cytokines	  encountered	  (reviewed	  
by	  Wakim	  &	  Bevan,	  2010;	   Srinivasula	   et	   al.,	   2013;	   figure	  1.4C).	   For	   example,	   a	  
short	   period	   of	   stimulation	   results	   in	   the	   formation	   of	   TCM	   while	   a	   longer	  
duration	   of	   stimulation	   promotes	   the	   differentiation	   of	   effector	   cells	   into	   TEM	  
(Badovinac	  and	  Harty,	  2007;	  Sallusto	  et	  al.,	  1999).	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Figure	  1.4.	  Proposed	  mechanisms	  for	  the	  development	  of	  memory	  T-­‐cells.	  A.	  Divergent	  
differentiation	   pathway	  where	   daughter	   cells	   from	   a	   naïve	   T-­‐cell	   can	   develop	   directly	  
into	  effector	  or	  memory	  T-­‐cells.	  B.	  Linear	  development	  of	  effector	  and	  memory	  T-­‐cells	  
where	   memory	   T-­‐cells	   are	   directly	   formed	   from	   effector	   cells.	   C.	   Differential	  
development	  pathway	  where	  the	  type	  of	  memory	  T-­‐cell	  formed	  depends	  on	  the	  duration	  
of	  antigenic	  stimulation.	  (adapted	  from	  Chang	  et	  al.,	  2007;	  Hu	  et	  al.,	  2001;	  Badovinac	  &	  
Harty,	  2007;	  Kaech,	  Wherry	  &	  Ahmed,	  2002;	  Wakim	  &	  Bevan,	  2010)	  
	  
1.4.1. Role	  of	  cytokines	  in	  T-­‐cell	  differentiation	  
Cytokines	  belonging	  to	  the	  γ-­‐chain	  family,	  for	  example	  IL-­‐2,	  IL-­‐4,	  IL-­‐7,	  and	  IL-­‐15,	  
have	  a	  crucial	  role	  in	  the	  maintenance	  of	  T-­‐cells	  and	  homeostasis.	  Being	  a	  strong	  
activation,	  growth	  and	  survival	  factor	  for	  T-­‐cells,	  the	  haematopoietic	  cytokine	  IL-­‐
7	  is	  especially	  important	  in	  the	  survival	  of	  naïve	  T-­‐cells.	  The	  mechanism	  behind	  
this	  occurs	  via	  an	  intracellular	  pathway	  which	  involves	  the	  induction	  of	  the	  anti-­‐
apoptotic	  protein	  Bcl-­‐2	  (von	  Freeden-­‐Jeffry	  et	  al.,	  1997;	  Ma	  et	  al.,	  2006).	  	  	  
	  
T-­‐cells	   can	   proliferate	   in	   response	   to	   cytokines	   in	   a	   T-­‐cell	   receptor	   (TCR)-­‐
independent	  manner	  (Geginat	  et	  al.,	  2003;	  reviewed	  by	  Seder	  et	  al.,	  2008).	  IL-­‐2,	  
TNF-­‐α	  and	  IFN-­‐γ	  are	  the	  main	  effector	  cytokines	  involved	  in	  T-­‐cell	  differentiation	  






















1.5).	   These	   specific	   cytokines	   are	   also	   used	   to	   define	   vaccine-­‐generated	  
responses	   against	   infections	   that	   require	   T-­‐cells	   for	   effective	   protection	  
(reviewed	  by	  Seder	  et	  al.,	  2008).	  The	  amount	  of	  IL-­‐2	  produced	  has	  an	  impact	  on	  
the	   proliferation,	   differentiation	   and	   survival	   of	   antigen-­‐specific	   T-­‐cells	   and	  
determines	  whether	  T-­‐cells	  will	  preferentially	  become	  terminally	  differentiated	  
effector	   cells	   or	   memory	   cells	   (Kalia	   et	   al.,	   2010).	   Strong,	   sustained	   IL-­‐2	  
production	   by	   different	   lymphocyte	   subsets	   (including	   CD4+	  and	   CD8+	   T-­‐cells)	  
have	   a	   paracrine	   effect	   where	   it	   causes	   other	   T-­‐cells	   to	   undergo	   chromatin	  
remodelling	   and	   display	   effector	   functions	   such	   as	   perforin	   and	   granzyme	  
expression	   (Pipkin	   et	   al.,	   2010;	   figure	   1.5A).	   On	   the	   other	   hand,	   short-­‐term	  
exposure	   to	   IL-­‐2	   results	   in	   an	   effector	   differentiation	   to	   a	   lesser	   extent	   and	  
promotes	   the	  generation	  of	   long-­‐lived	  memory	  T-­‐cells	   (figure	  1.5B;	  Kalia	  et	  al.,	  
2010;	  Pipkin	  et	  al.,	  2010).	  TNF-­‐α	  is	  one	  of	  the	  first	  effector	  cytokines	  produced	  
by	   activated	   CD4+	   T-­‐cells	   under	   conditions	   that	   favour	   Th1	   cellular	  
differentiation	  (Darrah	  et	  al.,	  2007).	  The	  ability	  of	  cells	  to	  produce	  TNF-­‐α	  is	  lost	  
as	   the	   cells	   become	  more	  differentiated,	  with	   terminally-­‐differentiated	   effector	  
cells	   lacking	   the	   ability	   to	   produce	   TNF-­‐α	   (Seder	   et	   al.,	   2008).	   IFN-­‐γ	   is	   only	  
produced	   by	   differentiated	   cells,	   which	   have	   undergone	   several	   rounds	   of	  
proliferation	   (Fritsch	   et	   al.,	   2005).	   Non-­‐lymphoid	   tissue-­‐resident	   TEM	   and	   TD	  
have	  been	  shown	  to	  produce	  more	  IFN-­‐γ	  than	  TCM,	  suggesting	  that	  it	  is	  part	  of	  a	  
mechanism	  for	  more	  rapid	  responses	  to	  re-­‐infections	  (figure	  1.5C;	  Fritsch	  et	  al.,	  
2005;	  Hamann	  et	  al.,	  1997).	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Figure	   1.5.	   Role	   of	   cytokines	   in	   T-­‐cell	   differentiation	   and	   the	   generation	   of	   immune	  
responses.	  A.	   Strong,	  persistent	   IL-­‐2	  production	  causes	   the	  activated	  T-­‐cells	   to	  secrete	  
effector	   molecules	   such	   as	   granzyme	   and	   perforin.	   B.	   Short-­‐term	   exposure	   to	   IL-­‐2	  
results	   in	   the	   differentiation	   of	   T-­‐cells	   into	   long-­‐lived	   memory	   T-­‐cells.	   C.	   TNF-­‐α	  
production	  by	  the	  less	  differentiated	  cells	  favours	  Th1	  cellular	  differentiation	  while	  IFN-­‐
γ	  is	  only	  produced	  by	  differentiated	  cells.	  	  
	  
1.4.2. HIV	  preferentially	  infects	  memory	  T-­‐cell	  subsets	  
Several	  studies	  have	  reported	  that	  HIV	  preferentially	  targets	  specific	  CD4+	  T-­‐cell	  
subsets	   based	   on	   factors	   like	   the	   level	   of	   activation	   and	   expression	   of	   HIV	   co-­‐
receptors	  CCR5	  and	  CXCR4	  (reviewed	  by	  Grossman	  et	  al.,	  2006	  &	  Picker,	  2006).	  
Memory	  CD4+	  T-­‐cells	  are	  the	  main	  targets	  of	  HIV	  (Schnittman	  et	  al.,	  1990)	  and	  a	  
massive	  depletion	  of	   this	   cell	  population	  occurs	  during	  primary	   infection,	  both	  
systemically	  and	  at	  mucosal	  sites	  (Mattapallil	  et	  al.,	  2005).	  TEM	  express	  higher	  
levels	  of	  CCR5	  than	  other	  memory	  T-­‐cell	  subsets,	  while	  CXCR4	  is	  predominantly	  
expressed	   on	   TCM	   and	   naïve	   cells	   (Sallusto	   et	   al.,	   1998;	   Geginat	   et	   al.,	   2001).	  
Since	   HIV	   first	   infects	   activated	   CD4+	   T-­‐cells	   and	   then	   relies	   on	   them	   for	  
dissemination	   following	   transmission	   across	   mucosal	   surfaces,	   the	  
differentiation	   status	   of	   mucosal	   CD4+	   T-­‐cells	   and	   their	   level	   of	   expression	   of	  
CCR5	   co-­‐receptor	   have	   been	   proposed	   to	   determine	   risk	   of	   HIV	   transmission.	  






























CCR5-­‐expressing	   TEM.	   TCM	   have	   been	   identified	   as	   one	   of	   the	   major	   cellular	  
compartments	  of	  the	  latent	  HIV	  reservoir	  (Chomont	  et	  al.,	  2009).	  	  
	  
During	  an	  HIV	  infection,	  the	  proportion	  of	  the	  different	  CD4+	  T-­‐cell	  subsets	  can	  
be	   used	   to	   indicate	   the	   extent	   of	   disease	   progression	   (reviewed	   by	   McCune,	  
2001).	   As	   disease	   progresses,	   there	   is	   an	   accumulation	   of	   short-­‐lived,	   highly	  
differentiated	  T-­‐cells,	  resulting	   in	   immunosenescence	  and	   immune	  dysfunction.	  
Thus,	  having	  increased	  frequencies	  of	  TD	  cells	  can	  be	  considered	  to	  be	  a	  sign	  of	  
clinical	  immunodeficiency	  (reviewed	  by	  Appay	  &	  Sauce,	  2008).	  	  
	  
It	   is	  worth	  noting	  that	  naïve	  T-­‐cells	  undergo	  distinct	  differentiation	  patterns	  to	  
generate	   effector	   and	   memory	   T-­‐cells	   (reviewed	   by	   Seder	   &	   Ahmed,	   2003;	  
Sallusto	   et	   al.,	   2004).	   It	   has	   been	   proposed	   that	   CD4+	   T-­‐cells	   follow	   a	   linear	  
differentiation	   pathway	   by	  which	   they	   gain	   their	   effector	   functions	   (Wu	   et	   al.,	  
2002):	  The	  more	  the	  CD4+	  T-­‐cells	  that	  are	  stimulated,	  the	  lower	  the	  potential	  of	  
forming	  memory	  T-­‐cells	  (figure	  1.6a).	  In	  contrast,	  CD8+	  T-­‐cells	  fully	  differentiate	  
into	   activated	   effector	   cells	   upon	   stimulation	   that	   can	   follow	   different	  
development	   pathways	   to	   form	   either	   memory	   T-­‐cells	   or	   terminally	  
differentiated	  cells	  (figure	  1.6b;	  reviewed	  by	  Seder	  &	  Ahmed,	  2003).	  It	  has	  been	  
suggested	  that	  naïve	  CD8+	  T-­‐cells	  are	  able	  to	  differentiate	  into	  effector	  cells	  more	  
rapidly	   than	   CD4+	   T-­‐cells	   and	   that	   CD8+	   T-­‐cells	   have	   greater	   proliferative	  
capacity	   upon	   encountering	   an	   antigen,	   and	   are	   thus	   able	   to	   establish	   a	   stable	  
population	   of	   memory	   T-­‐cells	   after	   the	   contraction	   phase	   than	   CD4+	   T-­‐cells	  
(Homann	   et	   al.,	   2001).	   On	   the	   other	   hand,	   naive	   CD4+	  T-­‐cells	   proliferate	   to	   a	  
lower	   degree	   and	   a	   higher	   percentage	   of	   the	   activated	   cells	   die	   after	   the	  
contraction	  phase	  (Homann	  et	  al.,	  2001;	  Foulds	  et	  al.,	  2002;	  reviewed	  by	  Seder	  &	  
Ahmed,	  2003).	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Figure	  1.6.	  Models	  for	  effector	  and	  memory	  T-­‐cell	  differentiation	  for	  CD4+	  and	  CD8+	  T-­‐
cells.	   a.	   Naïve	   CD4+	   T-­‐cells	   follow	   a	   linear	   development	   pathway	   where	   they	  
progressively	  gain	  functionality	  with	  further	  differentiation	  until	  they	  are	  optimised	  for	  
their	   effector	   function.	   Persistent	   antigenic	   stimulation	   leads	   to	   the	   formation	   of	   a	  
higher	  proportion	  of	  terminally	  differentiated	  T-­‐cells	  and	  a	  lower	  frequency	  of	  memory	  
T-­‐cells.	  b.	  When	  stimulated,	  naïve	  CD8+	  T-­‐cells	  directly	  form	  activated	  effector	  CD8+	  T-­‐
cells,	  most	  with	  cytolytic	  activity.	  These	  cells	  can	  follow	  two	  different	  pathways	  to	  form	  
either	  central	  or	  effector	  memory	  T-­‐cells.	  Persistent	  antigenic	  stimulation	  then	  leads	  to	  
the	  formation	  of	  terminally	  differentiated	  cells	  followed	  by	  apoptosis	  (taken	  from	  Seder	  
et	  al.,	  2008).	  	  
	  
1.4.3. Exhaustion	  of	  HIV-­‐specific	  T-­‐cells	  
It	   has	   been	   suggested	   that	   exhausted	   T-­‐cells	   represent	   a	   separate	   and	   distinct	  
state	  of	  T-­‐cell	  differentiation	  (reviewed	  by	  Wherry,	  2011).	  T-­‐cell	  exhaustion	  as	  a	  
result	  of	   chronic	  HIV	   infection	   is	   characterised	  by	  a	   state	  of	  T-­‐cell	  dysfunction,	  
reduced	   effector	   function	   and	   an	   altered	   transcriptional	   state	   compared	   to	  
functional	   effector	   cells	   or	   memory	   T-­‐cells.	   High	   levels	   of	   persistent	   cellular	  
activation	   has	   been	   proposed	   as	   a	   major	   trigger	   of	   proliferation	   and	   T-­‐cell	  
differentiation	  which	  results	  in	  the	  formation	  of	  cells	  with	  increased	  expression	  
of	  CD57	  (reviewed	  by	  Appay	  &	  Sauce,	  2008).	  CD57	  is	  a	  epitope	  expressed	  on	  T-­‐
lymphocytes	   and	   is	   considered	   to	   be	   a	   marker	   of	   replicative	   senescence.	   It	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defines	  cells	  with	  a	  high	  susceptibility	   to	  activation-­‐induced	  cell	  death	  and	   low	  
proliferative	   capacity	   even	   though	   they	   retain	   the	   ability	   to	   rapidly	   induce	   the	  
production	   of	   cytokines	   in	   the	   presence	   of	   antigens	   (Brenchley	   et	   al.,	   2003;	  
Burgers	   et	   al.,	   2009;	   Lopez-­‐Vergès	   et	   al.,	   2010;	   Papagno	   et	   al.,	   2004).	   Several	  
studies	   have	   shown	   the	   surface	   marker	   CD57	   to	   be	   a	   reliable	   marker	   of	  
replicative	  senescence	   in	  T-­‐cells	  and	  NK	  cells	  (Brenchley	  et	  al.,	  2003;	   Ibegbu	  et	  
al.,	  2005;	  Lopez-­‐Vergès	  et	  al.,	  2010).	  During	  HIV	  infection,	  T-­‐cell	  exhaustion	  can	  
be	  caused	  by	  several	  factors	  including	  high	  viral	  load,	  the	  lack	  of	  CD4+	  helper	  T-­‐
cells,	   inflammation	   and	   antigen-­‐presenting	   function	   (Barber	   et	   al.,	   2006;	  
Papagno	  et	  al.,	  2004;	  Wherry	  et	  al.,	  2007).	  Effros	  et	  al.	  (1996)	  suggested	  that	  T-­‐
cells	  expressing	  CD57	  have	  reached	  the	  irreversible	  shortening	  of	  telomeres	  that	  
restricts	   cell	   division	   (also	   known	   as	   the	   Hayflick	   limit),	   suggesting	   that	   HIV	  
induces	  more	  replication	  cycles	  in	  T-­‐cells	  from	  infected-­‐individuals	  compared	  to	  
T-­‐cells	  from	  seronegative	  individuals,	   leading	  to	  exhaustion	  of	  T-­‐cell	  responses.	  
Palmer	   et	   al.	   (2005)	   reported	   that	   CD57	  was	   expressed	   at	   significantly	   higher	  
levels	   in	   the	   TD	   compared	   to	   TCM	  or	   TEM	   subsets	   of	   CD4+	   T-­‐cells	   during	  HIV	  
infection,	   suggesting	   that	   the	  most	   terminally	   differentiated	  CD4+	  T-­‐cell	   subset	  
was	   expressing	   the	   highest	   levels	   of	   CD57.	   In	   CD8+	   T-­‐cells,	   increased	   CD57	  
expression	   has	   been	   associated	   with	   chronic	   immune	   activation	   during	   HIV	  
infection	   and	   frequencies	   of	   CD8+CD57+	  T-­‐cells	   correlate	  with	   the	   stage	  of	  HIV	  
disease	  progression	  (Betts	  et	  al.,	  2005;	  Papagno	  et	  al.,	  2004;	  Wood	  et	  al.,	  2005).	  
Some	  controversy	  has	  emerged	  about	  the	  proliferative	  capacity	  of	  CD8+CD57+	  T-­‐
cells:	  Chong	  et	  al.	  (2008)	  showed	  that	  CD8+CD57+	  T-­‐cells	  were	  capable	  of	  rapidly	  
expanding	   in	   numbers	   and	   this	   was	   accompanied	   by	   the	   production	   of	   high	  
levels	   of	   IL-­‐15	   while	   others	   have	   shown	   that	   they	   have	   limited	   proliferative	  
ability	  (Wherry	  et	  al.,	  2005;	  Barber	  et	  al.,	  2006;	  reviewed	  by	  Focosi	  et	  al.,	  2010).	  	  
	  
The	   function	   of	   CD8+CD57+	   T-­‐cells	   during	   HIV	   infection	   is	   unclear.	   EBV-­‐	   and	  
CMV-­‐infected	  (but	  HIV-­‐negative)	  individuals	  exhibit	  a	  coordinated	  up-­‐regulation	  
of	   CD57	   with	   down-­‐regulation	   of	   CD27	   [a	   T-­‐cell	   co-­‐stimulatory	   receptor	  
necessary	  for	  the	  generation	  and	  maintenance	  of	  T-­‐cell	  memory	  (Hendriks	  et	  al.,	  
2000)]	  by	  memory	  CD8+	  T-­‐cells.	  In	  contrast,	  HIV-­‐infected	  individuals	  accumulate	  
CD27highCD57low	  HIV-­‐specific	  CD8+	  T-­‐cells,	  which	  correlate	  with	  plasma	  viraemia	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(Hoji	  et	  al.,	  2007).	  Hoji	  et	  al.	   (2007)	  argued	   that	   this	  suggests	   that	  HIV-­‐specific	  
CD8+	  T-­‐cells	  maintain	  impaired	  effector	  differentiation	  during	  the	  course	  of	  HIV	  
infection	  and	  this	  lack	  of	  normal	  differentiation	  could	  have	  a	  role	  to	  play	  in	  the	  
failure	  of	  the	  immune	  system	  to	  control	  HIV	  infection.	  	  
	  
1.5. Immune	  activation	  
It	  is	  now	  widely	  accepted	  that	  generalised	  immune	  activation	  plays	  a	  major	  role	  
to	   play	   in	   HIV	   pathogenesis.	   The	   immune	   system	   is	   crucial	   in	   controlling	   HIV	  
infection	  and	  replication	  but	  long-­‐term	  control	  has	  been	  associated	  with	  chronic	  
immune	  activation	  and	  inflammation,	  subsequently	  leading	  to	  the	  exhaustion	  of	  
the	   host	   immune	   system	   and	   the	   onset	   of	   non-­‐AIDS-­‐defining	   illnesses	   (Deeks,	  
2011;	   Hunt,	   2012).	   Immune	   activation	   in	   HIV	   infection	   encompasses	   several	  
related	  events	  including	  cellular	  activation,	  proliferation,	  and	  ultimately	  cellular	  
death	   and	   the	   production	   of	   soluble	   immunomodulatory	   molecules.	   During	  
chronic	   immune	   activation,	   T-­‐cell	   activation	   has	   been	   shown	   to	   better	   predict	  
CD4+	  T-­‐cell	   loss	   and	  disease	   progression	   than	  plasma	   viral	   loads	   (Deeks	   et	   al.,	  
2004).	  Expression	  of	  CD38	  and	  HLA-­‐DR	  by	  memory	  T-­‐cells	  indicate	  the	  response	  
of	   the	   immune	  system	  against	  HIV	  antigens	  and	   is	  strongly	  associated	  with	  the	  
degree	  of	  systemic	  immune	  activation	  (Appay	  and	  Sauce,	  2008).	  	  
	  
1.5.1. Causes	  of	  immune	  activation	  during	  HIV	  infection	  
1.5.1.1. Direct	  activation	  as	  a	  result	  of	  HIV	  replication	  
The	   primary	   cause	   of	   T-­‐cell	   activation	   is	   thought	   to	   be	   through	   the	   direct	  
stimulation	  of	  T-­‐cells	  by	  HIV	  antigens	  (Rieckmann	  et	  al.,	  1991).	  During	  acute	  HIV	  
infection,	  HIV	  induces	  T-­‐cell	  responses	  (especially	  by	  CD8+	  T-­‐cells),	  which	  persist	  
throughout	   the	   infection.	   Binding	   of	   gp120	   to	   the	   CD4	   receptor	   is	   able	   to	  
trigger/enhance	  T-­‐cell	  activation	  via	   the	  production	  of	  TNF-­‐α	  (Lee	  et	  al.,	  2003;	  
Rieckmann	  et	  al.,	  1991).	  HIV	  Nef	  is	  also	  involved	  in	  the	  activation	  of	  lymphocytes	  
through	  the	  down-­‐regulation	  of	  the	  TCR-­‐CD3	  complex	  on	  infected	  cells	  (Wang	  et	  
al.,	   2000).	   The	   degree	   of	   CD8+	   T-­‐cell	   activation	   is	   also	   dependent	   on	   whether	  
these	  cells	  are	  stimulated	  by	  the	  dominant	  or	  subdominant	  HIV	  epitopes	  (Kaul	  et	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al.,	   2001a;	   Kiepiela	   et	   al.,	   2007).	   CD8+	   T-­‐cells	   specific	   for	   the	   more	   dominant	  
epitopes,	  such	  as	  p24	  Gag,	  have	  a	  more	  diverse	  Vβ	  repertoire	  than	  those	  which	  
recognise	  the	   less	  dominant	  epitopes	   like	  Env,	  and	  the	  degree	  of	  activation	  and	  
clonal	  expansion	  may	  therefore	  be	  greater	  for	  the	  dominant	  epitopes	  than	  for	  the	  
sub-­‐dominant	   ones	   (Kiepiela	   et	   al.,	   2007).	   In	   addition,	   the	   frequencies	   of	  
multifunctional	  CD8+	  T-­‐cells	  are	  higher	   for	   the	   immunodominant	  epitopes	   than	  
for	  the	  subdominant	  ones	  (Betts	  et	  al.,	  2006).	  	  
	  
In	  HIV-­‐infected	  individuals	  on	  HAART,	  one	  of	  the	  triggers	  of	   immune	  activation	  
could	  be	  ongoing	  HIV	  replication	  below	  the	  detection	  limit	  of	  clinically	  available	  
assays	  (Maldarelli	  et	  al.,	  2007).	  In	  addition,	  intensification	  of	  the	  treatment	  does	  
not	   seem	   to	   reduce	   the	   level	  of	   immune	  activation,	   except	   for	  only	  one	  clinical	  
trial	  with	   raltegravir	  which	   showed	   a	   significant	   reduction	   in	   T-­‐cell	   activation	  
after	  48	  weeks	  (Llibre	  et	  al.,	  2012).	  	  
	  
1.5.1.2. Bystander	  activation	  of	  T-­‐cells	  
HIV	  has	  also	  been	  proposed	  to	  cause	  immune	  activation	  via	  indirect	  mechanisms	  
(reviewed	  by	  Moir	  et	  al.,	  2011	  &	  Hunt,	  2012).	   It	   is	  a	  well-­‐documented	  fact	   that	  
the	  direct	  killing	  of	  HIV-­‐infected	  cells	  is	  not	  the	  predominant	  mechanism	  for	  the	  
massive	   depletion	   of	   CD4+	   T-­‐cells	   that	   happens	   during	   the	   chronic	   phase	   of	  
infection	   (reviewed	   by	  Douek	   et	   al.,	   2003;	  Doitsh	   et	   al.,	   2014).	   Several	   studies	  
have	   also	   shown	   that	   HIV-­‐specific	   cellular	   responses	   can	   induce	   activation	   of	  
surrounding	   immune	  cells,	  an	  effect	   termed	  as	  bystander	  effect	  (Li	  et	  al.,	  2005;	  
reviewed	   by	   Brenchley	   &	   Douek,	   2008	   &	   Moir	   et	   al.,	   2011).	   This	   includes	  
activation	   of	   cells	   through	  membrane-­‐bound	  molecules	   that	   bind	   to	   receptors	  
other	  than	  TCRs	  or	  through	  soluble	  factors.	  (reviewed	  by	  Lawn	  &	  Butera,	  2001;	  
Bangs	   et	   al.,	   2006).	   The	   depletion	  mainly	   occurs	   due	   to	   the	   activation-­‐induced	  
cell	   death	   of	   uninfected	   cells	   (Silvestri	   and	   Feinberg,	   2003).	   HIV	   infection	   has	  
been	   associated	  with	   changes	   in	   the	   inflammatory	  milieu	   and	   this	   alone	   could	  
lead	  to	  bystander	  activation.	  Certain	  cytokines	  (including	  IL-­‐2,	  IL-­‐6,	  IL-­‐7	  and	  IL-­‐
15)	  are	  capable	  of	  making	  resting	  cells	  more	  susceptible	  to	  HIV	  infection	  (Clerici	  
and	   Shearer,	   1993;	   Unutmaz	   et	   al.,	   1999).	   Type	   I	   IFNs	   and	   lipopolysaccharide	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(LPS)	  have	  also	  been	  shown	  to	  be	  potent	  cell	  activators	  of	  naïve	  and	  memory	  T-­‐
cells	  in	  a	  murine	  models	  and	  in	  humans	  (Tough	  et	  al.,	  1996;	  Kamath	  et	  al.,	  2005;	  
De	  et	  al.,	  2005).	  	  
	  
1.5.1.3. Microbial	  translocation	  induces	  immune	  activation	  
HIV	   infection	   has	   been	   linked	   to	   gut	   epithelial	   cell	   apoptosis	   and	   barrier	  
dysfunction,	   as	   a	   result	   of	   the	  massive	  CD4+	  T-­‐cell	   depletion	   that	   occurs	   in	   the	  
gut-­‐associated	  lymphoid	  tissue	  (Jiang	  et	  al.,	  2009;	  reviewed	  by	  Klatt	  et	  al.,	  2013).	  
This	   phenomenon,	   in	   conjunction	   with	   the	   preferential	   loss	   of	   Th17	   cells,	   is	  
termed	   microbial	   translocation.	   Because	   of	   this	   damage	   to	   the	   gut	   epithelial	  
barrier,	   there	   is	   an	   increased	   absorption	   of	   microbial	   products	   systemically	  
(such	  as	  LPS)	  across	  the	  damaged	  mucosal	  barrier,	  and	  increased	  concentration	  
of	   these	   microbial	   products	   in	   blood	   has	   been	   implicated	   in	   chronic	   T-­‐cell	  
activation	   in	   blood,	   and	   the	   eventual	   loss	   of	   CD4+	   T-­‐cell-­‐mediated	   immunity	  
(Brenchley	   et	   al.,	   2006).	   Subsequent	   studies	   have	   confirmed	   that	   levels	   of	  
microbial	   products	   in	   blood	   decrease	   in	   HIV-­‐infected	   individuals	   who	   have	  
initiated	   HAART,	   but	   these	   do	   not	   normalise	   to	   pre-­‐HIV-­‐infection	   levels	   and	  
continue	  to	  induce	  systemic	  monocyte	  and	  T-­‐cell	  activation	  as	  well	  as	  poorer	  T-­‐
cell	  recovery	  (Jiang	  et	  al.,	  2009;	  Marchetti	  et	  al.,	  2008).	  	  
	  
1.5.1.4. Co-­‐infections	  leading	  to	  sustained	  immune	  activation	  
HIV-­‐infected	   individuals	   often	   have	   other	   chronic	   viral	   infections	   which	   get	  
worse	   during	   untreated	   HIV	   infection,	   and	   these	   may	   exacerbate	   the	   level	   of	  
systemic	   immune	   activation.	   The	   most	   common	   co-­‐infection	   evident	   during	  
untreated	  HIV	   infection	   is	   chronic	   CMV	   infection,	  which	   accounts	   for	  ~10%	  of	  
circulating	  memory	  T-­‐cell	   specificities	   in	  HIV	  uninfected	   individuals	   (Sylwester	  
et	  al.,	  2005).	  In	  HIV-­‐positive	  individuals,	  even	  if	  they	  have	  been	  on	  HAART	  for	  a	  
long	  period	  of	  time,	  the	  CMV	  virus	  generates	  higher	  frequencies	  of	  CMV-­‐specific	  
T-­‐cell	   responses,	   contributing	   to	   the	   inflammatory	   environment	   (Naeger	   et	   al.,	  
2010).	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1.5.2. Role	  of	  mucosal	  antigens	  in	  chronic	  immune	  activation	  
Depletion	  of	  mucosal	  cells	   is	  rapidly	  followed	  by	  a	  state	  of	  generalised	  immune	  
activation	  (Brenchley	  et	  al.,	  2004;	  Mattapallil	  et	  al.,	  2005;	  reviewed	  by	  Xu	  et	  al.,	  
2013).	  This	  is	  categorised	  by	  increased	  numbers	  of	  T-­‐cells	  expressing	  activation	  
markers,	   higher	   frequencies	   of	   memory	   T-­‐cells,	   a	   faster	   rate	   of	   B-­‐	   and	   T-­‐cell	  
turnover	   and	   increased	   levels	   of	   pro-­‐inflammatory	   cytokines	   (reviewed	   by	  
Grossman	   et	   al.,	   2006).	   In	  mucosal	   tissues,	   all	   T-­‐cells	   -­‐	   not	   just	  HIV-­‐specific	   T-­‐
cells	  –	  become	  activated	  during	  HIV	  infection,	  although	  the	  exact	  reasons	  for	  this	  
are	   not	   clear.	   Grossman	   et	   al.	   (2006)	   suggested	   that	   the	   increased	   turnover	   of	  
mucosal	   T-­‐cells	   may	   be	   a	   result	   of	   recurrent	   antigenic	   stimulation	   and	   not	   a	  
homeostatic	   response	   to	   the	   killing	   of	   infected	   or	   uninfected	   cells.	   They	   also	  
propose	   that	  chronic	  activation	  may	   induce	  bursts	  of	   lymphocyte	  proliferation,	  
differentiation	  and	  death	  (Grossman	  et	  al.,	  2006).	  These	  overlapping	  bursts	  may	  
regenerate	  the	  pool	  of	  resting	  memory	  T-­‐cells	  and	  thereby	  generate	  a	  variety	  of	  
short-­‐lived	   but	   differentiated	   effector	   T-­‐cells	   which	   can	   migrate	   to	   mucosal	  
effector	  sites	  (Picker	  et	  al.,	  2004).	  	  
	  
1.5.3. Immune	  activation	  and	  inflammation	  
In	  addition	   to	  HIV	  antigens,	   the	  production	  of	   type	   I	   IFNs,	  mainly	  produced	  by	  
plasmacytoid	  DCs,	  has	  been	  proposed	  to	  be	  a	  major	  trigger	  of	  immune	  activation	  
(reviewed	   by	   Reizis	   et	   al.,	   2011).	   Activated	   plasmacytoid	   DCs	   and	   IFN-­‐α	   have	  
been	  shown	  to	  significantly	  contribute	  to	  chronic	  immune	  activation	  (Martinson	  
et	  al.,	  2010).	  High	  levels	  of	  pro-­‐inflammatory	  cytokines	  (such	  as	  TNF-­‐α,	  IL-­‐6,	  IL-­‐
1β)	  as	  well	  as	  chemokines	  (such	  as	  MIP-­‐1α,	  MIP-­‐1β	  and	  RANTES)	  are	  found	  both	  
in	  blood	  and	  mucosal	   tissues	  during	   the	   early	   stages	  of	  HIV	   infection	   (Freer	  &	  
Matteucci,	  2009;	  reviewed	  by	  Shey	  et	  al.,	  2013).	  	  
	  
1.5.4. T-­‐cell	  turnover	  during	  HIV	  infection	  
The	  intracellular	  nuclear	  protein	  Ki67	  is	  necessary	  for	  cellular	  proliferation	  and	  
is	   a	   useful	  marker	   for	   T-­‐cell	   proliferation	   (Scholzen	   and	   Gerdes,	   2000).	   In	   the	  
context	   of	   HIV	   infection,	   Ki67	   expression	   has	   also	   been	   used	   as	   a	   marker	   of	  
cellular	  activation	  (Sachsenberg	  et	  al.,	  1998).	  In	  a	  longitudinal	  study	  carried	  out	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by	  Al-­‐Harthi	  et	  al.	  (2007)	  comparing	  CD4+	  T-­‐cell	  dynamics	  during	  acute	  to	  early-­‐
treated	  HIV	  infection,	  they	  reported	  a	  significant	  reduction	  in	  the	  expression	  of	  
Ki67	   by	   CD4+	   memory	   and	   naïve	   T-­‐cells	   among	   the	   treated	   compared	   to	  
untreated	  individuals.	  These	  findings	  suggested	  that	  the	  increase	  in	  Ki67	  in	  CD4+	  
memory	  T-­‐cells	   is	  mainly	  driven	  by	   the	   individual’s	   viral	   load	   (Al-­‐Harthi	   et	   al.,	  
2007).	   In	   CD8+	   T-­‐cells,	   Hazenberg	   et	   al.	   (2000)	   reported	   that	   a	   decrease	   in	  
plasma	   viral	   load	   induced	   by	   HAART	   was	   associated	   with	   a	   decrease	   in	   the	  
frequencies	  of	  dividing	  CD8+	  T-­‐cells.	  They	  concluded	  that	  the	  T-­‐cell	  proliferation	  
seen	  during	  a	  chronic	  HIV	   infection	  was	  a	  consequence	  of	  generalised	   immune	  
activation	  (Hazenberg	  et	  al.,	  2000).	  	  
	  
1.5.5. Evidence	  for	  the	  role	  of	  immune	  activation	  in	  HIV/SIV	  pathogenesis	  
1.5.5.1. Evidence	  from	  natural	  hosts	  of	  SIV	  infection	  	  
Studies	  in	  non-­‐human	  primates	  showed	  that	  natural	  hosts	  of	  SIV	  infections	  (such	  
as	   sooty	   mangabeys	   and	   African	   green	   monkeys)	   often	   had	   lower	   levels	   of	  
immune	  activation	  despite	  having	  higher	  viral	  loads	  than	  non-­‐natural	  hosts	  such	  
as	  rhesus	  macaques	  (Broussard	  et	  al.,	  2001).	  	  In	  these	  natural	  hosts,	  chronic	  SIV	  
infection	  was	  accompanied	  by	  low	  levels	  of	  CD4+	  and	  CD8+	  T-­‐cell	  activation	  and	  
proliferation	  (Chakrabarti	  et	  al.,	  2000;	  Silvestri	  et	  al.,	  2003),	  reduced	  levels	  of	  T-­‐
cell	  apoptosis	  (Kim	  et	  al.,	  2007),	  and	  conserved	  bone	  marrow,	  thymus	  and	  lymph	  
node	   T-­‐cell	   regenerative	   capacity	   (Muthukumar	   et	   al.,	   2005;	   Silvestri	   et	   al.,	  
2003).	  In	  addition,	  the	  overall	  levels	  of	  T-­‐cell	  activation	  and	  proliferation	  in	  acute	  
SIV	  infections	  in	  sooty	  mangabeys	  were	  much	  lower	  than	  those	  seen	  during	  the	  
acute	   phase	   of	   pathogenic	   SIV	   infections	   in	   rhesus	   macaques.	   Furthermore,	  
Pandrea	  et	  al.	  (2008)	  showed	  that	  immune	  activation	  could	  be	  induced	  in	  African	  
green	  monkeys	  using	  microbial	  products	  to	  mimic	  microbial	  translocation.	  This	  
induced	   immune	   activation	   in	   African	   green	  monkeys	   resulted	   in	   a	   significant	  
level	   of	  mucosal	   CD4+	   T-­‐cell	   loss	   and	   a	   rise	   in	   viral	   loads,	   confirming	   that	   the	  
levels	   of	   immune	   activation	   and	   proliferation	   of	   target	   cells	   have	   a	   marked	  
impact	   on	   the	   pathogenicity	   of	   SIV/HIV	   infections.	   Pandrea	   et	   al.	   (2008)	  
suggested	  that	  therapeutic	  strategies	  aimed	  at	  reducing	  immune	  activation,	  used	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in	  conjunction	  with	  HAART,	  might	  be	  effective	  in	  halting	  the	  progression	  to	  AIDS	  
in	  chronically	  infected	  people.	  	  
	  
1.5.5.2. HIV-­‐2	  infection	  
Compared	   to	   infections	   with	   HIV-­‐1,	   HIV-­‐2	   infection	   is	   characterised	   by	  
significantly	  slower	  rates	  of	  progression	  and	  HIV-­‐2-­‐infected	  individuals	  are	  able	  
to	   maintain	   higher	   CD4	   counts	   compared	   to	   HIV-­‐1-­‐infected	   individuals	  
(Rowland-­‐Jones	   and	   Whittle,	   2007).	   Studies	   have	   shown	   that	   the	   lower	  
pathogenicity	  of	  HIV-­‐2	  was	  due	  to	  lower	  levels	  of	  lymphocyte	  activation	  (Michel	  
et	   al.,	   2000;	   Jaffar	   et	   al.,	   2005).	   Michel	   et	   al.	   (2000)	   reported	   that	  markers	   of	  
immune	   activation	   (β2-­‐microglobulin	   and	   HLA-­‐DR),	   which	   are	   associated	  with	  
disease	  progression	  in	  both	  HIV-­‐1	  and	  HIV-­‐2	  infected	  individuals,	  were	  lower	  in	  
HIV-­‐2	  than	  HIV-­‐1	  infected	  individuals.	  	  
	  
1.5.5.3. Methods	  to	  modulate	  immune	  activation	  
Statins	  are	  anti-­‐cholesterol	  drugs,	  which	  have	  been	   found	   to	  have	   in-­‐vitro	   anti-­‐
inflammatory	  and	  potential	  anti-­‐viral	  effects	  (reviewed	  by	  Jain	  &	  Ridker,	  2005).	  
Ganesan	  et	   al.	   (2011)	  evaluated	   the	  effect	  of	   atorvastatin	  on	   the	   level	  of	  HIV-­‐1	  
RNA	   and	   T-­‐cell	   activation	   markers	   in	   the	   blood	   of	   HIV-­‐infected	   individuals.	  
Despite	   finding	   no	   change	   in	   the	   plasma	   HIV-­‐1	   RNA	   levels,	   they	   reported	   a	  
significant	  decrease	  in	  T-­‐cell	  activation,	  especially	  in	  the	  CD8+	  T-­‐cell	  population	  
(Ganesan	   et	   al.,	   2011).	   The	   antimalarial	   drug	   hydroxychloroquine	   is	   known	   to	  
have	   immunomodulatory	   properties	   and	   is	   able	   to	   decrease	   inflammatory	  
cytokine	   production	   (Karres	   et	   al.,	   1998).	   Murray	   et	   al.	   (2010)	   showed	   that	  
chloroquine-­‐treated	   HIV-­‐infected	   individuals	   had	   decreased	   levels	   of	   memory	  
CD8+	  T-­‐cells	  activation	  (measured	  by	  CD38	  and	  HLA-­‐DR	  expression),	  decreased	  
CD4+	  and	  CD8+	  T-­‐cell	  proliferation	  and	  lower	  levels	  of	  LPS	  in	  plasma	  compared	  
to	  those	  not	  being	  treated	  with	  chloroquine.	  They	  reported	  no	  change	  in	  the	  level	  
of	   plasma	   HIV-­‐1	   RNA	   (Murray	   et	   al.,	   2010).	   Similarly,	   another	   drug	   called	  
Leflunomide,	   an	   anti-­‐rheumatoid	   arthritis	   drug	   that	   inhibits	   pyrimidine	  
synthesis,	  has	  been	  tested	  for	  its	  ability	  to	  reduce	  immune	  activation	  during	  HIV	  
infection	  (Read	  et	  al.,	  2010).	  HIV-­‐infected	   individuals	   treated	  with	  Leflunomide	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had	   reduced	   numbers	   of	   proliferating	   T-­‐cells,	   lower	   frequencies	   of	   activation	  
marker	   (HLA-­‐DR/CD38)	   expression	   by	   CD8+	   T-­‐cells	   and	   lower	   levels	   of	   co-­‐
receptor	   (CCR5	   and	   CXCR4)	   expression	   on	   both	   CD4+	   and	   CD8+	   T-­‐cells	   than	  
untreated	   individuals	   (Read	   et	   al.,	   2010).	   Therapy	   with	   prednisolone,	   a	  
glucocorticoid	  used	  to	  treat	  various	  inflammatory	  and	  auto-­‐immune	  conditions,	  
during	  HIV	   infection	  was	   found	   to	   reduce	  activation	  of	  CD8+	  T-­‐cells	   (measured	  
by	  CD38	  expression)	  and	  reduce	  the	  concentration	  of	  molecules	  known	  to	  drive	  
immune	   activation	   (including	   soluble	   CD14,	   LPS-­‐binding	   protein,	   soluble	  
urokinase	   plasminogen	   activator	   receptor,	   and	   soluble	   CD40L;	   Kasang	   et	   al.,	  
2012).	  	  
	  
1.6. HIV	  infection	  and	  the	  female	  genital	  tract	  
1.6.1. Anatomy	  of	  the	  female	  genital	  tract	  	  
The	   female	  genital	   tract	   consists	  of	   two	  main	   types	  of	  mucosal	   tissues	  –	   type	   I	  
and	   type	   II	  mucosa	   (reviewed	  by	  Xu	   et	   al.,	   2013).	   The	  upper	   genital	   tract	   (the	  
endocervix	  and	  endometrium)	  is	  made	  up	  of	  the	  type	  I	  mucosal	  surface,	  which	  is	  
covered	  with	  a	  single	   layer	  of	  columnar	  epithelial	  cells	  with	  tight	   junctions	  and	  
high	  levels	  of	  IgA	  (reviewed	  by	  Xu	  et	  al.,	  2013;	  Figure	  1.7).	  In	  contrast,	  the	  lower	  
genital	   tract	   (comprising	   the	   vagina	   and	   ectocervix)	   is	   made	   up	   of	   type	   II	  
mucosal	   tissues,	   with	   stratified	   squamous	   epithelia	   that	   lack	   luminal	   IgA	   and	  
mucosa-­‐associated	  lymphoid	  tissues	  (reviewed	  by	  Xu	  et	  al.,	  2013).	  	  
	  
While	   the	   mucosa	   of	   the	   gastrointestinal	   tract	   and	   the	   lungs	   are	   lined	   with	   a	  
single	   layer	   of	   epithelial	   cells	   (necessary	   for	   food	   absorption	   and	   air	   exchange	  
respectively),	  the	  cervicovaginal	  mucosa	  of	  the	  female	  reproductive	  tract	  differs	  
in	  that	  it	  is	  covered	  with	  multi-­‐layered	  stratified	  squamous	  epithelia.	  In	  addition,	  
the	  mucus	  composition	  within	  the	   female	  genital	   tract,	  commensal	  microbiome	  
and	  local	  immune	  responses	  all	  differ	  from	  the	  other	  mucosal	  tissues	  (reviewed	  
by	  Iwasaki,	  2010).	  The	  cervical	  transformation	  zone,	  which	  marks	  the	  transition	  
between	  the	  ectocervix	  and	  the	  endocervix,	  is	  the	  part	  of	  the	  female	  genital	  tract	  
most	   densely	   populated	   with	   T-­‐cells	   and	   APCs	   (reviewed	   by	   Iwasaki,	  
2010;Figure	   1.7).	   The	   rest	   of	   the	   vaginal	   mucosa	   contains	   much	   lower	  
 25 
frequencies	  of	  these	  immune	  cells.	  The	  density	  of	  immune	  and	  HIV	  target	  cells	  at	  
the	  cervical	   transformation	  zone	  has	   led	  many	   to	   suggest	   that	   this	   site	  may	  be	  
the	  major	  site	  for	  both	  cell-­‐mediated	  immune	  responses	  and	  vulnerability	  to	  HIV	  
infection	   (Pudney	  et	  al.,	  2005;	  Kaushic,	  2009;	   reviewed	  by	   Iwasaki,	  2010).	  The	  
distribution	  of	  epithelial	  cells	  in	  the	  genital	  tract	  is	  shown	  in	  figure	  1.7.	  	  
	  
Within	   the	   female	   genital	   tract,	   the	   relative	   susceptibility	   of	   the	   vaginal,	  
ectocervical	  and	  endocervical	  mucosa	  to	  HIV	  infection	  is	  unclear	  although	  some	  
have	  suggested	  that	  transmission	  can	  potentially	  occur	  in	  all	  three	  areas	  (Hladik	  
and	   Hope,	   2009).	   HIV	   infection	   could	   occur	   via	   translocation	   of	   HIV	   particles	  
across	  the	  columnar	  epithelium	  of	  the	  endocervical	  canal,	  which	  can	  then	  infect	  
sub-­‐epithelial	   mononuclear	   cells	   (Mestecky	   et	   al.,	   2009).	   The	   single	   layer	   of	  
polarised	   epithelium	   of	   the	   endocervix	   may	   be	   more	   susceptible	   to	   HIV	  
transmission	  than	  the	  non-­‐polarised	  multilayer	  ectocervix	  and	  vagina	  but	  factors	  
like	   micro-­‐ulcerations,	   breaks	   in	   the	   epithelium	   or	   co-­‐infections	   with	   sexually	  
transmitted	   diseases	   may	   increase	   the	   risk	   of	   transmission	   at	   these	   multi-­‐
layered	  sites	  (Broliden	  et	  al.,	  2008;	  Pope	  and	  Haase,	  2003).	  However,	  the	  vaginal	  
wall	  and	  the	  ectocervix	  have	  a	  much	  larger	  surface	  area	  than	  the	  endocervix	  and	  
breaches	   in	   their	   epithelium	  would	   also	   allow	   the	   penetration	   of	   HIV	   into	   the	  
mucosa	  (Hladik	  and	  Hope,	  2009).	  Stromal	  DCs	  have	  also	  been	  implicated	  in	  HIV	  
transmission:	   in	   addition	   to	   expressing	   CD4,	   they	   express	   CCR5	   (so	   can	   be	  
productively	   infected;	   Prakash	   et	   al.,	   2004)	   and	   also	   express	   dendritic	   cell-­‐
specific	   intercellular	   adhesion	   molecule-­‐3-­‐grabbing	   non-­‐integrin	   (DC-­‐SIGN;	  
which	   can	   bind	   and	   internalise	   HIV	   particles	   into	   DCs	   without	   causing	   a	  
productive	  infection;	  Jameson	  et	  al.,	  2002).	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Figure	   1.7.	   Structural	   characteristics	   of	   the	   female	   genital	   tract	   mucosa.	   The	   female	  
genital	   tract	  consists	  of	   the	  upper	  genital	   tract	  (uterus	  and	  endocervix)	  which	   is	  made	  
up	   of	   type	   I	   epithelia	   and	   the	   lower	   genital	   tract	   (vagina	   and	   ectocervix),	  made	   up	   of	  
type	   II	   epithelia.	   The	   transformation	   zone	   forms	   the	   boundary	   joining	   the	   columnar	  
epithelial	  cells	  and	  the	  stratified	  squamous	  epithelium	  (adapted	  from	  Iwasaki,	  2010).	  	  
	  
1.6.2. Determinates	  in	  the	  genital	  mucosa	  on	  rate	  of	  HIV	  transmission	  
The	  vast	  majority	  of	  new	  HIV	  infections	  occur	  via	  sexual	  transmission,	  involving	  
either	  the	  cervicovaginal	  or	  rectal	  mucosa	  in	  adults	  (reviewed	  by	  Hladik	  &	  Hope,	  
2009).	  Studies	  have	  proposed	   that	   rates	  of	  male-­‐to-­‐female	   transmission	  of	  HIV	  
are	   higher	   than	   female-­‐to-­‐male	   rates	   (Boily	   et	   al.,	   2009;	   Hughes	   et	   al.,	   2012).	  
Despite	  these	  estimates,	  others	  have	  argued	  that	  transmission	  across	  the	  female	  
cervicovaginal	   mucosa	   is	   relatively	   inefficient	   because	   of	   the	   multi-­‐layered	  
squamous	  epithelium	  that	  protects	  the	  vaginal	  vault	   in	  healthy	  women	  with	  no	  
ulcerative	  or	  inflammatory	  sexually	  transmitted	  infections	  (Hughes	  et	  al.,	  2012).	  
A	   study	   in	   HIV-­‐1	   serodiscordant	   couples	   from	   Africa	   estimated	   that	   as	   few	   as	  
1/900	   unprotected	   sexual	   exposures	   actually	   resulted	   in	   HIV	   transmission	  
(Hughes	  et	  al.,	  2012).	  The	  rate	  of	  HIV	  transmission	  was	  shown	  to	  depend	  on	  viral	  







2003).	   In	   women,	   cervicovaginal	   mucus	   acts	   as	   a	   physical	   barrier	   to	   HIV,	  
blocking	   the	   movement	   of	   viral	   particles	   and	   preventing	   contact	   of	   infectious	  
particles	  with	  the	  female	  cervicovaginal	  mucosa	  (Shukair	  et	  al.,	  2013).	  	  
	  
Although	  an	  HIV-­‐infected	  individual	  remains	  “infectious”	  to	  their	  sexual	  partners	  
throughout	  the	  course	  of	  their	  disease,	  several	  studies	  have	  suggested	  that	  rates	  
of	  transmission	  are	  higher	  during	  the	  acute	  (primary)	  and	  late	  stages	  of	  an	  HIV	  
infection	   because	   of	   the	   increased	   viral	   loads	   during	   these	   stages	   of	   disease	  
(Anderson	  and	  May,	  1988;	  Longini	  et	  al.,	  1989).	  A	  landmark	  study	  by	  Wawer	  et	  
al.	   (2005)	   in	   Uganda	   showed	   that	   the	   probability	   of	   HIV	   transmission	   to	  
uninfected	   partners	   during	   the	   first	   five	   months	   of	   infection	   was	   about	   8-­‐10	  
times	   higher	   than	   during	   the	   chronic	   phase	   and	   that	   the	   probability	   of	  
transmission	   also	   increased	   by	   4-­‐8	   times	   during	   the	   two	   years	   before	   death	  
(Wawer	  et	  al.,	  2005).	  	  
	  
Use	  of	   long-­‐activing	   injectable	  hormonal	   contraception	  methods	   in	  women	  has	  
been	  shown	  to	  almost	  double	  the	  risk	  of	  vaginal	  HIV	  transmission	  (Heffron	  et	  al.,	  
2012).	  Studies	  conducted	  in	  primates	  infected	  vaginally	  with	  SIV	  have	  suggested	  
that	   this	   most	   likely	   happens	   due	   to	   the	   thinning	   of	   the	   vaginal	   or	   the	  
ectocervical	  epithelium	  (Veazey	  et	  al.,	  2012).	  	  
	  
1.6.3. Anti-­‐viral	  immunity	  in	  the	  female	  genital	  tract	  
Because	  HIV	   transmission	   is	   estimated	   to	  be	   relatively	   inefficient,	  with	  <1%	  of	  
unprotected	  sexual	  exposures	  resulting	  in	  a	  productive	  HIV	  infection,	  some	  have	  
suggested	  that	  HIV	  must	  be	  quite	  vulnerable	  during	  the	  new	  infection	  of	  a	  host	  
(Kaul	   et	   al.,	   2008).	   The	   virus	   must	   encounter	   several	   barriers	   before	  
transmission	  can	  occur.	  Together,	  the	  vaginal	  or	  cervical	  epithelial	  layer,	  mucus	  
in	   the	   genital	   tract,	   acidic	   pH	   and	   innate	   immune	   responses	   generated	   by	  
commensals	   (via	   the	   production	   of	   anti-­‐microbial	   components)	   participate	   to	  
protect	  against	  HIV	  infection	  in	  the	  genital	  tract	  (Fredricks	  et	  al.,	  2005;	  Shukair	  
et	  al.,	  2013).	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In	  response	  to	  HIV	  infection,	   the	  squamous	  and	  columnar	  epithelial	  cells	  of	   the	  
genital	  mucosa	   (shown	   in	   figure	   1.8)	   are	   known	   to	   produce	   pro-­‐inflammatory	  
cytokines	   (such	   as	   IL-­‐6,	   IL-­‐8,	   and	   IFN-­‐β)	   and	   anti-­‐microbial	   peptides	   (such	   as	  
defensins;	  Kayisli	  et	  al.,	  2002;	  Valore	  et	  al.,	  1998).	  Tissue-­‐resident	  macrophages,	  
dendritic	  cells	  and	  γδ	  T-­‐cells	  (figure	  1.8)	  also	  secrete	  as	  cytokines	  and	  type	  I	  IFNs	  
(reviewed	  by	  Iwasaki,	  2010).	  γδ	  T-­‐cells	  within	  the	  mucosa	  have	  also	  been	  shown	  
to	  be	  able	  to	  lyse	  HIV-­‐infected	  target	  cells	  and	  produce	  suppressor	  factors	  such	  
as	   RANTES,	   MIP-­‐1α	   and	   MIP-­‐1β,	   which	   bind	   to	   CCR5	   and	   reduce	   SIV/HIV	  
infection	  (Lehner	  et	  al.,	  2000).	  	  
	  
DCs	  within	  the	  genital	  mucosa	  have	  been	  proposed	  to	  be	  the	  link	  between	  innate	  
and	   adaptive	   immune	   responses	   as	   they	   most	   efficiently	   present	   the	   foreign	  
antigens	   to	   naïve	   T-­‐cells	   (Cunningham	   et	   al.,	   2008).	   The	   female	   genital	   tract	  
contains	   several	   subsets	   of	   DCs,	   including	   submucosal	   plasmacytoid,	   myeloid	  
DCs	  and	  Langerhans	   cells	   (figure	  1.8;	  Cunningham	  et	   al.,	   2008).	   Instead	  of	   just	  
priming	   T-­‐cell	   responses	   during	   HIV	   infection,	   DC	   subsets,	   which	   express	   DC-­‐
SIGN,	   can	   also	   cause	   infection	   because	   they	   can	   internalise	   HIV	  without	   being	  
infected	   themselves	   and	   then	   transport	   the	   endocytosed	   viral	   particles	   across	  
the	   epithelium	  and	   transmit	   them	   to	  CD4+	  T-­‐cells	   (Ballweber	   et	   al.,	   2011).	  DC-­‐
SIGN	   is	   a	   membrane	   protein	   that	   binds	   to	   the	   envelope	   of	   HIV	   and	   causes	  
adhesion	   to	   DCs	   and	   the	   DC-­‐SIGN+	   DCs	   are	  mainly	   found	   in	   the	   sub-­‐epithelial	  
lamina	  propria	  (Geijtenbeek	  et	  al.,	  2000;	  Jameson	  et	  al.,	  2002).	  	  
	  
At	   mucosal	   surfaces	   such	   as	   the	   genital	   tract,	   induction	   of	   T-­‐cell	   responses	   is	  
essential	  for	  protection	  against	  infections,	  with	  CD8+	  T-­‐cells	  mainly	  participating	  
in	   viral	   clearance	   (Reynolds	   et	   al.,	   2005;	   Veazey	   et	   al.,	   2003)	   and	   CD4+	   T-­‐cells	  
mainly	  involved	  in	  host	  protection	  (Mascola	  &	  Montefiori,	  2010;	  Schoenberger	  et	  
al.,	   1998;	   reviewed	   by	   Iwasaki,	   2010).	   Synergy	   between	   CD4+	   and	   CD8+	   T-­‐cell	  
responses	  are	  essential	  during	  HIV	  infection	  as	  CD8+	  T-­‐cells	  play	  a	  major	  role	  in	  
controlling	  infection,	  although	  they	  are	  dependent	  on	  the	  functionality	  of	  CD4+	  T-­‐
cells	   for	   help	   during	   their	   priming	   and	   differentiation	   phases	   and	   for	   the	  
formation	   of	   memory	   T-­‐cells,	   and	   (reviewed	   by	   Iwasaki,	   2010).	   Figure	   1.8	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summarises	   the	   various	   innate	   and	   adaptive	   immune	   responses	   involved	   in	  
eliminating	  an	  infection	  in	  the	  genital	  tract.	  	  
	  
	  
Figure	  1.8.	  Anti-­‐viral	  immune	  responses	  in	  the	  female	  genital	  tract	  during	  HIV	  infection.	  
The	   transformation	   zone	   between	   the	   columnar	   epithelium	   of	   the	   endocervical	   canal	  
and	   endocervix	   and	   the	   squamous	   epithelium	   of	   the	   ectocervix	   form	   the	   boundary	  
between	   these	   two	   tissues.	   During	   infection,	   epithelial	   cells	   and	   innate	   leukocytes	  
secrete	   type	   I	   IFNs,	   cytokines	   and	   chemokines	   to	   recruit	   DCs,	   neutrophils,	  monocytes	  
and	   NK	   cells.	   Viral	   particles	   are	   endocytosed	   by	   DCs	   and	   presented	   to	   naïve	   T-­‐cells.	  
Activated	  T-­‐cells	  traffic	  to	  the	  site	  of	   infection.	  Virus-­‐specific	  IgG	  is	  transcytosed	  to	  the	  
vaginal	  lumen	  for	  additional	  protection	  (taken	  from	  Kumamoto	  &	  Iwasaki,	  2012).	  	  
	  
1.6.4. Mucosal	  CD4+	  T-­‐cell	  depletion	  during	  HIV	  infection	  
Within	   the	  genital	  mucosa,	  HIV	  has	  been	  proposed	   to	  be	   able	   to	   infect	   various	  
CD4+	  immune	  subsets	  expressing	  CCR5	  (or	  CXCR4),	  including	  lymphocytes,	  DCs,	  
and	   other	   cells	   of	   the	   macrophages/monocyte	   lineage	   throughout	   the	   lamina	  
propria	  and	  epithelia	  (reviewed	  by	  Hladik	  &	  McElrath,	  2009).	  Although	  the	  other	  
CD4	  expressing	  immune	  subsets	  have	  been	  suggested	  to	  be	  infectable	  with	  HIV,	  
it	  is	  widely	  accepted	  that	  CD4+	  T-­‐cells	  are	  likely	  to	  be	  the	  initial	  and	  main	  target	  
for	  HIV	  infection	  (McKinnon	  and	  Kaul,	  2012).	  CD4+	  T-­‐cells	   in	  the	  female	  genital	  
tract	   are	   dispersed	   through	   the	   sub-­‐mucosa	   of	   the	   vagina,	   ectocervix	   and	  
endocervix	   (reviewed	   by	   Shacklett,	   2009).	   They	   are	   predominantly	   activated	  
memory	   T-­‐cells	   that	   express	   high	   levels	   of	   CCR5	   compared	   to	   T-­‐cells	   in	   the	  
peripheral	  blood	  (Prakash	  et	  al.,	  2001;	  Rancez	  et	  al.,	  2012).	  In	  vitro	  studies	  using	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human	   cervical	   explant	   tissue	   have	   shown	   that	  HIV	   efficiently	   targets	   CD4+	   T-­‐
cells	   in	   the	   genital	  mucosa	   and	   this	   occurs	   even	   in	   the	   absence	   of	   Langerhans	  
cells	  (Gupta	  et	  al.,	  2002).	  Since	  higher	  frequencies	  of	  activated	  memory	  CD4+	  T-­‐
cells	   reside	  at	  mucosal	  surfaces	   than	   in	  blood,	   it	   is	   important	   to	  study	  mucosal	  
CD4+	  T-­‐cells	   in	   the	   context	   of	   HIV	   infection.	   Studies	   in	   SIV-­‐infected	   macaques	  
have	  shown	  that	  ~60%	  of	  mucosal	  memory	  CD4+	  T-­‐cells	  are	  infected	  in	  the	  first	  
days	  of	  infection,	  in	  contrast	  to	  only	  ~	  1%	  of	  mucosal	  CD4+	  T-­‐cells	  being	  infected	  
during	   the	   chronic	   phase	   (Mattapallil	   et	   al.,	   2005).	   Less	   is	   known	   about	  
proportion	   of	   CD4+	   T-­‐cells	   in	   the	   female	   genital	   tract	   that	   are	   infected	   by	  HIV	  
although	   previous	   studies	   have	   shown	   that	   genital	   tract	   CD4+	   T-­‐cells	   are	  
significantly	   more	   activated	   (expressing	   CD38,	   HLA-­‐DR	   and	   CCR5)	   than	   those	  
circulating	  in	  blood	  (Cohen	  et	  al.,	  2010;	  Prakash	  et	  al.,	  2001).	  	  
	  
Because	  of	   active	  HIV	   infection	  and	  death,	   it	   has	  been	  postulated	   that	  mucosal	  
CD4+	  T-­‐cell	   counts	   remain	   low	   throughout	   the	   course	   of	   HIV	   infection	   (purple	  
line	   in	   figure	  1.9)	  despite	   the	   fact	   that	  activated	  cells	   consistently	   traffic	   to	   the	  
mucosa	   to	  replenish	  CD4+	  T-­‐cell	  numbers	   (Brenchley	  et	  al.,	  2004;	  Mehandru	  et	  
al.,	  2004).	  Activation-­‐induced	  and	  bystander	  cell	  death	  has	  been	  proposed	  as	  the	  
predominant	  mechanisms	   for	   this	   although	   a	   smaller	   proportion	   of	   the	   T-­‐cells	  
are	  directly	  killed	  by	   the	  virus	   (Grossman	  et	  al.,	  2002;	  Hellerstein	  et	  al.,	  2003).	  
Studies	  in	  rhesus	  macaques	  infected	  with	  SIV	  have	  shown	  that	  memory	  CD4+	  T-­‐
cells	  within	  mucosal	   tissues	   have	   a	   half-­‐life	   of	   ~2	  weeks	   (Picker	   et	   al.,	   2004).	  
Effector	  memory	  T-­‐cells	  are	  generated	  by	  long-­‐lived	  cells	  that	  form	  only	  a	  small	  
fraction	   of	   the	   T-­‐cells	   activated	   during	   infection	   (Mehandru	   et	   al.,	   2004).	   As	   a	  
result,	   studies	   have	   shown	   that	   reconstitution	   of	   long-­‐lived	   CD4+	   T-­‐cells	   will	  
inevitably	   be	   very	   slow	   once	   the	   mucosal	   effector	   CD4+	   T-­‐cells	   have	   been	  
depleted	  (Guadalupe	  et	  al.,	  2003;	  Mehandru	  et	  al.,	  2004).	  	  
	  
In	   HIV-­‐infected	   individuals	   on	   HAART,	   studies	   have	   shown	   that	   recovery	   of	  
mucosal	   CD4+	   T-­‐cells	   is	   slower	   than	   that	   observed	   in	   blood	   (reviewed	   by	  
Grossman	  et	  al.,	  2006).	  One	  of	  the	  reasons	  proposed	  was	  that	  the	  regeneration	  of	  
TEM	   happens	   through	   the	   slow	   accumulation	   of	   long-­‐lived	   T-­‐cells,	   which	   are	  
only	  a	  small	  proportion	  of	   the	  recently	  activated	  cells	   (Guadalupe	  et	  al.,	  2003).	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The	  incomplete	  mucosal	  CD4+	  T-­‐cell	  reconstitution	  in	  individuals	  on	  HAART	  has	  
also	  been	  attributed	  to	  several	  other	  factors	  such	  as	  low	  levels	  of	  viral	  replication	  
happening	   below	   detectable	   level,	   the	   persistent	   highly	   inflammatory	  
environment	  in	  the	  genital	  tract	  or	  the	  low	  bioavailability	  of	  some	  antiretroviral	  
drugs	  in	  the	  genital	  mucosa	  (Kwara	  et	  al.,	  2008;	  Mkhize	  et	  al.,	  2010;	  Okoye	  and	  
Picker,	  2013).	  	  
	  
	  
Figure	  1.9.	  Qualitative	  measures	  of	  disease	  progression	  in	  blood	  and	  the	  mucosa.	  In	  the	  
acute	  phase,	  as	  viral	  loads	  go	  up,	  CD4+	  T-­‐cell	  numbers	  go	  down,	  to	  a	  much	  higher	  degree	  
in	  mucosal	   tissues.	   In	   the	   chronic	  phase,	  mucosal	  CD4+	  T-­‐cell	  numbers	   remain	   low.	  At	  
the	  onset	  of	  AIDS,	  changes	  seen	  in	  the	  chronic	  phase	  accelerate,	  the	  cellular	  regenerative	  
capacity	  decreases	  and	  mucosal	  CD4+	  T-­‐cells	  reach	  very	  small	   frequencies	  (taken	  from	  
Grossman	  et	  al.,	  2006).	  	  
	  
1.6.5. Role	  of	  genital	  tract	  inflammation	  during	  an	  HIV	  infection	  
During	   acute	   infection,	   the	   cytokine	   cascade	   that	   is	   mounted	   as	   a	   result	   of	  
infection	  has	  been	  suggested	   to	  have	  contrasting	  effects	   (Li	  et	  al.,	  2009).	  While	  
these	  cytokines	  may	  be	  important	  to	  up-­‐regulate	  anti-­‐viral	  responses	  in	  the	  host	  
to	   control	   viral	   replication,	   they	  have	   also	  been	  proposed	   to	  be	  detrimental	   as	  
they	  increase	  the	  frequency	  of	  target	  cells	  being	  recruited	  to	  the	  site	  of	  infection	  
and	  cause	   the	  activation	  of	  CD4+	  T-­‐cells	  which	  are	   the	  main	   target	  cells	   for	   the	  
virus	   (Li	   et	   al.,	   2009;	   reviewed	   by	   Haase	   et	   al.,	   2010;	   Katsikis	   et	   al.,	   2011).	  
Cytokines	   such	   as	  TNF-­‐α	   can	   increase	   anti-­‐viral	   immunity	   but	   it	   has	   also	   been	  
directly	   linked	   to	   enhanced	   viral	   replication	   through	   the	   induction	   of	   NF-­‐κβ	  
(Osborn	   et	   al.,	   1989;	   Nkwanyana	   et	   al.,	   2009).	   Li	   et	   al.	   (2009)	   showed	   that	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dampening	   inflammation	   in	   the	   genital	   mucosa	   could	   block	   infection	   in	  
macaques	  exposed	  vaginally	  to	  SIV.	  
	  
Changes	   in	   genital	   cytokine	   levels	   during	  HIV	   infection	  may	   influence	   immune	  
responses	  in	  this	  site	  and	  may	  impact	  on	  the	  degree	  of	  viral	  shedding	  into	  genital	  
secretions.	   McGowan	   et	   al.	   (2004)	   reported	   that	   individuals	   with	   elevated	  
concentrations	  of	  TNF-­‐α,	  RANTES,	  IL-­‐1β,	  IFN-­‐γ,	  IL-­‐10,	  and	  IL-­‐12	  in	  their	  genital	  
secretions	  also	  had	  higher	  viral	  loads	  in	  their	  genital	  tracts.	  Similarly,	  Mukura	  et	  
al.	  (2012)	  reported	  significantly	  higher	  levels	  of	  TNF-­‐α	  and	  RANTES,	  but	  also	  IL-­‐
1α,	   eotaxin,	   fractalkine,	   IL-­‐6,	   MCP-­‐1,	   MIP-­‐1α,	   MIP-­‐1β,	   and	   granulocyte-­‐
macrophage	   colony-­‐stimulating	   factor	   (GM-­‐CSF)	   in	   cervicovaginal	   lavage	  
samples	  collected	  from	  women	  who	  had	  detectable	  genital	  viral	  loads	  compared	  
to	  those	  with	  undetectable	  viral	  loads	  (Mukura	  et	  al.,	  2012).	  	  
	  
Pro-­‐inflammatory	  cytokines	  play	  an	  important	  role	  in	  the	  recruitment,	  activation	  
and	  differentiation	  of	  immune	  cells	  in	  the	  genital	  tract	  (Lajoie	  et	  al.,	  2008;	  Li	  et	  
al.,	  2009).	  Women	  chronically	   infected	  with	  HIV	  generally	  have	  higher	   levels	  of	  
pro-­‐inflammatory	   cytokine	   responses	   in	   their	   genital	   tracts	   than	   uninfected	  
women,	  which	  in	  turn	  contribute	  to	  cellular	  recruitment	  (reviewed	  by	  Lajoie	  et	  
al.,	  2012).	  Li	  et	  al	  (2009)	  showed	  that	  the	  endocervical	  epithelium	  of	  macaques	  
exposed	   to	   SIV	   produces	   MIP-­‐3α	   to	   recruit	   plasmacytoid	   DCs,	   which	   in	   turn	  
secrete	  IFN-­‐α,	   IFN-­‐β,	  MIP-­‐1α	  and	  MIP-­‐1β	  that	  promote	  inflammation	  and	  T-­‐cell	  
recruitment	   (Li	   et	   al.,	   2009).	   HIV-­‐infected	   women	   have	   been	   found	   to	   have	  
higher	  levels	  of	  the	  pro-­‐inflammatory	  cytokines	  IL-­‐1β,	  IL-­‐6	  and	  IL-­‐8	  compared	  to	  
healthy	   individuals	   (Nkwanyana	   et	   al.,	   2009).	   HIV-­‐infected	   commercial	   sex	  
workers	   (CSW)	   have	   significantly	   elevated	   levels	   of	   MCP-­‐1,	   MIP-­‐1β,	   RANTES,	  
MCP-­‐3,	   MIG,	   TNF-­‐α	   and	   IFN-­‐γ	   compared	   to	   HIV-­‐uninfected	   CSW	   and	   low	   risk	  
women	   (Lajoie	   et	   al.,	   2008).	   These	   cytokines	   and	   chemokines	   are	   secreted	   by	  
several	   types	   of	   epithelial,	   stromal	   and	   immune	   cells	   in	   the	   genital	   tract	  
(reviewed	  by	  Rancez	  et	  al.,	  2012).	  MCP-­‐1,	  MIP-­‐1β,	  RANTES,	  MCP-­‐3	  are	  known	  to	  
recruit	  neutrophils,	  monocytes,	  macrophages	  DCs,	  T-­‐cells	   and	  NK	  cells.	  MIG,	   in	  
contrast,	  attracts	  T-­‐cells	  and	  NK	  cells	  (reviewed	  by	  Rancez	  et	  al.,	  2012).	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1.6.6. Sexually	  transmitted	  infections	  that	  impact	  on	  HIV	  shedding	  
A	  strong	  association	  has	  consistently	  been	  demonstrated	  between	  the	  presence	  
of	   sexually	   transmitted	   infections	   (STIs)	   or	   bacterial	   vaginosis	   (BV)	   and	  
increased	  risk	  of	  HIV	  acquisition	  (reviewed	  by	  Ward	  &	  Rönn,	  2010).	  While	  STIs	  
are	   caused	   by	   infections	   with	   pathogens,	   bacterial	   vaginosis	   (BV)	   does	   not	  
involve	  a	  pathogenic	  infection	  but	  rather	  an	  imbalance	  in	  the	  composition	  of	  the	  
normal	   commensal	   vaginal	   flora,	   characterised	   by	   the	   depletion	   of	   hydrogen	  
peroxide-­‐producing	   lactobacilli	   and	   the	   proliferation	   of	   anaerobic	   bacteria	  
(Hillier,	  1998;	  reviewed	  by	  Atashili	  et	  al.,	  2008).	  Of	  all	  the	  STIs,	  the	  strongest	  risk	  
for	  HIV	  transmission	  has	  been	  associated	  with	  genital	  ulcer	  disease,	  gonorrhea,	  
syphilis	  and	  Trichomonas	  vaginalis	  (reviewed	  by	  Galvin	  &	  Cohen,	  2004	  &	  Ward	  &	  
Rönn,	  2010).	  STIs	  like	  HSV-­‐2	  and	  gonorrhea	  increase	  the	  risk	  of	  HIV	  infection	  by	  
causing	   microabrasions	   in	   the	   genital	   epithelial	   barrier,	   inflammation,	  
recruitment	  of	  activated	  HIV	  target	  cells	  into	  the	  mucosa,	  and	  by	  increasing	  viral	  
shedding	  in	  genital	  secretions	  (reviewed	  by	  Fox	  &	  Fidler,	  2010).	  	  
	  
HSV-­‐2	   is	  known	  to	  cause	  chronic	   infections,	  especially	   in	   immunocompromised	  
individuals,	   that	   manifest	   as	   symptomatic	   ulcerative	   disease	   at	   the	   genital	  
mucosa	   or	   as	   asymptomatic	   sub-­‐clinical	   disease	   during	   the	   latent	   phase	   of	  
infection	   (Celum	   et	   al.,	   2010).	   Studies	   have	   shown	   that	   both	   symptomatic	   and	  
asymptomatic	  HSV-­‐2	  can	  increase	  an	  individual’s	  risk	  of	  becoming	  infected	  with	  
HIV,	   but	   also	   increases	   the	   risk	   of	   an	   HIV-­‐infected	   individuals	   in	   discordant	  
relationships	  transmitting	  HIV	  to	  their	  uninfected	  partners	  (Johnson	  and	  Lewis,	  
2008).	   HSV-­‐2	   reactivation	   is	   highly	   inflammatory	   and	   cause	   ulcerative	   lesions	  
that	  increase	  plasma	  and	  genital	  tract	  HIV	  viral	  loads,	  independent	  of	  the	  level	  of	  
immunodeficiency	   (LeGoff	   et	   al.,	   2007).	   However,	   a	   large	   phase	   3	   clinical	   trial	  
aimed	  at	  treating	  HIV-­‐infected	  individuals	  co-­‐infected	  with	  HSV-­‐2	  with	  acyclovir	  
(to	  suppress	  HSV-­‐2	  reactivation)	  did	  not	  reduce	  HIV	  transmission	  rates	  despite	  
significant	  reductions	  in	  the	  plasma	  HIV	  viral	  load,	  showing	  that	  the	  lesions	  may	  
only	  be	  one	  of	  the	  factors	  causing	  the	  shedding	  of	  HIV	  (Celum	  et	  al.,	  2010).	  	  
	  
Mycoplasma	  genitalium	   is	   a	   STI	  of	   the	   genitourinary	   tract,	   associated	  with	   a	  2-­‐
fold	  increase	  in	  the	  risk	  of	  HIV	  acquisition	  (Mavedzenge	  et	  al.,	  2012;	  Vandepitte	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et	   al.,	   2012).	   Findings	   reported	  by	  Mavedzenge	   et	   al.	   (2012)	   suggested	   that	  M.	  
genitalium	  causes	  tissue	  damage	  as	  a	  result	  of	  host	  cell	  inflammatory	  responses,	  
which	  resulted	  in	  recruitment	  of	  activated	  HIV	  target	  cells	  to	  the	  endocervix.	  In	  
addition	  to	  increasing	  risk	  of	  HIV	  infection	  in	  uninfected	  women,	  M.	  genitalium	  is	  
also	  common	  in	  HIV-­‐infected	  individuals,	  especially	  in	  sub-­‐Saharan	  Africa	  where	  
it	  has	  a	  prevalence	  of	  11-­‐33%	  (Mavedzenge	  and	  Weiss,	  2009).	  	  
	  
Bacterial	  vaginosis	  (BV),	  although	  not	  caused	  by	  a	  pathogen,	  is	  the	  most	  common	  
abnormal	   vaginal	   condition	   that	   results	   in	   a	   vaginal	   pH	   increasing	   to	   >4.5	  
(normal	   pH	   ranges	  between	  4.0-­‐4.5).	   	   BV	   reduces	   the	   vaginal	   defence	   capacity	  
against	  HIV	   by	   influencing	   vaginal	   pH.	   A	   lower	   vaginal	   pH	   inhibits	   CD4+	  T-­‐cell	  
activation	  and	  proliferation	  so,	  the	  rise	  in	  vaginal	  pH	  resulting	  from	  the	  absence	  
of	  lactobacilli	  leads	  to	  an	  increased	  availability	  of	  activated	  CD4+	  T-­‐lymphocytes	  
(Schmid	  et	  al.,	  2000).	  BV	  has	  been	  linked	  to	  a	  reduction	  in	  the	  level	  of	  secretory	  
leukocyte	  protease	  inhibitor	   in	  vaginal	   fluid,	  a	  component	  that	  has	  been	  shown	  
to	  block	  HIV	  infection	   in-­‐vitro	  (Atashili	  et	  al.,	  2008;	  Draper	  et	  al.,	  1998).	  Genital	  
mucous	   has	   a	   protective	   effect	   against	   HIV	   because	   it	   traps	   HIV	   and	   prevents	  
contact	  with	  the	  genital	  mucosal	  barrier.	  	  BV	  has	  been	  shown	  to	  degrade	  mucous	  
via	   anaerobic	   bacteria	   secreting	   glycosidases	   and	   proteases	   (Olmsted	   et	   al.,	  
2003;	  Atashili	  et	  al.,	  2008).	  	  
	  
1.7. Highly	  Active	  Anti-­‐Retroviral	  Therapy	  (HAART)	  
Sustained	  highly	  active	  anti-­‐retroviral	  drug	  combination	  therapy,	  better	  known	  
as	  HAART,	  has	  been	  shown	  to	  significantly	  improve	  the	  quality	  of	  life	  and	  reduce	  
the	  mortality	  of	  HIV-­‐infected	   individuals	   (Johnson	  et	   al.,	   2013).	  The	  number	  of	  
HIV-­‐infected	   people	   receiving	   HAART	   has	   tripled	   over	   the	   last	   five	   years	  
(UNAIDS,	  2013).	  Importantly,	  there	  has	  been	  a	  significant	  rise	  in	  the	  number	  of	  
people	  receiving	  HAART	  in	  low-­‐	  and	  middle-­‐income	  countries,	  with	  an	  estimated	  
9.7	  million	  HIV-­‐infected	  people	  in	  2012	  being	  treated	  with	  HAART	  compared	  to	  
only	  1.6	  million	  in	  2011	  (UNAIDS,	  2013).	  Although	  this	  gain	  in	  absolute	  numbers	  
of	   HIV-­‐infected	   individuals	   being	   treated	   is	   important,	   it	   is	   also	   important	   to	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consider	   that	   only	   61%	   of	   the	   individuals	   eligible	   for	   treatment	   in	   these	  
countries	  currently	  have	  access	  to	  HAART	  (UNAIDS,	  2013).	  
Initiation	  of	  HAART	   is	   accompanied	  by	  a	   rapid	  decrease	   in	  plasma	  viraemia	   in	  
HIV-­‐infected	   individuals,	  accompanied	  by	  a	  rise	   in	  blood	  CD4	  counts	  (reviewed	  
by	   Swanstrom	   et	   al.,	   2012).	   HAART	   leads	   to	   the	   rapid	   elimination	   of	   cell-­‐free	  
virus	  with	  a	  half-­‐life	  of	   less	   that	  six	  hours	  and	  the	   loss	  of	  productively	   infected	  
cells	  with	  a	  half-­‐life	  of	  1.6	  days,	   causing	   the	  concentration	  of	  HIV-­‐1	   in	  blood	   to	  
drop	  by	  ~99%	   in	   the	   first	   two	  weeks	  of	   treatment	   (Perelson	  et	   al.,	   1997).	  The	  
current	   combination	   treatment	   strategies	   available	   through	   use	   of	   HAART	   are	  
able	  to	  suppress	  HIV-­‐RNA	  to	  levels	  below	  the	  detection	  limit	  of	  diagnostic	  assays.	  
However,	   HAART	   does	   not	   completely	   eliminate	   the	  HIV	   infection	   and	   a	   rapid	  
viral	  rebound	  occurs	  as	  soon	  as	  treatment	  is	  stopped	  (Chun	  et	  al.,	  1997;	  Ho	  and	  
Zhang,	  2000).	  	  
	  
The	  antiretroviral	  therapy	  era	  started	  in	  1986	  with	  the	  licensing	  of	  the	  first	  anti-­‐
HIV	  drug,	  a	  nucleoside	  reverse	  transcriptase	  inhibitor	  (NRTI)	  called	  zidovudine	  
(ZDV,	  previously	  called	  AZT)	  (Wright,	  1986).	  However,	  the	  benefits	  of	  using	  just	  
AZT	   as	  monotherapy	  were	   short-­‐lived	   and	   did	   not	   delay	   the	   onset	   of	   AIDS	   or	  
death,	   despite	   a	   significant	   initial	   reduction	   in	   the	   symptoms,	   because	  of	   rapid	  
emergence	  of	  AZT	  drug	  resistance	  mutations	   in	  HIV	  (St	  Clair	  et	  al.,	  1991).	  This	  
led	   to	   the	   introduction	   of	   combination	   nucleoside/nucleotide	   reverse	  
transcriptase	   inhibitor	   therapy	   where	   AZT	   was	   used	   in	   conjunction	   with	  
zalcitabine	   (ddC)	   or	   didanosine	   (ddI)	   in	   the	   early	   1990’s	   (Delta	   Coordinating	  
Committee,	  1996).	  Because	  of	   intolerable	  side-­‐effects	  of	  AZT,	   lamivudine	  (3TC)	  
and	   stavudine	   started	   to	   be	   prescribed	   along	   with	   ZDV	   in	   the	   mid-­‐1990’s	   to	  
improve	   both	   the	   durability	   and	   tolerability	   of	   anti-­‐retroviral	   treatments	  
(Kuritzkes	  et	  al.,	  1999).	  Currently,	  fixed-­‐dose	  once-­‐daily	  combination	  tablets	  are	  
most	   commonly	   used	   and	   are	   more	   efficacious,	   particularly	   because	   they	   are	  
easy	  to	  use,	  better	  tolerated	  and	  as	  a	  result	  there	  are	  higher	  rates	  of	  adherence	  to	  
the	  treatment.	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1.7.1. Types	  of	  anti-­‐retroviral	  drugs	  and	  mechanism	  of	  action	  
HAART	  predominantly	  targets	  viral	  replication	  and	  reduces	  viral	  loads	  in	  plasma	  
by	   99%	   within	   the	   first	   2	   weeks	   of	   treatment	   (Perelson	   et	   al.,	   1997)	   and	   to	  
undetectable	  levels	  within	  6	  months	  of	  HAART	  initiation	  (Chaisson	  et	  al.,	  2000).	  
All	  licensed	  antiretroviral	  drugs	  can	  be	  classified	  into	  seven	  different	  classes:	  (1)	  
nucleoside	   reverse	   transcriptase	   inhibitors	   (NRTIs),	   (2)	   nucleotide	   reverse	  
transcriptase	   inhibitors	   (NtRTIs),	   (3)	   non-­‐nucleoside	   reverse	   transcriptase	  
inhibitors	   (NNRTIs),	   (4)	   protease	   inhibitors	   (PIs),	   (5)	   cell	   entry/	   fusion	  
inhibitors	   (FIs),	   (6)	   co-­‐receptor	   inhibitors	   (CRIs),	   and	   (7)	   integrase	   inhibitors	  
(INIs).	  The	  combination	  approach	  encompassed	  in	  HAART	  generally	  consists	  of	  a	  
nucleoside/nucleotide	  backbone	  (two	  drugs	  among	  the	  NRTIs	  and	  NtRTIs)	  and	  
another	  drug	  class	  (selected	  from	  the	  different	  NNRTIs,	  PIs,	  INIs	  or	  CRIs).	  These	  
drugs	  target	  different	  stages	  of	  the	  HIV	  life	  cycle	  (figure	  1.10).	  	  
	  
	  
Figure	  1.10.	  Diverse	  mechanisms	  of	  action	  of	  the	  different	  antiretroviral	  agents	  at	  the	  
various	  stages	  of	  the	  HIV	  life	  cycle	  (taken	  from	  Breckenridge,	  2009)	  
	  
1.7.1.1. Mechanism	  of	  action	  of	  NRTIs,	  NtRTIs,	  and	  NNRTIs	  
NRTIs,	   NtRTIs	   and	   NNRTIs	   all	   act	   on	   HIV	   reverse	   transcriptase,	   which	  
transcribes	  the	  HIV	  single-­‐stranded	  RNA	  genome	  into	  double-­‐stranded	  pro-­‐viral	  
DNA	  (figure	  1.10).	  They	  work	  by	  substituting	  a	  chemically	  modified	  nucleoside	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into	  the	  transcribing	  DNA	  strand,	  stopping	  further	  transcription	  from	  occurring	  
(reviewed	  by	  Lichterfeld	  &	  Zachary,	  2011).	  The	  NRTIs	  and	  the	  NtRTIs	  bind	  to	  the	  
catalytic	   site	   of	   the	   enzyme	   while	   the	   NNRTIs	   interact	   with	   an	   allosteric	   site	  
(Tantillo	   et	   al.,	   1994).	   NtRTIs	   are	   different	   from	   NRTIs	   in	   that	   they	   have	   an	  
additional	  phosphonate	  group	  that	  makes	  them	  more	  resistant	  to	  cleavage	  after	  
they	  have	  bound	  to	  the	  3’-­‐end	  of	  the	  DNA	  strand	  (reviewed	  by	  De	  Clercq,	  2009).	  
Unlike	   NRTIs	   and	   NtRTIs,	   NNRTIs	   are	   allosteric,	   noncompetitive	   inhibitors	  
which	   act	   on	   a	   binding	   site	   close	   to	   the	   catalytic	   site	   of	   HIV-­‐1	   reverse	  
transcriptase	   (reviewed	   by	   De	   Clercq,	   2009).	   This	   binding	   restricts	   with	   the	  
substrate-­‐binding	  site	  and	  disrupts	  the	  enzyme’s	  normal	  function.	  
	  
NRTIs	  are	  the	  most	  commonly	  used	  anti-­‐HIV	  drugs	  in	  first	  line	  regimens	  in	  South	  
Africa,	   and	   at	   present,	   the	   seven	   licensed	   NRTIs	   are	   ZDV,	   ddI,	   ddC,	   stavudine	  
(d4T),	   lamivudine	  (3TC),	  abacavir	  (ABC)	  and	  emtricitabine	  (FTC)	  (WHO,	  2013).	  
The	  NtRTI,	  tenofovir	  (namely	  tenofovir	  disoproxil	  fumarate	  (TDF))	  is	  now	  one	  of	  
the	  most	  prescribed	  drugs	  for	  the	  treatment	  of	  HIV	  in	  the	  world	  (reviewed	  by	  De	  
Clercq,	   2009).	   The	   drugs	   that	   fall	   into	   the	   NNRTI	   category	   are	   nevirapine,	  
delavirdine,	  efavirenz	  and	  etravirine	  (WHO,	  2013).	  Worldwide,	  Efavirenz	   is	   the	  
most	  commonly	  prescribed	  drug	  from	  this	  class	  of	  anti-­‐HIV	  drugs.	  Etravirine	   is	  
used	  in	  second-­‐line	  regimens	  and	  is	  very	  effective	  in	  acting	  against	  HIV	  variants	  
which	   have	   escape	   mutations	   to	   the	   first	   line	   NNRTIs	   such	   as	   efavirenz	   and	  
nevirapine	  (Andries	  et	  al.,	  2004).	  	  
	  
1.7.1.2. Mechanism	  of	  action	  of	  PIs	  
PIs	  target	  HIV’s	  assembly	  stage	  by	  inhibiting	  the	  viral	  protease	  (figure	  1.10).	  PIs	  
use	  the	  ‘peptidomimetic’	  principle	  where	  they	  use	  a	  scaffold	  that	  resembles	  the	  
normal	   peptide	   linkage	   but	   cannot	   be	   cleaved	   (reviewed	   by	   De	   Clercq,	   2009).	  
This	  prevents	  the	  protease	  from	  working	  as	  intended,	  and	  blocks	  the	  production	  
of	  mature	   viral	   proteins	   from	  precursor	  molecules.	   There	   are	   10	  PIs	   currently	  
available	   for	   HIV	   treatment:	   saquinavir,	   ritonavir,	   indinavir,	   nelfinavir,	  
amprenavir,	   lopinavir,	   atazanavir,	   fosamprenavir,	   tipranavir	   and	   darunavir	  
(WHO,	  2013).	  Lopinavir	  is	  the	  most	  prescribed	  PI	  worldwide.	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1.7.1.3. Mechanisms	  of	  action	  of	  co-­‐receptor	  inhibitors	  (CRIs)	  
The	  only	   licensed	  CRI	   is	  maraviroc,	  which	   interacts	  with	   the	   co-­‐receptor	  CCR5	  
used	  by	  R5	  viruses	  to	  enter	  host	  cells	  (figure	  1.10).	  Since	  maraviroc	  is	  effective	  
only	   against	   R5-­‐tropic	   HIV	   variants,	   there	   is	   the	   danger	   of	   it	   selecting	   for	   X4	  
strains	   and	   a	   viral	   tropism	   test	   is	   usually	   done	   before	   prescribing	   this	   drug	  
(reviewed	  by	  De	  Clercq,	  2009).	  	  
	  
1.7.1.4. Mechanisms	  of	  action	  of	  integrase	  inhibitors	  (INIs)	  
INIs	  act	  by	  hindering	  the	  function	  of	  HIV	  integrase,	  which	  control	  the	  insertion	  of	  
the	  HIV-­‐1	  pro-­‐viral	  DNA	  into	  the	  host	  cell	  genome	  (figure	  1.10;	  Hare	  et	  al.,	  2011).	  
The	   two	   INIs	   currently	   approved	   for	   use	   internationally	   are	   the	   twice-­‐daily	  
raltegravir	  and	  dolutegravir,	  a	  once-­‐daily	  pill	  (Raffi	  et	  al.,	  2013).	  Raltegravir	  has	  
been	   on	   the	  market	   since	   2007	   and	   dolutegravir	  was	   just	   approved	   by	   the	  US	  
FDA	  in	  August	  2013.	  Dolutegravir	  was	  shown	  to	  be	  efficient	  in	  cases	  where	  HIV	  
had	  developed	  resistance	  to	  raltegravir	  and	  it	  is	  reported	  to	  be	  as	  well	  tolerated	  
as	   the	  raltegravir	   (Eron	  et	  al.,	  2013).	   In	   the	   future,	   the	  plan	   is	   to	  make	  a	   fixed-­‐
dose	  combination	  of	  abacavir,	   lamivudine	  and	  dolutegravir	  available,	   to	   further	  
simplify	  treatment	  (Waters	  and	  Barber,	  2013).	  	  
	  
1.7.1.5. Mechanisms	  of	  action	  of	  cell	  entry/fusion	  inhibitors	  (FIs)	  
The	  only	  FI	  commercially	  available	  is	  enfuvirtide	  (figure	  1.10).	  It	  is	  a	  polypeptide	  
which	  binds	  in	  a	  coil-­‐coil	  interaction	  with	  gp41	  and	  restricts	  fusion	  of	  the	  virus	  
with	  the	  outer	  membrane	  of	  the	  host	  cell	  (Matthews	  et	  al.,	  2004).	  It	   is	  however	  
not	   orally	   bioavailable	   and	   has	   to	   be	   given	   subcutaneously.	   As	   a	   result,	   it	   is	  
mostly	   used	   as	   salvage	   therapy	   when	   HIV-­‐infected	   individuals	   develop	   multi-­‐
drug	  resistant	  viruses	  (Xu	  et	  al.,	  2005).	  	  
	  
1.7.2. Debate	  on	  best	  time	  to	  start	  HAART	  
While	  the	  current	  WHO	  guidelines	  for	  initiation	  of	  HAART	  stipulates	  that	  an	  HIV-­‐
infected	   individual	   should	   initiate	  HAART	   if	   their	  CD4+	  T-­‐cell	   counts	   are	   lower	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than	   500	   cells/ml	   (WHO,	   2013),	   the	   standardised	   South	   African	   national	  
guidelines	   are	   yet	   to	   adopt	   this	   policy	   and	   currently	   require	   that	   HIV-­‐infected	  
individuals	   start	   HAART	   when	   their	   CD4+	   T-­‐cell	   counts	   reach	   <350	   cells/ml	  
(irrespective	  of	  their	  WHO	  clinical	  stage).	  In	  some	  specific	  cases	  in	  South	  Africa,	  
HAART	   should	   be	   started	   immediately,	   as	   outlined	   in	   table	   1.1	   It	   is	   currently	  
recommended	   that	   eligible	   HIV-­‐infected	   adults	   be	   initiated	   on	   the	   first-­‐line	  
regimen,	   which	   constitutes	   of	   tenofovir,	   efavirenz	   and	   emtricitabine	   or	  
lamivudine	  in	  South	  Africa.	  It	  is	  recommended	  that	  HIV-­‐infected	  adolescents,	  on	  
the	   other	   hand,	   be	   initiated	   on	   a	   different	   treatment	   combination,	   which	  
comprises	   abacavir,	   lamivudine	   and	   efavirenz	   (2	   NRTIs	   and	   an	   NNRTI,	  
respectively)	  as	  tenofovir	  has	  been	  associated	  with	  a	  higher	  rate	  of	  bone	  mineral	  
density	  loss	  (Stellbrink	  et	  al.,	  2010).	  	  
	  
In	  the	  case	  of	  virological	  failure	  despite	  being	  on	  HAART,	  it	  is	  recommended	  that	  
HIV-­‐infected	  individuals	  be	  switched	  to	  the	  recommended	  second-­‐line	  regimen.	  
In	  South	  Africa,	   this	   consists	  of	   zidovudine,	   lamivudine	  and	   lopinavir/ritonavir	  
or	   a	   combination	   of	   tenofovir,	   lamivudine	   or	   emtricitabine	   and	  
lopinavir/ritonavir	   (2	   NRTIs	   and	   protease	   inhibitors	   respectively)	   (The	   South	  
African	  Antiretroviral	  Treatment	  Guidelines,	  2013).	  	  
	  
Table	  1.1.	  South	  African	  national	  guidelines	  for	  HAART	  
Eligibility	  to	  start	  lifelong	  HAART:	  
• CD4 count ≤350 cells/ml irrespective of WHO clinical stage 
• All types of TB (in patients with TB drug resistant or sensitive, 
including extra pulmonary TB) irrespective of CD4 count 
• WHO stage 3 or 4 irrespective of CD4 count 
HAART	  initiation	  within	  7	  days	  of	  being	  eligible:	  
• HIV positive women who are pregnant or breast feeding 
• Patients with low CD4 <200	  cells/ml 
• Patients with Stage 4, irrespective of CD4 counts 





1.7.3. WHO	  new	  guidelines	  and	  current	  system	  
The	  WHO	  issued	  new	  guidelines	  in	  June	  2013,	  requiring	  HIV-­‐infected	  individuals	  
to	   be	   initiated	   on	  HAART	  as	   soon	   as	   their	   CD4	   counts	   fell	   below	  500	   cells/ml,	  
immediately	   if	   they	  were	   pregnant,	   if	   they	   had	  HIV	   serodiscordant	   partners,	   if	  
they	  had	  TB	  or	  Hepatitis	  B,	  or	   if	   they	  were	  children	  ≤5	  years	  old.	  This	  decision	  
was	  motivated	   by	   several	   recent	   studies	  which	   have	   shown	   the	   advantages	   of	  
starting	  HAART	  earlier	  than	  CD4	  counts	  ≤350cells/ml	  (Cohen	  et	  al.,	  2011;	  Severe	  
et	  al.,	  2010;	  Walensky	  et	  al.,	  2009).	  These	  new	  treatment	  guidelines	  will	  demand	  
a	  significant	  scale-­‐up	  in	  the	  current	  treatment	  program	  to	  ensure	  that	  every	  HIV-­‐
infected	  individual	  who	  needs	  HAART	  receives	  it.	  With	  the	  current	  South	  African	  
treatment	   guidelines,	  ~61%	  of	   eligible	  HIV-­‐infected	   individuals	   have	   access	   to	  
HAART	   (UNAIDS,	   2013).	   In	   low-­‐	   and	   middle-­‐income	   countries	   (including	  
countries	   in	   sub-­‐Saharan	   Africa),	   a	   higher	   proportion	   of	   HIV-­‐infected	   women	  
than	  men	  were	  on	  HAART,	  with	  73%	  of	   eligible	  women	  being	   treated	   in	  2012	  
compared	   to	   only	  57%	  of	  men	   (UNAIDS,	   2013).	   The	   impact	   of	  HAART	   roll-­‐out	  
and	  scale-­‐up	  in	  South	  Africa	  is	  clearly	  evident,	  with	  the	  life	  expectancy	  of	  South	  
African	  HIV-­‐infected	   individuals	  being	  an	  average	  of	  11.3	  years	   longer	   in	  2011	  
than	   it	   was	   in	   2003	   (Bor	   et	   al.,	   2013).	   If	   the	   new	   WHO	   guidelines	   are	  
implemented	   in	   South	   Africa,	   an	   even	   bigger	   scale-­‐up	   of	   treatment	   will	   be	  
necessary	   as	   the	   current	   numbers	   on	   HAART	   represent	   only	   34%	   of	   the	   28.3	  
million	   individuals	   with	   CD4	   counts	   ≤500cells/ml	   who	   will	   be	   eligible	   for	  
therapy	  (UNAIDS,	  2013).	  Intensifying	  the	  treatment	  program	  will	  help	  limit	  the	  
circulation	   of	   HIV	   within	   the	   population	   and	   thus,	   reduce	   the	   number	   of	   new	  
infections.	  	  
	  
1.7.4. Bioavailability	  of	  HAART	  drugs	  and	  toxicity	  
South	   African	   HAART	   guidelines	   require	   that	   all	   new	   HIV-­‐infected	   individuals	  
who	  are	  eligible	  to	  start	  HAART	  be	  put	  on	  the	  first	  line	  regimen	  consisting	  of	  one	  
NNRTI	   (efavirenz)	   and	   two	   NRTIs	   (tenofovir	   and	   emtricitabine/lamivudine)	  
(The	  South	  African	  Antiretroviral	  Treatment	  Guidelines,	  2013).	  NRTIs	  and	  NNRTIs	  
are	  usually	  given	  together	  during	  treatment	  as	  they	  have	  a	  complementary	  effect	  
(Breckenridge,	   2009;	   King	   et	   al.,	   2002).	   These	   ARVs	   have	   very	   wide	   tissue	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bioavailability	  ranges,	  with	  a	  capacity	  to	  penetrate	  tissues	  of	  25%,	  50-­‐60%,	  86%	  
and	   93%	   for	   tenofovir,	   efavirenz,	   lamivudine	   and	   emtricitabine,	   respectively	  
(Breckenridge,	  2009).	  The	  NNRTIs	  have	  a	  higher	  plasma	  half-­‐life	  than	  the	  other	  
drug	  classes,	  with	  efavirenz	  being	  active	  for	  ~30-­‐40	  hours	  compared	  to	  tenofovir	  
being	  active	  for	  only	  17	  hours,	  lamivudine	  for	  5-­‐7	  hours	  and	  emtricitabine	  for	  1-­‐
2	   hours	   (Anderson	   and	   Rower,	   2010;	   Breckenridge,	   2009).	   NRTIs	   cause	   side	  
effects,	   including	   nausea,	   appetite	   loss	   and	   fever,	   while	   NNRTIs	   may	   cause	  
disorientation	  and	  gastrointestinal	  complications	  (Breckenridge,	  2009).	  	  
	  
1.7.5. Impact	  of	  HAART	  on	  genital	  shedding	  and	  inflammation	  
Several	   studies	  have	   reported	   that	  plasma	  viral	   loads	  are	   the	  best	  predictor	  of	  
genital	  HIV	  loads	  in	  infected	  individuals	  (Anderson	  and	  Cu-­‐Uvin,	  2008;	  Kovacs	  et	  
al.,	   2001).	   Although	   plasma	   HIV	   load	   is	   a	   recognised	   predictor	   of	   genital	   HIV	  
shedding,	   concomitant	   genital	   tract	   infections	   with	   Neisseria	   gonorrhoeae,	  
Chlamydia	  trachomatis,	  Trichomonas	  vaginalis	  and	  Candida	  albicans	  may	  further	  
influence	  genital	  tract	  HIV	  loads,	  through	  recruitment	  of	  HIV-­‐infected	  cells	  to	  the	  
genital	   tract	   in	   response	   to	   the	   infection	   or	   as	   a	   result	   of	   the	   increased	  
production	  of	   inflammatory	  cytokines,	  which	  facilitate	  HIV	  replication	  (Johnson	  
and	  Lewis,	  2008).	  Mukura	  et	  al.	   (2012)	  showed	  that	  elevated	  concentrations	  of	  
chemotactic	  and	  inflammatory	  cytokines	  (including	  RANTES,	  eotaxin,	  fractalkine,	  
IL-­‐1α,	   IL-­‐6,	  MCP-­‐1,	  MIP-­‐1β,	  MIP-­‐1	  α,	  TNF-­‐α	  and	  GM-­‐CSF)	  were	  associated	  with	  
higher	  genital	  viral	  loads.	  In	  support	  of	  this,	  Mitchell	  et	  al.	  (2011)	  reported	  that	  
IL-­‐1β	   and	   IL-­‐8	   were	   strongly	   associated	   with	   cervicovaginal	   HIV-­‐RNA	   levels,	  
after	  adjusting	  for	  plasma	  viral	  load	  and	  vaginal	  co-­‐infections.	  	  
	  
Just	   as	   HAART	   causes	   a	   decrease	   in	   plasma	   viral	   loads	   in	   HIV-­‐infected	  
individuals,	   it	   has	   also	   been	   strongly	   associated	   with	   a	   suppression	   of	   genital	  
tract	  viral	   loads	   (Cu-­‐Uvin	  et	   al.,	   2006;	  Fiore	  et	   al.,	   2003).	  However,	  HIV	   can	  be	  
detected	   in	   mucosal	   secretions	   in	   some	   HIV-­‐infected	   individuals	   with	   fully	  
suppressed	   plasma	   viral	   loads	   (Chun	   et	   al.,	   2008;	  Mehandru	   et	   al.,	   2006).	   The	  
effect	   that	   HAART	   has	   on	   HIV	   shedding	   in	   the	   female	   genital	   tract	   has	   been	  
shown	   to	   be	   dependent	   on	   several	   factors,	   including	   STIs,	   hormonal	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contraception	  use	  and	  pharmacokinetics	  of	  the	  drugs	  used	  (reviewed	  by	  Else	  et	  
al.,	   2011).	   Cohen	   et	   al.	   (2007)	   showed	   that	   highly	   protein-­‐bound	  drugs	   have	   a	  
lower	   bioavailability	   in	   the	   genital	   tract.	   The	   standard	   South	   African	   first	   line	  
HAART	   regimen	   consists	   of	   2	   NRTIs	   and	   1	   NNRTI	   or	   PI	   (The	   South	   African	  
Antiretroviral	  Treatment	  Guidelines,	   2013).	  Min	  et	  al.	   (2004)	   showed	   that	   there	  
were	   lower	   concentrations	   of	  NNRTIs	   and	  PIs	   available	   in	   genital	   tract	   tissues	  
compared	  to	  blood.	  Kwara	  et	  al.	  (2008),	  in	  contrast,	  showed	  that	  NNRTIs	  had	  the	  
highest	  penetrative	  capacity	   to	  cervocovaginal	  sites	   (Kwara	  et	  al.,	  2008;	  Min	  et	  
al.,	   2004).	   A	   study	   conducted	   by	   Graham	   et	   al.	   (2007)	   showed	   that	   HIV-­‐RNA	  
levels	  decreased	  significantly	  in	  plasma	  within	  2	  days	  of	  initiating	  HAART	  [which	  
consisted	  of	  2	  NRTIs	  (stavudine	  and	  lamivudine)	  and	  one	  NNRTI	  (nevirapine)],	  
while	  viral	  loads	  in	  vaginal	  secretions	  decreased	  only	  after	  4	  days.	  Importantly,	  
they	  reported	  that	  35%	  of	  the	  women	  in	  their	  study	  failed	  to	  fully	  suppress	  HIV	  
in	  genital	  secretions,	  indicating	  an	  ongoing	  risk	  of	  HIV	  transmission	  (Graham	  et	  
al.,	  2007).	  	  
	  
1.7.6. Effect	  of	  HAART	  on	  immune	  activation	  
Given	  the	  role	  of	  immune	  activation	  in	  disease	  progression	  during	  untreated	  HIV	  
infection,	  several	  studies	  were	  conducted	  to	  explore	  changes	  in	  activation	  during	  
treatment	  with	  HAART.	  HAART	  has	  been	  very	   effective	   in	   reducing	   the	  overall	  
mortality	  associated	  with	  HIV	  although	  excessive	  immune	  activation	  still	  persists	  
in	  certain	  HIV-­‐infected	  individuals	  with	  low	  CD4+	  T-­‐cell	  recovery	  (Anthony	  et	  al.,	  
2003;	  Hunt	  et	  al.,	  2003b).	  In	  HIV-­‐infected	  individuals	  on	  HAART,	  elevated	  levels	  
of	   T-­‐cell	   activation	   have	   been	   associated	   with	   lower	   CD4+	   T-­‐cell	   restoration,	  
cardiovascular	  diseases	  and	  increased	  mortality	  (reviewed	  by	  Hunt,	  2012	  &	  Klatt	  
et	  al.,	  2013).	  In	  individuals	  who	  have	  been	  on	  HAART	  for	  several	  years,	  there	  is	  
an	  overall	  decline	  in	  the	  level	  of	  T-­‐cell	  activation	  although	  it	  still	  remains	  higher	  
than	   observed	   in	   HIV	   negative	   individuals	   (Hunt	   et	   al.,	   2003b;	   Valdez	   et	   al.,	  
2002).	  In	  a	  recent	  study	  by	  Vigneault	  et	  al.	  (2011)	  in	  which	  the	  transcritome	  of	  
people	  on	  HAART	  compared	  to	  HIV-­‐uninfected	  individuals	  was	  compared,	  >500	  
gene	   transcripts	   involved	   in	   immune	  activation	  are	   significantly	  overexpressed	  
in	   those	   on	  HAART.	   	   This	   compelling	   study	   serves	   to	   emphasise	   the	   failure	   of	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HAART-­‐treated	   individuals,	   despite	   full	   viral	   suppression,	   to	   lower	   activation	  
levels	  to	  those	  observed	  in	  HIV	  negative	  people	  (Vigneault	  et	  al.,	  2011).	  A	  study	  
comparing	  the	  degree	  of	  T-­‐cell	  activation	  before	  HAART	  treatment,	  and	  after	  one	  
year	  on	  HAART,	  showed	  that	  CD8+	  T-­‐cell	  activation	  predicted	  slower	  CD4+	  T-­‐cell	  
reconstitution	   even	   on	   HAART	   (Hunt	   et	   al.,	   2011a).	   Ongoing	   CD8+	   T-­‐cell	  
activation,	   even	   on	   HAART,	   could	   predict	   higher	   risk	   of	   mortality	   due	   to	   HIV	  
infection	   (Hunt	  et	  al.,	  2011a).	  HAART-­‐mediated	  viral	   suppression	  reduces	  both	  
CD4+	   and	   CD8+	   T-­‐cell	   activation	   although	   it	   remains	   higher	   than	   in	   uninfected	  
individuals	   (Neuhaus	   et	   al.,	   2010).	   Other	   markers	   of	   immune	   activation	  
systemically,	   (such	   as	   IP-­‐10,	   IFN-­‐α,	   IL-­‐6	   or	   D-­‐dimer)	   remain	   higher	   in	   HIV-­‐
infected	  individuals	  on	  HAART	  compared	  to	  uninfected	  individuals	  (reviewed	  by	  
Hunt,	  2012).	  The	  level	  of	  immune	  activation	  observed	  in	  HIV-­‐infected	  individuals	  
on	  HAART	   also	   depends	   on	   how	  early	  HAART	  was	   initiated	   (Jain	   et	   al.,	   2013).	  
Some	   studies	   have	   reported	   that	   markers	   of	   monocytes	   activation	   (such	   as	  
CD163)	  decrease	  to	  almost	  normal	  levels	  if	  HAART	  was	  started	  during	  the	  acute	  
phase	   of	   HIV	   infection	   but	   remain	   elevated	   if	   HAART	   was	   started	   during	   the	  
chronic	   phase	   of	   infection	   (Burdo	   et	   al.,	   2011).	   Similarly,	   Jain	   et	   al.	   (2013)	  
showed	   that	   individuals	   initiating	   HAART	   within	   the	   first	   six	   months	   of	   HIV	  
infection	   had	   lower	   levels	   of	   CD4+/CD8+	   T-­‐cell	   activation	   and	   a	   smaller	   HIV	  
reservoir	  during	  long-­‐term	  therapy	  compared	  to	  patients	  who	  started	  HAART	  at	  
least	  two	  years	  after	  infection.	  	  
	  
1.7.7. Impact	  of	  HAART	  on	  activation	  and	  inflammation	  
HAART	   can,	   to	   some	   extent,	   dampen	   the	   increased	   immune	   activation	   and	  
inflammation	   that	   occurs	   during	   HIV	   infection	   (reviewed	   by	   Deeks,	   2011).	  
Keating	   et	   al.	   (2011)	   showed	   that	   being	   on	   HAART	   was	   associated	   with	   a	  
decrease	   in	   plasma	   IP-­‐10	   and	   TNF-­‐α	   concentrations	   and	   an	   increase	   in	   IL-­‐12	  
(p40)	   and	   IL-­‐15	   (necessary	   for	   the	  maintenance	   of	   long-­‐lived	  memory	   T-­‐cells	  
and	  to	  induce	  cellular	  proliferation	  of	  NK	  cells;	  Villinger	  &	  Ansari,	  2010;	  Yu	  et	  al.,	  
2011)	  concentrations	  compared	  to	  untreated	  HIV-­‐infected	  women.	  They	  further	  
reported	  that	  HAART-­‐treated	  individuals	  had	  a	  plasma	  cytokine	  profile	  similar	  to	  
that	  of	   the	  HIV-­‐uninfected	  women.	  Similarly,	  Amirayan-­‐Chevillard	  et	   al.	   (2000)	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reported	  that	  individuals	  on	  HAART	  had	  decreased	  concentrations	  of	  TNF-­‐	  α,	  but	  
also	   IL-­‐1β,	   IL-­‐6	   and	   IL-­‐10	   compared	   to	   HIV-­‐infected	   individuals	   not	   taking	  
HAART.	   Concentrations	   of	   these	   cytokine	   increased	   again	   once	   treatment	   was	  
interrupted,	  indicating	  that	  the	  changes	  in	  cytokine	  production	  seen	  was	  directly	  
due	   to	   HAART	   (Amirayan-­‐Chevillard	   et	   al.,	   2000).	   In	   another	   study	   that	   used	  
proteomics	   to	   compare	   plasma	   cytokines	   from	   HAART	   treated	   and	   untreated	  
individuals	  confirmed	  that	  IP-­‐10	  but	  also	  MIG	  was	  significantly	  lower	  following	  
24	  weeks	  on	  treatment	  (Relucio	  et	  al.,	  2005).	  	  
	  
Even	   though	   HAART	   does	   suppress	   HIV	   replication,	   the	   levels	   of	   immune	  
activation	  and	  inflammation	  in	  HAART-­‐treated	  individuals	  do	  not	  return	  to	  levels	  
typically	   observed	   before	   infection	   (French	   et	   al.,	   2009;	   Hunt	   et	   al.,	   2003b;	  
Marchetti	  et	  al.,	  2008;	  Neuhaus	  et	  al.,	  2010).	  As	  a	  result,	  these	  individuals	  are	  still	  
vulnerable	   to	   other	   chronic	   diseases,	   such	   as	   cardiovascular,	   renal	   and	   liver	  
disease,	  due	   to	   the	  persistently	  high	   levels	  of	   inflammation	  (Hunt	  et	  al.,	  2011a;	  
Kuller	  et	  al.,	  2008;	  Rodger	  et	  al.,	  2009).	  Relative	  to	  uninfected	  individuals,	  HIV-­‐
infected	  individuals	  on	  HAART	  have	  higher	  levels	  of	  C-­‐reactive	  protein,	  D-­‐dimer,	  
IL-­‐6	   and	   other	   markers	   of	   activation	   (Boulware	   et	   al.,	   2011b;	   Neuhaus	   et	   al.,	  
2010).	  As	  a	  result,	  some	  studies	  have	  explored	  anti-­‐inflammatory	  drugs,	  such	  as	  
statins,	   in	   an	   attempt	   to	   counteract	   the	   high	   levels	   of	   T-­‐cell	   activation	   and	  
chronic	   immune	  dysfunction	   that	   cause	   faster	  disease	  progression	   (Ganesan	  et	  
al.,	   2011;	   reviewed	   by	   Card,	   Ball	   &	   Fowke,	   2013).	   In	   addition	   to	   statins,	   other	  
drugs	   that	   has	   been	   tested	   to	   reduce	   persistent	   immune	   activation	   during	  
HAART	  include	  choroquine,	  type	  I	  interferon	  blockers	  and	  cyclooxygenase	  type	  2	  
inhibitors	   (reviewed	   by	   Card	   et	   al.,	   2013).	   Alternatively,	   treating	   co-­‐infections	  
may	  reduce	  systemic	  immune	  activation.	  Hunt	  et	  al.	  (2011)	  tested	  the	  effect	  that	  
valganciclovir	   (an	   anti-­‐viral	   agent	   against	   CMV	   infections)	   had	   on	   HAART-­‐
treated	   patients	   who	   were	   failing	   to	   reconstitute	   CD4+	   T-­‐cell	   counts	   despite	  
having	   fully	   suppressed	   plasma	   viral	   loads.	   They	   found,	   after	   eight	   weeks	   of	  
treatment	  with	  valganciclovir,	  that	  CD38	  and	  HLA-­‐DR	  expression	  by	  CD8+	  T-­‐cells	  
and	  the	   level	  of	  CRP	   in	  plasma	  decreased	  significantly	  compared	  to	   the	  control	  
group,	  suggesting	  that	  better	  management	  of	  CMV	  may	  improve	  health	  outcomes	  
in	  HAART-­‐treated	  individuals	  (Hunt	  et	  al.,	  2011b).	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An	  alternative	  approach	  that	  has	  been	  proposed	   in	   the	  use	  a	  new	  class	  of	  anti-­‐
retroviral	   drugs	   called	   Anti-­‐Viral-­‐HyperActivation	   Limiting	   Therapeutics	   (AV-­‐
HALTS;	  Lori	  et	  al.,	  2012).	  One	  of	  these,	  called	  VS411,	  consists	  of	  a	  combination	  of	  
didanosine	   and	   hydroxycarbamide.	   Lori	   et	   al.	   (2012)	   reported	   that	   VS411	  
treatment	   of	   HIV-­‐infected	   individuals	   resulted	   in	   a	   significant	   decrease	   in	   the	  
level	   of	   plasma	  HIV-­‐1	   RNA,	   a	   rise	   in	   CD4+	   T-­‐cell	   counts,	   reduced	   proliferation	  
(Ki67	  expression)	  reduced	  programmed	  cell	  death	  (PD)-­‐1	  receptor	  expression	  (a	  
marker	  of	  exhaustion),	  and	  reduced	  expression	  of	  activation	  markers	  CD38	  and	  
HLA-­‐DR.	  This	  class	  of	  drugs	  has	  been	  designed	  to	  act	  both	  as	  an	  anti-­‐retroviral	  
agent	  and	  an	   immune-­‐modulatory	  agent,	   thereby	   limiting	  both	  viral	  replication	  
and	  excessive	  immune	  activation	  (Lori	  et	  al.,	  2012).	  	  
	  
Unlike	   these	   observations	   in	   blood	   plasma,	   a	   different	   trend	   was	   seen	   at	   the	  
mucosa	   following	   initiation	   of	   HAART	   where	   immune	   activation	   and	  
inflammation	   does	   not	   return	   to	   levels	   observed	   before	   infection:	   unlike	   in	  
blood,	  no	  immune	  reconstitution	  was	  evident	  in	  the	  gut	  mucosa	  in	  HIV-­‐infected	  
individuals	   who	   had	   been	   on	   HAART	   for	   ~7	   years,	   who	   had	   ~50-­‐60%	   lower	  
numbers	   of	   lamina	   propria	   T-­‐cells	   than	   normal	   pre-­‐infection	   levels,	   and	  
persistent	   depletion	   of	   memory	   T-­‐cells	   (Mehandru	   et	   al.,	   2006).	   In	   a	   study	  
comparing	   colon	  mucosal	   levels	   of	   cytokines	   before	   HAART	   and	   9	  months	   on	  
treatment,	  Schulbin	  et	  al.	  (2008)	  reported	  that	  tissue	  levels	  of	  TNF-­‐α,	  IFN-­‐γ,	  IL-­‐4,	  
IL-­‐6	  and	  IL-­‐10	  did	  not	  change	  pre-­‐	  versus	  post-­‐treatment	  (Schulbin	  et	  al.,	  2008).	  
Nkwanyana	   et	   al.	   (2009)	   showed	   that	   there	  was	   no	   difference	   in	   the	   levels	   of	  
inflammatory	   cytokines	   in	   genital	   fluid	   collected	   from	   chronically	  HIV-­‐infected	  
women	  on	  and	  off	  HAART.	  	  
	  
1.7.8. Latent	  HIV	  reservoirs	  and	  HAART	  
One	  of	  the	  major	  limitations	  of	  HAART	  is	  that	   latent	  HIV	  reservoirs	  continue	  to	  
exist	   in	  HIV-­‐infected	  but	   resting	  CD4+	  T-­‐cells,	   that	  have	  HIV	   integrated	   in	   their	  
host	  DNA	  (Coiras	  et	  al.,	  2009).	  Because	  of	  these	  latent	  reservoirs,	  viral	  load	  will	  
rapidly	   rebound	   to	   detectable	   levels	   once	   HAART	   is	   discontinued,	   to	   levels	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similar	   to	   those	   experienced	   before	  HAART	  was	   initiated	   (Hatano	   et	   al.,	   2010;	  
Trono	   et	   al.,	   2010).	   Even	   if	   fully	   suppressive	   HAART	   is	  maintained	   long-­‐term,	  
mathematical	   estimates	   on	   the	   latent	   reservoir	   half-­‐life	   suggest	   that	   it	   would	  
take	   ~70	   years	   to	   completely	   eliminate	   the	   latent	   reservoirs	   (Blankson	   et	   al.,	  
2002;	  Finzi	  et	  al.,	  1999;	  Siliciano	  et	  al.,	  2003).	  	  
	  
1.7.9. HAART	  and	  immune	  reconstitutions	  inflammatory	  syndrome	  (IRIS)	  	  
IRIS	   is	   an	   immune	   reconstitution	   disease	   which	   occurs	   in	   a	   significant	  
proportion	  of	  people	  who	  initiate	  HAART	  worldwide,	  including	  about	  10-­‐27%	  of	  
South	  Africans	  (Haddow	  et	  al.,	  2012).	   IRIS	   is	  characterised	  by	  an	  excessive	  and	  
unregulated	  immune	  response	  to	  previously	  sub-­‐clinical	  infections	  (reviewed	  by	  
Chahroudi	  &	  Silvestri,	  2012	  &	  Dhasmana	  et	  al.,	  2008).	  The	  pathogenic	  effect	  of	  
IRIS	   is	   still	   unclear	   although	   immune	   suppression	   as	   a	   result	   of	   HIV	   infection	  
seems	   to	   cause	   IRIS	   (Miller	   et	   al.,	   2004;	   reviewed	   by	   French,	   2009).	   IRIS	  was	  
found	   to	   be	   common	   in	   HIV-­‐infected	   individuals	   on	   HAART	  who	   experience	   a	  
drastic	   decrease	   in	   HIV-­‐RNA	   levels	   and	   a	   rapid	   increase	   in	   CD4+	   T-­‐cell	   counts	  
compared	   to	   baseline.	   The	   most	   common	   reported	   causes	   of	   IRIS	   are	   TB	  
(Mycobacterum	   avium	   complex	   and	   Mycobacterium	   tuberculosis),	   CMV,	  
cryptococcal	  meningitis	  (Cryptococcus	  neoformans)	  and	  hepatitis	  virus	  infections	  
(Cheng	  et	  al.,	  2000;	  Elliott	  et	  al.,	  2009;	  Race	  et	  al.,	  1998).	  At	  the	  genital	  mucosa,	  
HIV-­‐related	   IRIS	   was	   found	   to	   cause	   dermatological	   problems	   due	   to	   genital	  
herpes	  simplex	  (HSV)-­‐2	  and	  human	  papilloma	  virus	  (HPV)	  (Ratnam	  et	  al.,	  2006).	  
In	   a	   study	   conducted	   in	   South	   African	   women,	   profiling	   of	   blood	   cytokines	  
showed	   a	   positive	   relationship	   between	   concentrations	   of	   IFN-­‐γ	   and	   IL-­‐6	   and	  
risk	   of	   developing	   IRIS,	   mostly	   in	   individuals	   with	   TB,	   lip	   zoster	   Kaposi’s	  
sarcoma	   and	   cryptococcal	   meningitis	   (Worsley	   et	   al.,	   2010).	   Treatment	   with	  
HAART	  results	  in	  a	  shift	  from	  a	  Th2	  to	  a	  Th1	  cytokine	  profile,	  which	  may	  result	  in	  
an	  increase	  in	  IFN-­‐γ	  levels	  (Shankar	  et	  al.,	  2007).	  This	  increase	  may	  be	  due	  to	  the	  
higher	   number	   of	   activated	   IFN-­‐γ-­‐producing	   T-­‐cells	   present	   in	   the	   circulation	  
after	  stimulation	  with	  pathogen-­‐specific	  antigens	  (French	  et	  al.,	  2009).	   IL-­‐6	  is	  a	  
marker	  of	  persistent	  immune	  activation	  and	  it	  was	  suggested	  that	  it	  plays	  a	  role	  
in	  the	  development	  of	  IRIS	  (Stone	  et	  al.,	  2002),	  although	  it	  is	  unclear	  whether	  it	  is	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a	  cause	  or	  a	  consequence	  of	  IRIS	  (Worsley	  et	  al.,	  2010).	  Trials	  have	  been	  carried	  
out	   where	   the	   treatment	   of	   IRIS	   with	   corticosteroids	   or	   non-­‐steroidal	   anti-­‐
inflammatory	  drugs	  (NSAIDs)	  have	  been	  evaluated	  (Meintjes	  et	  al.,	  2012a).	  The	  
glucocorticoid	  predinisolone	  had	  marked	  anti-­‐inflammatory	  effects	  and	  caused	  a	  
significant	  decrease	  in	  the	  serum	  concentrations	  of	  IL-­‐6,	  IL-­‐10,	  IL12	  (p40),	  TNF-­‐
α,	   IFN-­‐γ	   and	   IP-­‐10	   (Meintjes	   et	   al.,	   2012b).	   NSAIDs	   prevent	   the	   formation	   of	  
prostaglandin	  mediators	  of	  inflammation	  and	  have	  been	  recommended	  as	  a	  first-­‐
line	  treatment	  for	  mild	  IRIS	  (Meintjes	  et	  al.,	  2012a).	  	  This	  suggests	  that	  some	  of	  
the	  immediate	  gains	  in	  immune	  function	  during	  HAART,	  especially	  in	  individuals	  
starting	   with	   low	   CD4+	   T-­‐cell	   counts,	   are	   potentially	   counter-­‐balanced	   by	   the	  
detrimental	   effects	   of	   IRIS,	   where	   a	   reconstituting	   immune	   system	   responds	  
inappropriately	   to	   previously	   sub-­‐clinical	   infections.	   	  While	   the	   focus	   of	  many	  
IRIS	  studies	  has	  been	  on	  systemic	  diseases	  such	  as	  tuberculosis	  and	  cryptococcal	  
meningitis,	  the	  potential	  effects	  of	  IRIS	  in	  the	  female	  genital	  tract	  in	  response	  to	  
STIs	  is	  important	  to	  consider.	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1.8. Aims	  and	  objectives	  
The	   overall	   aim	   of	   this	   study	   was	   to	   investigate	   the	   impact	   of	   HAART	   on	   the	  
levels	   of	   inflammatory	   cytokines	   and	   immune	   activation,	   proliferation	   and	  
exhaustion	   of	   T-­‐cells	   collected	   from	   the	   female	   genital	   tract	   and	   blood	   of	  
chronically	  HIV-­‐infected	  women	  about	  to	  initiate	  or	  already	  taking	  HAART.	  
	  
Rationale	  
HIV	   infection	   is	  marked	  by	   the	  progressive	   loss	  of	  CD4+	  T-­‐cells	   (Anthony	  et	  al.,	  
2003;	  Sousa	  et	  al.	   ,	  2002)	  and	   immune	  activation	  has	  been	  described	  as	  one	  of	  
the	   major	   causes	   of	   both	   HIV	   pathogenesis	   and	   associated	   CD4+	   T-­‐cell	   loss	  
(reviewed	   by	   Hunt,	   2012;	   Papagno	   et	   al.,	   2004).	   Initiating	   HAART	   has	   been	  
shown	  to	  significantly	  improve	  the	  lifestyle	  and	  raise	  the	  life	  expectancy	  of	  HIV-­‐
positive	   individuals	   (Johnson	   et	   al.,	   2013).	   The	   current	   HAART	   regimes	  
recommend	  simultaneous	  administration	  of	  three	  drugs,	  which	  enable	  the	  rapid	  
suppression	  of	  blood	  and	  genital	  viral	  replication	  to	  undetectable	  levels	  in	  most	  
individuals	   (reviewed	   by	   Lichterfeld	   &	   Zachary,	   2011).	   In	   blood,	   HAART	   has	  
been	   shown	   to	   play	   a	   crucial	   role	   in	   suppressing	   the	   viral	   load,	   reconstituting	  
CD4+	  T-­‐cell	  counts	  and	  in	  dampening	  HIV-­‐induced	  immune	  activation	  (reviewed	  
by	   Hunt,	   2012).	   However,	   individuals	   who	   have	   underlying	   opportunistic	  
infections	   have	   a	   higher	   chance	   of	   developing	   a	   series	   of	   inflammatory	  
symptoms	   termed	   immune	  reconstitution	   inflammatory	  syndrome	  (IRIS)	  when	  
starting	  HAART	  (Chahroudi	  and	  Silvestri,	  2012).	  IRIS	  is	  characterised	  by	  a	  rapid	  
phase	  of	  restoration	  of	  pathogen-­‐specific	  immunity	  to	  subclinical	  infections	  and	  
an	   overwhelming	   inflammatory	   response,	   leading	   to	   a	   paradoxical	   clinical	  
deterioration	  (Dhasmana	  et	  al.,	  2008).	  The	  risk	  factors	  and	  biomarkers	  of	  IRIS	  in	  
blood	   have	   been	   relatively	   well	   researched,	   especially	   in	   patients	   with	  
opportunistic	   infections	   such	   as	  Mycobacterium	  avium	  (mycobacterial	   disease),	  
Cryptococcus	   neoformans	   (cryptococcal	   meningitis)	   and	   CMV	   (Mahnke	   et	   al.,	  
2012).	  Fewer	  studies	  have	  documented	  the	  impact	  of	  HAART	  in	  the	  genital	  tract	  
and	  how	  the	  T-­‐cell	  distribution	  and	  differentiation	  profiles	  in	  the	  genital	  mucosa	  
differ	  from	  that	  of	  blood.	  The	  genital	  mucosa	  is	  an	  effector	  tissue	  site,	  constantly	  
exposed	  to	  organisms	  (including	  commensal	  and	  other	  opportunistic	   infections	  
with	  pathogenic	  viruses,	  bacteria,	  parasites	  and	  fungi)	  as	  well	  as	  antigens	   from	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the	   outside	   environment.	   Immune	   suppression	   during	   HIV	   infection	   and	  
subsequent	  immune	  reconstitution	  following	  initiation	  of	  HAART	  may	  therefore	  
influence	   immune	   responses	   to	   this	   overwhelming	   multitude	   of	   antigen	   and	  
pathogens	  typically	  encountered	  at	  this	  mucosal	  barrier.	  The	  effect	  of	  HAART	  on	  
immune	  responses	  and	  reconstitution	   in	   the	  genital	  mucosa	  may	  be	   influenced	  
by	   local	   factors	   in	   the	   genital	   microenvironment,	   including	   genital	   tract	  
inflammation	  or	  presence	  of	  common	  cytokine	  receptor	  γ-­‐chain	  family	  cytokines,	  
such	   as	   IL-­‐2,	   IL-­‐7	  or	   IL-­‐15,	  which	   are	   crucial	   for	   the	   formation	   and	   survival	   of	  
memory	  T-­‐cells).	  Recruitment,	  activation	  and	  differentiation	  of	   immune	  cells	   in	  
the	   genital	   tract	   have	   been	   linked	   to	   elevated	   levels	   of	   pro-­‐inflammatory	  
cytokines	  (such	  as	   IL-­‐1β	  and	  IL-­‐6)	  and	  have	  also	  been	  shown	  to	  be	   involved	   in	  
the	  differentiation	  of	  helper	  T-­‐cells	  via	  the	  Th1	  pathway	  (Crowley-­‐Nowick	  et	  al.,	  
2000;	   Nkwanyana	   et	   al.,	   2009)	   but	   the	   role	   of	   HAART	   in	   reducing	   genital	  
inflammation	   has	   not	   been	   fully	   elucidated.	   Also,	   the	   influence	   of	   other	  
underlying	   infections	   in	   the	   genital	  mucosa	   on	   immune	   reconstitution	   and	   the	  
inflammatory	  response	  during	  the	  initiation	  of	  HAART	  is	  still	  unclear	  (Couppié	  et	  
al.,	  2006;	  Posavad	  et	  al.,	  2004).	  Overall,	  while	  several	  studies	  have	  detailed	   the	  
longitudinal	   effects	   of	   HAART	   on	   the	   systemic	   immune	   activation	   and	  
inflammation,	  there	  are	  very	  few	  studies	  describing	  its	  impact	  in	  the	  genital	  tract	  
immune	  reconstitution,	  especially	  those	  describing	  the	  initial	  changes	  happening	  
at	  the	  very	  start	  of	  therapy	  in	  chronic	  HIV	  infected	  individuals.	  	  
	  
Specific	  Objective	  1:	  
To	  compare	  the	  level	  of	  inflammatory	  cytokines,	  and	  concomitant	  differentiation,	  
activation	  and	  exhaustion	  of	  T-­‐cells	  isolated	  from	  the	  genital	  tract	  and	  blood	  in	  a	  
cross-­‐sectional	  study	  of	  chronically	  HIV-­‐infected	  women	  on	  HAART.	  	  
	  
Hypothesis:	   HIV-­‐infected	   women	   on	   HAART	   will	   have	   reconstituted	   CD4+	   T-­‐cell	  
numbers	  in	  both	  blood	  and	  the	  genital	  compartment,	  that	  correlate	  with	  length	  of	  
time	   on	   HAART.	   A	   higher	   level	   of	   inflammation	   in	   the	   female	   genital	   tract	  
compared	  to	  blood	  will	  result	  in	  a	  higher	  degree	  of	  T-­‐cell	  activation	  at	  the	  mucosa	  
compared	   to	   in	   blood.	  Higher	   degrees	   of	   T-­‐cell	   activation	  may,	   in	   turn,	   cause	   an	  
imbalance	   in	   the	   quality	   of	   T-­‐cells	   present	   in	   the	   genital	   tract,	   with	   a	   higher	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proportion	  of	  effector	  memory	  T-­‐cells	  and	  a	  smaller	  proportion	  of	  central	  memory	  
T-­‐cells.	  
	  
Specific	  Objective	  2:	  To	  investigate	  the	  temporal	  association	  between	  initiation	  
of	   HAART	   on	   local	   genital	   versus	   blood	   T-­‐cell	   reconstitution,	   differentiation,	  
activation,	   exhaustion	   and	   inflammation	   in	   a	   longitudinal	   study	   of	   chronically	  
HIV-­‐infected	  women	  immediately	  before	  and	  1	  month	  after	  starting	  HAART.	  	  
	  
Hypothesis:	   Initiation	   of	   HAART	   will	   suppress	   both	   plasma	   viraemia	   and	   HIV	  
shedding	   in	   the	   genital	   tract	   and	   reduce	   the	   level	   of	   T-­‐cell	   activation	   in	   both	  
compartments	  as	  well	  as	   improving	   local	  genital	   tract	  and	  blood	  T-­‐cell	  numbers.	  
HIV-­‐infected	  women	   initiating	  HAART	  may	   exhibit	   symptoms	   of	   “genital	   IRIS”	   to	  




Chapter	  2.	  Materials	  and	  Methods	  
	  
2.1 Description	  of	  women	  enrolled	  in	  the	  study	  
A	   total	   of	   26	   HIV-­‐infected	   women	   were	   recruited	   from	   the	   Nyanga	   East	   Day	  
Clinic	  (Cape	  Town,	  South	  Africa)	  for	  this	  study	  to	  compare	  the	  impact	  of	  HAART	  
on	   CD4+	   T-­‐cell	   immune	   reconstitution	   and	   inflammation	   in	   the	   female	   genital	  
tract	   and	   blood.	   Of	   these	   26	   HIV-­‐infected	   women,	   15/26	   (57.7%)	   were	   on	  
antiretroviral	  therapy	  at	  the	  time	  of	  study	  and	  were	  included	  in	  a	  cross-­‐sectional	  
study	   (Chapter	   3).	   The	   remaining	   11/26	   (42.3%)	   women	   were	   recruited	  
immediately	  prior	  to	  starting	  HAART	  and	  1	  month	  after	  starting	  HAART	  (Chapter	  
4).	   Ethics	   approval	   was	   obtained	   for	   the	   study	   from	   the	   Faculty	   of	   Health	  
Sciences	  Research	  Ethics	  Committee	  (HREC	  Ref	  206/2002	  for	  the	  cross-­‐sectional	  
study	   and	   HREC	   Ref	   154/2012	   for	   the	   longitudinal	   study).	   Written	   informed	  
consent	  was	  obtained	  from	  all	  women.	  	  
	  
2.2 Clinical	  samples	  collection	  
At	   each	   visit,	   whole	   anti-­‐coagulated	   blood	   (~30	   ml)	   was	   collected	   from	   each	  
woman	   into	   acid	   citrate	   dextrose	   (ACD)	   vacutainers	   for	   isolation	   of	   peripheral	  
blood	   mononuclear	   cells	   (PBMCs).	   A	   cervical	   cytobrush	   sample	   was	   also	  
collected	  using	  a	  Digene	  cervical	  sampler	  (Qiagen,	  Hilden,	  Germany)	  according	  to	  
the	  method	  described	  by	  Gumbi	  et	  al.	  (2008).	  Briefly,	  the	  cytobrush	  was	  inserted	  
into	   the	   endocervical	   os	   under	   speculum	   examination,	   rotated	   360o	   to	   obtain	  
cervical	   cells	   and	   then	   placed	   in	   3ml	   of	   transport	  medium	   (10%	   FBS	   in	   RPMI	  
supplemented	  with	  penicillin,	  streptomycin,	  fungin	  and	  L-­‐glutamine,	  also	  known	  
as	  R10).	   Immediately	  after	  sampling,	   the	  cytobrush	  was	  kept	  at	  4oC	   in	  a	  bench	  
top	   cooler	   and	   transported	   to	   the	   laboratory	   for	   further	  processing	  within	  4-­‐6	  
hours	  of	  collection.	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2.3 Processing	  cervical	  mononuclear	  cells	  (CMCs)	  
The	   cervical	   cytobrush	   was	   rotated	   against	   the	   side	   of	   the	   15ml	   transport	  
centrifuge	  tube	  to	  dislodge	  the	  cells	  from	  the	  cytobrush.	  Using	  a	  sterile	  Pasteur	  
pipette,	   transport	  medium	  was	  used	   to	   flush	   the	   cytobrush	  bristles	  ~30	   times.	  
The	   cytobrush	   bristles	   were	   then	   gently	   scraped	   with	   the	   tip	   of	   the	   Pasteur	  
pipette	  to	  remove	  any	  remaining	  cells	  and	  the	  cytobrush	  removed	  from	  the	  tube	  
and	  discarded.	  The	  tube	  containing	  the	  cell	  suspension	  was	  centrifuged	  at	  320g	  
for	   10	   minutes	   to	   pellet	   the	   cervical	   cells.	   The	   supernatant	   fraction	   from	   the	  
cytobrush	   was	   transferred	   to	   two	   cryovials:	   (1)	   for	   measurement	   of	   genital	  
shedding	   of	   HIV-­‐RNA;	   and	   (2)	   for	   measurement	   of	   secreted	   cytokine	  
concentrations	  by	  luminex.	  The	  cell	  pellet	  was	  retained	  for	  cellular	  assays	  of	  the	  
CMC	  phenotype.	  The	  pelleted	  cells	  were	  resuspended	  in	  3ml	  of	  R10	  and	  washed	  
again	  by	  centrifuging	  at	  320g	  for	  10	  minutes.	  The	  supernatant	  was	  discarded	  and	  
the	  cell	  pellet	  was	  resuspended	  in	  100μl	  plain	  PBS	  for	  cell	  counting	  (section	  2.5)	  
and	  then	  used	  immediately	  for	  flow	  cytometry.	  	  
	  
2.4 PBMC	  isolation	  
PBMC	   isolation	  was	  carried	  out	  according	   to	   the	  protocol	  described	  previously	  
(Gumbi	   et	   al.,	   2008)	   using	   Ficoll-­‐Hypaque	   density	   gradient	   centrifugation	   and	  
Leucosep	  tubes	  (Greiner	  Bio	  One,	  Frickenhausen,	  Germany).	  Red	  blood	  cells	  and	  
granulocytes	  have	  a	  higher	  density	  than	  Ficoll	  and	  so,	  after	  centrifugation,	  they	  
collect	  below	  the	  Ficoll	  layer	  (underneath	  the	  porous	  polyethylene	  barrier)	  while	  
the	  mononuclear	  cells	  collect	  just	  above	  the	  barrier.	  	  
	  
All	  blood	  samples	  were	  processed	  within	  four	  hours	  of	  collection.	  Ficoll-­‐Hypaque	  
(15ml)	   was	   added	   to	   each	   of	   two	   50ml	   Leucosep®	   tubes	   (Greiner	   Bio-­‐one;	  
Frickenhausen,	  Germany)	  and	  the	  tubes	  were	  centrifuged	  at	  1257g	  for	  1	  minute	  
for	  the	  Ficoll	  to	  cross	  the	  porous	  barrier.	  Equal	  amounts	  of	  the	  whole	  blood	  were	  
then	  poured	  into	  the	  two	  tubes,	  which	  were	  then	  centrifuged	  at	  the	  same	  speed	  
for	  15	  minutes.	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A	   sterile	   Pasteur	   pipette	   was	   used	   to	   transfer	   the	   upper	   plasma	   layer	   to	   four	  
cryovials	   (for	   subsequent	   cytokine	   concentration	   measurement	   by	   Luminex).	  
The	   rest	  of	   the	  plasma	   layer	  and	  most	  of	   the	  platelets	  were	  discarded.	  Using	  a	  
fresh	   sterile	  pipette,	   the	   ‘buffy’	   layer	  of	  PBMCs	   (just	   above	   the	  porous	  barrier)	  
was	  carefully	   transferred	   from	  both	  Leucosep	   tubes	   to	  a	   sterile	  15ml	   tube	  and	  
1%	   wash	   buffer	   was	   used	   to	   top	   up	   the	   volume	   to	   15ml.	   The	   tube	   was	  
centrifuged	  at	  320g	  for	  10	  minutes	  and	  then	  the	  supernatant	  was	  discarded	  and	  
the	  cell	  pellet	  was	  loosened.	  The	  volume	  was	  made	  up	  to	  15ml	  using	  R10,	  the	  cell	  
suspension	   was	   mixed	   and	   the	   tube	   was	   centrifuged	   again	   at	   320g	   for	   10	  
minutes.	  The	  supernatant	  was	  discarded	  and	   the	  cell	  pellet	  was	  dislodged.	  The	  
PBMC	   were	   resuspended	   in	   2ml	   of	   R10	   for	   cell	   counting	   (section	   2.5)	   and	  
subsequently	  cryopreserved	  in	  liquid	  nitrogen	  (section	  2.6).	  	  
	  
2.5 Trypan	  Blue	  cell	  counting	  and	  viability	  measurement	  
The	  concentration	  and	  viability	  of	  PBMCs	  and	  CMCs	   isolated	  from	  each	  women	  
were	  determined	  using	  Trypan	  Blue	  counting	  on	  a	  light	  microscope.	  Trypan	  blue	  
cell	  counting	  is	  a	  dye-­‐exclusion	  assay	  based	  on	  the	  principle	  that	  live	  viable	  cells	  
are	  able	   to	  actively	   transport	   the	  dye	  particles	  out	  of	   the	  cells	   (appearing	  clear	  
under	  a	  light	  microscope)	  while	  dead	  cells	  do	  not	  (appearing	  blue	  under	  a	  light	  
microscope).	   The	   cell	   count	   was	   done	   using	   an	   improved	   Neubauer	   chamber,	  
which	  gave	  both	  the	  total	   lymphocyte	  count	  and	  the	  percentage	  viability	  of	   the	  
sample.	   Briefly,	   a	   10μl	   aliquot	   of	   the	   PBMCs	   or	   CMCs	  was	  mixed	  with	   10μl	   of	  
Trypan	   Blue	   and	   the	   mixture	   was	   carefully	   loaded	   onto	   the	   Neubauer	  
haemocytometer.	  The	  cell	  count	  was	  done	  at	  400x	  magnification.	  First,	  the	  total	  
number	   of	   cells	   (including	   all	   cells	   irrespective	   of	   whether	   they	   were	   stained	  
with	   dye	   or	   not)	   in	   two	   squares	   (A	   and	   B	   as	   shown	   in	   the	   figure	   2.1)	   were	  
counted.	  Second,	   the	  numbers	  of	  dead	  cells	   (only	   those	  stained	  with	   trypan)	   in	  
two	   squares	   were	   counted.	   The	   total	   number	   of	   viable	   cells	   as	   well	   as	   the	  
percentage	  viability	  was	  determined	  using	  the	  following	  formulae:	  
	  
1.	  Number	  of	  live	  cells	  =    !   !"#$ !  !  (!"#$)
!




2.%  𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 100 −   
𝐴 𝑑𝑒𝑎𝑑 + 𝐵(𝑑𝑒𝑎𝑑)
𝐴 𝑙𝑖𝑣𝑒 +   𝐵(𝑙𝑖𝑣𝑒)
  𝑥  100 
	  
	  
After	  determining	  PBMC	  numbers,	  cells	  were	  centrifuged	  at	  320g	  for	  10	  minutes	  
to	   pellet	   cells	   and	   the	   supernatant	   was	   discarded	   before	   adding	   the	   freezing	  
medium	  for	  cryopreservation	  (section	  2.6).	  	  
	  
	  
Figure	   2.1.	   Summary	  of	  method	  used	   for	  Trypan	  Blue	   cell	   counting.	  A	  10μl	   aliquot	  of	  
sample	  mixed	  with	  10μl	  of	  Trypan	  Blue	  dye	  was	  loaded	  onto	  the	  slide	  (as	  shown	  in	  blue	  
in	   the	   diagram).	   Using	   a	   microscope	   at	   400x	   magnification,	   the	   number	   of	   cells	  
appearing	  blue	  or	  clear	  were	  counted	  in	  2	  squares	  (labelled	  A	  and	  B)	  and	  the	  equations	  
described	   above	   were	   used	   to	   determine	   the	   number	   of	   viable	   cells	   in	   the	   10μl	   of	  
sample.	  	  
	  
2.6 Cryopreservation	  of	  PBMCs	  
PBMCs	  were	   cryopreserved	   in	   liquid	  nitrogen	   immediately	  after	   isolation	   from	  
whole	   blood.	   To	   prepare	   PBMCs	   for	   cryopreservation,	   freezing	   medium	   (FBS	  
containing	   10%	  DMSO)	  was	   used.	   The	   presence	   of	   10%	  DMSO	   in	   the	   freezing	  
medium	  served	   to	   reduce	  both	   the	   size	   and	   the	  number	  of	   ice	   crystals	   formed	  
during	  the	  freezing	  step	  by	  lowering	  the	  solute	  concentration,	  resulting	  in	  lower	  
ionic	   stress.	  All	   reagents	  were	  kept	  on	   ice	  during	   the	  process	   to	   slow	  down	  or	  










PBMCs	  pellets	  (section	  2.5)	  were	  resuspended	  in	  1ml	  of	  FBS,	  followed	  by	  1ml	  of	  
20%	  DMSO	  in	  FBS	  drop	  wise	  while	  mixing	  continuously.	  The	  cell	  suspension	  was	  
then	   transferred	   to	   two	   cryovials	   (1ml	   in	   each)	   and	   these	  were	   placed	   in	   pre-­‐
cooled	   ‘Mr	   Frosty®’	   (Nalgene;	   Rochester,	   NY,	   USA)	   freezing	   containers.	   These	  
were	  then	  placed	  at	  -­‐80oC	  overnight.	  In	  the	  “Mr	  Frosty”	  container,	  the	  cells	  were	  
surrounded	  by	  a	  layer	  of	  isopropanol,	  allowing	  the	  temperature	  to	  decrease	  from	  
-­‐4oC	  to	  -­‐80oC	  by	  1oC	  increments	  to	  limit	  the	  extent	  of	  cell	  death.	  The	  next	  day,	  the	  
cryopreservation	  tubes	  were	  transferred	  to	  liquid	  nitrogen.	  	  
	  
2.7 Thawing	  of	  PBMCs	  
PBMCs	  were	  thawed	  the	  day	  before	  each	  experiment	  to	  allow	  cells	  to	  “rest”	  and	  
to	  allow	  any	  apoptotic	  cells	  that	  were	  dying	  as	  a	  result	  of	  freeze/thawing	  to	  die	  
before	  the	  assay	  was	  carried	  out.	  Thawing	  was	  done	  quickly	  while	  dilution	  of	  the	  
freezing	  medium,	  containing	  DMSO,	  with	  R1	  (1%	  FBS	  in	  RPMI)	  was	  done	  slowly	  
to	  avoid	  cell	  death	  and	  clumping.	  For	  this	  study,	  PBMCs	  were	  thawed	  by	  placing	  
cryovials	  in	  a	  37oC	  waterbath	  until	  only	  a	  small	  ice	  crystal	  remained	  in	  the	  vial.	  
Each	   vial	   was	   then	   wiped	   with	   70%	   alcohol	   and	   transferred	   to	   the	   biosafety	  
hood.	  R1	  was	  added	  to	  the	  cryovial	  drop	  wise	  while	  mixing	  continuously	  and	  the	  
cell	   suspension	   was	   transferred	   to	   a	   sterile	   15ml	   tube.	   The	   cryoprotectant,	  
DMSO,	   has	   to	   be	   diluted	   at	   least	   30-­‐fold	   to	   limit	   the	   extent	   of	   cell	   death	   and	  
therefore,	   the	   volume	   was	   made	   up	   to	   15ml	   with	   more	   R1.	   The	   tube	   was	  
centrifuged	   at	   320g	   for	   10	   minutes,	   the	   supernatant	   was	   discarded	   and	   the	  
pelleted	  cells	  were	  resuspended	  in	  500μl	  of	  diluted	  DNase	  to	  prevent	  clumping	  
of	   dead	   cells.	   The	   cell	   suspension	  was	   allowed	   to	   stand	   for	   2	  minutes	   at	   room	  
temperature.	   The	   volume	   was	   made	   up	   to	   15ml	   with	   R10	   and	   the	   tube	   was	  
centrifuged	   at	   320g	   for	   10	  minutes.	   The	   supernatant	  was	   discarded,	   the	   pellet	  
was	  loosened	  and	  the	  cells	  were	  resuspended	  in	  5ml	  of	  R20.	  The	  cells	  were	  left	  
to	   incubate	   in	   a	   5%	  CO2	   and	  37oC	   incubator	   overnight	   before	   carrying	   out	   the	  
experiment	  the	  next	  day.	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2.8 Intracellular	  staining	  (ICS)	  and	  flow	  cytometry	  
A	  ten-­‐colour	  polychromatic	  flow	  cytometry	  panel	  was	  designed	  and	  optimised	  as	  
part	   of	   this	   study	   (described	   in	   detail	   in	   appendix	   II)	   to	  measure	   the	  memory	  
phenotype	   (CD45RO	   and	   CCR7),	   level	   of	   activation	   (CD38	   and	   HLA-­‐DR),	  
proliferation	   (Ki67)	   and	   exhaustion	   (CD57)	   of	   CD4+	   and	   CD8+	   T-­‐cells	   isolated	  
from	  PBMCs	  and	  CMCs.	  A	  dump	  channel	  was	  also	  added	  in	  the	  panel	  to	  exclude	  
dead	  cells,	  B-­‐cells	  and	  monocytes	  (with	  VIVID,	  CD14	  and	  CD19,	  respectively).	  
2.9 Staining	  the	  PBMC	  and	  CMC	  samples	  
CMC	  samples	  were	  stained	  and	  assessed	  in	  real	  time	  (fresh)	  while	  PBMC	  samples	  
were	   cryopreserved,	   thawed	   and	   assessed	   in	   batches.	   For	   PBMCs,	   cells	   were	  
adjusted	   to	   1x106	   cells/ml	   with	   PBS.	   An	   aliquot	   of	   1ml	   was	   transferred	   to	   a	  
sterile	   tube.	  For	  CMCs,	   the	  whole	  sample	  was	  used	   in	  a	  single	   tube	   for	  a	  single	  
staining	   reaction	   because	   cell	   numbers	   from	   a	   single	   cytobrush	   are	   generally	  
low.	  	  
	  
Before	   adding	   antibodies	   to	   each	   tube,	   PBMCs	   and	   CMCs	   were	   centrifuged	   at	  
320g	   for	   10	   minutes	   and	   the	   supernatant	   was	   discarded.	   The	   cell	   pellet	   was	  
loosened,	  resuspended	   in	  100μl	  of	  PBS	  and	  transferred	  to	  one	  of	   the	  wells	   in	  a	  
96-­‐well	  V-­‐bottomed	  plate	  (Corning;	  Tewksbury	  MA).	  The	  plate	  was	  centrifuged	  
at	  1215g	  at	  4oC	  for	  3	  minutes,	  the	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  
loosened.	  The	  cells	  were	  washed	  once	  more	  with	  150μl	  PBS	  to	  ensure	  that	  all	  the	  
protein	   in	   solution	  was	   removed.	   The	   supernatant	  was	   discarded	   and	   the	   cell	  
pellet	  was	  resuspended	  in	  50μl	  of	  pre-­‐titrated	  Vivid	  (live/dead	  cell	  marker).	  The	  
plate	  was	  allowed	  to	  incubate	  in	  the	  dark	  at	  room	  temperature	  for	  20	  minutes.	  
The	  cells	  were	  washed	  twice	  with	  PBS	  (with	  100μl	  for	  the	  first	  wash	  and	  150μl	  
for	   the	   second	   wash)	   and	   the	   plate	   was	   centrifuged	   at	   1215g	   at	   4oC	   for	   3	  
minutes.	   The	   cells	   were	   first	   stained	   for	   the	   extracellular	   markers	   (CD8,	   CD4,	  
CD14,	   CD19,	   CCR7,	   HLA-­‐DR,	   CD45RO,	   CD38	   and	   CD57)	   using	   an	   extracellular	  
staining	   cocktail	   of	   pre-­‐titrated	   antibody	   volumes	   for	   in	   PBS	   (procedure	  
described	   in	   appendix	   II,	   section	  A2.3).	   For	   this,	   50μl	   of	   the	   antibody	  mix	  was	  
added,	   the	  cell	  suspension	  was	  carefully	  mixed	  and	  the	  plate	  was	   incubated	  on	  
ice	  for	  30min	  before	  washing	  twice	  with	  PBS,	  as	  described	  earlier.	  The	  cell	  pellet	  
 57 
was	   loosened	  and	   resuspended	   in	  100μl	  of	  Cytofix/Cytoperm	  (BD	  Biosciences)	  
to	  fix	  and	  permeabilise	  the	  cells	  and	  the	  plate	  was	  placed	  on	  ice	  to	  incubate	  for	  
20	  minutes.	  After	  this,	  the	  cells	  were	  washed	  twice	  with	  PermWash	  (with	  100μl	  
and	   150μl	   respectively)	   and	   the	   plate	   was	   centrifuged	   at	   1215g	   at	   4oC	   for	   3	  
minutes	   both	   times.	   Next,	   50μl	   of	   the	   intracellular	   staining	   cocktail	   containing	  
pre-­‐titrated	  volumes	  of	  antibodies	  for	  CD3	  and	  Ki67	  in	  PBS	  was	  added,	  the	  cell	  
suspension	   was	   carefully	   mixed	   and	   the	   plate	   was	   placed	   on	   ice	   for	   30min.	  
Staining	   for	   CD3	   was	   done	   following	   permeabilisation	   (intracellularly)	   as	  
stimulation	  of	  cells	  can	  sometimes	  cause	  the	  internalization	  of	  the	  CD3	  receptor,	  
which	  is	  usually	  expressed	  on	  the	  surface	  of	  T-­‐cells.	  The	  cells	  were	  again	  washed	  
twice	   with	   PermWash.	   The	   supernatant	   was	   discarded	   and	   the	   pellet	   was	  
dislodged.	  The	  cells	  were	  resuspended	  with	  100μl	  Cellfix	  to	  fix	  them	  and	  the	  cells	  
suspension	  was	  transferred	  to	  a	  5ml	  FACS	  tube.	  The	  well	  was	  rinsed	  again	  with	  
150μl	  Cellfix,	  which	  was	   also	   transferred	   to	   the	  FACS	   tube.	  The	   tube	  was	   then	  
wrapped	  in	  aluminium	  foil	  (to	  keep	  it	  in	  the	  dark)	  and	  stored	  in	  the	  fridge,	  at	  4oC,	  
until	   acquisition	   of	   flow	   cytometry	   data	   using	   the	   BD	   LSRFortessaTM.	   All	   the	  
samples	   were	   acquired	   within	   48	   hours	   of	   staining.	   For	   PBMCs,	   1x106	  events	  
were	  acquired	  while	  the	  whole	  sample	  was	  acquired	  for	  CMCs.	  The	  data	  obtained	  
was	  then	  analysed	  using	  FlowJo	  software	  (version	  9.6.2;	  Treestar;	  Ashland,	  OR)	  
	  
2.9.1 Preparation	  of	  compensation	  tubes	  
Compensation	   tubes	   are	   prepared	   every	   time	   a	   sample	  was	   acquired.	   Samples	  
have	   to	  be	  compensated	   to	  avoid	  spectral	  overlap	  when	  several	   fluorochromes	  
are	  simultaneously	  used	  (described	  in	  appendix	  II).	  For	  compensation,	  a	  control	  
tube	  (no	  antibodies)	  and	  a	  series	  of	  singly-­‐stained	  tubes	  for	  each	  antibody	  in	  the	  
panel	  were	  prepared.	  A	  total	  of	  11	  compensation	  tubes	  were	  used	  in	  this	  study,	  
one	   for	   each	  of	   the	   ten	   fluorochromes	   and	  one	   for	   the	  unstained	   control.	  Both	  
negative	   and	   positive	   BD	   CompBeadsTM	   (BD	   Biosciences)	   were	   used	   for	   the	  
compensation	  tubes.	  The	  positive	  CompBeads	  are	  used	  to	  bind	  to	  the	  Kappa	  light	  
chain	   of	   immunoglobulins	   raised	   in	   mice,	   rats	   or	   hamsters	   and	   emit	   a	   strong	  
fluorescence	  signal	  irrespective	  of	  the	  attached	  antibody.	  The	  unstained	  control	  
tube	   was	   included	   to	   determine	   the	   background	   noise	   produced	   from	   the	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scattered	   light	   falling	   on	   the	   detector	   and	   the	   singly-­‐stained	   tubes	   are	   used	   to	  
determine	   the	   range	   of	   each	   of	   the	   fluorochromes	   in	   the	   panel	   (Seddon	   et	   al.,	  
2003).	  	  
	  
To	   the	   eleven	  5ml	   FACS	   tubes	   to	   be	   used	   for	   compensation,	   100μl	   of	   PBS	  was	  
added,	  followed	  by	  one	  drop	  each	  of	  the	  positive	  and	  the	  negative	  CompBeadsTM	  
beads.	  For	  this	  study,	  except	  for	  the	  anti-­‐CCR7-­‐PECy7	  compensation	  tube	  (where	  
anti-­‐rat	   beads	   were	   used	   because	   this	   monoclonal	   was	   raised	   in	   rats),	   anti-­‐
mouse	   beads	   were	   used	   for	   all	   other	   compensation	   tubes	   (because	   all	   other	  
monoclonal	  antibodies	   included	   in	   the	  panel	  were	   from	  mice).	  The	  CompBeads	  
vials	   were	   vortexed	   thoroughly	   for	   about	   1	   minute	   to	   avoid	   clumping	   of	   the	  
beads.	  The	  pre-­‐titrated	  volume	  of	  each	  antibody	  (detailed	  in	  Appendix	  II,	  section	  
A2.3)	   was	   added	   to	   each	   of	   the	   respective	   compensation	   tube.	   For	   the	   dump	  
channel,	   either	   anti-­‐CD14-­‐PacificBlue	   or	   anti-­‐CD19-­‐PacificBlue	   was	   used.	   The	  
tubes	  were	  incubated	  on	  ice	  for	  20min	  before	  washing	  the	  beads	  by	  adding	  1ml	  
of	   PBS	   and	   centrifuging	   at	   1215g	   at	   4oC	   for	   3	   minutes.	   The	   supernatant	   was	  
discarded	   and	   the	   beads	   were	   fixed	   in	   250μl	   of	   Cellfix.	   The	   tubes	   were	   then	  
wrapped	  into	  aluminium	  foil	  and	  kept	  at	  4oC	  in	  the	  fridge	  until	  acquisition	  on	  the	  
BD	  LSRFortessa.	  	  
	  
2.9.2 Fluorescence	  Minus	  One	  (FMO)	  controls	  
FMO	  controls,	  in	  flow	  cytometry,	  consist	  of	  cells	  treated	  with	  all	  the	  antibodies	  of	  
the	   panel	   being	   investigated	   except	   one	   (described	   in	   detail	   in	   appendix	   II,	  
section	  A2.6).	   In	  addition	  to	  showing	  the	  amount	  of	  non-­‐specific	  binding	  (since	  
the	  cells	  have	  been	  labelled	  with	  all	  the	  fluorochromes	  except	  one),	  FMO	  controls	  
help	   to	  define	   the	  position	  of	   the	  positive	  population	  as	  well	   as	   the	   location	  of	  
double	  positives	  on	  the	  scatter	  plots.	  	  
	  
To	  prepare	  the	  FMO	  controls,	  50μl	  Vivid	  was	  added	  to	  aliquots	  of	  1x106	  cells	  in	  a	  
96-­‐well	   V-­‐bottomed	   plate	   and	   the	   plate	   incubated	   in	   the	   dark	   at	   room	  
temperature.	   After	   washing	   the	   cells	   with	   PBS,	   extracellular	   and	   intracellular	  
staining	   (as	  previously	  described	   in	  Section	  2.8)	  was	   carried	  out	  while	  making	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sure,	   for	   each	   particular	   tube,	   that	   the	   antibody	   for	  which	   the	   FMO	  was	   being	  
carried	  out	  was	  not	   included.	  The	  cells	  were	  resuspended	  with	  100μl	  Cellfix	   to	  
fix	  them	  and	  the	  cells	  suspension	  was	  transferred	  to	  a	  5ml	  FACS	  tubes.	  Each	  well	  
was	  rinsed	  again	  with	  150μl	  Cellfix,	  which	  was	  also	  transferred	  to	  the	  respective	  
FACS	   tubes.	  The	   tubes	  were	   then	  wrapped	   in	   aluminium	   foil	   (to	   keep	   it	   in	   the	  
dark)	   and	   stored	   in	   the	   fridge,	   at	   4oC,	   until	   acquisition	   of	   using	   the	   BD	  
LSRFortessaTM	  and	  at	  least	  100,000	  events	  were	  acquired	  for	  each	  tube	  
	  
2.9.3 Quantitative	  determination	  of	  cytokine	  concentrations	  
Multiplex	  luminex	  flow	  cytometry	  was	  used	  to	  measure	  cytokine	  concentrations	  
in	   blood	   plasma	   and	   cervical	   secretions	   (collected	   and	   stored	   as	   described	   in	  
sections	  2.3	  and	  2.4)	  obtained	  from	  8/15	  of	  the	  women	  from	  the	  cross-­‐sectional	  
part	  of	   the	  study	   (Chapter	  3)	  and	   for	  all	   (11/11)	  women	   from	  the	   longitudinal	  
study	  (Chapter	  4).	  A	  Human	  Cytokine	  Group	  I	  10-­‐plex	  kit	   (Bio-Rad Laboratories 
Inc®)	  was	  used	  to	  determine	  the	  concentration	  of	  seven	  inflammatory	  cytokines	  
(IL-­‐1β,	   IL-­‐6,	   IL-­‐8,	   IP-­‐10,	   MIP-­‐1α,	   MIP-­‐1β	   and	   TNF-­‐	   α),	   two	   hematopoietic	  
cytokines	  (IL-­‐7	  and	  G-­‐CSF)	  and	  a	  regulatory	  cytokine	  (IL-­‐10).	  	  
	  
Bio-­‐Plex	   luminex	   kits	   (Bio-Rad Laboratories Inc®)	   are	   composed	   of	  microscopic	  
magnetic	   polystyrene	   beads	   ~5.6μm	   in	   diameter,	   which	   have	   distinct	   spectral	  
properties	   to	   allow	   discrimination	   between	   the	   different	   assays	   (Tighe	   et	   al.,	  
2013).	   The	   beads	   are	   dyed	  with	   specific	   proportions	   of	   red	   and	   near-­‐infrared	  
fluorophores,	   which	   define	   the	   different	   spectral	   capabilities	   for	   each	   bead	  
population.	   The	   luminex	   apparatus	   used	   to	   read	   the	   plates	   in	   this	   study	  had	   a	  
three-­‐colour	   signal	   detection	   system.	   Two	   of	   the	   colours	   are	   used	   for	   the	  
microsphere	   classification	   and	   the	   third	   colour	   to	   measure	   the	   fluorescence	  
intensity	  from	  the	  different	  wells.	  In	  principle,	  the	  assay	  is	  similar	  to	  a	  sandwich	  
ELISA.	  The	  magnetic	  beads	  were	  coupled	  with	  capture	  antibodies	  specific	  for	  the	  
cytokine	   of	   interest.	  When	   the	   samples	   are	   added	   to	   the	   wells,	   these	   coupled	  
beads	  bind	  to	  the	  biomarker	  of	  interest.	  The	  unbound	  protein	  is	  removed	  using	  a	  
series	  of	  wash	  steps	  and	  then	  a	  biotinylated	  detection	  antibody	  is	  added,	  forming	  
the	  sandwich	  complex.	  Finally,	   streptavidin-­‐phycoerythrin	   (SA-­‐PE)	  conjugate	   is	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added,	  where	  the	  phycoerythrin	  works	  as	  the	  fluorescent	  signal	  recorded	  by	  the	  
Luminex	  instrument.	  	  
	  
2.9.4 Preparation	  of	  the	  samples	  
Plasma	  and	  cervical	  supernatant	  samples	  were	  gently	  thawed	  by	  placing	  them	  on	  
ice	   at	   4oC	   overnight.	   Immediately	   before	   starting	   the	   assay,	   the	   samples	   were	  
centrifuged	   at	   1950g	   for	   10	   minutes	   at	   4oC	   in	   SPIN-­‐X®	   centrifuge	   tube	   filters	  
(0.22μm	   cellulose	   acetate	   filters;	   Corning	   Inc,	   NY)	   to	   exclude	   any	   particulate	  
debris.	  	  
	  
2.9.5 Preparation	  of	  the	  standards	  
Samples	  for	  the	  standard	  curves	  were	  prepared	  by	  1:4	  serial	  dilution	  according	  
to	  the	  manufacturers	  guidelines,	  with	  separate	  standard	  curves	  being	  prepared	  
for	   plasma	   and	   genital	   secretions.	   Briefly,	   the	   individual	   lyophilised	   standards	  
for	   each	   cytokine	  provided	   in	   the	   kit	  were	   reconstituted	  using	  500μl	  R10.	  The	  
vial	  was	  vortexed	  gently	  for	  1-­‐3	  seconds	  and	  then	  placed	  on	  ice	  for	  30	  minutes.	  
The	  dilution	  series	  for	  plasma	  samples	  was	  made	  up	  using	  the	  provided	  serum-­‐
based	  standard	  diluent	  while	  the	  one	  for	  the	  genital	  samples	  was	  made	  up	  using	  
more	  R10	  as	  diluent.	   For	   the	  plasma	   standard	   curve,	   the	   standard	  diluent	  was	  
used	   as	   the	   blank,	   while	   R10	   was	   used	   for	   the	   blank	   for	   the	   genital	   sample	  
standard	  curve.	  	  
	  
2.9.6 Preparation	  of	   coupled	  beads,	  detection	  antibodies	  and	  streptavidin-­‐
PE	  
Each	  of	  the	  96	  wells	  required	  5μl	  of	  coupled	  beads	  adjusted	  to	  a	  final	  volume	  of	  
50μl.	  To	  prepare	  the	  coupled	  beads,	  4.6ml	  of	  assay	  buffer	  was	  added	  to	  a	  15ml	  
tube,	   followed	   by	   575μl	   of	   the	   stock	   coupled	   beads	   (10X)	   for	   each	   of	   the	  
cytokines	  to	  obtain	  a	  final	  volume	  of	  5.75ml	  of	  1X	  coupled	  beads.	  The	  tube	  was	  
wrapped	  in	  foil	  and	  allowed	  to	  equilibrate	  for	  20	  minutes	  before	  use.	  Each	  well	  
of	   the	   assay	   required	  2.5μl	   of	   detection	   antibody	   adjusted	   to	   a	   final	   volume	  of	  
25μl.	  To	  achieve	  this,	  2.4ml	  of	  assay	  buffer	  was	  added	  to	  a	  15ml	  tube,	   followed	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by	   300μl	   of	   the	   stock	   detection	   antibodies	   (10X)	   for	   each	   of	   the	   cytokines	   to	  
obtain	  a	   final	  volume	  of	  3ml	  of	  1X	  detection	  antibodies.	  Each	  well	   in	   the	  assay	  
required	  0.5μl	  of	  streptavidin-­‐PE	  adjusted	  to	  a	   final	  volume	  of	  50μl.	  To	  achieve	  
this,	  5.94ml	  of	   assay	  buffer	  was	  added	   to	  a	  15ml	   tube,	   followed	  by	  60μl	  of	   the	  
stock	  streptavidin-­‐PE	  (100X)	  for	  each	  of	  the	  cytokines	  to	  obtain	  a	  final	  volume	  of	  
6ml	   of	   a	   1X	   solution	   of	   streptavidin-­‐PE.	   This	   solution	   was	   only	   made	   up	   10	  
minutes	  before	   it	  was	  needed.	  The	  tube	  was	  again	  wrapped	   in	   foil	   to	  protect	   it	  
from	  light	  until	  needed.	  	  
	  
2.9.7 Detailed	  method	  for	  the	  Luminex	  assay	  
The	  diluted	  coupled	  beads	  were	  vortexed	  for	  30	  seconds	  at	  medium	  speed	  and	  
poured	  into	  a	  petri	  dish.	  Using	  a	  multichannel	  pipette,	  50μl	  was	  added	  to	  all	  the	  
96	  wells.	  The	  plate	  was	  covered	  with	  a	  layer	  of	  sealing	  tape,	  wrapped	  in	  foil	  and	  
allowed	  to	  incubate	  on	  a	  shaker	  for	  30	  minutes.	  The	  plate	  was	  then	  washed	  twice	  
as	  follows:	  100μl	  of	  wash	  buffer	  was	  added	  to	  each	  well,	  the	  plate	  was	  placed	  on	  
the	   shaker	   for	   30	   seconds	   and,	   using	   a	   hand-­‐held	   magnetic	   plate	   washer	  
(Milliplex®),	   the	  plate	  was	   inverted	  and	  all	   the	   liquid	  was	  discarded.	  The	  plate	  
was	  then	  blotted	  on	  a	  clean	  piece	  of	  tissue	  to	  remove	  any	  excess	  liquid.	  After	  this,	  
50μl	   of	   the	   standards,	   blanks	   and	   samples	  were	   added	   to	   the	   respective	  wells,	  
the	   plate	   was	   covered	   with	   sealing	   tape,	   wrapped	   in	   foil	   and	   was	   allowed	   to	  
incubate	  at	  room	  temperature	  on	  a	  shaker	   for	  30	  minutes.	  The	  standards	  were	  
added	  in	  duplicates	  and	  two	  wells	  were	  used	  as	  blanks	  for	  each	  standard	  curve.	  
The	  samples	  were	  not	  diluted	  before	  being	  added	  to	  the	  wells.	  	  The	  sealing	  tape	  
was	   removed	   and	   the	   plate	  was	   then	  washed	   three	   times	   as	   described	   above.	  
Using	  a	  multichannel	  pipette,	  25μl	  of	  diluted	  detection	  antibodies	  was	  added	  to	  
each	  well.	  The	  plate	  was	  covered	  with	  a	  new	  sheet	  of	  sealing	   tape,	  wrapped	   in	  
foil	  and	  incubated	  on	  the	  shaker	  for	  30	  minutes.	  After	  incubation,	  the	  plate	  was	  
washed	  three	  times	  again	  and	  125μl	  of	  assay	  buffer	  was	  added	  to	  each	  well.	  The	  
plate	  was	  covered	  with	  a	  clean	  sheet	  of	  sealing	  tape	  and	  placed	  on	  the	  shaker	  at	  
1100rpm	  for	  30	  minutes.	  The	  sealing	  tape	  was	  then	  removed	  and	  the	  plate	  was	  
placed	   on	   the	   reader	   to	   be	   read	   and	   analysed	   using	   the	   Bio-­‐Plex	   Manager	  
softwareTM	   6.0	   at	   a	   low	   PMT	   setting.	   	   All	   incubation	   periods	   were	   closely	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monitored	   and	   kept	   consistent	   for	   optimal	   assay	   performance	   and	  
reproducibility.	  	  
	  
The	  sensitivity	  of	  the	  kit	  ranged	  from	  0.3pg/ml	  to	  2.6pg/ml	  for	  the	  ten	  cytokines	  
measured.	   The	   fluorescence	   data	   was	   acquired	   using	   a	   Bio-­‐PlexTM	   Suspension	  
Array	   Reader	   (Bio-­‐Rad	   Laboratories	   Inc®)	   and	   a	   5	   PL	   regression	   formula	  was	  
used	   to	  derive	   the	   cytokine	   concentrations	   from	   the	   standard	   curves.	  Cytokine	  
concentrations	  that	  were	  read	  as	   ‘below	  detectable	   level’	  were	  reported	  as	  half	  
the	   value	   of	   the	   lowest	   concentration	   measured	   for	   that	   particular	   cytokine	  
(Roberts	  et	  al.,	  2010).	  Figure	  2.2	  gives	  a	  summary	  of	  the	  steps	  described	  above.	  	  
	  
	  
Figure	  2.2.	  Steps	  involved	  in	  preparing	  the	  plate	  for	  analysis	  by	  the	  multiplex	  Luminex	  
platform	  (Geng	  and	  Ma,	  2012).	  	  
	  
2.10 Measurement	  of	  HIV	  loads	  
Viral	  loads	  in	  the	  genital	  secretions	  and	  plasma	  samples	  (collected	  as	  described	  
in	  sections	  2.3	  and	  2.8)	  from	  8/15	  of	  the	  women	  from	  the	  cross-­‐sectional	  study	  
and	   all	   (11/11)	   of	   the	   women	   from	   the	   longitudinal	   study	   were	   determined	  
using	  the	  Abbott®	  m2000	  RealTime	  HIV-­‐1	  assay	  by	  the	  NHLS	  Diagnostic	  Virology	  
Laboratory	   (Groote	   Schuur	  Hospital).	   This	   assay	   consists	   of	   an	   in-­‐vitro	   reverse	  
transcription-­‐polymerase	  chain	  reaction	  (RT-­‐PCR)	  assay	   for	   the	  quantitation	  of	  
HIV-­‐1	   over	   the	   range	   of	   40	   to	   10,000,000	   copies/ml.	   Using	   a	   partially	   double	  
stranded	   probe,	   it	   targets	   the	   integrase	   region	   of	   the	   polymerase	   gene	   in	   the	  
virus	   (http://www.abbottmolecular.com/products/infectious-­‐diseasesrealtime-­‐
pcr/hiv-­‐1-­‐assay.html).	   The	   detection	   limit	   of	   the	   assay	   was	   40	   HIV-­‐RNA	  
copies/ml	  (Abbott	  Laboratories,	  2013).	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2.11 Screening	  for	  sexually	  transmitted	  infections	  (STIs)	  
All	  11	  women	  involved	  in	  the	  longitudinal	  study	  (Chapter	  4)	  were	  screened	  for	  
STIs,	   including	   Neisseria	   gonorrhoeae,	   Chlamydia	   trachomatis,	   Trichomonas	  
vaginalis	  and	  Mycoplasma	  genitalium	  at	  each	  of	  visit	  by	  nucleic	  acid	  amplification	  
using	   a	   real-­‐time	  multiplex	  PCR	  assay	   (Lewis	   et	   al.,	   2013).	   STI	   testing	  was	  not	  
done	  on	  the	  15	  women	  enrolled	  in	  the	  cross-­‐sectional	  study	  (Chapter	  3).	  Testing	  
for	   STIs	   was	   performed	   at	   the	   Centre	   for	   HIV	   and	   STIs,	   National	   Institute	   for	  
Communicable	  Diseases	  in	  the	  laboratory	  of	  Prof	  David	  Lewis.	  A	  MG	  Real-­‐TM	  kit	  
(Sacace	   Biotechnologies)	   was	   used	   for	  Mycoplasma	   genitalium	   and	   the	   target	  
region	  of	  the	  kit	  was	  DNA	  gyrase	  subunit	  B.	  Similar	  kits	  using	  the	  general	  Sacace	  
protocol	  was	  used	  for	  the	  three	  other	  STIs	  with	  a	  specific	  target	  region	  for	  each	  
of	   them.	   Genomic	   DNA	   extracted	   from	   M.	   genitalium	   (ATCC	   33530),	   N.	  
gonorrhoeae	  (ATCC	  700825	  or	  ATCC	  49226	  or	  WHO	  Control	  strains),	  T.	  vaginalis	  
(ATCC	  30001)	  and	  C.	  trachomatis	  (VR-­‐885)	  were	  used	  as	  positive	  controls	  in	  this	  
assay.	  	  
	  
2.12 Statistical	  analysis	  
Statistical	   analysis	   was	   performed	   using	   GraphPad	   Prism	   (version	   6.0;	   San	  
Diego).	   The	   Shapiro-­‐Wilk	   test	   was	   used	   to	   determine	   the	   distribution	   of	  
variables.	   The	  Mann-­‐Whitney	  U	   test	  was	   used	   to	   compare	   unmatched	   samples	  
while	  the	  Wilcoxon	  Signed	  Rank	  test	  was	  used	  for	  paired	  samples.	  Correlations	  
between	  the	  different	  groups	  were	  determined	  by	  the	  non-­‐parametric	  Spearman	  
rank	  correlation	  test.	  Linear	  regression	  was	  used	  to	  determine	  the	  relationship	  




Chapter	  3.	  Impact	  of	  long-­‐term	  HAART	  in	  
chronic	  HIV-­‐infected	  women	  
	  
3.1 Introduction	  
Chronic	  HIV	  infection	  is	  marked	  by	  the	  progressive	  loss	  of	  CD4+	  T-­‐cells,	  excessive	  
immune	   activation,	   inflammation,	   exhaustion	   and	   an	   overall	   immune	  
dysfunction.	  (reviewed	  by	  Hunt,	  2012).	  HAART	  has	  a	  differential	  effect	  on	  T-­‐cell	  
activation	   and	   phenotype	   in	   blood	   and	   in	   the	   genital	   tract.	   HAART	   given	   to	  
individuals	  infected	  with	  HIV	  has	  consistently	  been	  shown	  to	  improve	  quality	  of	  
life,	   prevent	   AIDS	   and	   reduce	   the	   rate	   of	   mortality	   and	   morbidity.	   In	   blood,	  
HAART	   leads	   to	   durable	   viral	   suppression,	   in	   association	   with	   significant	  
reconstitution	  in	  CD4+	  T-­‐cell	  numbers	  (reviewed	  by	  Okoye	  &	  Picker,	  2013).	  CD4+	  
T-­‐cell	   reconstitution	  was	   in	   turn	  associated	  with	  decreased	   immune	  activation,	  
inflammation,	  T-­‐cell	  exhaustion	  (reviewed	  by	  Sauce	  et	  al.,	  2013),	  and	  correction	  
of	   the	   imbalance	   in	   the	   distribution	   of	   the	   different	   memory	   T-­‐cell	   subsets	  
(Hellerstein	   et	   al.,	   2003).	   Compared	   to	   HIV-­‐negative	   individuals,	   HIV-­‐infected	  
individuals	   have	   been	   shown	   to	   have	   high	   levels	   of	   immune	   activation	   and	  
inflammatory	  cytokine	  concentrations	  systemically,	  which	  do	  not	  return	  to	  pre-­‐
infection	   levels	  even	  after	  several	  years	  on	  HAART.	  Several	  recent	  studies	  have	  
also	   shown	   that	   CD4+	   T-­‐cell	   counts	   continue	   to	   slowly	   decrease,	   even	   in	   the	  
presence	  of	  HAART	  (reviewed	  by	  Okoye	  &	  Picker,	  2013),	  in	  combination	  with	  a	  
continued	  accumulation	  of	  exhausted	  T-­‐cells,	  (reviewed	  by	  Sauce	  et	  al.	  ,	  2013).	  	  
	  
There	   are	   fewer	   studies	   on	   the	   impact	   of	   HAART	   on	   immune	   activation,	  
inflammation,	  memory	  marker	  distribution	  and	  exhaustion	  in	  T-­‐cells	  circulating	  
to	  the	  genital	  tract,	  the	  site	  where	  most	  of	  the	  HIV	  infections	  occur	  and	  how	  this	  
compares	   to	   blood	   (Coombs	   et	   al.,	   2001).	   Typically,	   immunity	   in	   the	   female	  
genital	   tract	   is	  not	  contained	  within	  organised	   lymphoid	   tissues	  such	  as	   lymph	  
nodes	  and	  Peyer’s	  patches	  found	  in	  the	  gut	  associated	  lymphoid	  tissue.	  Instead,	  
DCs,	  B-­‐	  and	  T-­‐cells	  present	  in	  or	  beneath	  the	  epithelial	  barrier	  in	  lamina	  propria	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of	   the	   vagina	   and	   cervix	   may	   be	   involved	   in	   the	   response	   to	   HIV	   infection	  
(reviewed	   by	   Iwasaki,	   2010).	   Exposure	   of	   the	   genital	  mucosa	   to	  HIV	   has	   been	  
shown	  to	   lead	  to	   the	  upregulation	  of	  cytokines/chemokine	  and	  their	  receptors,	  
resulting	  in	  the	  activation	  and	  recruitment	  of	  more	  T-­‐cells	  (reviewed	  by	  Xu	  et	  al.,	  
2013).	  Cytokines	  such	  as	  interferons,	  TNF-­‐	  α	  MIP-­‐1α,	  MIP-­‐1β	  and	  RANTES	  have	  
been	  found	  to	  be	  overexpressed	  in	  the	  genital	  tract	  (Lajoie	  et	  al.,	  2008;	  reviewed	  
by	  Xu	  et	  al.,	  2013).	  In	  the	  mucosa,	  as	  in	  blood,	  HIV	  infection	  is	  accompanied	  by	  a	  
drastic	   depletion	   of	   the	   activated,	   memory	   CD4+	   T-­‐cells	   (Gumbi	   et	   al.,	   2011;	  
Mehandru	  et	  al.,	  2004).	  	  
	  
Nkwanyana	   et	   al.	   (2009)	   evaluated	   the	   effect	   of	   HIV	   infection	   and	   HAART	   on	  
genital	  tract	  inflammation	  and	  mucosal	  memory	  cell	  distribution	  in	  women.	  They	  
found	   that	   T-­‐cells	   isolated	   from	   the	   female	   genital	   tract	   were	   predominantly	  
effector	  memory	  T-­‐cells.	  They	  also	  showed	   that	  T-­‐cells	   from	  the	   female	  genital	  
tract	  were	  predominantly	  CD8+	  in	  HIV-­‐positive	  women	  (CD4:CD8	  ratio	  of	  0.4)	  as	  
opposed	   being	   predominantly	   CD4+	   T-­‐cells	   in	   HIV-­‐negative	   women	   (CD4:CD8	  
ratio	   of	   2.7).	   HIV-­‐infected	   women	   had	   higher	   concentrations	   of	   the	   pro-­‐
inflammatory	  cytokines	  IL-­‐1β,	  IL-­‐6	  and	  IL-­‐8	  in	  their	  genital	  secretions	  than	  HIV-­‐
negative	  women.	  Concentrations	  of	  these	  cytokines	  correlated	  broadly	  with	  the	  
number	   of	   immune	   cells	   recovered	   from	   the	   cervical	   cytobrush	   samples,	  
suggesting	  that	  they	  played	  a	  role	  in	  recruitment	  of	   immune	  cells	  to	  the	  female	  
genital	  tract	  (Nkwanyana	  et	  al.,	  2009).	  Jaspan	  et	  al.	  (2011)	  subsequently	  showed	  
that	  T-­‐cells	  derived	   from	   the	  genital	  mucosa	  of	  HIV-­‐infected	  women	  expressed	  
higher	   frequencies	   of	   the	   activation	   markers	   CD38	   and	   HLA-­‐DR	   and	   that	   the	  
extent	   of	   activation	   detected	   in	   genital	   tract	   T-­‐cells	   significantly	   reflected	   the	  
degree	   of	   activation	   of	   both	   CD4+	   and	   CD8+	   T-­‐cells	   in	   blood.	   Liebenberg	   et	   al.	  
(2010)	   showed	   that,	   in	   terms	   of	   T-­‐cell	   exhaustion	   in	   a	   chronic	   HIV	   infection,	  
there	  were	  comparable	   levels	  of	  senescence	  between	  cervical	  and	  blood	  T-­‐cells	  
and	  that	  the	  levels	  of	  the	  exhaustion	  marker	  CD57	  did	  not	  differ	  from	  the	  genital	  
levels	  in	  uninfected	  women.	  Also,	  similarly	  to	  blood,	  there	  was	  an	  accumulation	  
of	   terminally	   differentiated	   cells	   in	   the	   genital	   tract	   of	   chronic	   HIV-­‐infected	  
individuals	   on	   HAART,	   in	   addition	   to	   the	   fact	   that	   the	   extent	   of	   CD4+	   T-­‐cell	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depletion	   that	  occurred	   in	   the	   cervix	  was	   linked	   to	   that	   in	  blood	   (Gumbi	  et	  al.,	  
2011).	  	  
	  
The	  aim	  of	  this	  chapter	  was	  to	  determine	  whether	  HAART	  impacted	  on	  the	  level	  
of	   activation,	   proliferation,	   exhaustion	   or	   maturation	   of	   T-­‐cells	   in	   women	  
chronically	   infected	  with	  HIV.	  Furthermore,	   the	   impact	  of	  secreted	  genital	   tract	  
inflammatory	   and	   homeostatic	   cytokines	   on	   the	   degree	   of	   differentiation	   and	  
activation	  of	  genital	  T-­‐cells	   in	  HIV-­‐infected	  women	  on	  HAART	  was	  evaluated.	  It	  
was	   hypothesised	   that	   higher	   levels	   of	   genital	   tract	   inflammatory	   cytokine	  
concentrations	  would	  be	   associated	  with	   a	   greater	  number	  of	   activated	  T-­‐cells	  
being	  detected	  in	  cervical	  cytobrush	  samples,	  accompanied	  by	  an	  increase	  in	  T-­‐
cell	  differentiation	  and	  a	  higher	  proportion	  of	  effector	  memory	  T-­‐cells.	  	  
	  
3.2 Methods	  and	  Materials	  
For	   this	   chapter,	   15	   chronically	  HIV-­‐infected	  women	   on	  HAART	  were	   enrolled	  
(materials	  and	  methods	  section	  2.1).	  All	  women	  were	  pre-­‐menopausal,	  were	  not	  
pregnant	   and	   had	   not	   undergone	   a	   hysterectomy.	   At	   the	   time	   of	   the	   visit,	   all	  
chronically	  HIV-­‐infected	  women	  were	  on	  HAART.	  Blood	  and	  a	  cervical	  cytobrush	  
sample	  were	   collected	   from	  each	  woman	   for	   the	   extraction	  of	  PBMC	  and	  CMC,	  
respectively	  (materials	  and	  methods	  sections	  2.3	  and	  2.4).	  Flow	  cytometry	  was	  
carried	  out	  to	  characterise	  the	  blood	  and	  cervical	  T-­‐cells	  (materials	  and	  methods	  
section	   2.8	   and	   appendix	   II).	   Plasma	   and	   genital	   cytokine	   concentrations	  were	  




3.3.1 Clinical	  description	  of	  cohort	  
The	  median	  age	  of	  the	  women	  included	  in	  the	  study	  was	  39	  years	  (IQR:	  36-­‐41).	  
Women	   who	   were	   menstruating	   at	   the	   time	   of	   sampling,	   who	   were	   post-­‐
menopausal	   or	   who	   had	   undergone	   a	   hysterectomy	   were	   excluded.	   Of	   these,	  
14/15	   (93.33%)	   women	   were	   on	   a	   first	   line	   HAART	   regimen	   (Table	   3.1)	   and	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1/15	   (6.66%)	   was	   on	   a	   second	   line	   HAART	   regimen	   (Table	   3.1).	   The	   median	  
CD4+	  count	  of	  the	  women	  was	  518	  cells/ml	  (IQR:	  377-­‐626)	  and	  the	  median	  time	  
on	  therapy	  for	  the	  15	  HAART-­‐treated	  individuals	  was	  85	  months	  (IQR:	  31-­‐102).	  
Table	  3.1	  summarises	  the	  clinical	  characteristics	  of	  this	  cohort	  of	  women.	  	  
	  










NY029	   35	   508	   1st	  line:	  Nevirapine,	  Combivira	   102	  
NY162	   39	   535	  
1st	  line:	  Efavirenz,	  additional	  data	  not	  
available	  
42	  
NY186	   39	   559	   1st	  line:	  3TCb,	  AZTc,	  Nevirapine	   99	  
NY254	   40	   626	   1st	  line:	  Efavirenz,	  Combivir	   43	  
NY219	   37	   693	   1st	  line:	  3TC,	  Tenofovir,	  Efavirenz	   19	  
NY226	   35	   151	  
1st	  line:	  3TC,	  AZT,	  Stavudine,	  
Nevirapine	  
85	  
NY233	   53	   146	  
1st	  line:	  Lamivudine,	  Stavudine,	  
Nevirapine	  
31	  
NY006	   34	   518	   1st	  line:	  3TC,	  Tenofovir,	  Nevirapine	   101	  
NY110	   42	   342	   1st	  line:	  3TC,	  Stavudine,	  Nevirapine	   38	  
NY149	   38	   1014	   1st	  line:	  3TC,	  AZT,	  Efavirenz	   94	  
NY167	   36	   502	   1st	  line:	  3TC,	  Tenofovir,	  Nevirapine	   26	  
NY191	   41	   486	   1st	  line:	  Nevirapine,	  Combivir	   119	  
NY221	   40	   377	   1st	  line:	  3TC,	  Tenofovir,	  Efavirenz	   15	  
NY61	   41	   551	   1st	  line:	  3TC,	  Tenofovir,	  Efavirenz	   109	  
NY248	   39	   944	   2
nd	  line:	  AZT,	  Didanosine,	  Lopinavir,	  
Ritonavir	  
103	  
Median	   39	   518	   	   85	  
aCombivir-­‐	  Single	  dose	  combination	  of	  Zidovudine	  and	  Lamivudine;	  b3TC	  –	  Lamivudine;	  
cAZT	  –	  Zidovudine	  
	  
3.3.2 Comparison	  of	  T-­‐cell	  distribution	  between	  genital	  tract	  and	  blood	  
Figure	  3.1	  shows	  the	  representative	  gating	  strategy	  used	  to	  define	  the	  CD4+	  and	  
the	  CD8+	  T-­‐cell	  populations	  isolated	  from	  cervical	  cytobrushes	  (genital	  tract)	  and	  
blood	  of	  HIV-­‐infected	  women	  on	  HAART	  (detailed	  further	  in	  Appendix	  II).	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Figure	   3.1.	   Representative	   flow	   cytometry	   plots	   showing	   the	   level	   of	   expression	   of	  
CD3+CD4+	   and	   CD3+CD8+	   T-­‐cells	   from	   blood	   (A)	   and	   from	   the	   genital	   tract	   (cervical	  
cytobrush)	  (B).	  The	  parameters	  SSC	  (side	  scatter)	  and	  FSC	  (forward	  scatter)	  were	  used	  
to	  sort	  the	  cells	  according	  to	  granularity	  and	  size	  to	  identify	  the	  lymphocyte	  population.	  
These	  cells	  were	  then	  gated	  on	  CD3+	  T-­‐cells	  and	  then	  further	  on	  CD4+	  and	  CD8+	  T-­‐cells.	  	  
	  
In	   blood,	   HIV-­‐infected	   women	   on	   HAART	   had	   a	   median	   CD4:CD8	   ratio	   of	   0.7	  
(figure	   3.2),	   indicating	   that	   these	  women	   had	   fewer	   CD4+	   T-­‐cells	   compared	   to	  
CD8+	   T-­‐cells.	   In	   contrast,	   the	   median	   CD4:CD8	   ratio	   for	   cervical	   mononuclear	  
cells	  was	  1.2,	   indicating	   the	  CD4+	  T-­‐cells	  were	   the	   dominant	  T-­‐cell	   population.	  
There	  was	  no	  significant	  difference	  and	  no	  correlation	  between	  blood	  and	  genital	  
tract	  CD4:CD8	  ratios.	  Barrett	  et	  al.	  (2012)	  proposed	  that	  CD4:CD8	  ratios	  can	  be	  
used	  as	  a	  surrogate	  to	  characterise	  an	  “immune	  risk	  phenotype”,	  similarly	  to	  the	  
use	   of	   total	   CD4	   counts,	   with	   CD4:CD8	   <1	   reflecting	   immune	   dysfunction	  
predisposing	  to	  several	  co-­‐morbidities.	  Previous	  studies	  in	  healthy	  seronegative	  
individuals	   have	   reported	   that	   blood	   CD4:CD8	   ratios	   were	   typically	   >1.6	  
(Margolick	  et	  al.,	  2006)	  and	  that	  cervical	  CD4:CD8	  ratios	  were	  2.7	  (Nkwanyana	  et	  
al.,	   2009),	   suggesting	   that	   the	  women	   enrolled	   in	   this	   study,	   despite	   being	   on	  







































































Figure	   3.2.	   CD4:CD8	   ratios	   in	   blood	   ()	   and	   cervical	   ()	   compartments.	   Each	   dot	  
represents	   an	   individual	   woman’s	   CD4:CD8	   ratio	   in	   either	   blood	   or	   from	   cervical	  
cytobrushes	  (cervix).	  	  The	  box	  and	  whisker	  plots	  represent	  the	  median	  (centre	  line),	  and	  
interquartile	  range,	  while	  the	  error	  bars	  represent	  the	  range.	  The	  horizontal	  dotted	  line	  
shows	  the	  threshold	  (CD4:CD8	  ratio=1),	  below	  which	  the	  ratio	  becomes	  inverted.	  	  
	  
Previous	  studies	  have	  shown	  that	  CD4+	  T-­‐cell	  reconstitution	  was	  dependent	  on	  
the	   length	  of	   time	  HIV-­‐infected	  women	  had	  been	  on	  HAART	  and	   that,	  although	  
the	   CD4+	   T-­‐cell	   count	   increased	   the	   most	   in	   the	   first	   2-­‐3	   months,	   this	  
reconstitution	  persisted	  for	  up	  to	  4	  years	  in	  individuals	  on	  therapy	  (Guihot	  et	  al.,	  
2011;	  Hunt	  et	  al.,	  2003a).	  Therefore,	  the	  impact	  of	   length	  of	  time	  on	  HAART	  on	  
CD4+	  T-­‐cell	  reconstitution	  in	  this	  study	  was	  investigated	  (figure	  3.3).	  There	  was	  
no	   significant	   relationship	   between	   the	   length	   of	   time	   for	   which	   HIV-­‐infected	  
women	  had	  been	  on	  HAART	  and	  the	  CD4:CD8	  ratios	  in	  either	  compartment.	  	  
	  
	  
Figure	   3.3.	   Relationship	   between	   time	   on	   HAART	   and	   changes	   in	   CD4:CD8	   ratios	   in	  
blood	   (A)	   and	   the	   female	   genital	   tract	   (B).	   The	  black	   line	   shows	   the	   linear	   regression	  
line	  and	  the	  shaded	  area	  around	  the	  line	  represents	  the	  95%	  confidence	  interval	  for	  the	  
mean.	  Each	  dot	  represents	  an	  individual	  woman’s	  ratio	  relative	  to	  the	  length	  of	  time	  she	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Next,	   CD4+	   and	   the	   CD8+	   T-­‐cell	   subsets	   were	   further	   divided	   into	   the	   four	  
memory	  subsets	  (naïve,	  TCM,	  TEM	  and	  TD),	  based	  on	  the	  surface	  expression	  of	  
CD45RO	   and	   CCR7	   (figure	   3.4).	   CD45RO	   has	   been	   proposed	   to	   be	   useful	   in	  
defining	  T-­‐cell	  memory	  because	   it	   is	  a	  glycoprotein	  preferentially	  expressed	  on	  
memory	  cells	  and	  has	  been	  reported	  to	  enhance	  receptor-­‐mediated	  activation	  of	  
T-­‐cells	   (reviewed	   by	  Mahnke	   et	   al.,	   2013).	   CCR7,	   a	   chemokine	   receptor	  which	  
controls	   homing	   of	   cells	   to	   secondary	   lymphoid	   organs,	   has	   been	   reported	   to	  
distinguish	  naïve	  and	  central	  memory	  T-­‐cells	  (Sallusto	  et	  al.,	  1999).	  Naïve	  T-­‐cells	  
have	   been	   suggested	   to	   be	   CD45RO-­‐	  but	   CCR7+,	   central	   memory	   T-­‐cells	   to	   be	  
double	   positive	   (CD45RO+CCR7+),	   effector	   memory	   to	   express	   CD45RO+CCR7-­‐	  
and	   terminally	   differentiated	   (CD45RO-­‐CCR7-­‐)	   T-­‐cells	   (Sallusto	   et	   al.,	   1999;	  
reviewed	  by	  Mahnke	  et	  al.,	  2013).	  	  
	  
	  
Figure	   3.4.	   Representative	   plots	   showing	   how	   CD3+CD4+	   and	   CD3+CD8+	   T-­‐cells	   were	  
subdivided	  into	  the	  different	  memory	  subsets	  using	  the	  maturational	  markers	  CD45R0	  
and	  CCR7.	  	  
	  
To	   determine	   whether	   the	   distribution	   of	   the	   T-­‐cell	   memory	   subsets	   differed	  
between	  blood	  and	  the	  genital	  tract,	  the	  proportion	  of	  the	  CD4+	  and	  the	  CD8+	  T-­‐
cell	   subsets	   expressing	   memory	   markers	   were	   compared	   between	  
compartments	  (figure	  3.5).	  TEM	  were	  the	  predominant	  memory	  subtype	  in	  both	  
blood	  and	   the	  genital	   tract.	   In	  blood,	  CD4+	  TEM	  cells	  made	  up	  36.0%	  and	  CD8+	  
TEM	  cells	  made	  up	  40.3%	  of	  all	  CD3+	  T-­‐cells.	  In	  the	  genital	  tract,	  CD4+	  TEM	  cells	  
made	  up	  66.7%	  and	  CD8+	  TEM	  cells	  made	  up	  74.0%	  of	  all	  CD3+	  T-­‐cells.	  	  
	  













































































In	  both	  compartments,	  differentiated	  CD8+	  T-­‐cell	  subsets	  formed	  the	  majority	  of	  
all	  T-­‐cells,	  with	  the	  TEM	  and	  TD	  being	  present	  at	  higher	  frequencies	  than	  naïve	  
and	   TCM	   (Figure	   3.5A	   and	   3.5B).	   In	   the	   CD4+	   T-­‐cell	   population,	   memory	  
(CD45RO+)	   T-­‐cells	   outnumbered	   naïve	   (CD45RO-­‐)	   T-­‐cells,	  with	   CD4+	   TEM	   cells	  
being	  the	  most	  prevalent	  followed	  by	  TCM	  cells	  (Figure	  3.5C	  and	  3.5D).	  Overall,	  
when	   comparing	   memory	   subset	   distribution	   between	   blood	   and	   the	   genital	  
tract,	   the	  genital	   compartment	  had	  a	  significantly	   lower	  percentage	  of	  naïve	  T-­‐
cells	  and	  TD	  and	  a	  higher	  percentage	  of	  TEM	  compared	  to	  blood	  (figure	  3.5B	  and	  
D).	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Figure	   3.5.	   Comparison	  between	   the	  percentage	  of	  memory	   subsets	   in	  blood	   and	   the	  
genital	   tract	   for	   CD8+	   (A	   and	  B)	   and	  CD4+	  T-­‐cells	   (C	   and	  D).	   The	   blue,	   red,	   green	   and	  
purple	   slices	   of	   the	   pie	   charts	   (A	   and	   C)	   represent	   the	   percentage	   of	   naïve,	   central	  
memory,	  effector	  memory	  and	  terminally	  differentiated	  T-­‐cells	  respectively.	  In	  B	  and	  D,	  
PBMC	  are	  represented	  by	   the	  red	  circles	   ()	  and	   the	  CMC	  by	   the	  blue	  circles	   ().	  A	  p	  
value	  of	  ≤0.05	  was	  considered	  to	  be	  significant.	  	  
	  
3.3.3 Comparison	  of	  T-­‐cell	  activation	  in	  blood	  and	  the	  genital	  tract	  
Using	   CD38	   and	  HLA-­‐DR	   as	  markers	   of	   T-­‐cell	   activation,	   the	   frequencies	   of	   T-­‐
cells	  expressing	  any	  combination	  of	  these	  markers	  were	  measured	  for	  blood	  and	  
cervical	   cytobrush	   cells	   (figure	  3.6).	  Generally,	   higher	   frequencies	   of	   genital	  T-­‐
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Figure	  3.6.	  Comparison	  between	  T-­‐cell	  activation	  in	  blood	  and	  the	  female	  genital	  tract	  
of	  HIV-­‐infected	  women	  on	  HAART.	  A.	  Representative	  plots	  showing	  how	  CD3+CD4+	  and	  
CD3+CD8+	   T-­‐cells	   were	   distinguished	   based	   on	   surface	   expression	   of	   the	   activation	  
markers	   CD38	   and	   HLA-­‐DR.	   CD38+HLA-­‐DR+	   T-­‐cells	   are	   those	   that	   express	   both	  
activation	  markers.	  B.	  Differences	  in	  the	  percentages	  of	  CD38+,	  HLA-­‐DR+	  and	  CD38+HLA-­‐
DR+	  in	  CD4+	  T-­‐cells.	  C.	  Differences	  in	  the	  percentage	  of	  the	  different	  activation	  markers	  
for	   CD8+	   T-­‐cells.	   The	  Wilcoxon	   matched-­‐pairs	   signed	   rank	   test	   was	   used	   to	   compare	  
groups	  and	  a	  p	  value	  of	  ≤0.05	  was	  considered	  significant.	  The	  purple	  box	  and	  whisker	  
plots	  represent	  the	  percentage	  expression	  of	  the	  markers	  in	  blood	  and	  the	  blue	  box	  and	  
whisker	  plots	  represent	  the	  percentage	  expression	  in	  the	  genital	  tract.	  	  
	  
T-­‐cells	  were	   subdivided	  according	   to	   their	  memory	  marker	  expression	  profiles	  
and	  assessed	  for	  their	  respective	  levels	  of	  activation	  (figure	  3.7).	  CD4+	  TEM	  from	  
the	  genital	  tract	  generally	  were	  more	  activated	  than	  those	  from	  blood,	  and	  this	  
difference	  was	  significant	  for	  CD4+	  TEM	  cells	  expressing	  both	  CD38	  and	  HLA-­‐DR	  
(p=0.02).	  The	  level	  of	  activation	  in	  TCM	  tended	  to	  be	  higher	  in	  CD4+	  cervical	  T-­‐
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cells	  compared	  to	  blood,	  although	  not	  significantly.	  In	  contrast,	  CD4+	  TD	  in	  blood	  
had	   significantly	   higher	   frequencies	   of	   CD38+,	   HLA-­‐DR+	   and	   doubly	   activated	  
cells	  compared	  to	  T-­‐cells	  derived	  from	  the	  genital	  tract	  (p<0.0001	  for	  CD38	  and	  
HLA-­‐DR	   individually	   and	   p=0.0002	   for	   expression	   of	   both	  markers).	   Similarly,	  
significantly	  higher	  frequencies	  of	  naïve	  CD4+	  T-­‐cells	  from	  blood	  expressed	  CD38	  
(p=0.0002),	   HLA-­‐DR	   (p=0.0034)	   or	   both	   markers	   (p<0.0001)	   compared	   to	   T-­‐
cells	  in	  the	  genital	  tract,	  although	  naïve	  cells	  were	  generally	  detected	  at	  very	  low	  
frequencies	  in	  the	  genital	  tract	  compared	  to	  blood.	  	  
	  
Similarly	  to	  CD4+	  T-­‐cells,	  a	  significantly	  higher	  percentage	  of	  naïve	  CD8+	  T-­‐cells	  
from	  blood	  expressed	  CD38+,	  HLA-­‐DR+	  and	  CD38+HLA-­‐DR+	  compared	  to	  naïve	  T-­‐
cells	   from	   the	   female	   genital	   tract	   (p=0.0005,	   p=0.0002	   and	   p<0.0001,	  
respectively).	  Higher	  frequencies	  of	  CD8+	  TD	  cells	  in	  blood	  expressed	  CD38,	  HLA-­‐
DR	   or	   a	   combination	   of	   both	   markers	   (p=0.0181,	   p=0.0123	   and	   p=0.0022,	  
respectively)	   compared	   to	   those	   in	   the	   female	   genital	   tract.	   In	   contrast,	  
significantly	  higher	  frequencies	  of	  genital	  CD8+	  TCM	  cells	  expressed	  HLA-­‐DR	  and	  





Figure	   3.7.	   Comparison	   between	   activation	   status	   of	  memory	   T-­‐cell	   subsets	   in	   blood	  
and	  the	  genital	  tract.	  A-­‐C.	  Percentage	  of	  CD38+,	  HLA-­‐DR+	  and	  CD38+HLA-­‐DR+	  expression	  
in	   the	   CD4+	   T-­‐cell	   subsets.	   D-­‐F.	   Percentage	   of	   CD38+,	   HLA-­‐DR+	   and	   CD38+HLA-­‐DR+	  
expression	   in	   the	   CD8+	   T-­‐cell	   subsets.	   Wilcoxon	   matched-­‐pairs	   signed	   rank	   test	   was	  
used	   to	   for	   statistical	   comparisons	   and	   p	   values	   of	   ≤0.05	   was	   considered	   significant.	  
Blood	  CD4+	  and	  CD8+	  T-­‐cells	  are	  represented	  by	  the	  red	  and	  pink	  bars	  respectively	  while	  
the	  genital	  CD4+	  and	  CD8+	  T-­‐cells	  are	  shown	  in	  dark	  blue	  and	  pale	  blue	  respectively.	  	  
	  
Previous	   studies	  have	   suggested	   that	   length	  of	   time	   an	  HIV-­‐infected	   individual	  
has	  been	  on	  HAART	  impacts	  significantly	  on	  the	  level	  of	  T-­‐cell	  activation	  (Hunt	  et	  
al.,	  2003b;	  Robbins	  et	  al.,	  2009).	  To	  investigate	  this,	  the	  degree	  of	  activation	  for	  
each	  HIV-­‐infected	  women	  included	  in	  this	  study	  was	  compared	  to	  the	   length	  of	  
time	  she	  had	  been	  on	  therapy	  (figure	  3.8).	  No	  significant	  relationship	  was	  found	  
between	   the	  percentage	  of	   activation	  marker	  expression	  and	   length	  of	   time	  on	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Figure	   3.8.	   Relationship	   between	   time	   on	   HAART	   and	   activation	   marker	   expression	  
levels	  in	  blood	  and	  the	  genital	  tract	  for	  CD4+	  (A	  and	  B)	  and	  CD8+	  (C	  and	  D)	  T-­‐cells.	  The	  
black	  line	  shows	  the	  regression	  line	  and	  the	  shaded	  area	  around	  the	  line	  represents	  the	  
95%	   confidence	   interval	   for	   the	  mean.	   The	   red	   and	   dark	   blue	   dots	   represent	   CD4+	   T-­‐
cells	   in	   blood	   and	   the	   genital	   tract	   respectively	   while	   the	   pink	   and	   light	   blue	   dots	  
represent	  CD8+	  T-­‐cells	  in	  the	  two	  compartments.	  	  
	  
Jaspan	  et	  al.	  (2011)	  previously	  reported	  that	  the	  extent	  of	  T-­‐cell	  activation	  in	  the	  
genital	   tract	   of	   HIV-­‐infected	   women	   (naïve	   to	   HAART)	   correlated	   with	   that	  
present	   in	   blood.	   To	   determine	   whether	   the	   level	   of	   T-­‐cell	   activation	   in	   the	  
genital	   tract	   was	   related	   to	   level	   of	   activation	   in	   blood	   in	   this	   study,	   linear	  
regression	   models	   were	   used	   to	   compare	   the	   different	   activation	   markers	  
between	   the	   two	   compartments	   (figure	   3.9).	   The	   frequency	   of	   CD4+	   T-­‐cells	  
expressing	   CD38+	   in	   blood	   significantly	   predicted	   the	   frequency	   in	   the	   genital	  
compartment	  (β	  coefficient=0.279;	  p=0.03).	  Similarly,	  the	  level	  of	  CD8+	  T-­‐cells	  in	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Figure	   3.9.	   Relationship	   between	   levels	   of	   T-­‐cell	   activation	   in	   blood	   and	   the	   genital	  
compartment.	   T-­‐cells	   expressing	   the	   activation	   markers	   CD38	   and	   HLA-­‐DR,	   or	   co-­‐
expression	   of	   both	   were	   compared	   between	   compartments.	   The	   CD4+	   T-­‐cells	   are	  
represented	  by	  green	  circles	  ()	  and	  the	  CD8+	  T-­‐cells	  by	  purple	  circles	  ().Simple	  linear	  
regression	  models	  were	  used	  and	  β-­‐coefficients	  represent	  the	  percentage	  by	  which	  the	  
median	  frequency	  of	  each	  immune	  activation	  marker	  expression	  in	  the	  genital	  tract	  will	  
increase	  with	   every	   percentage	   increase	   of	   the	   corresponding	  marker	   in	   the	   blood.	   p	  
values	  of	  ≤0.05	  were	  considered	  to	  be	  significant.	  	  
	  
3.3.4 Comparison	  of	  proliferation	  and	  exhaustion	  markers	  on	  T-­‐cells	   from	  
blood	  and	  the	  genital	  compartment	  during	  HIV	  infection	  
T-­‐cell	  turnover	  (characterised	  by	  the	  presence	  of	  the	  proliferation	  marker	  Ki67)	  
and	  exhaustion	  (characterised	  by	  the	  presence	  of	  the	  senescence	  marker	  CD57)	  
are	   useful	   clinical	   disease	   progression	  markers,	   and	   their	   expression	   has	   been	  
shown	   to	   be	   down-­‐regulated	   by	   consistent	   suppressive	   HAART	   (Mohri	   et	   al.,	  
2001;	  Palmer	  et	  al.,	  2005).	  The	  frequencies	  of	  T-­‐cells	  expressing	  these	  markers	  
were	  compared	  in	  blood	  and	  the	  genital	  tract	  (figure	  3.10).	  	  
	  























Figure	  3.10.	  Representative	  plots	  showing	  the	  gating	  strategy	  used	  to	  determine	  levels	  
of	   proliferation	   (Ki67+	   T-­‐cells)	   and	   senescence	   (CD57+	   T-­‐cells)	   from	   CD3+CD4+	   and	  
CD3+CD8+	  T-­‐cells.	  	  
	  
To	  determine	  whether	  there	  was	  a	  difference	  between	  the	  proliferative	  capacity	  
and	   cell	   turnover	   between	   CD4+	   and	   CD8+	   T-­‐cells	   within	   compartments,	   the	  
percentage	   of	   T-­‐cells	   expressing	   Ki67	   was	   compared	   in	   blood	   and	   the	   genital	  
tract	   (figure	  3.11A).	  Comparable	   frequencies	  of	  CD4+	  and	  CD8+	  T-­‐cells	   in	  blood	  
expressed	  Ki67,	  indicating	  that	  CD4+	  T-­‐cells	  were	  proliferating	  as	  much	  as	  CD8+	  
T-­‐cells.	   In	   contrast,	   significantly	   higher	   frequencies	   of	   CD4+	   T-­‐cells	   expressed	  
Ki67	  compared	  to	  the	  CD8+	  T-­‐cells	   in	  the	  female	  genital	   tract	  (p=0.0001;	   figure	  
3.11B),	  suggesting	  that	  CD4+	  T-­‐cells	  in	  the	  genital	  tract	  were	  proliferating	  more	  
than	  CD8+	  T-­‐cells.	   For	  both	  CD4+	  and	   the	  CD8+	  T-­‐cells,	   genital	   cells	  were	  more	  
actively	   proliferating	   than	   those	   in	   blood	   (20-­‐fold	   difference	   for	   CD4+T-­‐cells:	  
p=0.0151;	  7.3-­‐fold	  difference	  for	  CD8+	  T-­‐cells:	  p=0.0004;	  figures	  3.11C	  and	  D).	  	  
	  



































































Figure	   3.11.	   Comparison	   between	   the	   frequencies	   of	   proliferating	   (Ki67+)	   T-­‐cell	  
populations	   in	   blood	   and	   the	   female	   genital	   tract.	   A.	   Comparison	   between	   Ki67	  
expression	  by	  T-­‐cells	  in	  blood.	  B.	  Comparison	  between	  Ki67	  expression	  by	  T-­‐cells	  in	  the	  
genital	  tract.	  C.	  Comparison	  between	  blood	  and	  cervical	  Ki67	  expression	  by	  CD4+	  T-­‐cells.	  
D.	   Comparison	  between	  blood	   and	   cervical	  Ki67	   expression	  by	  CD8+	  T-­‐cells.	   The	  pink	  
and	  dark	  blue	  dots	  represent	  CD4+	  and	  CD8+	  T-­‐cells	  in	  either	  compartment	  while	  the	  red	  
dots	  represent	  T-­‐cells	  from	  blood	  and	  the	  pale	  blue	  dots	  represent	  cervical	  T-­‐cells.	  The	  
Mann	  Whitney	  U	  test	  was	  used	  to	  compare	  each	  of	  the	  two	  groups	  and	  p	  values	  of	  ≤0.05	  
were	  considered	  to	  be	  significant.	  	  
	  
Since	   time	   on	   HAART	   has	   previously	   been	   proposed	   to	   impact	   on	   the	   overall	  
level	   of	   activation	   (Hunt	   et	   al.,	   2003b)	   and	   elevated	   activation	   of	   T-­‐cells	   may	  
impact	   on	   cell	   turnover	   (Catalfamo	   et	   al.,	   2008;	   Hazenberg	   et	   al.,	   2000),	   the	  
relationship	   between	   time	   on	   HAART	   and	   the	   frequency	   of	   T-­‐cells	   expressing	  
Ki67	  was	  evaluated	  (figure	  3.12).	  There	  was	  no	  significant	  change	  in	  the	  level	  of	  
expression	  of	  Ki67	  over	  time	  on	  HAART	  for	  both	  CD4+	  and	  CD8+	  T-­‐cells	  in	  blood	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Figure	   3.12.	   Relationship	   between	   length	   of	   time	   on	   HAART	   and	   Ki67	   expression	  
(indicating	  cell	  turnover)	  for	  T-­‐cells	  in	  blood	  (A	  and	  B)	  and	  the	  genital	  tract	  (C	  and	  D).	  
The	  black	  line	  shows	  the	  regression	  line	  and	  the	  shaded	  area	  around	  the	  line	  represents	  
the	  95%	  confidence	  interval	  for	  the	  mean.	  Red	  dots	  represent	  T-­‐cells	  in	  blood	  while	  blue	  
dots	  represent	  cells	  from	  the	  female	  genital	  tract.	  
	  
Previous	   studies	   have	   shown	   that	   proliferating	  T-­‐cells	   (a	   subset	   of	   cells	  which	  
closely	   track	   with	   plasma	   viral	   load)	   are	   mainly	   memory	   (CD45RO+),	   and	  
predominantly	   TCM	   cells	   (Lempicki	   et	   al.,	   2000;	   Sieg	   et	   al.,	   2005).	   Thus,	   the	  
memory	  T-­‐cell	  distribution	  of	  proliferating	  cells	  for	  the	  women	  in	  this	  study	  was	  
investigated	   (figure	   3.13).	   In	   blood,	   significantly	   fewer	   naïve	   CD4+	   T-­‐cells	  
expressed	  Ki67	   compared	   to	   the	   three	  more	  differentiated	  CD4+	  T-­‐cell	   subsets	  
(figure	  3.13A),	  with	  CD4+	  TCM	  having	  the	  highest	   frequencies	  of	  Ki67	  of	  all	   the	  
memory	  subsets.	  Similarly,	  significantly	  fewer	  naïve	  CD8+	  T-­‐cells	  expressed	  Ki67	  
compared	   to	   the	   other	   memory	   subsets	   (Figure	   3.13B).	   In	   the	   genital	   tract,	  
higher	  frequencies	  CD4+	  TCM	  expressed	  Ki67	  compared	  to	  the	  other	  memory	  T-­‐
cell	   subsets	   (figure	   3.13C).	   Ki67	  was	   not	   expressed	   on	   the	   CD4+	   naïve	   and	  TD	  
cells	   for	  most	   of	   the	  women.	   For	   CD8+	   T-­‐cells,	   the	   TEM	   cells	   tended	   to	   be	   the	  
most	   likely	   memory	   T-­‐cell	   subset	   to	   express	   Ki67,	   although	   there	   was	   no	  
significant	   difference	   in	   the	   percentage	   expression	   of	  Ki67	   between	   any	   of	   the	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Figure	   3.13.	   Comparison	   between	   the	   level	   of	   proliferation	   within	   the	   naïve	   and	  
memory	  T-­‐cell	   subsets	   in	  blood	  and	   the	   female	   genital	   tract.	  Ki67	  expression	  by	  CD4+	  
and	  CD8+	  T-­‐cells	   in	  blood	  (A-­‐B)	  and	  the	  genital	   tract	  (C-­‐D).	  Naïve	  T-­‐cells	  are	  shown	  as	  
red	  boxes,	  central	  memory	  T-­‐cells	  as	  green	  boxes,	  effector	  memory	  T-­‐cells	  as	  blue	  boxes	  
and	   terminally	   differentiated	   T-­‐cells	   as	   purple	   boxes.	   One-­‐way	   ANOVA	   was	   used	   to	  
compare	  the	  different	  subsets	  and	  the	  comparisons	  that	  were	  significant	  after	  adjusting	  
for	  multiple	   comparisons	  are	   shown.	  p	  values	  ≤0.05	  were	   considered	   to	  be	   significant	  
where	  *	  is	  p=≤	  0.05;	  **	  is	  p≤	  0.01;	  ***	  is	  p≤	  0.001	  and	  ****	  is	  p≤	  0.0001.	  	  
	  
Next,	   the	   extent	   of	   senescence/exhaustion	   in	   the	   different	   T-­‐cell	   subsets	   was	  
determined	   (figure	   3.14).	   Overall,	   there	   was	   a	   significantly	   higher	   level	   of	  
expression	  of	  CD57	  in	  the	  CD8+	  than	  in	  the	  CD4+	  T-­‐cell	  population,	  irrespective	  of	  
which	  compartment	  it	  was	  found	  in	  (figure	  3.14A	  and	  B,	  p<0.0001	  for	  blood	  and	  
p=0.0017	   for	   the	   cervix).	   However,	   there	   were	   comparable	   levels	   of	   T-­‐cell	  
exhaustion	  blood	  and	  cervical	  cells	  for	  both	  CD4+	  and	  CD8+	  T-­‐cells	  (figure	  3.14C	  
and	   D).	   The	   level	   of	   CD57	   expression	   in	   both	   blood	   and	   the	   cervix	   was	  
independent	  of	  the	  length	  of	  time	  for	  which	  the	  women	  were	  on	  HAART	  (figure	  
3.15).	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Figure	   3.14.	   Comparison	   between	   the	   frequency	   of	   senescence	   marker	   expression	  
(CD57)	   by	   T-­‐cells	   in	   blood	   and	   the	   genital	   tract.	   Expression	   of	   CD57	   by	   CD4+	   T-­‐cells	  
(yellow)	  and	  CD8+	  T-­‐cells	  (green)	  in	  (A)	  blood	  or	  (B)	  genital	  tract.	  Expression	  of	  CD57	  in	  
blood	  (purple)	  and	  the	  genital	  compartment	  (green)	  by	  (C)	  CD4+	  and	  (D)	  CD8+	  T-­‐cells.	  	  
	  
	  
Figure	  3.15.	  Relationship	  between	  time	  on	  HAART	  and	  T-­‐cell	  exhaustion	  in	  blood	  and	  
the	   cervix	   for	   CD4+	   (A	   and	  B)	   and	   CD8+	   (C	   and	   D)	   T-­‐cells.	   The	   black	   line	   shows	   the	  
regression	   line	   and	   the	   shaded	   area	   around	   the	   line	   represents	   the	   95%	   confidence	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Previous	   studies	   have	   shown	   a	   positive	   association	   between	   CD57	   expression	  
and	   the	   differentiation	   status	   of	   T-­‐cells,	   with	   higher	   frequencies	   of	   the	   most	  
differentiated	  T-­‐cells	  expressing	  CD57	  than	  less	  differentiated	  T-­‐cells	  (Hoji	  et	  al.,	  
2007;	  reviewed	  by	  Appay	  &	  Sauce,	  2008).	  In	  support	  of	  this,	  naïve	  CD4+	  T-­‐cells	  in	  
blood	  had	  significantly	  lower	  levels	  of	  CD57	  expression	  compared	  to	  all	  the	  other	  
memory	   subsets	   (figures	   3.16A	   and	   B).	   Higher	   frequencies	   of	   the	   two	   more	  
differentiated	   CD4+	   T-­‐cell	   subsets	   (TEM	   and	  TD	   cells)	   expressed	   of	   CD57	   than	  
the	   two	   less	   differentiated	   subsets	   (naïve	   and	   TCM	   cells).	   Of	   the	   more	  
differentiated	  subsets	  in	  blood,	  CD4+	  TEM	  cells	  expressed	  higher	  frequencies	  of	  
CD57	   than	   TD	   cells.	   For	   blood	   CD8+	   T-­‐cells,	   TEM	   cells	   expressed	   significantly	  
higher	   levels	   of	   CD57	   compared	   to	   the	   other	   subsets.	   Similarly,	   in	   the	   genital	  
tract,	   CD4+	  TEM	  cells	   expressed	   the	  most	   CD57,	   although	  TCM	  had	   the	   second	  
highest	  expression	  of	  CD57	  (figure	  3.16C).	  For	  genital	  tract	  CD8+	  T-­‐cells,	  the	  two	  
more	  differentiated	  T-­‐cell	  subsets	  expressed	  higher	  levels	  of	  CD57	  (highest	  TEM	  
followed	  by	  TD;	  figure	  3.16D)	  than	  the	  two	  less	  differentiated	  T-­‐cell	  subsets.	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Figure	   3.16.	   Comparison	   between	   the	   level	   of	   CD57	   expression	   by	   memory	   T-­‐cell	  
subsets	   in	   blood	   and	   the	   female	   genital	   tract.	   (A-­‐B)	   Differences	   in	   the	   percentages	   of	  
CD57	  in	  blood	  CD4+	  and	  CD8+	  T-­‐cells.	  (C-­‐D)	  Percentages	  of	  cervical	  CD57+CD4+	  and	  CD8+	  
T-­‐cell	  subsets.	  Naïve	  T-­‐cells	  are	  shown	  in	  red,	  central	  memory	  T-­‐cells	  in	  green,	  effector	  
memory	  T-­‐cells	  in	  blue	  and	  terminally	  differentiated	  T-­‐cells	  in	  purple.	  One-­‐way	  ANOVA	  
was	   used	   to	   compare	   the	   different	   subsets	   and	   the	   comparisons	   that	  were	   significant	  
after	  adjusting	  for	  multiple	  comparisons	  are	  shown.	  p	  values	  ≤0.05	  were	  considered	  to	  
be	  significant	  where	  *	  is	  p=≤	  0.05;	  **	  is	  p≤	  0.01;	  ***	  is	  p≤	  0.001	  and	  ****	  is	  p≤	  0.0001.	  	  
	  
To	   establish	   whether	   there	   was	   any	   relationship	   between	   the	   level	   of	   T-­‐cell	  
activation	   (HLA-­‐DR	   and	   CD38	   expression)	   and	   the	   level	   of	   exhaustion	   (CD57	  
expression),	   frequencies	   of	   the	   different	   markers	   of	   activation	   and	   the	  
senescence	   marker	   CD57	   were	   compared	   (table	   3.2).	   For	   CD8+	   T-­‐cells,	   a	  
significant	   positive	   relationship	   was	   observed	   between	   activation	   marker	  
expression	   and	   CD57	   expression.	   This	   suggests	   that	   the	   activated	   CD8+	   T-­‐cells	  
are	   also	   those	  who	   have	   been	   through	   the	  most	   replicative	   cycles	   and	   are	   the	  
most	  exhausted	  cells.	   	  The	   same	   trend	  was	  observed	   for	  CD4+	  T-­‐cells,	   although	  
these	  were	  not	  significant.	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Table	  3.2.	  Relationships	  between	  T-­‐cell	  activation	  markers	  and	  senescence.	  	  








	   CD38+	   0.6167	   0.1783	  -­‐	  0.8508	   0.0099	  
HLA-­‐DR+	   0.5092	   0.001886	  –	  0.8081	   0.0460	  







	   CD38+	   0.3522	   -­‐0.1895	  –	  0.7296	   0.1796	  
HLA-­‐DR+	   0.1432	   -­‐0.3933	  –	  0.6069	   0.5940	  
CD38+HLA-­‐DR+	   0.2264	   -­‐0.3180	  –	  0.6585	   0.3943	  
*Spearman	  correlation	  coefficients	  and	  95%	  confidence	  intervals	  
	  
3.3.5 Comparison	   between	   cytokine	   profiles	   in	   blood	   and	   the	   genital	  
compartment	  
Concentrations	   of	   10	   cytokines	  were	  measured	   in	  matched	  plasma	  and	   genital	  
tract	  secretions	  from	  the	  HIV-­‐infected	  women	  included	  in	  this	  cohort	  who	  were	  
on	  HAART	  (figure	  3.17).	  Of	  these	  10	  cytokines,	  7/10	  were	  inflammatory	  (IL-­‐1β,	  
IL-­‐6,	   IL-­‐8,	   IP-­‐10,	  MIP-­‐1α,	  MIP-­‐1β	  and	  TNF-­‐	  α),	  2/10	  were	  haematopoietic	   (IL-­‐7	  
and	  G-­‐CSF)	   and	   IL-­‐10	  was	   considered	   to	   be	   a	   regulatory	   cytokine.	   All	   7	   of	   the	  
inflammatory	   cytokines	  were	  detected	  at	   significantly	  higher	   concentrations	   in	  
the	   genital	   compartment	   compared	   to	   blood	   plasma	   (IL-­‐1β:	   p=0.0078;	   IL-­‐6:	  
p=0.0078;	   IL-­‐8:	   p=0.0078;	   IP-­‐10:	   p=0.0078;	   MIP-­‐1α:	   p=0.0078;	   MIP-­‐1β:	  
p=0.0156;	   TNF-­‐α:	   p=0.0078).	   	   In	   addition,	   1/2	   of	   the	   hematopoietic	   cytokines	  
were	  detected	  at	  significantly	  higher	  concentrations	  in	  genital	  secretions	  versus	  
plasma	  (G-­‐CSF:	  p=0.0078).	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Figure	  3.17.	  Comparison	  of	  the	  concentrations	  of	  the	  different	  inflammatory,	  regulatory	  
and	  hematopoietic	  cytokines	  between	  blood	  and	  the	  genital	  tract.	  The	  box	  and	  whisker	  
plots	  show	  the	  range	  of	  concentration	  for	  the	  cytokines	  in	  each	  compartment.	  The	  line	  at	  
the	   centre	   of	   the	   box	   represents	   the	   median	   concentration,	   the	   box	   shows	   the	  
interquartile	   range	   and	   the	   error	   bars	   below	   and	   above	   give	   the	   minimum	   and	  
maximum	  values.	  The	  Wilcoxon	  matched-­‐pairs	  signed	  rank	  test	  was	  used	  for	  statistical	  
comparisons	  	  
	  
3.3.6 Relationship	  between	  cytokine	  concentrations	  and	  T-­‐cell	  activation	  
The	   relationship	   between	   the	   concentration	   of	   cytokines	   in	   each	   compartment	  
and	  the	  respective	  levels	  of	  T-­‐cell	  activation	  was	  evaluated	  (data	  not	  shown).	  In	  
the	   genital	   tract,	   there	   was	   a	   significant	   positive	   association	   between	   the	  
concentration	  of	  IL-­‐8	  and	  frequencies	  of	  activated	  CD4+	  T-­‐cells	  expressing	  CD38	  
and	   HLA-­‐DR	   (rho=0.9286	   and	   p=0.0009).	   This	   association	   was	   still	   weakly	  
significant	  after	  adjusting	  for	  multiple	  comparisons	  (p	  =	  0.054	  after	  applying	  the	  
Bonferroni	   correction)	   In	   blood,	   no	   similar	   association	   was	   found	   between	  
cytokines	  in	  plasma	  and	  CD4+	  T-­‐cell	  activation.	  On	  the	  other	  hand,	  plasma	  IP-­‐10	  
correlated	   significantly	   with	   the	   total	   level	   of	   activation	   in	   the	   CD8+	   T-­‐cell	  
population	  (ρ=0.7143,	  p=0.0465).	  The	  same	  trend	  was	  seen	  for	  the	  level	  of	  G-­‐CSF	  
and	  total	  CD8+	  T-­‐cell	  activation	  (ρ=0.8503,	  p=0.0075).	  
	  
Next,	   linear	   regression	   modelling	   was	   used	   to	   determine	   whether	   the	  
concentrations	   of	   cytokines	   could	   predict	   the	   level	   of	   T-­‐cell	   activation	   in	   each	  
compartment	   (figure	  3.18).	  While	   cytokine	  concentrations	   in	  genital	   secretions	  
had	  no	  significant	  prognostic	  value	  for	  T-­‐cell	  activation	  (data	  not	  shown),	  plasma	  



















































































































CD38+	  expression	  in	  CD8+	  T-­‐cells	  (MIP-­‐1β:	  β	  coefficient	  =	  1.0403;	  p	  =	  0.0233;	  IP-­‐
10:	  β	  coefficient	  =	  108.9;	  p	  =	  0.0026;	  G-­‐CSF:	  β	  coefficient	  =	  1.398;	  p	  =	  0.0339)	  as	  
well	  as	  CD38+HLA-­‐DR+	  expression	  (MIP-­‐1β:	  β	  coefficient	  =	  7.499;	  p	  =	  0.0299;	  IP-­‐
10:	  β	  coefficient	  =	  836.7;	  p	  =	  0.0008;	  G-­‐CSF:	  β	  coefficient	  =	  10.32;	  p	  =	  0.0347).	  In	  
addition,	   plasma	   IP-­‐10	   concentration	   could	   significantly	   predict	   CD8+HLA-­‐DR+	  
expression	   (MIP-­‐1β:	   β	   coefficient	   =	   555.9;	   p	   =	   0.0026).	   Figure	   3.18	   shows	   the	  
predictive	  value	  for	  the	  expression	  of	  the	  two	  activation	  markers	  CD38	  and	  HLA-­‐
DR	  and	  for	  the	  doubly-­‐activated	  CD8+	  T-­‐cells.	   
	  
	  
Figure	   3.18.	  Association	  between	   the	   level	  of	  plasma	  cytokines	  and	  blood	  CD8+	  T-­‐cell	  
activation.	   Cytokine	   concentrations	   were	   modelled	   against	   T-­‐cells	   expressing	   the	  
activation	  markers	  CD38	  and	  HLA-­‐DR,	  or	   the	  co-­‐expression	  of	  both.	  The	   inflammatory	  
cytokines	   are	   represented	  by	  blue	   circles	   (),	   the	   regulatory	  one	  by	   green	   circles	   ()	  
and	  the	  hematopoietic	  cytokines	  by	  pink	  circles	  ().	  
	  






















































While	   a	   number	   of	   excellent	   studies	   have	   investigated	   the	   effect	   of	  HAART	   on	  
immune	  reconstitution	  during	  HIV	  infection	  (Rönsholt	  et	  al.,	  2012;	  reviewed	  by	  
Guihot	  et	  al.,	  2011	  &	  Hunt,	  2012),	  comparatively	  few	  studies	  have	  described	  the	  
impact	   of	   antiretroviral	   drugs	  on	   immune	   reconstitution	   at	   the	   genital	  mucosa	  
(Jaspan	  et	  al.,	  2011;	  Mkhize	  et	  al.,	  2010;	  Nkwanyana	  et	  al.,	  2009).	  Antiretroviral	  
drug	   classes	  have	  been	   shown	   to	  differ	   in	   their	  bioavailability	   at	  mucosal	   sites	  
(Else	   et	   al.,	   2011)	   and	   some	   studies	   have	   noted	   a	   dysregulation	   between	   HIV	  
suppression	   systemically	   and	   at	   the	   mucosa	   during	   HAART	   (Cummins	   et	   al.,	  
2006;	  Mukura	  et	  al.,	  2012;	  reviewed	  by	  Anderson	  &	  Cu-­‐Uvin,	  2008).	  This	  chapter	  
therefore	  compared	  the	  impact	  of	  HAART	  on	  the	  differentiation	  status,	  immune	  
activation	   and	   exhaustion	   in	   CD4+	   and	   CD8+	   T-­‐cells	   isolated	   from	   the	   genital	  
mucosa	  from	  HIV-­‐infected	  women,	  and	  investigated	  the	  effect	  of	  systemic	  versus	  
mucosal	  cytokines	  on	  T-­‐cell	  activation.	  	  
	  
Although	   absolute	   CD4+	   counts	   (and	   plasma	   viral	   load	   to	   a	   lesser	   extent)	   are	  
used	   in	   clinical	   settings	   to	   describe	   the	   stage	   of	   an	   HIV	   infection	   and	   make	  
treatment	  decisions,	  blood	  CD4:CD8	  ratios	  have	  also	  previously	  been	  shown	  to	  
be	  a	  good	  indicator	  of	  HIV	  disease	  progression	  (Margolick	  et	  al.,	  2006,	  Taylor	  et	  
al.,	  1989).	  Taylor	  et	  al.	  (1989)	  showed	  that	  CD4:CD8	  ratios	  had	  a	  slightly	  better	  
prognostic	   value	   that	   either	   CD4+	   T-­‐cell	   percentages	   or	   absolute	   CD4+	   T-­‐cell	  
counts.	   One	   of	   the	   most	   interesting	   findings	   from	   this	   chapter	   was	   that	   HIV-­‐
infected	   women	   on	   HAART	   had	   a	   CD4:CD8	   ratio	   in	   blood	   of	   0.7	   and	   in	   their	  
genital	  tracts	  of	  1.2.	  Although	  all	  the	  women	  in	  this	  study	  were	  on	  HAART,	  it	  was	  
interesting	  to	  note	  that	  their	  cervical	  CD4:CD8	  ratios	  were	  more	  similar	  to	  those	  
found	  in	  HIV-­‐infected	  women	  naïve	  to	  HAART	  (CD4:CD8	  ratio	  of	  0.4;	  Nkwanyana	  
et	   al.,	   2009)	   than	   to	   HIV	   negative	   African	   women	   (CD4:CD8	   ratio	   of	   2.7;	  
Nkwanyana	   et	   al.,	   2009).	   This	   suggests	   that	   the	   HIV-­‐infected	   women	   in	   this	  
study,	  despite	  being	  on	  HAART	  for	  a	  median	  of	  85	  months	  (~7	  years),	  had	  not	  
reconstituted	   their	   CD4+	   T-­‐cell	   numbers	   to	   those	   typically	   observed	   pre-­‐HIV-­‐
infection.	  Also,	  both	  the	  blood	  and	  genital	  CD4:CD8	  ratios	  were	   independent	  of	  
time	  on	  HAART.	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Genital	   tract	  T-­‐cells	  were	   found	  to	  be	  predominantly	  TEM.	  Genital	  CD4+	  T-­‐cells	  
showed	  the	  highest	  proliferation	  potential	  (as	  measured	  by	  Ki67	  staining)	  while	  
genital	  CD8+	  T-­‐cells	  showed	  the	  highest	  levels	  of	  immunosenescence	  (measured	  
by	   CD57	   expression).	   Replicative	   senescence	   (CD57	   expression)	   in	   the	   genital	  
CD8+	   T-­‐cell	   population	   was	   positively	   associated	   with	   the	   extent	   of	   their	  
activation.	   A	   hypothesis	   of	   this	   study	   was	   that	   genital	   tract	   inflammatory	  
cytokine	   levels	  would	  positively	  predict	  higher	   levels	  of	  T-­‐cell	  activation	   in	   the	  
genital	   tract.	   In	   support	   of	   this,	   a	   positive	   relationship	  was	   observed	   between	  
genital	   tract	   IL-­‐8	   concentrations	   and	   CD4+	   T-­‐cell	   activation	   (measured	   by	   the	  
frequency	  of	  CD38+HLA-­‐DR+	  expression).	   IL-­‐8	  has	  been	  shown	  to	  be	  one	  of	   the	  
predominant	   cytokines	   found	   in	   the	   genital	   tract	   (Narimatsu	   et	   al.,	   2005).	  	  
Narimatsu	   et	   al.	   (2005)	   showed	   that	   African	   women	   on	   average	   have	   higher	  
physiological	  levels	  of	  IL-­‐8	  in	  the	  genital	  cytokine	  milieu	  compared	  to	  individuals	  
from	   the	   United	   States.	   T-­‐cells	   are	   particularly	   sensitive	   to	   IL-­‐8-­‐chemotaxis	  
(through	   the	   expression	   of	   IL-­‐8-­‐induced	   adhesion	   molecules)	   even	   in	   the	  
presence	  of	  relatively	   low	  concentrations	  of	  the	  cytokine	  (Roux	  et	  al.,	  2000).	   In	  
addition,	   Jaspan	   et	   al.	   (2011)	   showed	   that	   the	   level	   of	   activation	   at	   the	   genital	  
mucosa	  may	  be	  dependent	  on	  the	  systemic	  immune	  activation	  levels.	  In	  this	  case,	  
IL-­‐8	   could	   be	   one	   of	   the	   chemotactic	   factors	   involved	   in	   the	   migration	   of	  
activated	   T-­‐cells	   from	   the	   blood)	   to	   the	   genital	   mucosa	   (Jaspan	   et	   al.,	   2011;	  
reviewed	   by	   Iwasaki,	   2010).	   Although	   lower	   levels	   of	   inflammatory	   cytokines	  
were	   measured	   in	   matching	   blood	   plasma	   than	   in	   the	   genital	   tract,	   a	   similar	  
positive	  association	  was	  noted	  between	  the	  degree	  of	  activation	  by	  blood	  T-­‐cells	  
(CD8+CD38+,	  CD8+HLA-­‐DR+	  and	  CD8+CD38+HLA-­‐DR+)	  and	  plasma	  concentrations	  
of	  MIP-­‐1β,	  IP-­‐10	  and	  G-­‐CSF.	  	  
	  
T-­‐cells	  have	  been	  shown	  to	  consist	  of	  diverse	  populations	  of	  naïve	  and	  memory	  
subsets,	   including	  TEM,	  TCM,	  TD	  and	  naïve	  T-­‐cells	   (reviewed	  by	  Mahnke	  et	  al.,	  
2013).	  These	  phenotypically	  different	  memory	  subsets	  have	  distinct	  and	  specific	  
functions	   (Jameson	   and	  Masopust,	   2009;	   Sallusto	   et	   al.,	   1999).	   In	   this	   chapter,	  
the	   distribution	   of	   the	   different	   T-­‐cell	   memory	   subsets	   differed	   significantly	  
between	  blood	  and	  the	  genital	  tract.	  T-­‐cells	  derived	  from	  the	  female	  genital	  tract	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were	  predominantly	  TEM,	  with	  only	   low	  frequencies	  of	  naïve	  and	  TD	  subtypes.	  
Shin	  and	  Iwasaki	  (2013)	  recently	  reported	  that	  TCM	  tend	  to	  home	  to	  secondary	  
lymphoid	   organs	   (including	   draining	   lymph	   nodes	   and	   spleen),	   while	   TEM	  
circulate	  through	  non-­‐lymphoid	  tissues	  such	  as	  the	  genital	  and	  gut	  mucosa.	  This	  
may	  explain	  the	  higher	  percentage	  of	  TEM	  in	  the	  genital	  compartment	  compared	  
to	  frequencies	  detected	  in	  blood.	  Studies	  have	  shown	  that	  CD8+	  TEM	  contribute	  
significantly	   to	   recall	   responses	   to	   non-­‐lymphoid	   tissues	   (Hikono	   et	   al.,	   2007;	  
Klonowski	   et	   al.,	   2006).	   The	   high	   levels	   inflammatory	   chemokines	   present	   in	  
tissues	  such	  as	  the	  genital	   tract	  may	  account	   for	  recruitment	  of	  CD4+	  and	  CD8+	  
TEM	  to	  the	  cervical	  tissues	  under	  a	  chemokine	  gradient	  (Hikono	  et	  al.,	  2007).	  	  
	  
Overall,	  T-­‐cells	  from	  the	  genital	  compartment	  of	  HIV-­‐infected	  women	  on	  HAART	  
in	   this	  study	  were	  more	  activated	   than	   those	   in	  blood,	  with	  TEM	   in	   the	  genital	  
tract	  being	  the	  most	  activated	  of	  all	  T-­‐cell	  subsets	  isolated	  from	  the	  cervix.	  While	  
genital	  TEM	  and	  TCM	  cells	  were	  found	  to	  be	  generally	  more	  activated	  than	  those	  
in	  blood,	  naïve	  and	  TD	  in	  blood	  were	  less	  activated	  in	  the	  genital	  tract.	  Dianzani	  
et	   al.	   (1994)	   showed	   that,	   in	   healthy	   individuals,	   CD38	   is	   constitutively	  
expressed	  at	  relatively	   low	  levels	  by	  naïve	  T-­‐cells	  and	   is	  down-­‐regulated	   in	  the	  
memory	   T-­‐cells	   (Dianzani	   et	   al.,	   1994;	   reviewed	   by	   Almeida	   et	   al.,	   2002).	  
However,	   in	   HIV	   infection,	   its	   expression	   increases	   drastically	   in	   activated	  
memory	   cells,	   which	   may	   explain	   why	   genital	   TCM	   and	   TEM	   had	   the	   highest	  
CD38	  expression	  in	  this	  study	  (Savarino	  et	  al.,	  2000).	  	  
	  
This	   study	   found	   that	   CD38	   expression	   by	   blood	   CD4+	   and	   CD8+	   T-­‐cells	   was	  
significantly	   predictive	   of	   CD38	   expression	   by	   T-­‐cells	   derived	   from	   the	   genital	  
tract.	  It	  has	  also	  previously	  been	  shown	  that	  activated	  CD4+	  and	  CD8+	  T-­‐cells	  are	  
recruited	  to	  the	  cervix	  in	  the	  presence	  of	  a	  concurrent	  infection	  or	  inflammation	  
(Prakash	  et	  al.,	  2003;	  Gumbi	  et	  al.,	  2008).	  HIV	  in	  the	  genital	  tract	  could	  cause	  the	  
secretion	  of	  cytokines	  such	  as	  IL-­‐8,	  MCP-­‐1	  and	  MIP-­‐1β	  or	  antimicrobial	  peptides	  
such	  as	  human	  β-­‐defensin-­‐1	  and	  -­‐2,	  which	  facilitate	  the	  recruitment	  of	   immune	  




For	   this	  study,	   it	  was	   found	   that	  genital	  CD4+	  T-­‐cells	  had	  a	  higher	  proliferative	  
capacity	  than	  CD8+	  T-­‐cells	  and	  that	  Ki67	  expression	  was	  higher	  in	  genital	  T-­‐cells	  
than	  those	   isolated	   from	  blood.	  Furthermore,	  TEM	  and	  TCM	  cells	   in	   the	  genital	  
tract	  expressed	   the	  highest	   frequencies	  of	  Ki67	  compared	   to	   the	  other	  subsets,	  
with	  CD4+	  TCM	  cells	  expressing	  the	  highest	  frequencies.	  This	  confirms	  previous	  
reports	   that	   Ki67	   expression	   by	   T-­‐cells	   during	   HIV	   infection	   is	   increased	  
compared	   to	   HIV-­‐negative	   individuals,	   and	   that	   this	   increase	   in	   cell	   cycling	  
occurs	   mostly	   in	   the	   memory	   CD4+	   and	   CD8+	   T-­‐cell	   subsets	   (Lempicki	   et	   al.,	  
2000;	  Picker	  et	  al.,	  2004;	  Sieg	  et	  al.,	  2005).	  This	   is	   important	  as	  CD4+	  T-­‐cells	  at	  
the	  genital	  mucosa	  are	  the	  main	  targets	  of	  HIV	  infection	  (reviewed	  by	  Bhardwaj	  
et	  al.,	  2012).	  The	  fact	  that	  there	  were	  quite	  a	  small	  proportion	  of	  CD4+	  TCM	  cells	  
in	  the	  genital	  tract	  may	  have	  been	  influenced	  by	  this.	  In-­‐vitro	  studies	  have	  shown	  
that	  blood	  T-­‐cells	  from	  HIV-­‐infected	  individuals,	  particularly	  those	  that	  are	  TCM,	  
enter	  the	  S-­‐phase	  of	  proliferation	  more	  readily	  than	  other	  memory	  subsets	  or	  T-­‐
cells	   from	   HIV	   negative	   individuals	   because	   of	   bystander	   immune	   activation	  
(Sieg	   et	   al.,	   2005).	   These	   cells	   are	  more	   susceptible	   to	   cell	   death	   by	   apoptosis	  
(Patki	  et	  al.,	  2000),	  possibly	  leading	  to	  the	  depletion	  of	  this	  T-­‐cell	  subset.	  	  
	  
Results	  from	  this	  chapter	  show	  that	  there	  were	  significantly	  higher	  frequencies	  
of	  CD57	  expression	  in	  the	  CD8+	  T-­‐cells	  populations	  compared	  to	  the	  CD4+	  T-­‐cells	  
in	  both	  blood	  and	  the	  genital	   tract	  of	  HIV-­‐infected	  women	  on	  HAART,	  although	  
no	  difference	  between	   compartments	  was	  observed.	  This	   is	   in	   agreement	  with	  
data	   published	   in	   Liebenberg	   et	   al.	   (2010),	   where	   they	   report	   that	   CD57	  
expression	   by	   T-­‐cells	   was	   similar	   in	   blood	   and	   the	   genital	   tract	   of	   chronically	  
HIV-­‐infected	   women.	   The	   higher	   frequency	   of	   CD57	   expression	   in	   CD8+	   than	  
CD4+	  T-­‐cells	  could	  be	  the	  result	  of	  CD4+	  T-­‐cells	  being	  target	  cells	  for	  HIV,	  which	  
may	   be	   depleted	   as	   a	   result	   of	   being	   infected	   before	   they	   become	  
immunosenescent.	   An	   alternative	   explanation	   could	   be	   that	   there	   is	   a	   real	  
accumulation	  of	  CD8+CD57+	  T-­‐cells.	  Chronic	  viral	  infections	  are	  accompanied	  by	  
a	  dysregulation	  in	  the	  normal	  CD57+	  apoptotic	  mechanisms	  (Wood	  et	  al.,	  2009),	  
which	  may	   result	   in	   an	   imbalance	   in	   the	   rate	   of	   proliferation	   and	   apoptosis	   of	  
these	   cells,	   leading	   to	   the	   accumulation	   of	   an	   exhausted	   CD8+CD57+	   T-­‐cell	  
population	  (reviewed	  by	  Focosi	  et	  al.,	  2010).	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An	  important	  finding	  from	  this	  chapter	  was	  that	  the	  extent	  of	  genital	  tract	  CD8+	  
T-­‐cell	   activation	   was	   significantly	   associated	   with	   the	   degree	   of	   exhaustion	   in	  
this	   T-­‐cell	   population,	   with	   the	   most	   activated	   CD8+	   T-­‐cells	   (CD38+	   HLA-­‐DR+)	  
also	   being	   the	  most	   exhausted	   (CD57+).	   A	   similar	   trend	  was	   not	   observed	   for	  
CD4+	  T-­‐cells,	  although	  the	  fact	  that	  CD4+	  T-­‐cells	  are	  also	  the	  direct	  targets	  for	  HIV	  
infection,	   particularly	   activated	   CD4+	   T-­‐cells,	   may	   have	   confounded	   this	  
observation.	   Papagno	   et	   al.	   (2004)	   also	   showed	   that	   elevated	   activation	   and	  
differentiation	   have	   an	   impact	   on	   the	   level	   of	   replicative	   senescence.	  
Furthermore,	   Nixon	   and	   Landay	   (2010)	   have	   also	   previously	   reported	   that	  
persistent	   T-­‐cell	   activation	   drives	   proliferation	   and	   T-­‐cell	   differentiation	   and	  
increased	  expression	  of	  CD57.	  	  
	  
In	   blood,	   plasma	   MIP-­‐1β,	   IP-­‐10	   and	   G-­‐CSF	   concentrations	   were	   positively	  
associated	  with	  the	  level	  of	  CD38	  expression	  by	  blood	  CD8+	  T-­‐cells.	  Saunders	  et	  
al.	   (2011)	   reported	   that	   MIP-­‐1β	   and	   IP-­‐10	   were	   involved	   in	   non-­‐cytolytic	  
suppression	   (via	   the	   secretion	  of	   still	   unknown	  soluble	  mediators;	  Overman	  et	  
al.,	  2007)	  of	  HIV	  by	  CD8+	  T-­‐cells,	  implying	  that	  this	  relationship	  may	  be	  indirect	  
rather	  than	  direct.	  The	  presence	  of	  viral	  antigens	  would	  trigger	  an	  inflammatory	  
response	  involving	  MIP-­‐1β	  and	  IP-­‐10	  from	  CD8+	  T-­‐cells,	  usually	  accompanied	  by	  
the	   upregulation	   of	   the	   activation	   marker	   CD38	   (including	   the	   non-­‐cytolytic	  
mechanisms;	  Appay	  &	  Sauce,	  2008),	  so	  as	  to	  reduce	  viraemia	  and	  in	  turn,	  reduce	  
the	   level	   of	   systemic	   activation.	   Thus,	   the	   change	   in	   the	   level	   of	   expression	   of	  
CD38	  by	  CD8+	  T-­‐cells	  could	  match	  the	  concentration	  of	  secreted	  MIP-­‐1β	  and	  IP-­‐
10.	   Simmons	   et	   al.	   (2013)	   also	   showed	   that	   IP-­‐10	   in	   blood	   plasma	   correlated	  
positively	   with	   activation	   of	   T-­‐cells,	   and	   concentrations	   of	   this	   cytokine	  
predicted	  the	  level	  of	  expression	  of	  CD38	  and	  HLA-­‐DR	  in	  blood	  CD8+	  T-­‐cells.	  IP-­‐
10	  is	  the	  cognate	  ligand	  for	  CXCR3,	  a	  receptor	  which	  is	  readily	  induced	  on	  T-­‐cells	  
upon	  activation	  via	  TLR	  7/9	   in	  an	  HIV	   infection	  (reviewed	  by	  Groom	  &	  Luster,	  
2011).	  This	   inflammatory	  cytokine	  causes	  the	  migration	  of	   immune	  cells	   to	  the	  
site	   of	   infection,	   including	   activated	   CD8+	   T-­‐cells	   (Padovan	   et	   al.,	   2002).	   This	  
could	   account	   for	   the	  positive	   relationship	  between	   the	   concentration	  of	   IP-­‐10	  
and	   the	  degree	  of	  plasma	  CD8+	  T-­‐cell	   activation.	  G-­‐CSF,	  on	   the	  other	  hand,	  has	  
anti-­‐inflammatory	   properties	   and	   it	   able	   to	   modulate	   cytokine	   release	   by	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monocytes.	  G-­‐CSF	  secretion	  has	  been	  suggested	  to	  contribute	  to	  attenuating	  the	  
level	   of	   activation	   and	   secretion	   of	   IFN-­‐γ	   via	   the	   inhibition	   of	   the	   pro-­‐
inflammatory	  cytokines	  IL-­‐12	  and	  TNF-­‐α	  (Boneberg	  et	  al.,	  2000),	  suggesting	  that	  
G-­‐CSF	  may	  have	  an	  indirect	  or	  opposite	  effect	  on	  the	  level	  of	  systemic	  activation.	  
	  
Secretions	   collected	   from	   the	   genital	   tract	   had	   significantly	   higher	  
concentrations	  of	  8/10	  cytokines	  measured	  in	  this	  study	  than	  blood	  plasma.	  Of	  
these,	  7/8	  elevated	  cytokines	  belonged	  to	  the	  inflammatory	  class	  (IL-­‐1β,	  IL-­‐6,	  IL-­‐
8,	   IP-­‐10,	  MIP-­‐1α,	  MIP-­‐1β,	   TNF-­‐α)	   and	  1/8	  belonged	   to	   the	  hematopoietic	   class	  
(G-­‐CSF).	  This	  suggests	  a	  comparatively	  higher	  level	  of	  inflammation	  at	  the	  cervix	  
compared	  to	  blood.	  In	  chronic	  HIV-­‐infected	  individuals	  on	  HAART,	  low-­‐levels	  of	  
viraemia	  have	  been	  shown	  to	  induce	  a	  pro-­‐inflammatory	  response	  at	  the	  genital	  
tract	  which	  contributes	  to	  cell	  recruitment	  (reviewed	  by	  Rajasuriar	  et	  al.,	  2013).	  
Several	  factors	  could	  also	  contribute	  to	  inflammation	  at	  the	  genital	  tract	  (such	  as	  
STIs	   including	   Neisseria	   gonorrhoeae,	   Chlamydia	   trachomatis	   or	   Trichomonas	  
vaginalis,	  and	  bacterial	  vaginosis)	  have	  been	  associated	  with	  the	  recruitment	  of	  a	  
large	   number	   of	   inflammatory	   cells	   (reviewed	   by	   Mayer	   &	   Venkatesh,	   2011).	  
Antigenic	  stimulation	  from	  these	  STIs	  or	  bacterial	  vaginosis	  could	  also	  trigger	  an	  
inflammatory	   cascade	  and	  could	   contribute	   to	   the	  higher	   levels	  of	   cytokines	   in	  
the	  genital	  compartment	  (Galvin	  and	  Cohen,	  2004).	  This	  might	  also	  explain	  the	  
higher	  level	  of	  activation	  in	  the	  T-­‐cell	  populations	  in	  the	  genital	  tract	  compared	  
to	  blood.	  	  
	  
Previous	  studies	  have	  shown	  that	  systemic	  immune	  activation	  and	  inflammatory	  
markers	   remain	   elevated	   in	   HIV-­‐infected	   individuals	   on	   HAART	   (reviewed	   by	  
Klatt	   et	   al.,	   2013).	   Sustained	   levels	   of	   elevated	   immune	   activation	   has	  
consequences	   for	   these	  HIV-­‐infected	   individuals	   because	   it	   places	   them	  at	   risk	  
for	   non-­‐opportunistic	   co-­‐morbidities,	   such	   as	   cardiovascular	   disease,	   type	   II	  
diabetes	  or	  liver	  disease	  (reviewed	  by	  Hunt,	  2012	  &	  Klatt	  et	  al.,	  2013).	  Persistent	  
immune	   activation	   and	   inflammation	   in	   HIV-­‐infected	   individuals	   on	   HAART	  
could	   be	   driven	   by	   several	   factors,	   such	   as	   low-­‐level	   viraemia	   despite	   HAART	  
(below	  the	  level	  of	  detection),	  co-­‐infections	  with	  other	  pathogens	  (such	  as	  CMV),	  
or	   ongoing	  microbial	   translocation	   (as	   a	   result	   of	   incompletely	   constituted	   gut	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mucosal	  barrier	  function).	  Intensification	  of	  therapy	  in	  such	  individuals	  has	  been	  
used	  in	  an	  attempt	  to	  dampen	  the	  effect	  of	  low	  levels	  of	  ongoing	  HIV	  replication	  
on	   T-­‐cell	   activation	   (Dinoso	   et	   al.,	   2009;	   Hunt	   et	   al.,	   2013;	   Llibre	   et	   al.,	   2012;	  
McMahon	  et	  al.,	  2010).	  The	  only	  clinical	  trial	  that	  has	  shown	  some	  success	  used	  
raltegravir	   for	  48	  weeks	   in	  participants	  on	  a	  HAART	  regimen	  consisting	  of	   two	  
NRTI/NtRTI	   inhibitors	   and	   a	   PI	   or	   a	   NNRTI.	   In	   this	   study,	   raltegravir	   led	   to	   a	  
significant	  decrease	  in	  residual	  HIV	  replication	  and	  CD8+	  T-­‐cell	  activation	  (Llibre	  
et	   al.,	   2012).	   Systemic	   markers	   of	   microbial	   translocation	   (such	   as	   LPS	   and	  
bacterial	  DNA)	   are	   significantly	   reduced	   in	   individuals	  who	   are	   on	  HAART	  but	  
these	  do	  not	  return	  to	  pre-­‐infection	  levels	  and	  are	  associated	  with	  increased	  T-­‐
cell	   activation	   and	   higher	   soluble	   CD14	   and	  D-­‐dimer	   levels	   (Funderburg	   et	   al.,	  
2010).	   Other	   chronic	   viral	   infections	   also	   contribute	   to	   the	   persistent	   immune	  
activation.	   Hunt	   et	   al.	   (2011)	   showed	   that	   treatment	   with	   Valganciclovir	   (an	  
antiviral	  drug	  used	  to	  treat	  CMV	  infections)	  decreased	  CD8+	  T-­‐cell	  activation	  in	  
individuals	  co-­‐infected	  with	  HIV	  and	  CMV,	  who	  had	  elevated	  immune	  activation	  
despite	  undetectable	  viral	  loads	  (Hunt	  et	  al.,	  2011b).	  	  
	  
In	  this	  study,	  HIV-­‐infected	  women	  on	  HAART	  had	  higher	  levels	  of	  activation	  and	  
inflammation	   in	   the	   genital	   tract	   compared	   to	   blood.	   Previous	   studies	   have	  
shown	   that	   there	  may	   be	   a	   link	   between	   the	   systemic	   and	   genital	   tract	   T-­‐cell	  
activation	   and	   inflammation	   (reviewed	   by	   Xu	   et	   al.,	   2013).	   Stimulation	   by	  HIV	  
viral	   antigens	   in	   the	   genital	   tract	   would	   result	   in	   a	   rapid	   upregulation	   of	  
cytokines,	   chemokines	   and	   chemokine	   receptors,	   leading	   to	   the	   recruitment	   of	  
activated	  T-­‐cells	   and	  DCs.	   These	   infiltrating	   cells	   have	   been	   shown	   to	   produce	  
interferons	  and	  chemoattractants	  such	  as	  MIP-­‐1α,	  MIP-­‐1β	  and	  RANTES	  (Prakash	  
et	  al.,	  2001).	  These,	  in	  turn,	  recruit	  more	  activated	  T-­‐cells,	  especially	  CD4+CCR5+	  
T-­‐cells.	   Also.	   Activated	  memory	   T-­‐cells,	   especially	   memory	   CD4+CCR5+	   T-­‐cells,	  
have	   been	   shown	   to	   be	   preferentially	   recruited	   to	   sites	   where	   HIV	   infections	  
occur,	   facilitating	   faster	   and	  more	  effective	   immune	   response	  against	   the	  virus	  
(reviewed	  by	  Masopust	  &	  Schenkel,	  2013).	  Also,	  HIV	  infection	  of	  CD4+	  T-­‐cells	  and	  
immune	   dysregulation	   at	   mucosal	   surfaces	   results	   in	   HIV-­‐specific	   and	   non-­‐
specific	   immune	   activation,	   which	   continuously	   produces	   new	   effector	   T-­‐cells	  
(reviewed	  by	  Xu	  et	  al.,	  2013).	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In	  summary,	  this	  Chapter	  describes	  both	  clinical	  and	  phenotypic	  characteristics	  
of	   T-­‐cells	   from	  blood	   and	   the	   female	   genital	   tract	   that	   failed	   to	   reconstitute	   to	  
levels	   found	   in	   healthy	   uninfected	   women,	   even	   after	   ~7	   years	   of	   being	   on	  
HAART	   (Nkwanyana	   et	   al.,	   2009).	   This	   suggest	   that,	   once	   viral	   suppression	  
occurred	   after	   initiation	   of	  HAART	  and	   the	   initial	   reconstitution	   of	   CD4+	  T-­‐cell	  
counts,	   the	   immune	   system	   does	   not	   reconstitute	   to	   levels	   typically	   detected	  
before	  HIV	   infection,	   even	   if	   an	   individual	   consistently	   uses	  HAART	   for	   a	   long	  
period	  of	  time.	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Chapter	  4.	  Impact	  of	  intiation	  of	  HAART	  in	  
chronic	  HIV-­‐infected	  women	  
	  
4.1 Introduction	  
Since	   the	   introduction	   and	  massive	   scale-­‐up	   in	   access	   to	   HAART,	   HIV-­‐infected	  
individuals	   have	   experienced	   a	   significant	   improvement	   in	   both	   their	   life	  
expectancy	   and	  quality	   of	   life.	   In	   South	  Africa,	   Johnson	   et	   al.	   (2013)	   estimated	  
that	  HIV-­‐infected	  individuals	  starting	  HAART	  have	  life	  expectancies	  ~80%	  of	  the	  
normal	   life	   expectancy	   of	   HIV-­‐negative	   individuals.	   Current	   HAART	   guidelines	  
are	  based	  on	  the	  simultaneous	  administration	  of	  three	  drugs	  and	  have	  been	  very	  
successful	   in	   rapidly	   suppressing	   viral	   replication	   to	   levels	   below	   clinical	  
detectable	  levels	  in	  most	  patients	  (Lichterfeld	  and	  Zachary,	  2011).	  	  
	  
Several	   studies	   have	   shown	   that	   HAART	   plays	   a	   crucial	   role	   in	   reducing	   HIV-­‐
induced	   immune	   activation	   and	   is	   associated	  with	   a	   better	   clinical	   outcome	   in	  
the	  long	  term	  (reviewed	  by	  Hunt,	  2012).	  Key	  studies	  have	  shown	  that	  the	  earlier	  
HAART	   is	   initiated	   during	   HIV	   infection,	   the	   better	   the	   chances	   of	   CD4+	   T-­‐cell	  
reconstitution.	  Le	  et	  al.	  (2013)	  showed	  that	  starting	  HAART	  within	  the	  first	  four	  
months	   of	   infection	   was	   associated	   with	   better	   CD4+	   T-­‐cell	   recovery.	   In	   a	  
longitudinal	   study	   investigating	   clinical	   changes	   following	   initiation	   of	  HAART,	  
Robbins	  et	  al.	   (2009)	  reported	  that	   individuals	  who	  started	  HAART	  when	  their	  
CD4+	  T-­‐cell	  counts	  were	  >350	  cells/ml	  reconstituted	  to	   levels	  almost	  similar	  to	  
HIV	  negative	  individuals,	  but	  that	  the	  same	  immune	  reconstitution	  did	  not	  occur	  
in	  individuals	  with	  lower	  CD4+	  T-­‐cell	  counts.	  Furthermore,	  they	  found	  that	  CD4+	  
T-­‐cell	   numbers	   reconstituted	   in	   two	   phases:	   the	   highest	   rate	   of	   CD4+	   T-­‐cell	  
increase	   occurred	   in	   the	   first	   eight	   weeks	   after	   initiating	   HAART	   and	   a	   more	  
gradual	   increase	   occurring	   afterwards.	   HIV-­‐infected	   individuals	   with	   baseline	  
CD4+	  T-­‐cell	   counts	   >350	   cells/ml	   had	  normalised	  CD4+	   naïve	   and	  memory	   cell	  
counts	   by	   48	   weeks,	   but	   those	   with	   CD4+	   T-­‐cell	   counts	   <350	   cells/ml	   never	  
recovered	  their	  CD4+	  naïve/memory	  T-­‐cell	  ratios	  to	  pre-­‐infection	  levels	  (Robbins	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et	  al.,	  2009).	  Irrespective	  of	  baseline	  CD4+	  T-­‐cell	  counts,	  levels	  of	  T-­‐cell	  activation	  
persisted	   throughout	   the	   3	   years	   of	   follow-­‐up	   and	   the	   lower	   the	   CD4+	   T-­‐cell	  
count	  was	  when	  HAART	  was	   initiated,	   the	   longer	  T-­‐cell	   activation	  persisted	   in	  
blood	  (Robbins	  et	  al.,	  2009).	  	  
	  
Less	   is	  known	  about	   the	   impact	  of	  HAART	  in	  T-­‐cell	  reconstitution	  and	   immune	  
activation	   in	   the	   genital	   tract	   of	   HIV-­‐infected	   women.	   Differences	   in	   the	  
bioavailability	   of	   antiretroviral	   drugs	   in	   tissues	   such	   as	   the	   genital	   tract	  
compared	  to	  blood	  may	  influence	  HAART	  reconstitution	  at	  mucosal	  sites.	  Studies	  
have	   shown	   that	   NRTIs	   had	   a	   better	   penetrative	   capacity	   to	   the	   mucosa	  
compared	  to	  NNRTIs	  (Kwara	  et	  al.,	  2008;	  Min	  et	  al.,	  2004).	   In	  a	  cross-­‐sectional	  
study	   comparing	   HIV-­‐infected	   women	   on	   HAART	   with	   those	   naïve	   to	   HAART,	  
Mkhize	   et	   al.	   (2010)	   reported	   that	   women	   on	   HAART	   had	   higher	   CD4+	   T-­‐cell	  
percentages	  in	  the	  genital	  tract	  than	  those	  not	  taking	  HAART,	  and	  was	  also	  able	  
to	   fully	  suppress	  the	  genital	  viral	   load.	   In	  about	  10-­‐27%	  of	  cases,	  opportunistic	  
diseases	  may	  worsen	  during	  the	  period	  of	  immune	  reconstitution	  soon	  after	  the	  
initiation	  of	  HAART	  (Haddow	  et	  al.,	  2012),	  leading	  to	  IRIS	  in	  both	  blood	  and	  the	  
genital	   tract.	   In	   the	   genital	   tract,	   the	   two	   main	   causes	   of	   IRIS	   were	   the	  
reactivation	   of	   genital	   herpes	   (Yudin	   and	  Kaul,	   2008)	   and	   the	   re-­‐apparition	   of	  
genital	  warts	   (Meys	  et	   al.,	   2010),	   resulting	   in	  excessive	   immune	  activation	  and	  
inflammation	  in	  spite	  of	  HIV-­‐RNA	  suppression	  on	  HAART	  (Martin-­‐Blondel	  et	  al.,	  
2012).	  	  
	  
The	   aim	   of	   this	   chapter	   was	   to	   investigate	   changes	   in	   immune	   activation,	  
maturation	   and	   inflammation	   in	   the	   genital	   tract	   of	   HIV-­‐infected	   women	  
immediately	  before	  and	  1	  month	  after	  initiation	  of	  HAART,	  and	  to	  compare	  these	  
changes	  at	  the	  mucosa	  to	  those	  observed	  in	  blood.	  The	  hypothesis	  being	  tested	  
was	  that	  initiating	  HAART	  would	  improve	  CD4+	  T-­‐cell	  counts	  in	  the	  genital	  tract,	  
reduce	   the	   level	   of	   T-­‐cell	   activation	   and	   inflammation	   in	   the	   genital	   tract	   and	  
reduce	   genital	   tract	   viral	   loads.	   These	   improvements	   in	   CD4	   counts	   and	   viral	  
load	  would	  mirror	  those	  detected	  in	  blood.	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4.2 Materials	  and	  methods	  
For	  this	  part	  of	   the	  study,	  11	  HIV-­‐infected	  women	  who	  were	  eligible	   to	   initiate	  
HAART	  were	  enrolled	  from	  the	  Nyanga	  East	  Day	  Hospital	  (Nyanga,	  Cape	  Town)	  
(Chapter	  2	  section	  2.1).	  All	  women	  eligible	  for	  study	  were	  pre-­‐menopausal	  and	  
had	   not	   undergone	   a	   hysterectomy.	   3/11	   (27.3%)	   women	   were	   not	   on	  
contraception,	  5/11	  (45.4%)	  were	  on	  Petogen	  and	  3/11	  (27.3%)	  on	  Nur	  Isterate.	  	  
From	   each	   HIV-­‐infected	   woman,	   blood	   and	   a	   cervical	   cytobrush	   sample	   was	  
obtained	   immediately	   prior	   to	   initiation	   of	   HAART	   and	   after	   one	   month	   on	  
therapy.	  Blood	  and	  a	  cervical	  cytobrush	  sample	  were	  collected	  for	  the	  extraction	  
of	  PBMC	  and	  CMC,	  respectively	  (Chapter	  2	  sections	  2.3	  and	  2.4).	  Polychromatic	  
flow	   cytometry	   (Appendix	   II)	   was	   carried	   out	   to	   characterise	   the	   blood	   and	  
cervical	  T-­‐cells	   (Chapter	  2	   section	  2.8).	  Multiplex	  Luminex	   flow	  cytometry	  was	  
used	   to	   determine	   the	   inflammatory	   cytokine	   profile	   in	   the	   blood	   plasma	   and	  
genital	   fluid	   (Chapter	   2	   section	   2.11).	   In	   addition,	   the	   samples	   obtained	   from	  
each	  woman	  were	   screened	   for	  Neisseria	   gonorrhoeae,	   Chlamydia	   trachomatis,	  
Trichomonas	  vaginalis	  and	  Mycoplasma	  genitalium	  at	  both	  time	  points	  (Chapter	  2	  
section	  2.13).	  	  
	  
4.3 Results	  
4.3.1 Description	  of	  participants	  
Eleven	  HIV-­‐positive	  women	  starting	  HAART	  were	  enrolled	  into	  this	  longitudinal	  
study	   immediately	   before	   and	   1	   month	   after	   starting	   HAART	   (table	   4.1).	   The	  
median	   age	   of	   these	   women	   was	   31	   years	   (IQR:	   26-­‐38).	   Importantly,	   these	  
women	   had	   a	  median	   CD4	   count	   of	   200	   cells/ml	   (IQR:	   123-­‐314)	   at	   their	   first	  
visits	   (immediately	   prior	   to	   initiating	   HAART),	   despite	   current	   guidelines	   in	  
South	   Africa	   recommending	   that	   HAART	   should	   be	   initiated	   with	   CD4	   counts	  
were	   350	   cells/ml.	   Their	   median	   plasma	   viral	   loads	   were	   127122	   copies/ml	  
(IQR:	  4002-­‐229227).	  Of	  the	  11	  women,	  10/11	  had	  detectable	  viral	  loads	  in	  their	  
genital	  secretions	  and	  their	  median	  genital	  tract	  viral	  loads	  were	  2490	  copies/ml	  
(IQR:	   1342-­‐7981).	   All	   women	   were	   initiated	   on	   a	   first	   line	   HAART	   regimen,	  
consisting	   of	   a	   NNRTI	   (efavirenz)	   and	   two	   NRTIs	   (tenofovir	   and	  
emtricitabine/lamivudine)	   as	   per	   the	   South	   African	   antiretroviral	   treatment	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guidelines	   (The	   South	   African	   Antiretroviral	   Treatment	   Guidelines,	   2013).	   After	  
being	   on	   HAART	   for	   1	   month,	   their	   plasma	   viral	   loads	   had	   declined	   to	   253	  
copies/ml	   (IQR:	   40-­‐1595;	  with	   4/11	  women	  being	   completely	   suppressed	   and	  
7/11	  women	  having	  viral	   loads	  <1500	  copies	  per	  ml).	  Only	  2/11	  women	  were	  
still	   shedding	   low	   levels	  of	  HIV	   in	   their	  genital	   tracts	   (183	  and	  872	  copies/ml)	  
and	   both	   of	   these	   women	   still	   had	   detectable	   plasma	   viral	   loads	   (2814	   and	  
34848	  copies/ml,	  respectively).	  
	  







Viral	  load	  at	  visit	  1	  
(copies/ml)	  




Plasma	   Genital	   Plasma	   Genital	  
HTCell1	   32	   153	   127122	   6250	   323	   LDLa	   FTCb,	  EFVc,	  TDFd	  
HTCell2	   24	   85	   139577	   2490	   1121	   LDL	   3TCe,	  EFV,	  TDF	  
HTCell3	   27	   123	   1597123	   199958	   2814	   183	   3TC,	  EFV,	  TDF	  
HTCell4	   20	   306	   4688	   1572	   LDL	   LDL	   3TC,	  EFV,	  TDF	  
HTCell5	   33	   314	   2526	   550	   LDL	   LDL	   3TC,	  EFV,	  TDF	  
HTCell6	   42	   41	   1122888	   6716	   1595	   LDL	   3TC,	  EFV,	  TDF	  
HTCell7	   39	   333	   2600	   1463	   LDL	   LDL	   FTC,	  EFV,	  TDF	  
HTCell8	   38	   336	   34350	   1342	   253	   LDL	   FTC,	  EFV,	  TDF	  
HTCell9	   31	   233	   4002	   LDL	   LDL	   LDL	   FTC,	  EFV,	  TDF	  
HTCell10	   26	   200	   130831	   30617	   34848	   872	   FTC,	  EFV,	  TDF	  
HTCell11	   30	   198	   229227	   7981	   184	   LDL	   FTC,	  EFV,	  TDF	  
Median	   31	   200	   127122	   2490	   253	   <40	  (LDL)	   	  
aLDL	  –	  Lower	  than	  detectable	  level	  
bFTC	  –	  Emtricitabine;	  cEFV-­‐	  Efavirenz;	  dTDF	  –	  Tenofovir;	  e3TC	  –	  Lamivudine	  
	  
4.3.2 Impact	  of	  HAART	  initiation	  on	  plasma	  and	  genital	  viral	  loads	  
Immediately	   before	   starting	   HAART,	   the	   11	   HIV-­‐infected	  women	   in	   this	   study	  
had	  a	  median	  plasma	  viral	  load	  of	  127122	  copies/ml	  (IQR:	  4002-­‐229227),	  with	  
10/11	  women	  shedding	  HIV-­‐RNA	  into	  their	  genital	  secretions	  (median	  of	  4370	  
copies/ml,	   ranging	   from	   550	   to	   199,958	   RNA	   copies/ml).	   After	   one	   month	   of	  
HAART,	   there	   was	   a	   significant	   decrease	   in	   both	   the	   plasma	   and	   genital	   viral	  
loads	   (p=0.001	   and	   p=0.002,	   respectively)	   with	   post-­‐treatment	   plasma	   viral	  
loads	  ranging	  from	  <40	  to	  34,848	  RNA	  copies/ml	  and	  genital	  tract	  loads	  ranging	  
from	  <40	  to	  872	  RNA	  copies/ml	  (figure	  4.1A).	  Within	  compartments,	  there	  was	  a	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significant	   correlation	   between	   viral	   loads	   at	   the	   two	   time	   points	   (for	   plasma:	  
rho=0.8095	   and	   p=0.0025;	   for	   cervix:	   rho=0.6607	   and	   p=0.0269;	   figure	   4.1B),	  
suggesting	  that	  the	  decrease	  in	  viral	  load	  due	  to	  HAART	  may	  depend	  on	  the	  viral	  
load	  at	   initiation	  of	   therapy.	  There	  was	  also	  a	  positive	  association	  between	  the	  
plasma	   and	   the	   genital	   viral	   loads	   both	   at	   baseline	   and	   after	   one	   month	   on	  
therapy	   (Baseline:	   rho=0.8545	   and	   p=0.0008;	   for	   cervix:	   rho=0.6901	   and	  
p=0.0188;	  figure	  4.1C).	  	  
	  
Figure	  4.1.	  Relationship	  between	  plasma	  and	  genital	  tract	  viral	  loads	  in	  women	  before	  
and	  after	  they	  had	  initiated	  HAART.	  A.	  Difference	  in	  the	  log	  viral	  loads	  between	  the	  time	  
of	   initiation	   of	   HAART	   ()	   and	   after	   one	   month	   on	   treatment	   ().	   B.	   Correlation	  
between	  the	  baseline	  (immediately	  prior	  to	   initiating	  HAART)	  and	  month	  1	  viral	   loads	  
for	  the	  blood	  ()	  and	  cervical	  compartments	  ().	  C.	  Correlation	  between	  the	  plasma	  ()	  
and	   cervical	   supernatant	   ()	   log	   viral	   loads	   at	   baseline	   and	   month	   1.	   The	   Wilcoxon	  
Signed	  Rank	  test	  for	  paired	  samples	  for	  used	  for	  A	  while	  the	  Spearman	  rank	  correlation	  
test	   was	   used	   for	   B	   and	   C.	   A	   p	   value	   of	   ≤0.05	   was	   considered	   to	   be	   statistically	  
significant.	  	  
	  
4.3.3 Changes	  in	  T-­‐cell	  distribution	  in	  the	  genital	  tract	  and	  blood	  following	  
initiation	  of	  HAART	  
CD4:CD8	   T-­‐cell	   ratios	   from	   blood	   and	   cervical	   cytobrushes,	   as	   an	   indicator	   of	  
CD4+	   T-­‐cell	   reconstitution,	   were	   measured	   immediately	   prior	   to	   the	   start	   of	  
therapy	  and	  1	  month	  after	  initiation	  of	  HAART	  (figure	  4.2).	  An	  inverted	  CD4:CD8	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ratio	   of	   less	   than	   1.0	   is	   a	   characteristic	   of	   an	   HIV	   infection	   (shown	   as	   a	   grey	  
dotted	  line	  in	  figure	  4.2),	  and	  has	  previously	  been	  shown	  to	  be	  a	  useful	  correlate	  
of	   absolute	   CD4+	   T-­‐cell	   counts	   (Sainz	   et	   al.,	   2013).	   An	   inverted	   ratio	   is	   an	  
indication	   that	   T-­‐cells	   were	   predominantly	   CD8+	   T-­‐cells	   as	   opposed	   to	   the	  
predominant	   CD4+	   T-­‐cell	   profile	   found	   in	   healthy	   uninfected	   individuals	  
(Margolick	   et	   al.,	   2006).	   In	   South	   African	   women,	   Nkwanyana	   et	   al.	   (2009)	  
showed	   that	   healthy	   HIV-­‐negative	  women	   had	   a	   CD4:CD8	   ratio	   of	   2.7	   in	   their	  
genital	  tracts	  but	  didn’t	  report	  on	  blood	  CD4:CD8	  ratios.	  Margolick	  et	  al.	  (2006)	  
reported	  that	  HIV	  negative	  African	  American	  women	  had	  a	  blood	  CD4:CD8	  ratio	  
of	  1.6,	  although	  they	  didn’t	  report	  on	  genital	  tract	  CD4:CD8	  ratios.	  	  
	  
Overall,	   there	  were	  no	  differences	   in	   the	   frequencies	   of	   CD4+	   and	  CD8+	  T-­‐cells	  
obtained	  before	  and	  after	  HAART	   initiation	   in	  either	   the	  genital	   tract	  or	  blood.	  
Immediately	  before	  starting	  HAART,	   the	  median	  blood	  CD4:CD8	  ratio	   for	   these	  
HIV-­‐infected	   women	  was	   0.466	   (IQR:	   0.148-­‐0.614).	   After	   1	  month	   on	   HAART,	  
their	  median	  blood	  CD4:CD8	  ratio	  was	   largely	  unchanged	  at	  0.391	  (IQR:	  0.222-­‐
0.689),	  indicating	  that	  no	  observable	  CD4+	  T-­‐cell	  reconstitution	  in	  these	  women	  
within	   the	   first	  month	   of	   HAART	   (despite	   significant	   improvements	   in	   plasma	  
viral	   loads,	   table	   4.1).	   In	   contrast	   to	   blood,	   CD4:CD8	   ratios	   in	   the	   genital	   tract	  
were	   a	   median	   of	   0.096	   (IQR:	   0.034-­‐0.391)	   immediately	   prior	   to	   initiating	  
HAART	  indicating	  that	  the	  women	  enrolled	  in	  this	  study	  had	  almost	  undetectable	  
CD4+	  T-­‐cell	  counts	  in	  their	  cervical	  cytobrushes	  (CD8+	  T-­‐cells	  outnumbered	  CD4+	  
T-­‐cells	  10:1).	   	  After	  1	  month	  on	  HAART,	  genital	   tract	  CD4:CD8	  ratios	  were	  still	  
very	  low	  with	  a	  median	  of	  0.194	  (IQR:	  0.113-­‐0.396).	  	  
	  
The	  median	  CD4:CD8	  ratios	   in	  this	  cohort	  of	  HIV-­‐infected	  women	  who	  had	  just	  
started	  HAART	  were	  compared	  with	  the	  15	  HIV-­‐infected	  women	  who	  had	  been	  
on	  HAART	  for	  a	  long	  period	  of	  time	  (median	  of	  85	  months;	  figure	  4.3).	  The	  HIV-­‐
infected	   women	   in	   this	   chapter	   who	   had	   only	   recently	   initiated	   HAART	   had	  
significantly	   lower	   CD4:CD8	   ratios	   than	   those	   from	  women	  who	   have	   been	   on	  
therapy	  for	  85	  months	  (blood:	  p	  =	  0.0359;	  cervix:	  p	  =	  0.0025).	  This	  suggests	  that	  
a	  longer	  period	  of	  time	  may	  be	  needed	  for	  HAART	  to	  restore	  CD4+	  T-­‐cell	  counts	  
 102 




Figure	   4.2.	   Impact	   of	  HAART	   initiation	   on	   CD4:CD8	   ratios	   in	   both	   the	   blood	   ()	   and	  
genital	   ()	   compartments.	   Baseline	   indicates	   the	   time	   point	   immediately	   prior	   to	  
initiation	  of	  HAART;	  and	  1	  month	  after	  initiation	  of	  HAART.	  The	  grey	  dotted	  line	  shows	  
the	  threshold	  (plasma	  CD4:CD8	  ratio=1)	  below	  which	  the	  ratio	  becomes	  inverted	  while	  
the	  black	  dotted	  line	  shows	  the	  average	  ratio	  for	  healthy	  uninfected	  women.	  	  
	  
	  
Figure	  4.3.	  Comparison	  between	  the	  CD4:CD8	  ratios	  of	  HIV-­‐infected	  women	  who	  have	  
been	  on	  HAART	   for	  1	  month	  with	  HIV-­‐infected	  women	  who	  have	  been	  on	  HAART	   for	  
longer	  in	  the	  blood	  ()	  and	  cervical	  ()	  compartments.	  	  
	  
4.3.4 Impact	   of	   HAART	   on	   T-­‐cell	   maturation	   marker	   expression	   in	   the	  
genital	  compartment	  and	  blood	  
Untreated	   HIV	   infection	   has	   been	   characterised	   by	   an	   imbalance	   in	   the	  
distribution	   of	   the	   different	   naïve/memory	  T-­‐cell	   subsets,	   because	   some	  T-­‐cell	  




















































to	  activation	  induced	  cell	  death	  than	  other	  subsets	  (Hellerstein	  et	  al.,	  2003).	  The	  
memory	   composition	  of	  T-­‐cells	   in	   blood	   and	   in	   the	   genital	   tract	   (from	   cervical	  
cytobrushes)	  was	   compared	   in	  women	   immediately	   before	   and	   1	  month	   after	  
they	   started	   HAART.	   Generally,	   HAART	   did	   not	   seem	   to	   influence	   the	  
predominant	  T-­‐cell	  memory	  subsets	   in	  either	  the	  genital	   tract	  or	  blood.	  Genital	  
CD4+	  and	  CD8+	  T-­‐cells	  were	  mostly	  TEM	  irrespective	  of	  HAART	  status,	  with	  the	  
other	  memory	  subsets	  being	  present	  at	  much	  lower	  proportions	  (figures	  4.4	  B,	  D,	  
F	   and	  H).	  Blood	  CD4+	  T-­‐cells	   consisted	  mainly	  of	   naïve	   and	  TEM	  cells	  with	  TD	  
being	  present	  at	  the	  lowest	  frequencies	  (figures	  4.4	  A	  and	  C).	  Blood	  CD8+	  T-­‐cells,	  
in	  contrast,	  TD	  and	  TEM	  cells	  were	  found	  in	  the	  highest	  proportions,	  with	  TCM	  
being	  found	  at	  the	  lowest	  frequencies	  (figures	  4.4	  E	  and	  G).	  	  
	  
It	  was	  interesting	  to	  note	  that	  genital	  frequencies	  of	  TEM	  decreased,	  which	  was	  
accompanied	  by	  an	  increase	  in	  the	  proportion	  of	  TCM	  for	  both	  CD4+	  and	  CD8+	  T-­‐
cells,	  significantly	  so	  for	  the	  CD4+	  TCM	  subset	  (p	  =	  0.0313).	  Reconstitution	  in	  the	  
proportion	  of	  the	  long-­‐lived	  memory	  subsets	  has	  previously	  been	  reported	  to	  be	  
an	  early	  sign	  of	  immune	  reconstitution	  (Hellerstein	  et	  al.,	  2003).	  For	  this	  study,	  
however,	  one	  month	  on	  HAART	  may	  not	  be	  enough	  time	  to	  correct	  the	  immune	  
dysfunction	  seen	  in	  chronic	  HIV	  infection.	  	  




Figure	  4.4.	  Distribution	  of	  the	  different	  naïve/memory	  subsets	  for	  the	  CD4+	  and	  CD8+	  T-­‐
cell	   populations	   in	   blood	   and	   the	   genital	   tract	   of	   HIV-­‐infected	   women	   immediately	  
before	  initiation	  of	  HAART	  (A	  and	  B)	  and	  after	  1	  month	  on	  HAART	  (C	  and	  D).	  The	  blue,	  
red,	  green	  and	  purple	  slices	  represent	  the	  percentage	  of	  naïve,	  central	  memory,	  effector	  
memory	  and	  terminally	  differentiated	  T-­‐cells	  respectively.	  	  
	  
4.3.5 Impact	   of	   HAART	   on	   T-­‐cell	   activation	   in	   blood	   and	   the	   	   genital	  
compartment	  
Previous	   studies	   have	   shown	   that	   T-­‐cell	   activation	   in	   blood	   decreases	  
significantly	  after	  HAART	  is	  initiated,	  despite	  the	  poor	  recovery	  of	  gut-­‐associated	  
lymphoid	   CD4+	   T-­‐cells	   (Giorgi	   et	   al.,	   1998;	   reviewed	   by	   Brenchley	   &	   Douek,	  
2008).	  It	  was	  suggested	  that,	  in	  an	  HIV	  infection,	  it	  is	  the	  level	  of	  HIV	  replication	  
that	   mainly	   drives	   immune	   activation	   and	   the	   rapid	   viral	   suppression	   after	  
starting	   therapy	   leads	   to	   an	   equally	   rapid	   and	   marked	   decrease	   in	   immune	  
activation	   (reviewed	   by	   Hunt,	   2007).	   Studies	   comparing	   changes	   in	   immune	  
activation	  and	  inflammation	  after	  initiation	  of	  HAART	  and	  the	  effect	  on	  CD4+	  T-­‐
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To	  determine	  whether	  1	  month	  of	  HAART	  had	  an	  effect	  on	  activation	  of	  T-­‐cells,	  
frequencies	   of	   CD4+	   and	   CD8+	   T-­‐cells	   expressing	   CD38	   and	   HLA-­‐DR	   were	  
compared	  between	  the	  two	  time	  points	  (figure	  4.5).	  In	  blood,	  activation	  of	  T-­‐cells	  
was	  generally	  lower	  following	  1	  month	  of	  HAART	  compared	  to	  before	  initiation	  
of	   HAART	   (CD4+CD38+:	   p=0.001;	   CD4+CD38+HLA-­‐DR+:	   p=0.0322;	   CD4+total	  
activation:	   p=0.001;	   CD8+CD38+:	   p=0.0029;	   CD8+HLA-­‐DR+:	   p=0.0068;	  
CD8+CD38+HLA-­‐DR+:	   p=0.0137;	   CD8+total	   activation:	   p=0.002).	   In	   contrast,	  
HAART	  initiation	  did	  not	  seem	  to	  reduce	  genital	  T-­‐cell	  activation.	  The	  frequency	  
of	   activated	   CD8+	   T-­‐cells	   from	   the	   genital	   tract	   was	   similar	   before	   and	   after	  
initiation	  of	  HAART	  (figure	  4.5D).	  In	  more	  than	  half	  of	  the	  women	  studied,	  CD4+	  
T-­‐cells	   from	   the	  genital	   tract	  actually	   seemed	  slightly	  more	  activated	   (HLA-­‐DR,	  
CD38	   and	   total	   activation)	   after	   1	   month	   on	   HAART	   compared	   to	   before	  
initiating	  HAART,	  although	  this	  was	  not	  significant	  (figure	  4.5C)	  	  
	  
	  
Figure	  4.5.	  Comparison	  of	  pre-­‐	  versus	  post-­‐HAART	  activation	  in	  genital	  tract	  and	  blood	  
T-­‐cell	  populations.	  (A-­‐B)	  Differences	  in	  the	  percentages	  of	  CD38+,	  HLA-­‐DR+,	  CD38+HLA-­‐
DR+	  and	  total	  activation	  in	  blood	  CD4+	  and	  CD8+	  T-­‐cells	  (shown	  in	  blue	  and	  purple).	  (C-­‐
D)	  Differences	  in	  the	  percentage	  of	  the	  different	  activation	  markers	  in	  genital	  CD4+	  and	  
CD8+	  T-­‐cells	  (shown	  in	  pink	  and	  green).	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4.3.6 Effect	  of	  HAART	  initiation	  on	  T-­‐cell	  proliferation	  and	  exhaustion	  in	  the	  
genital	  tract	  and	  blood	  
To	  determine	   the	   effect	   of	   initiating	  HAART	  on	   the	   level	   of	   T-­‐cell	   proliferation	  
and	   exhaustion,	   frequencies	   of	   Ki67+	   and	   CD57+	   T-­‐cells	   were	   compared	  
immediately	  before	  and	  1	  month	  after	  starting	  HAART,	  respectively.	  No	  change	  
in	   the	   level	   of	   proliferation	   (Ki67	   expression)	   by	   T-­‐cells	   from	   blood	   and	   the	  
genital	  tract	  was	  observed	  (data	  not	  shown).	  Similarly,	  HAART	  initiation	  did	  not	  
seem	  to	  influence	  frequencies	  of	  T-­‐cells	  in	  blood	  expressing	  CD57.	  	  
	  
In	  contrast,	   in	   the	  genital	  compartment,	   frequencies	  of	  T-­‐cells	  expressing	  CD57	  
were	   significantly	   elevated	   after	   1	   month	   of	   HAART	   (p=0.0322	   for	   CD4+	   and	  
p=0.0078	   for	   CD8+	   T-­‐cells;	   figure	   4.6).	  When	   the	   genital	   cells	  were	   subdivided	  
into	  naïve/memory	  subsets,	   it	  was	   found	  that	   this	   increase	   in	  CD57	  expression	  




Figure	   4.6.	   Comparison	   between	   the	   frequency	   of	   T-­‐cells	   expressing	   the	   senescence	  
marker	   CD57	   before	   and	   1	   month	   after	   starting	   HAART.	   A.	   Comparing	   the	   level	   of	  
expression	  of	  CD57	  in	  CD4+	  T-­‐cells.	  B.	  Percentage	  of	  CD57+	  cells	  in	  the	  blood	  and	  genital	  
CD8+	  T-­‐cells.	  The	  peripheral	  blood	  mononuclear	  cells	  are	  represented	  by	   the	   light	  and	  
dark	  blue	  box-­‐and-­‐whisker	  plots	   and	   the	   cervical	  mononuclear	   cells	  by	   light	   and	  dark	  
box-­‐and-­‐whisker	  plots.	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Figure	  4.7.	  Comparing	  the	  level	  of	  exhaustion	  within	  the	  naïve/memory	  subsets	  in	  the	  
cervix	  A.	  Differences	  in	  the	  percentages	  of	  CD57	  in	  CD4+	  T-­‐cells.	  B.	  Percentages	  of	  CD57	  
in	  CD8+	  T-­‐cell	  subsets.	  Naïve	  T-­‐cells	  are	  shown	  in	  blue,	  central	  memory	  T-­‐cells	  in	  orange,	  
effector	  memory	  T-­‐cells	  in	  green	  and	  terminally	  differentiated	  T-­‐cells	  in	  lavender.	  	  
	  
4.3.7 Effect	   of	   HAART	   on	   cytokine	   concentrations	   in	   blood	   and	   genital	  
secretions	  
The	   concentrations	   of	   seven	   inflammatory	   cytokines	   (IL-­‐1β,	   IL-­‐6,	   IL-­‐8,	   IP-­‐10,	  
MIP-­‐1α,	  MIP-­‐1β	  and	  TNF-­‐	  α),	  two	  hematopoietic	  cytokines	  (IL-­‐7	  and	  G-­‐CSF)	  and	  
a	   regulatory	   cytokine	   (IL-­‐10)	   were	   measured	   in	   blood	   plasma	   and	   genital	  
secretions	   collected	   immediately	   before	   and	   after	   1	   month	   on	   HAART	   (figure	  
4.8).	   In	   blood	   plasma,	   most	   cytokines	   remained	   unchanged	   after	   1	   month	   on	  
HAART	   with	   only	   IP-­‐10	   being	   significantly	   lower	   after	   1	   month	   of	   HAART	  
(p=0.05).	   Similarly,	   in	   genital	   secretions,	   most	   cytokines	   remained	   unchanged	  
after	   1	   month	   on	   HAART	   with	   only	   IL-­‐10	   being	   significantly	   lower	   after	  
treatment	  (p=0.0068).	  This	  suggests	  that	  one	  month	  on	  therapy	  may	  not	  be	  long	  
enough	  to	  impact	  significantly	  on	  blood	  and	  genital	  cytokine	  levels.	  The	  fact	  that	  
the	  isolated	  changes	  in	  the	  cytokine	  levels	  was	  different	  between	  blood	  and	  the	  
genital	  tract	  could	  be	  due	  compartmentalization	  between	  the	  two	  sites	  (Coombs	  
et	   al.,	   2001).	   The	   concentrations	   of	   cytokines	   in	   the	   genital	   tract	   could	   also	  be	  
influenced	  by	  other	  confounders	  such	  as	  the	  levels	  of	  immune	  activation	  (Sodora	  
and	   Silvestri,	   2008),	   hormone	   regulation	   or	   the	   presence	   of	   other	   sexually	  
transmitted	  diseases	   (Ghanem	  et	   al.,	   2005;	  Kaushic	   et	   al.,	   2011).	   Each	  of	   these	  
factors	  would	  have	  a	  specific	   impact	  on	  the	  type	  of	   inflammatory	  response	  and	  
which	  cytokines	  would	  be	  preferentially	  secreted	  locally.	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Figure	   4.8.	   Comparison	   of	   the	   cytokine	   concentrations	   from	   the	   time	   of	   initiation	   of	  
HAART	  to	  one	  month	  on	  antiretroviral	  therapy	  in	  blood	  and	  the	  cervical	  compartment.	  
The	   dark	   and	   pale	   blue	   box-­‐and-­‐whisker	   plots	   represent	   the	   concentrations	   of	  
inflammatory	  cytokines	  at	  baseline	  and	  after	  one	  month	  respectively.	  The	  dark	  and	  light	  
green	  plots	   show	  the	  concentrations	  of	   the	   regulatory	  cytokine	  at	   the	   two	   time	  points	  
and	  the	  dark	  and	   light	  pink	  plots	  represent	   the	  hematopoietic	  cytokine	  concentrations	  
at	  the	  two	  time	  points.	  	  
	  
The	   change	   in	   plasma	   concentrations	   of	   IP-­‐10	   correlated	   significantly	   with	   a	  
similar	   decrease	   in	   the	   level	   of	   CD4+	   T-­‐cell	   activation	   in	   blood	   (table	   4.2).	   In	  




























































































































chemokine	   level	  and	  the	  decrease	   in	  plasma	  viral	   load	  seen	  after	  one	  month	  of	  
therapy	   where	   larger	   decreases	   in	   IP-­‐10	   concentrations	   predicted	   a	   higher	  
degree	  of	  plasma	  viral	  load	  suppression	  (table	  4.2).	  	  
	  
Table	  4.2.	  Correlation	  between	  plasma	  IP-­‐10	  and	  CD4+	  T-­‐cell	  activation	  on	  HAART	  	  












CD38+	   0.7000	   0.0204	  
HLA-­‐DR+	   0.8636	   0.0012	  
CD38+HLA-­‐DR+	   0.7909	   0.0055	  
Total	  activation	   0.8091	   0.0039	  
	   Plasma	  viral	  load	   -­‐0.6818	   0.0208	  
	  
4.3.8 Relationship	   between	   cytokine	   levels	   at	   baseline	   and	   1	   month	   on	  
HAART	  
To	  determine	  whether	  the	  level	  of	  each	  cytokine	  before	  initiation	  of	  HAART	  has	  
an	   impact	   on	   the	   its	   respective	   concentration	   after	   1	  month	   on	  HAART,	   linear	  
regression	  models	  were	   used,	   comparing	   the	   baseline	   concentrations	   to	   those	  
after	  one	  month	  on	  HAART	  (figure	  4.9).	  Initial	  cytokine	  concentrations	  in	  plasma	  
were	   found	   to	   significantly	   predict	   concentrations	   measurable	   1	   month	   after	  
starting	   HAART,	   with	   IP-­‐10	   having	   the	   highest	   β	   coefficient	   (β	   coefficient	   =	  
1.9364;	  p	  =	  0.0021).	  In	  the	  genital	  tract,	  a	  similar	  trend	  was	  seen	  although	  only	  
the	   baseline	   IL-­‐8	   concentrations	   were	   significantly	   predictive	   of	   IL-­‐8	  
concentrations	  at	  1	  month	  on	  HAART	  (β	  coefficient	  =	  0.1980;	  p	  =	  0.0343).	  This	  
suggests	   that,	   while	   baseline	   plasma	   concentrations	   of	   cytokines	   influence	   the	  
extent	  of	  decrease	  observed	  on	  HAART	   in	  blood,	   the	  relationship	   in	   the	  genital	  
tract	  between	  starting	  cytokine	  concentrations	  and	  their	  decrease	  during	  HAART	  
is	   possibly	   also	   influenced	  by	  other	   factors	  driving	   local	   inflammation,	   such	   as	  




Figure	  4.9.	  Relationship	  between	  cytokine	  concentrations	  at	  baseline	  and	  after	  1	  month	  
on	  HAART	  in	  blood	  and	  the	  genital	  tract.	  The	  inflammatory	  cytokines	  are	  shown	  in	  blue,	  
the	  regulatory	  cytokine	  in	  green	  and	  the	  hematopoietic	  cytokines	  in	  pink.	  	  
	  
4.3.9 Impact	  	  of	  HAART	  on	  STI	  prevalence	  
Previous	   studies	   have	   shown	   that	   initiation	   of	   HAART	   is	   associated	   with	  
reactivation	  of	  sub-­‐clinical	  STIs	   including	  HSV-­‐2	  and	  HPV	  (Yudin	  &	  Kaul,	  2008;	  
Meys	   et	   al.,	   2010),	   possibly	   as	   the	   result	   of	   IRIS.	   To	   investigate	   the	   impact	   of	  
HAART	   on	   prevalence	   of	   common	   STIs	   in	   this	   study,	   the	   presence	   of	  Neisseria	  
gonorrhoeae,	   Chlamydia	   trachomatis,	   Trichomonas	   vaginalis	   and	   Mycoplasma	  
genitalium	   was	   determined	   in	   women	   before	   and	   1	   month	   after	   they	   had	  
initiated	  HAART	  (table	  4.3).	  	  While	  no	  women	  in	  this	  study	  had	  gonorrhoeae	  or	  
infection	  with	  T.	   vaginalis,	   4/11	  women	  were	   infected	  with	  M.	  genitalium	   and	  
2/11	  women	  were	   infected	  with	  C.	   trachomatis.	   After	   initiating	  HAART,	   3/4	  of	  
the	  women	  infected	  with	  M.	  genitalium	  were	  still	   infected,	  the	  2	  women	  with	  C.	  
trachmatis	   infections	   cleared	   their	   infections	   while	   another	   1	   women	   became	  
infected,	   and	   2/11	   women	   became	   infected	   with	   T.	   vaginalis.	   	   Since	   HPV	   and	  
HSV-­‐2	   were	   not	   measured	   in	   this	   study,	   no	   inference	   can	   be	   made	   about	  












































































































































Table	  4.3.	  STI	  prevalence	  immediately	  before	  starting	  HAART	  and	  after	  1	  month	  	  
Patient	  
ID	  
Visit	  1	  (Baseline) Visit	  2	  (Month	  1) 	  
NG	   CT	   TV	   MG	   NG	   CT	   TV	   MG	   	  
HTCell1	   	   	   	   	   	   	   	   	   	  
HTCell2	   	   	   	   	   	   	   	   	   	  
HTCell3	   	   	   	   	   	   	   	   	   	  
HTCell4	   	   	   	   	   	   	   	   	   	  
HTCell5	   	   	   	   	   	   	   	   	   	  
HTCell6	   	   	   	   	   	   	   	   	   	  
HTCell7	   	   	   	   	   	   	   	   	   	  
HTCell8	   	   	   	   	   	   	   	   	   	  
HTCell9	   	   	   	   	   	   	   	   	   	  
HTCell10	   	   	   	   	   	   	   	   	   	  
HTCell11	   	   	   	   	   	   	   	   	   	  
NG	   –	   Neisseria	   gonorrheae;	   CT	   -­‐	   Chlamydia;	   TV	   –	   Trichomonas	   vaginalis;	   MG	   –	  
Mycoplasma	  genitalium	  
	  
To	   investigate	   whether	   these	   fluctuations	   in	   STI	   prevalence	   before	   and	   after	  
initiating	   HAART	   influenced	   cytokine	   concentrations	   in	   genital	   secretions,	  
standardised	  genital	  cytokine	  concentrations	  were	  compared	  in	  women	  with	  and	  
without	  an	  STI	  at	  each	  study	  visit	   (figure	  4.10).	  Median	  cytokine	   levels	  did	  not	  
differ	   in	   women	   with	   or	   without	   an	   STI	   for	   either	   of	   the	   two	   visits.	   Before	  
starting	  HAART,	  the	  women	  with	  no	  STIs	  tended	  to	  have	  a	  higher	  level	  of	  IL-­‐1β,	  
IL-­‐8,	  IL-­‐7,	  MIP-­‐1β,	  TNF-­‐α	  and	  IL-­‐10	  and	  lower	  levels	  of	  IL-­‐6,	  MIP-­‐1α,	  and	  G-­‐CSF	  
compared	  to	  those	  with	  an	  STI.	  After	  starting	  HAART,	  women	  with	  no	  STIs	  had	  
higher	   levels	   of	   MIP-­‐1β,	   IL-­‐7	   and	   IL-­‐10	   and	   lower	   levels	   of	   IL-­‐1β,	   IL-­‐6,	   IP-­‐10,	  
TNF-­‐α	  and	  G-­‐CSF.	  Unlike	  other	  studies	  showing	  that	  that	  STIs	  cause	  an	  increase	  
in	   inflammation	   in	   the	   genital	   tract,	   no	   similar	   findings	  were	   observed	   in	   this	  




Figure	   4.10.	   Influence	   of	   STIs	   on	   the	   difference	   in	   cytokine	   concentrations	   between	  
women	   before	   and	   1	   month	   after	   starting	   HAART.	   The	   coloured	   dots	   represent	   the	  
standardised	  concentrations	  of	  each	  cytokine	  and	  the	  grey	  lines	  show	  the	  difference	  in	  
levels	  of	  each	  cytokine	  between	  the	  two	  groups	  of	  women	  at	  each	  time	  point.	  Cytokine	  
concentrations	  were	  standardised	   to	  ensure	   that	  all	  variables	  contribute	  evenly	   to	   the	  
analysis.	  This	  was	  done	  by	  dividing	  the	  distance	  of	  each	  data	  point	  from	  the	  mean	  by	  its	  
standard	   deviation,	   meaning	   that	   each	   point	   on	   the	   graphs	   have	   a	   mean	   of	   0	   and	   a	  
standard	  deviation	  of	  1.	  	  
	  
In	   a	   more	   detailed	   analysis,	   the	   relative	   cytokine	   profile	   of	   each	   woman	   was	  
compared	  between	  visits	  1	  and	  2,	  and	  ranked	  according	  to	  whether	  the	  women	  
had	   an	   STI	   or	   not	   (figure	   4.11).	   Participant	   HTCell10	   had	   a	   relatively	   lower	  
cytokine	   profile	   after	   one	   month	   on	   HAART	   compared	   to	   pre-­‐HAART,	   which	  
could	  be	  attributed	  to	  the	  fact	  that	  she	  had	  chlamydia	  at	  visit	  1	  which	  cleared	  by	  
the	  1	  month	  visit.	  Participant	  HTCell2,	  who	  had	  a	  M.	  genitalium	  infection	  at	  both	  
visits	  but	  no	  other	  changes	  in	  STI	  profile,	  had	  a	  marked	  increase	  in	  the	   level	  of	  
cervical	   inflammatory	   cytokines	   during	   the	   first	   month	   of	   HAART.	   Chronic	  M.	  
genitalium	   infection	   has	   been	   associated	  with	   a	   potent	   inflammatory	   response	  
due	   to	   the	   recruitment	  of	  monocytes	  and	  macrophages	   to	   the	   cervical	  mucosa.	  
Except	   for	   these	   two	   women,	   the	   overall	   concentrations	   of	   cytokines	   in	   the	  
genital	   secretions	   for	   these	   women	   was	   relatively	   conserved	   over	   time,	  
irrespective	  of	  whether	  they	  had	  an	  STIs	  or	  not.	  Although	  common	  bacterial	  STIs	  
were	  evaluated	   in	   this	  study,	  a	   limitation	  was	  that	  HSV-­‐2	  reactivation	  and	  HPV	  
infection	   were	   not	  measured.	   	   Fluctuations	   in	   these	   viral	   infections	  may	   have	  
accounted	  for	  fluctuations	  in	  genital	  cytokine	  levels.	  
	  


























Figure	   4.11.	   Heat	  map	   showing	   the	   relative	   cytokine	   concentrations	   for	   each	  women	  
immediately	   before	   and	   one	   month	   after	   starting	   HAART.	   The	   lightest	   green	   colour	  
represents	  the	  10%	  lowest	  concentrations	  for	  each	  individual	  cytokine,	  black	  shows	  the	  
intermediate	   concentrations	   and	   the	   brightest	   red	   represents	   the	   10%	   highest	  
concentrations	  for	  each	  cytokine.	  The	  STI	  status	  is	  shown	  above	  each	  heat	  map.	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The	   impact	   of	   starting	   HAART	   on	   the	   immune	   reconstitution	   and	   change	   in	  
immune	  activation	  and	  inflammation	  in	  peripheral	  blood	  has	  been	  well	  studied	  
(Keating	  et	  al.,	  2011;	  reviewed	  by	  Hunt,	  2012	  &	  Klatt	  et	  al.,	  2013)	  but	  there	  are	  
fewer	   studies	   on	   similar	   changes	   in	   the	   female	   genital	   tract.	   These	   studies	  
showed	  that	  initiating	  HAART	  brought	  significant	  improvements	  to	  the	  systemic	  
immune	   activation	   and	   is	   associated	   with	   viral	   suppression,	   reconstitution	   of	  
CD4+	  T-­‐cell	  counts	  and	  a	  decrease	  in	  HIV-­‐specific	  immune	  response,	  even	  though	  
it	   was	   not	   completely	   restored	   to	   levels	   found	   in	   HIV-­‐negative	   individuals	  
(reviewed	  by	  Hunt,	  2012;	  Le	  et	   al.,	   2013).	  On	   the	  other	  hand,	  previous	   studies	  
have	   argued	   that	  due	   to	   factors	   such	  as	  poorer	   tissue	  bioavailability	  of	   certain	  
antiretroviral	   drugs,	   ongoing	   low-­‐level	   viral	   replication	   and	   a	   highly	  
inflammatory	  environment,	  the	  same	  immune	  reconstitution	  was	  not	  seen	  in	  the	  
genital	  tract	  (Kwara	  et	  al.,	  2008;	  Mkhize	  et	  al.,	  2010).	  	  
	  
The	   aim	   of	   this	   chapter	   was	   to	   measure	   the	   change	   in	   the	   levels	   of	   immune	  
activation,	  maturation	  and	  inflammation	  in	  the	  genital	  tract	  immediately	  before	  
and	  1	  month	  after	  initiation	  of	  HAART	  in	  both	  the	  female	  genital	  tract	  and	  blood.	  
The	  women	  in	  this	  study	  only	  started	  HAART	  much	   later	   in	   infection	  when	  the	  
disease	  had	  already	  progressed	  and	  the	  CD4+	  T-­‐cell	  counts	  were	  well	  below	  350	  
cells/ml.	  	  In	  this	  longitudinal	  study,	  one	  month	  on	  HAART	  had	  some	  clear	  gains	  
in	  terms	  of	  both	  clinical	  and	  phenotypic	  characteristics	  of	  the	  11	  chronically	  HIV-­‐
infected	   women	   in	   this	   study.	   Treatment	   was	   successful	   in	   suppressing	   the	  
plasma	   and	   genital	   viral	   loads	   in	   most	   women	   and	   the	   degree	   by	   which	   the	  
genital	   viral	   load	   decreased	   was	   directly	   proportional	   to	   the	   change	   in	   each	  
woman’s	  plasma	  viral	  load.	  Also,	  the	  decrease	  in	  plasma	  viral	  load	  after	  1	  month	  
on	  HAART	  was	  directly	  proportional	  to	  her	  viral	   load	  in	  plasma	  at	   immediately	  
prior	   to	   initiating	  HAART.	  Despite	  marked	   improvements	   in	  viral	   load	  and	  HIV	  
genital	   shedding,	   significant	  differences	   in	   the	   reconstitution	  of	  T-­‐cell	  numbers	  
were	  not	  observed	  during	  the	  short	  follow-­‐up	  in	  this	  study.	  While	  there	  was	  no	  
significant	   difference	   in	   the	   distribution	   of	   the	   different	   naïve/memory	   T-­‐cell	  
subsets	   in	   blood	   after	   one	  month	   on	  HAART,	   therapy	  was	   accompanied	   by	   an	  
increase	  in	  the	  proportion	  of	  the	  TCM	  subset	  and	  a	  decrease	  in	  the	  TEM	  subset	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for	   both	   genital	   CD4+	   and	   CD8+	   T-­‐cells.	   Initiating	   HAART	   caused	   a	   significant	  
decrease	   in	  blood	  T-­‐cell	   activation.	  However,	   a	  different	   trend	  was	   seen	   in	   the	  
genital	   compartment	   where	   no	   significant	   change	   in	   T-­‐cell	   activation	   was	  
observed.	  HAART	  had	  no	  significant	  impact	  on	  the	  level	  of	  CD57	  in	  blood	  T-­‐cells.	  
On	  the	  other	  hand,	   there	  was	  a	  significant	   increase	   in	  the	   level	  of	  genital	  T-­‐cell	  
senescence,	   which	   occurred	   mainly	   in	   memory	   T-­‐cell	   subsets.	   A	   significant	  
decrease	   in	   plasma	   IP-­‐10	   concentration	   was	   observed	   after	   one	   month	   on	  
HAART	  and	  this	  change	  correlated	  significantly	  with	  a	  similar	  decrease	  in	  plasma	  
viral	  loads	  as	  well	  as	  to	  the	  decrease	  seen	  in	  CD4+	  T-­‐cell	  activation.	  It	  was	  found	  
that	   the	   resulting	   plasma	   cytokine	   concentrations	   after	   one	  month	   on	   HAART	  
could	   significantly	   be	   predicted	   based	   on	   the	   concentrations	   at	   initiation	   of	  
treatment.	  In	  the	  genital	  tract,	  most	  cytokines	  remained	  largely	  unchanged	  pre-­‐	  
versus	  post-­‐treatment	  with	  the	  exception	  of	  IL-­‐10	  which	  was	  significantly	  lower	  
after	   HAART	   treatment	   than	   before.	   Finally,	   the	   STIs	   tested	   for	   in	   this	   study	  
(Neisseria	   gonorrhoeae,	   Chlamydia	   trachomatis,	   Trichomonas	   vaginalis	   and	  
Mycoplasma	   genitalium)	   appeared	   to	   have	   no	   overall	   qualitative	   effect	   on	   the	  
cytokine	  levels	  in	  the	  genital	  tract.	  	  
	  
Several	  studies	  have	  shown	  that	   the	  strongest	  predictor	  of	  being	  able	   to	  detect	  
HIV	   in	   the	   genital	   tract	   is	   plasma	   viral	   load	   (Kaul	   et	   al.,	   2008;	   Mukura	   et	   al.,	  
2012),	  and	  this	  was	  shown	  to	  be	  true	  for	  women	  on	  HAART	  as	  well	  (Kovacs	  et	  al.,	  
2001).	   HIV-­‐infected	   women	   on	   HAART	   who	   were	   not	   fully	   suppressed	  
systemically	  were	   the	  ones	  who	  more	   frequently	   shed	   the	   virus	   (Kovacs	   et	   al.,	  
2001).	  In	  this	  study,	  the	  two	  women	  who	  were	  still	  shedding	  after	  one	  month	  on	  
HAART	   (HTCell3	   and	   HTCell10)	   were	   also	   those	   who	   had	   the	   highest	   plasma	  
viral	  loads	  on	  treatment	  (2814	  and	  34848	  copies/ml	  respectively).	  There	  could	  
also	  be	  other	   factors	   influencing	   the	   genital	   viral	   load,	   such	   as	   the	  presence	  of	  
sexually	   transmitted	   infections	   (M.	   genitalium	   in	   the	   case	   of	   HTCell3	   and/or	  
other	  STIs	  not	  tested	  for	  in	  this	  study),	  compartmentalization	  of	  the	  infection	  or	  
the	   differential	   bioavailability	   of	   the	   antiretroviral	   drugs	   for	   each	   participant.	  
However,	  in	  this	  study,	  all	  the	  participants	  were	  on	  first	  line	  regimens	  consisting	  
of	   antiretroviral	   drugs	  with	   similar	   bioavailabilities.	   The	   only	   difference	   noted	  
was	   that	   some	  women	  were	   on	   emtricitabine	  while	   others	  were	   on	   stavudine,	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but	   these	   two	  drugs	  have	   the	  same	  efficiency	   in	  mucosal	   tissues	   (Dropulic	  and	  
Cohen,	   2010).	   There	   was	   a	   significant	   relationship	   between	   the	   two	   visits	   for	  
both	   the	   plasma	   and	   genital	   viral	   loads,	   suggesting	   that	   the	   extent	   to	   which	  
HAART	  induces	  viral	  load	  suppression	  may	  be	  dependent	  on	  the	  viraemia	  when	  
HAART	  was	  initiated.	  	  
	  
	  Margolick	   et	   al.	   (2006)	   found	   that	   the	  median	   blood	  CD4:CD8	   ratio	   in	  African	  
American	  HIV-­‐negative	  individuals	  was	  1.6.	   	  Nkwanyana	  et	  al.,	  (2009)	  reported	  
that	   the	   median	   genital	   CD4:CD8	   ratio	   in	   HIV	   negative	   black	   South	   African	  
women	   was	   2.7.	   In	   this	   study,	   blood	   and	   genital	   CD4:CD8	   ratios	   were	   below	  
these	  previously	  reported	  thresholds,	  even	  after	  one	  month	  on	  HAART	  (0.391	  for	  
blood	  and	  0.194	  for	  the	  genital	  tract).	  There	  were	  also	  no	  significant	  differences	  
in	   the	  blood	  and	  genital	   tract	  CD4:CD8	   ratios	  between	   the	   time	  of	   initiation	  of	  
HAART	   and	   one	   month	   after,	   suggesting	   that	   there	   was	   no	   significant	   CD4	  
immune	   reconstitution.	   Compared	   to	   women	  who	   have	   been	   on	   HAART	   for	   a	  
longer	   period	   of	   time	   (~85	   months;	   Chapter	   3),	   CD4:CD8	   ratios	   measured	   in	  
women	   in	   this	  Chapter	  were	  significantly	   lower.	  This	   indicates	   that	  one	  month	  
on	  treatment	  is	  unlikely	  to	  be	  long	  enough	  to	  result	  in	  a	  significant	  reconstitution	  
in	  CD4+	  T-­‐cell	  numbers	  and	  to	  correct	  the	  immune	  imbalance.	  	  
	  
HAART	  appeared	  to	  have	  no	  effect	  on	  the	  memory	  distribution	  of	  blood	  T-­‐cells.	  
On	   the	   other	   hand,	   in	   the	   cervix,	   being	   on	   HAART	   was	   accompanied	   by	   an	  
increase	  in	  long-­‐lived	  TCM	  cells	  and	  an	  associated	  decrease	  in	  TEM	  for	  both	  CD4+	  
and	   CD8+	   T-­‐cells.	   Central	   memory	   T-­‐cells	   are	   long-­‐lived	   cells	   and	   have	   been	  
reported	   to	   have	   a	   stronger	   proliferative	   capacity	   than	   TEM	   (Jameson	   and	  
Masopust,	   2009).	   The	   formation	   of	   long-­‐lived	   memory	   T-­‐cells	   has	   previously	  
been	  shown	  to	  be	  predictive	  of	  a	  better	  outcome	  in	  HIV-­‐infected	  individuals	  on	  
HAART	   and	   a	   lower	   mortality	   rate	   (Rönsholt	   et	   al.,	   2012).	   Less	   differentiated	  
cells	  such	  as	  TCM	  typically	  produce	  the	  early	  cytokine	  IL-­‐2,	  especially	  in	  the	  CD4+	  
T-­‐cell	  population	  (Kalia	  et	  al.,	  2010).	  This	  cytokine	  plays	  an	  important	  role	  in	  the	  
differentiation	   and	   survival	   of	   antigen-­‐specific	   T-­‐cells	   (Seder	   et	   al.,	   2008).	  
Exposure	   to	   IL-­‐2	  was	  also	   found	   to	  enhance	   the	  survival	  of	   short-­‐lived	  CD8+	  T-­‐
cells	   (Kalia	   et	   al.,	   2010).	   A	   bigger	   proportion	   of	   antigen-­‐specific	   T-­‐cells	   would	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allow	  better	  control	  of	  HIV	  infection	  and	  this	  could	  be	  one	  of	  the	  reasons	  why	  the	  
presence	  of	  TCM	  is	  associated	  with	  a	  better	  outcome	  during	  HIV	  infection.	  	  
	  
Importantly,	  there	  was	  an	  overall	  decrease	  in	  the	  frequency	  of	  activated	  T-­‐cells	  
in	   blood	   following	   initiation	   of	  HAART,	   suggesting	   that	  HAART	   impacts	   on	   the	  
level	  of	  activation	  in	  blood	  relatively	  quickly	  although	  reconstitution	  in	  absolute	  
CD4+	  T-­‐cell	  counts	  may	  take	  a	  bit	  longer	  to	  achieve.	  In	  the	  genital	  tract,	  however,	  
there	   was	   no	   significant	   change	   in	   T-­‐cell	   activation.	   This	   sustained	   T-­‐cell	  
activation	   could	   be	   due	   to	   the	   presence	   of	   other	   opportunistic	   diseases	   and	  
common	   infections	   such	   as	   STIs	   or	   helminthes	   infections.	   Certain	   STIs	   such	   as	  
HSV-­‐2	  and	  HPV	  have	  also	  been	  found	  to	  trigger	  excessive	  immune	  responses	  and	  
inflammation	   (as	   part	   of	   IRIS)	   soon	   after	   immune	   reconstitution	   occurs	   on	  
treatment	  with	  HAART.	  Cohen	  et	  al.	  (2011)	  have	  shown	  that,	  even	  in	  the	  absence	  
of	   an	  HIV	   infection,	   individuals	   in	   sub-­‐Saharan	  Africa	   have	  high	   frequencies	   of	  
activated	   genital	   T-­‐cells.	   They	   speculate	   that	   these	   differences	   could	   be	  
attributed	  to	  environmental	  factors,	  co-­‐infections,	  or	  due	  to	  host	  genetics	  (Cohen	  
et	  al.,	  2011;	  reviewed	  by	  Mouser	  et	  al.,	  2012).	  Similar	  factors	  might	  be	  masking	  
the	  effect	  of	  HAART	  on	  the	  level	  of	  activation	  in	  the	  genital	  tract	  in	  this	  study.	  
	  
HAART	  treatment	  did	  not	  influence	  the	  level	  of	  exhaustion	  of	  T-­‐cells	  (measured	  
by	  expression	  of	  CD57)	  in	  blood.	  In	  contrast,	  there	  was	  a	  significant	  increase	  in	  
genital	   tract	  T-­‐cell	   senescence,	  particularly	   for	   the	  CD8+	  T-­‐cell	  population.	  This	  
increase	   in	   CD57	   expression	   by	   genital	   tract	   T-­‐cells	  was	   predominantly	   in	   the	  
memory	  subsets	  (TCM	  and	  TEM).	  Migueles	  et	  al.	  (2009)	  similarly	  reported	  that	  
genital	   T-­‐cell	   senescence	   persists	   even	   after	   starting	   HAART,	   in	   addition	   to	  
broader	   T-­‐cell	   dysfunction	   such	   as	   defective	   proliferative	   capacity	   and	   loss	   of	  
their	   cytotoxic	   capacity.	   The	  more	   severe	   degree	   of	   exhaustion	   in	   CD8+	  T-­‐cells	  
could	  be	  attributed	  to	  the	  fact	  that	  the	  HIV	  infection	  resulted	  in	  smaller	  numbers	  
of	  helper	  CD4+	  T-­‐cells	  to	  maintain	  the	  CD8+	  T-­‐cell	  population	  (Virgin	  et	  al.,	  2009).	  	  
	  
Fleury	   et	   al.	   (1998)	   showed	   that	   there	   is	   a	   late	   increase	   in	   the	   fraction	   of	  
proliferating	   cells	   in	   individuals	   starting	   HAART	   (measured	   at	   24	   weeks	   after	  
initiation	  of	  HAART)	  in	  both	  blood	  and	  lymph	  nodes.	  The	  lack	  of	  change	  in	  Ki67	  
 118 
expression	  seen	  in	  this	  study	  could	  simply	  be	  because	  one	  month	  is	  too	  short	  a	  
period	   for	   quantifiable	   differences	   to	   occur.	  Another	   explanation	   could	  be	   that	  
there	  was	  there	  was	  a	  large	  percentage	  of	  CD57+	  exhausted	  T-­‐cells,	  which	  have	  
been	  shown	  in	  previous	  studies	  to	  be	  proliferation-­‐incompetent	  (Brenchley	  et	  al.,	  
2003;	  Migueles	  et	  al.,	  2009;	  Palmer	  et	  al.,	  2005).	  	  
	  
Of	   the	   cytokines	  measured	   in	  blood,	   concentrations	  of	   IP-­‐10	  were	   significantly	  
lower	  following	  1	  month	  on	  HAART	  compared	  to	  pre-­‐HAART	  concentrations.	  In	  
addition,	   decrease	   in	   plasma	   viraemia	   (which	   was	   significantly	   lower	   post-­‐
HAART	   initiation)	   was	   positively	   associated	   to	   the	   change	   in	   blood	   IP-­‐10	  
concentrations.	   Roberts	   et	   al.	   (2010)	   similarly	   reported	   that	   elevated	   IP-­‐10	  
levels	  were	  associated	  with	  higher	  plasma	  viral	  loads.	  Simmons	  et	  al.	  (2013)	  also	  
showed,	   in	   a	   cross-­‐sectional	   study	   comparing	   pre-­‐ART	   individuals	   to	   those	   on	  
HAART,	  that	  IP-­‐10	  plasma	  concentration	  was	  most	  significantly	  associated	  with	  
HIV-­‐1	  viral	  load.	  Furthermore,	  this	  chapter	  shows	  that	  the	  decrease	  in	  plasma	  IP-­‐
10	   concentrations	   during	   the	   first	  month	   on	   treatment	  was	   accompanied	   by	   a	  
proportional	  decrease	  in	  CD4+	  T-­‐cell	  activation.	  IP-­‐10	  is	  produced	  in	  response	  to	  
type	   I	   or	   II	   interferons	   (reviewed	   by	   Hunt,	   2012).	   An	   interferon	   response	   is	  
crucial	   in	  enhancing	  Th1	   responses	   in	  an	  adaptive	   immune	  response	   (Nuvor	  et	  
al.,	   2012).	   A	   decrease	   IP-­‐10	   could	   be	   an	   indirect	   measure	   of	   lower	   interferon	  
responses	  and	  thus,	  could	  be	  linked	  to	  the	  decrease	  in	  activation.	  	  
	  
In	  the	  genital	  tract,	  a	  significant	  decrease	  in	  IL-­‐10	  concentration	  was	  observed	  in	  
women	   who	   had	   initiated	   HAART	   compared	   to	   their	   matching	   pre-­‐HAART	  
concentrations.	  	  This	  finding	  could	  reflect	  the	  slight	  increase	  observed	  in	  genital	  
CD4+	   T-­‐cell	   activation.	   IL-­‐10,	   which	   is	   considered	   to	   be	   an	   anti-­‐inflammatory	  
cytokine,	   has	   also	   been	   shown	   to	   cause	   down-­‐regulation	   of	   Th1	   cytokine	  
production	   by	  monocytes	   and	  macrophages	   (reviewed	   by	   Couper	   et	   al.,	   2008)	  
and	   directly	   act	   on	   CD4+	   T-­‐cells	   by	   inhibiting	   production	   of	   certain	   pro-­‐
inflammatory	   cytokines	   (Joss	   et	   al.,	   2000).	   Thus,	   a	   marked	   decrease	   in	   the	  
production	   of	   this	   cytokine	   in	   the	   genital	   tract	   could	   lead	   to	   an	   increased	  
inflammatory	  response	  and	  a	  rise	  in	  the	  level	  of	  expression	  of	  activation	  markers	  
seen	   in	   the	   genital	   CD4+	   T-­‐cell	   population.	   Aside	   from	   IL-­‐10,	   all	   of	   the	   other	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cytokines	   measured	   were	   not	   different	   in	   the	   genital	   tract	   pre-­‐	   versus	   post-­‐
HAART	  initiation.	  
	  
In	   blood,	   concentrations	   of	   all	   10	   cytokines	   before	   initiation	   of	   HAART	   were	  
found	  to	  significantly	  predict	  their	  respective	  concentrations	  after	  one	  month	  on	  
HAART	   (particularly	   for	   IP-­‐10).	   However,	   in	   the	   genital	   tract,	   this	   relationship	  
was	  not	  as	  strong	  with	  only	  IL-­‐8	  concentrations	  between	  time	  points	  correlating.	  
The	   weaker	   associations	   pre-­‐	   versus	   post-­‐HAART	   in	   the	   female	   genital	  
compartment	   could	   potentially	   be	   due	   to	   the	   potentially	   larger	   number	   of	  
confounders	   present	   at	   the	   genital	   mucosa.	   For	   example,	   cytokine	   production	  
and	  changes	  in	  the	  genital	  inflammatory	  environment	  could	  largely	  be	  driven	  by	  
infections	  with	  secondary	  STIs	  rather	  than	  directly	  from	  HAART-­‐related	  effects.	  
Behavioural	   disinhibition	   in	   individuals	   who	   have	   initiated	   HAART	   may	   also	  
influence	  the	  results	  in	  this	  study.	  Several	  studies	  have	  reported	  that	  initiation	  of	  
HAART	   was	   linked	   to	   increases	   in	   riskier	   sexual	   behaviour	   for	   a	   variety	   of	  
reasons	   (Boily	   et	   al.,	   2004;	  McClelland	   et	   al.,	   2006;	  Wilson	   et	   al.,	   2004).	   These	  
individuals	  may	  perceive	  their	  risk	  of	  transmission	  to	  their	  sexual	  partners	  to	  be	  
lower	  because	  their	  viral	  loads	  are	  reduced.	  Wilson	  and	  Minkoff	  (2001)	  reported	  
increasing	  inconsistencies	  in	  condom	  use	  as	  the	  women	  on	  HAART	  believed	  that	  
they	  would	  not	  be	  transmitting	  the	  virus	  to	  their	  partner	  if	  they	  were	  on	  HAART.	  
Another	   explanation	   could	   be	   that	   women	   start	   to	   feel	   better	   as	   their	   clinical	  
symptoms	   subside.	   Treatment	   with	   HAART	   is	   typically	   accompanied	   with	   an	  
improvement	  in	  the	  physiological	  and	  psychological	  effects	  of	   infection,	   leading	  
to	   more	   risky	   behaviour	   (such	   as	   lack	   of	   condom	   use	   or	   having	   multiple	  
partners)	   once	   the	   feeling	   of	   illness	   decreases	   (Wilson	   et	   al.,	   2004).	   These	  
practices	   would	   put	   the	   individuals	   at	   risk	   for	   other	   STIs,	   which	   may	   in	   turn	  
influence	   the	   rate	   of	   reconstitution	   in	   the	   genital	   tract	   cytokine	   milieu.	  
Alternatively,	   immune	  reconstitution	  in	  the	  genital	  tract	  could	  be	  influenced	  by	  
the	  development	  of	   IRIS	  after	  starting	  HAART.	  For	  example,	   the	  reactivation	  of	  
HSV-­‐2	  or	  the	  formation	  of	  genital	  warts	  soon	  after	  genital	  HIV-­‐RNA	  suppression	  




Although	   previous	   studies	   have	   shown	   that	   STIs	   result	   in	   increased	   mucosal	  
levels	   of	   inflammatory	   cytokines	   (Galvin	   and	   Cohen,	   2004;	   Modjarrad	   and	  
Vermund,	  2010),	  STIs	  measured	  in	  this	  small	  cohort	  of	  women	  did	  not	  seem	  to	  
influence	   the	   inflammatory	   environment	   in	   their	   genital	   tracts.	   Apart	   from	  
sample	   size,	   the	   lack	   of	   association	   between	   the	   level	   of	   inflammation	   and	   the	  
presence	   of	   STIs	  may	   be	   due	   to	   a	   number	   of	   additional	   factors,	   including	   STIs	  
which	  were	  not	  tested	  for,	  the	  stage	  in	  menstrual	  cycle	  at	  which	  the	  participants	  
were	   sampled	   (Wira	   and	   Fahey,	   2008),	   their	   choice	   of	   hormone	   contraceptive	  
(Baeten	  et	  al.,	  2001;	  Ghanem	  et	  al.,	  2005),	  or	  vaginal	  hygiene	  practices	  (Hilber	  et	  
al.,	   2007).	   Some	  studies	  have	   reported	  a	  higher	  degree	   in	  higher	  HIV	  shedding	  
during	   the	   luteal	   phase	   of	   the	   menstrual	   cycle,	   which	   would	   influence	   the	  
cytokine	   concentrations	   detected	   in	   the	   genital	   fluid	   at	   the	   time	   of	   sampling	  
(Benki	  et	  al.,	  2004;	  reviewed	  by	  Anderson	  &	  Cu-­‐Uvin,	  2011).	  Progesterone-­‐based	  
contraceptives	  such	  as	  depot	  medroxy-­‐progesterone	  acetate	  also	  have	  an	  effect	  
on	  HIV	  shedding	  and	  the	  regulation	  of	   immune	  responses	   in	   the	   female	  genital	  
tract	  (reviewed	  by	  Stringer	  &	  Antonsen,	  2008).	  	  
	  
In	  summary,	  while	  changes	  in	  immune	  reconstitution	  and	  dampening	  in	  immune	  
activation	   was	   observed	   in	   blood	   in	   this	   study,	   similar	   reconstitution	   and	  
dampening	  of	  activation	  were	  not	  observed	  in	  the	  genital	  mucosal	  environment.	  
Several	  studies	  have	  reported	  that	  HAART	  improves	  systemic	  immunity	  as	  CD4+	  
T-­‐cell	  number	  reconstitute.	  However,	  improvements	  in	  immunity	  after	  initiation	  
of	  HAART	   can	   lead	   to	  other	   clinical	  manifestations	  due	   to	   the	  dysregulation	  of	  
the	   immune	   system	   or	   due	   to	   an	   inflammatory	   response	   to	   previously	   sub-­‐
clinical	  pathogens	  and	  residual	  antigens	  that	  were	  not	  being	  recognised	  during	  
HIV-­‐induce	  immune	  suppression	  (IRIS).	  These	  infections	  then	  become	  clinically	  
relevant	   as	   the	   immune	   system	   starts	   to	   reconstitute	   on	  HAART	   (reviewed	   by	  
Chahroudi	  &	  Silvestri,	  2012	  &	  Dhasmana	  et	  al.,	  2008).	  The	  women	  in	  this	  study	  
met	  many	  of	  the	  criteria	  that	  would	  put	  them	  at	  risk	  for	  HIV-­‐related	  IRIS,	  as	  they	  
started	  HAART	  when	  their	  CD4+	  T-­‐cell	  counts	  were	  low	  (median	  of	  200	  cells/ml)	  
and	   treatment	  with	  HAART	  was	   accompanied	   by	   a	   rapid	   decrease	   in	  HIV-­‐RNA	  
(reviewed	  by	  Dhasmana	  et	   al.,	   2008).	  Antonelli	   et	   al.	   (2010)	   showed	   that	  HIV-­‐
infected	   individuals	   who	   develop	   IRIS	   had	   elevated	   frequencies	   of	   highly	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activated	   CD4+	   T-­‐cells	   in	   blood	   compared	   to	   those	   who	   did	   not	   develop	   IRIS	  
(Antonelli	  et	  al.,	  2010).	  Genital	   immune	  reconstitution,	  occurring	  in	  the	  women	  
in	   this	   study	   who	   were	   initiating	   HAART,	   may	   have	   had	   a	   stronger	   immune	  
response	  against	  previously	  subclinical	  genital	  tract	  infections,	  leading	  to	  higher	  




Chapter	  5.	  Discussion	  and	  Conclusion	  
	  
Despite	   extensive	   research	   describing	   changes	   in	   immune	   activation	   and	  
inflammation	   in	   blood	   of	   HIV-­‐infected	   individuals	   initiating	   HAART,	   relatively	  
little	   is	  known	  about	   local	  changes	  occurring	  at	   the	  genital	  mucosa.	  The	  aim	  of	  
this	   study	   was	   to	   compare	   the	   impact	   of	   HAART	   on	   inflammation	   and	   local	  
immune	   reconstitution	   in	   the	   female	   genital	   tract	   of	   chronically	   HIV-­‐infected	  
women	   by	   comparing	   genital	   mucosal	   and	   blood	   cytokine	   profiles,	   T-­‐cell	  
differentiation	  status,	  level	  of	  activation,	  proliferation	  and	  exhaustion.	  This	  study	  
found	   that	   HIV-­‐infected	   women	   initiating	   HAART	   experienced	   a	   rapid	  
suppression	  of	  plasma	  and	  genital	   tract	  viral	   loads	   (within	  1	  month	  of	   starting	  
therapy;	   Chapter	   4).	   While	   this	   suppression	   in	   viraemia	   was	   associated	   with	  
significantly	  lower	  levels	  of	  T-­‐cell	  activation	  in	  blood,	  the	  immune	  activation	  and	  
inflammation	  levels	  in	  the	  genital	  tract	  were	  not	  reduced	  during	  early	  HAART.	  In	  
the	   female	   genital	   tract,	   short	   term	   HAART	   therapy	   was	   accompanied	   by	   the	  
accumulation	  of	  an	  exhausted	  memory	  T-­‐cell	  population	  that	  was	  not	  observed	  
in	   blood.	   Furthermore,	   this	   study	   showed	   that	   long	   term	   HAART	   (~7	   years;	  
Chapter	   3)	   in	   HIV-­‐infected	   women	   did	   not	   completely	   reconstitute	   T-­‐cells	   to	  
levels	   found	   in	  HIV-­‐negative	  women,	  with	   a	  marked	  T-­‐cell	   imbalance	   and	  high	  
levels	  of	  inflammation	  still	  being	  present,	  especially	  in	  the	  genital	  tract.	  	  
	  
5.1 Development	   of	   tools	   to	   investigate	   immune	   reconstitution	  
during	  HAART	  
To	  address	  the	  objectives	  of	  this	  study,	  a	  robust	  10-­‐colour	  flow	  cytometry	  panel	  
was	   designed	   and	   optimised	   to	   measure	   the	   phenotypical	   characteristics	   of	  
blood	  and	  genital	  CD4+	  and	  CD8+	  T-­‐cells.	  This	   involved	  the	  selection	  of	  specific	  
markers	  that	  would	  be	  most	  relevant	  to	  be	  study	  (described	  in	  Appendix	  II).	  The	  
panel	   selected	  was	   aimed	   at	  measuring	   the	   frequency	   of	   CD3+	   T-­‐cells	   and	   the	  
CD4+	   and	  CD8+	  T-­‐cell	   subpopulations.	   The	   cellular	  markers	   CCR7	   and	  CD45RO	  
were	  used	  to	  identify	  the	  naïve,	  memory	  and	  differentiated	  T-­‐cells.	  The	  degree	  of	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immune	   activation	   (CD38	   and	   HLA-­‐DR	   expression),	   proliferation	   (Ki67)	   and	  
exhaustion	  (CD57)	  was	  also	  measured.	  	  
	  
5.2 T-­‐cell	  defects	  and	  incomplete	  immune	  reconstitution	  detected	  in	  
the	   female	   genital	   tract	   and	   blood	   of	   HIV-­‐infected	   women	   on	  
long-­‐term	  HAART	  
Chapter	  3	  compared	  the	   impact	  of	   long-­‐term	  HAART	  (~7	  years)	  on	  markers	  of	  
immune	   activation,	   inflammation,	   T-­‐cell	   differentiation,	   and	   exhaustion	   in	   the	  
female	  genital	  tract	  and	  blood	  of	  women	  chronically	   infected	  with	  HIV.	  Women	  
in	   this	   study	   had	   CD4:CD8	   ratios	   similar	   to	   HIV-­‐infected	   but	   HAART-­‐naïve	  
individuals,	  despite	  having	  been	  on	  HAART	  for	  about	  7	  years.	  Although	  this	  part	  
of	   the	  study	  was	  not	   longitudinal,	  comparing	   long-­‐term	  HAART	  CD4:CD8	  ratios	  
to	  previously	  published	   ratios	   (Margolick	  et	  al.,	   2006;	  Nkwanyana	  et	  al.,	   2009)	  
indicates	  that	  CD4+	  T-­‐cells	  had	  not	  reconstituted	  to	  pre-­‐infection	  levels.	  CD4:CD8	  
ratios	  were	  used	  as	  a	  clinical	   indicator	  of	  HIV	  disease	  progression	  in	  this	  study	  
(Margolick	  et	  al.,	  2006;	  Taylor	  et	  al.,	  1989).	  The	  fact	  that	  genital	  CD4:CD8	  ratios	  
were	  more	  similar	  to	  that	  of	  HIV-­‐infected	  women	  who	  were	  naïve	  to	  HAART	  than	  
HIV-­‐negative	   women	   [as	   reported	   by	   Nkwanyana	   et	   al.	   (2009)]	   showed	  
incomplete	  CD4	  reconstitution	  at	  the	  genital	  mucosa.	  	  
	  
In	   this	   study,	   genital	   T-­‐cells	   were	   shown	   to	   be	   predominantly	   TEM	   cells.	  
Although	   TEM	   cells	   are	   known	   to	   circulate	   through	   non-­‐lymphoid	   tissue	  
(including	  the	  genital	  mucosa;	  reviewed	  by	  Shin	  &	  Iwasaki,	  2013),	  accumulation	  
of	   this	  memory	   T-­‐cell	   subset	   in	   the	   genital	  mucosa	   could	   also	   be	   the	   result	   of	  
chemokine/cytokine-­‐dependent	   recruitment	   of	   activated	   and	   differentiated	   T-­‐
cells	   (Gumbi	  et	  al.,	  2008;	  Hikono	  et	  al.,	  2007;	  Prakash,	  2003).	   Interestingly,	   the	  
level	  the	  T-­‐cell	  activation	  in	  blood	  (measured	  by	  CD38	  expression)	  was	  shown	  to	  
significantly	   predict	   levels	   of	   T-­‐cell	   activation	   in	   genital	   T-­‐cells.	   This	   suggests	  
that	   elevated	   levels	   of	   activation	   systemically	   may	   provide	   a	   large	   pool	   of	  
activated	   cells	   to	   traffic	   to	   mucosal	   tissues	   such	   as	   the	   genital	   mucosa.	  
Furthermore,	   genital	   CD4+	   T-­‐cell	   activation	   was	   significantly	   associated	   with	  
genital	   IL-­‐8	  concentrations,	  a	  chemotactic	  cytokine	  which	  may	  be	   implicated	   in	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the	  recruitment	  of	  activated	  T-­‐cells	  to	  the	  genital	  tract	  (Narimatsu	  et	  al.,	  2005).	  
This	  suggests	   that	  chemotactic	   recruitment	  of	  activated	  T-­‐cells	  may	  also	  play	  a	  
role	   in	   homing	   of	   these	   cells	   to	   the	   genital	   mucosa.	   Previous	   studies	   have	  
described	  a	  relationship	  between	  chronic	  T-­‐cell	  activation	  and	  continuous	  T-­‐cell	  
proliferation	   and	   differentiation,	   leading	   to	   the	   accumulation	   of	   an	   activated,	  
senescent	  T-­‐cell	  population	  (Nixon	  and	  Landay,	  2010;	  Papagno	  et	  al.,	  2004).	   In	  
support	   of	   this,	   this	   study	   showed	   that	   genital	   CD8+	   T-­‐cell	   activation	   was	  
positively	  associated	  with	  the	  extent	  of	  exhaustion	  in	  this	  T-­‐cell	  population.	  	  
	  
An	  important	  observation	  from	  this	  study	  was	  that	   immune	  activation	  in	  blood	  
and	  at	  the	  genital	  mucosa	  does	  not	  completely	  subside	  with	  long	  periods	  of	  time	  
on	  HAART.	   This	   has	   long-­‐term	   consequences	   for	   these	  HIV-­‐infected	  women	   as	  
persistent	   immune	   activation	   puts	   them	   at	   a	   higher	   risk	   of	   non-­‐opportunistic	  
diseases	  such	  as	  cardiovascular	  disease,	  type	  II	  diabetes	  or	  cancer	  (reviewed	  by	  
Hunt,	   2012;	   Klatt	   et	   al.,	   2013).	   In	   addition	   to	   having	   higher	   levels	   of	   immune	  
activation	   (especially	   in	   the	   CD4+	   T-­‐cell	   population)	   compared	   to	   blood,	   the	  
genital	   tract	   had	   significantly	   higher	   levels	   of	   inflammation	   (measured	   by	  
expression	   of	   10	   inflammatory,	   anti-­‐inflammatory	   and	   haematopoietic	  
cytokines).	   The	   comparatively	   elevated	   levels	   of	   immune	   activation	   and	  
inflammation	  in	  the	  genital	  tract	  of	  these	  HIV-­‐infected	  women	  who	  have	  been	  on	  
long-­‐term	   HAART	   could	   be	   due	   to	   several	   factors	   such	   as	   the	   presence	   of	  
opportunistic	   infections	   or	   low-­‐level	   viraemia	   (reviewed	   by	   Rajasuriar	   et	   al.,	  
2013).	   It	  has	  been	  proposed	   that	  ongoing	  HIV	   replication,	   occurring	  below	   the	  
detection	   limits	   of	   current	   assays,	   could	   be	   triggering	   a	   pro-­‐inflammatory	  
response	  (hence	  the	  elevated	  levels	  of	  cytokines)	  which	  leads	  to	  the	  recruitment	  
of	   activated	  T-­‐cells	   to	   the	   genital	   tract	   (Mavigner	   et	   al.,	   2009;	  Ostrowski	   et	   al.,	  
2008).	   Alternatively,	   antigenic	   stimulation	   from	   opportunistic	   pathogens,	  
including	  STIs	  and	  BV,	  could	  also	  induce	  an	  inflammatory	  response,	  contributing	  
to	   the	   highly	   inflammatory	   milieu	   in	   the	   genital	   tract	   (reviewed	   by	   Mayer	   &	  
Venkatesh,	   2011).	   Findings	   from	   this	   study	   also	   showed	   that	   the	   heightened	  
inflammatory	   levels	   and	   immune	   activation	   in	   the	   genital	   tract	   was	   also	  
accompanied	   by	   the	   accumulation	   of	   exhausted	   T-­‐cells	   and	   the	   continued	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imbalance	  in	  the	  proportions	  of	  the	  different	  memory	  T-­‐cells	  subsets,	  leading	  to	  
an	  overall	  immune	  dysfunction.	  	  
	  
Several	   groups	   explored	   the	   inclusion	   of	   anti-­‐inflammatory	   or	  
immunomodulatory	  drugs,	   in	  conjunction	  with	  HAART,	   to	  dampen	   the	  ongoing	  
immune	   activation	   and	   lower	   inflammation	   (reviewed	   by	   Hunt,	   2012).	   One	  
strategy	  which	   has	   shown	   some	   success	  was	   intensification	   of	   treatment	  with	  
raltegravir,	  which	   led	   to	  a	  significant	  decrease	   in	  T-­‐cell	  activation	  (Llibre	  et	  al.,	  
2012).	  According	  to	  the	  authors,	  this	  selective	  reduction	  of	  immune	  activation	  in	  
CD8+	   T-­‐cells	   was	   a	   result	   of	   raltegravir	   blocking	   residual	   productive	   viral	  
replication	   occurring	   despite	   suppressive	   HAART.	   Another	   strategy	   that	   has	  
been	  tested	  was	  to	  treat	  common	  co-­‐infections	  to	  reduce	  immune	  activation.	  For	  
example,	  treatment	  of	  CMV	  co-­‐infection	  with	  Valganciclovir	  resulted	  in	  a	  marked	  
decrease	   in	   CD8+	   T-­‐cell	   activation	   (Hunt	   et	   al.,	   2011b).	   Statins	   and	  
glucocorticoids	   such	   as	   atorvastatin	   and	   prednisolone	   have	   potent	   anti-­‐
inflammatory	  and	  anti-­‐viral	  properties	  which	  were	   found	  to	  cause	  a	  significant	  
decrease	   in	   CD8+	   T-­‐cell	   activation	   and	   the	   production	   of	   molecular	   drivers	   of	  
immune	  activation	  such	  as	  soluble	  CD14	  or	  LPS-­‐binding	  protein	  (Ganesan	  et	  al.,	  
2011;	  Kasang	  et	  al.,	  2012).	  These	  approaches	  could	  be	  another	  way	  to	  correct	  the	  
immune	   imbalance	   caused	   by	   the	   chronic	   HIV	   infection	   and	   allow	   a	   more	  
efficient	  CD4	  reconstitution	  and	  a	  better	  long-­‐term	  outcome	  in	  the	  chronic	  HIV-­‐
infected	  individuals	  on	  HAART.	  	  
	  
5.3 Early	   gains	   from	   HAART	   initiation	   in	   reducing	   immune	  
activation	   and	   inflammation	   in	   blood	   but	   not	   at	   the	   genital	  
mucosa	  
Chapter	   4	   assessed	   the	   early	   temporal	   changes	   occurring	   in	   clinical	   and	  
phenotypic	  characteristics	  of	  HIV-­‐infected	  women	  from	  the	  time	  of	   initiation	  of	  
HAART	  to	  after	  one	  month	  on	  treatment.	  Treatment	  for	  a	  month	  was	  successful	  
in	  suppressing	  the	  plasma	  and	  genital	  viral	  loads	  in	  most	  HIV-­‐infected	  women.	  In	  
this	   study,	   the	   decrease	   in	   genital	   viral	   loads	  was	   proportional	   to	   that	   seen	   in	  
blood,	   confirming	   that	   the	   plasma	   viral	   load	  was	   a	   strong	   predictor	   of	   genital	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shedding	   (Kaul	   et	   al.,	   2008;	   Kovacs	   et	   al.,	   2001).	   Despite	   early	   marked	   viral	  
suppression,	  however,	  there	  was	  no	  similar	  evidence	  of	  early	  CD4	  reconstitution	  
(indicated	  by	  CD4:CD8	  ratios).	  CD4:CD8	  ratios	  were	  significantly	   lower	   in	  HIV-­‐
infected	  women	  who	  had	  just	  initiated	  HAART	  (Chapter	  4)	  compared	  to	  women	  
who	  had	  been	  on	   long-­‐term	  HAART	  (~7	  years;	  Chapter	  3),	   suggesting	   that	  one	  
month	  of	  treatment	  was	  too	  short	  for	  any	  discernable	  CD4	  reconstitution.	  	  
	  
While	  one	  month	  on	  HAART	  appeared	  too	  short	   for	  the	  correction	  of	  the	  T-­‐cell	  
imbalance	  in	  blood,	  there	  was	  an	  increase	  in	  the	  proportion	  of	  long-­‐lived	  central	  
memory	  T-­‐cells,	  accompanied	  by	  a	  decrease	   in	  the	  short-­‐lived	  effector	  memory	  
T-­‐cells	   in	   the	   genital	   tract.	   This	   could	   be	   indicative	   of	   an	   improvement	   in	   the	  
genital	  tract	  immunity	  as	  the	  formation	  of	  long-­‐lived	  memory	  T-­‐cells	  was	  found	  
to	  predict	  an	  overall	  better	  outcome	  and	  a	   lower	  mortality	  rate	   in	  HIV-­‐infected	  
individuals	  (Rönsholt	  et	  al.,	  2012).	  	  
	  
There	   was	   a	   significant	   decrease	   in	   systemic	   immune	   activation	   after	   starting	  
HAART	  (measured	  by	  CD38	  and	  HLA-­‐DR	  expression	  by	  T-­‐cells),	  which	  coincided	  
with	  significant	  reductions	  in	  plasma	  viral	  loads.	  In	  contrast,	  a	  different	  scenario	  
was	   seen	   in	   the	   genital	   tract	   where	   there	   was	   no	   significant	   change	   in	   T-­‐cell	  
activation,	  where	  a	  slight	  increase,	  if	  anything,	  in	  CD4+	  T-­‐cell	  activation	  was	  seen	  
after	   one	  month	   on	   HAART.	   This	   lack	   of	   change	   in	   genital	   immune	   activation	  
could	  be	  the	  result	  of	  a	  number	  of	  occurrences	  that	  have	  contrasting	  effects	  on	  
the	   overall	   immune	   response.	   The	   positive	   gains	   due	   to	   HAART	   on	   HIV-­‐RNA	  
suppression	   and	   immune	   activation	   could	   have	   been	   masked	   by	   the	   negative	  
effects	   of	   other	   opportunistic	   infections	   in	   the	   genital	   tract,	   as	   has	   been	  
documented	  to	  happen	  during	  IRIS.	  Within	  the	  first	  few	  weeks	  of	  staring	  HAART,	  
a	  significant	  proportion	  of	  HIV-­‐infected	  individuals	  experience	  IRIS	  (Meintjes	  et	  
al.,	   2012a).	   IRIS	   refers	   to	   a	   syndrome	   where,	   where	   soon	   after	   immune	  
reconstitution	   occurs,	   the	   immune	   system	   starts	   responding	   to	   subclinical	  
infections	   in	  an	  uncontrolled	  manner,	   resulting	   in	  excessive	   immune	  activation	  
and	  inflammation,	  despite	  being	  on	  HAART	  (reviewed	  by	  Chahroudi	  &	  Silvestri,	  
2012).	   In	   this	   study,	   treatment	   with	   HAART	   was	   accompanied	   by	   an	   early	  
accumulation	  of	  exhausted	  CD4+	  and	  CD8+	  T-­‐cells	  in	  the	  genital	  tract,	  which	  could	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be	  due	  to	  the	  general	  T-­‐cell	  dysfunction	  caused	  by	  chronic	  HIV	  infection,	  where	  
T-­‐cells	  become	  proliferation-­‐incompetent	  and	  also	  lose	  their	  cytotoxic	  potential	  
(Migueles	  et	  al.,	  2009).	  	  
	  
Treatment	  with	  HAART	  resulted	  in	  significantly	  lower	  concentrations	  of	  IP-­‐10	  in	  
blood	  of	  HIV-­‐infected	  women.	  The	  decrease	  in	  plasma	  IP-­‐10	  after	  one	  month	  on	  
HAART	   correlated	   with	   a	   decrease	   in	   CD4+	   T-­‐cell	   activation	   and	   plasma	   viral	  
load.	  Since	  IP-­‐10	  is	  known	  to	  be	  induced	  by	  type	  I	  and	  II	  interferon	  responses	  as	  
a	  result	  of	  TLR7/8	  signalling	  by	  HIV	  (reviewed	  by	  Chang	  &	  Altfeld,	  2010	  &	  Hunt,	  
2012),	  this	  decreased	  production	  of	  IP-­‐10	  could	  be	  an	  indirect	  measure	  of	  type	  I	  
and	   II	   interferon	   responses,	   a	   consequence	   of	   lower	   viral	   loads	   (reviewed	   by	  
Hunt,	  2012;	  Nuvor	  et	  al.,	  2012).	  	  
	  
In	   the	   genital	   tract,	   a	   significant	   decrease	   in	   the	   concentration	   of	   the	   anti-­‐
inflammatory	  cytokine	  IL-­‐10	  was	  observed	  in	  HIV-­‐infected	  women	  who	  had	  just	  
initiated	  HAART.	  IL-­‐10	  has	  been	  shown	  to	  directly	  suppress	  T-­‐cell	  activation	  and	  
the	   production	   of	   pro-­‐inflammatory	   cytokines	   such	   as	   IFN-­‐γ	   (Donnelly	   et	   al.,	  
1999).	  Although	  it	   is	  difficult	  to	  infer	  causation,	  the	  reduction	  in	  IL-­‐10	  found	  in	  
this	  study	  could	   influence	  CD4+	  T-­‐cell	  activation	   in	   the	  genital	   tract,	  which	  was	  
slightly,	   although	   not	   significantly,	   elevated	   post-­‐	   versus	   pre-­‐HAART	   initiation.	  
Since	   it	   has	   immunomodulatory	  properties,	   a	   decrease	   in	   IL-­‐10	   could	   result	   in	  
up-­‐regulation	   of	   Th1	   cytokines	   in	   response	   to	   pathogen-­‐specific	   recognition	  by	  
the	  genital	  immune	  cells,	  leading	  to	  uncontrolled	  increases	  in	  immune	  activation	  
and	  inflammation	  (reviewed	  by	  Price	  et	  al.,	  2009;	  Tadokera	  et	  al.,	  2013).	  	  
	  
In	  this	  study,	  common	  bacterial	  STIs	  (including	  Neisseria	  gonorrhoeae,	  Chlamydia	  
trachomatis,	  Trichomonas	  vaginalis	  and	  Mycoplasma	  genitalium)	  did	  not	  seem	  to	  
impact	  on	  the	  genital	  inflammatory	  milieu.	  This	  suggests	  that	  other	  factors,	  such	  
as	  common	  viral	  STIs	  not	  tested	  for	  in	  this	  study	  (including	  HSV-­‐2	  and	  HPV),	  the	  
type	  of	  hormonal	   contractive	   the	  women	  may	  have	  been	  using	  or	   the	  phase	  of	  
the	  menstrual	  cycle	  at	  the	  time	  of	  sampling,	  may	  have	  been	  at	  play	  (Baeten	  et	  al.,	  
2001;	  Wira	  and	  Fahey,	  2008).	  Ratnam	  et	  al.	  (2006)	  showed	  that	  the	  reactivation	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of	   HSV-­‐2	   and	   HPV	   infections	   in	   the	   female	   genital	   tract	   of	   women	   initiating	  
HAART	  were	  the	  two	  most	  common	  features	  of	  IRIS	  in	  the	  genital	  mucosa.	  	  
	  
Uncontrolled	  immune	  activation	  and	  inflammation	  are	  detrimental	  to	  the	  overall	  
outcome	   of	   treatment	   with	   HAART	   as	   they	   may	   slow	   down	   the	   rate	   of	   CD4	  
reconstitution	   in	   HIV-­‐infected	   individuals	   initiating	   treatment.	   A	   strategy	   to	  
counteract	   the	   possible	   genital	   HIV-­‐associated	   IRIS-­‐type	   signatures	   emerging	  
from	  the	  current	  study	  might	  be	  to	  treat	  women	  with	  anti-­‐inflammatory	  drugs,	  
in	  conjunction	  with	  the	  prescribed	  HAART	  regimen,	  during	  the	  first	  few	  weeks	  of	  
therapy.	   Corticosteroids	   (such	   as	   prednisolone)	   and	   NSAIDs	   have	   been	  
suggested	   for	   the	   dampening	   of	   systemic	   immune	   activation	   (Meintjes	   et	   al.,	  
2012a).	   A	   similar	   approach,	   aimed	   at	   reducing	   genital	   immune	   activation	   and	  
inflammation,	   could	   be	   useful	   in	   controlling	   the	   extent	   of	   local	   immune	  
responses.	  Mucosal	  long-­‐lived	  T-­‐cells	  are	  drastically	  depleted	  during	  chronic	  HIV	  
infection	  and	  are	  slow	  to	  be	  reconstituted	  (Grossman	  et	  al.,	  2006;	  Mehandru	  et	  
al.,	  2004).	  Reducing	  the	  excessive	  inflammatory	  environment	  in	  the	  genital	  tract	  
might	   help	   in	   forming	   and	   maintaining	   a	   larger	   pool	   of	   resting	   long-­‐lived	  
memory	   T-­‐cells	   and	   contribute	   to	   improving	   the	   overall	   genital	   immune	  
reconstitution	  on	  HAART.	  	  
	  
5.4 Some	  of	  the	  limitations	  of	  this	  study	  
A	  limitation	  of	  this	  study	  was	  that	  absolute	  CD4+	  T-­‐cell	  counts	  were	  not	  available	  
for	   the	   women	   in	   this	   study	   although	   CD4:CD8	   ratios,	   a	   reliable	   measure	   of	  
disease	  progression,	  were	  used	  in	  both	  chapters	  as	  an	  indirect	  measure	  of	  CD4+	  
T-­‐cell	   reconstitution.	   Information	   about	   hormonal	   contraception	   was	   only	  
available	   for	   the	  11	  women	   in	   the	   longitudinal	  study	  and	  data	  about	  any	  other	  
medication	   was	   not	   recorded.	   In	   chapter	   3,	   correlations	   were	   carried	   out	  
between	  the	  different	  variables	  and	  time	  on	  HAART	  but	  the	  wide	  range	  of	  times	  
on	  HAART	  (15-­‐119	  months)	  may	  have	   limited	   the	  statistical	  significance	  of	   the	  
tests.	   Furthermore,	   both	   the	   cross-­‐sectional	   and	   the	   longitudinal	   studies	   had	   a	  
relatively	  small	  sample	  size	  (including	  only	  15	  and	  11	  women	  respectively)	  and	  
this	   is	   likely	   to	   have	   influenced	   the	   statistical	   power	   for	   the	   study.	   Testing	   for	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additional	   genital	   tract	   infections	   (particularly	   HSV-­‐2	   and	  HPV	   infections)	   and	  
collecting	   information	   about	   hormone	   contraceptive	   choice	   would	   have	   given	  
more	   insight	  on	   the	  what	   the	  confounders	  of	   the	  effect	  of	  HAART	  on	  genital	  T-­‐
cell	  activation	  and	  inflammation	  could	  have	  been.	  	  
	  
5.5 Conclusion	  
This	  study	  showed	  that	  the	  chronically	  HIV-­‐infected	  women	  on	  long	  term	  HAART	  
were	  not	  fully	  immune	  reconstituted	  despite	  being	  on	  HAART	  for	  a	  ~7	  years,	  in	  
both	   their	   genital	   compartment	   and	   in	   blood.	   Ongoing	   T-­‐cell	   activation	   and	  
inflammation	   could	   impair	   the	   ability	   of	   an	   HIV-­‐infected	   individual’s	   immune	  
system	  to	  reconstitute	  and	  to	  correct	  immune	  imbalances	  caused	  by	  the	  chronic	  
HIV	   infection	   but	   could	   also	   have	   long	   term	   consequences.	   The	   inability	   to	  
dampen	  the	  elevated	  levels	  of	  activation	  and	  inflammation	  can	  also	  lead	  to	  non-­‐
AIDS-­‐related	   non-­‐immunological	   diseases	   (reviewed	   by	   Klatt	   et	   al.,	   2013).	  
Uncontrolled	   immune	   activation	   in	   individuals	   developing	   HIV-­‐associated	   IRIS	  
could	  have	  a	  significant	  negative	   impact	  on	  morbidity	  and	  mortality	  (Barber	  et	  
al.,	   2012).	   In	   the	   genital	   tract,	   persistent	   inflammation	   and	   immune	   activation	  
could	   increase	   the	   risk	   of	   HIV	   genital	   shedding	   even	   though	   viral	   suppression	  
may	  have	  been	  achieved	  systemically.	  Excessive	  immune	  responses	  in	  the	  genital	  
tract	  would	  prevent	  the	  reconstitution	  of	  mucosal	  long-­‐lived	  memory	  T-­‐cells	  and	  
could	  also	  induce	  the	  reactivation	  of	  certain	  STIs	  such	  as	  HSV-­‐2	  or	  HPV,	  putting	  
the	   women	   at	   a	   greater	   risk	   of	   shedding	   and	   transmitting	   the	   infection	   to	  
potential	  partners.	  	  
	  
This	   study	   suggests	   that	   treatment	   with	   HAART	   would	   be	   more	   effective	   in	  
correcting	   immune	   dysfunction	   in	   the	   genital	   tract	   in	   a	   situation	   where	   the	  
excessive	   immune	   activation	   and	   elevated	   pro-­‐inflammatory	   cytokine	  
production	  could	  be	  prevented.	  Just	  as	  immunomodulatory	  or	  anti-­‐inflammatory	  
drugs	   have	   been	   used	   to	   control	   immune	   activation	   in	   blood	   (Ganesan	   et	   al.,	  
2011;	  Hunt	  et	  al.,	  2011b;	  Meintjes	  et	  al.,	  2012a),	  dampening	  of	  the	  genital	  tract	  
immune	  activation	  or	  inflammation	  could	  be	  achieved	  through	  the	  simultaneous	  
use	  of	  different	   formulations	  of	  similar	  anti-­‐inflammatory	  drugs	  such	  as	  statins	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or	  glucocorticoids,	  many	  of	  which	  are	  already	  licensed	  for	  topical	  use	  in	  humans.	  
This	  would	   allow	   for	   better	   local	   immune	   reconstitution	   and	   lower	   the	   risk	   of	  
both,	   shedding	  of	  HIV	  and	   infection	  with	  potentially	  subclinical	  STIs	  present	   in	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DESCRIPTION OF THE CYTOKINES/CHEMOKINES MEASURED IN THE STUDY 
 
Table A1.2. Function of the different cytokines relevant to this study 
Class Cytokine Function 
Pro-inflammatory IL-1β HIV-infected individuals in the acute phase show markedly higher levels of IL-1β, which is then 
suppressed on HAART. Involved in HIV expression and replication via binding of NFκβ to the HIV-1 long 
terminal repeat1,2.  
 IL-6 Is important in the transition between acute and chronic inflammation3. Is one of the major stimulator of 
acute phase protein production. Induces the development of cellular and humoral immune responses 
including B-cell differentiation, antibody secretion and T-cell activation4.  
 IL-8/ 
CXCL8 
Has inflammatory and anti-microbial properties. Secretion is triggered by presence of Nef5. Is present at 
much higher levels in HIV-infected individuals6 and is one of the predominant cytokines in the female 
genital tract during infection7. Stimulates chemotaxis of basophils and T-cells and induces neutrophils to 
release lysosomal enzymes8.  
 MIP-1α/ 
CCL3 
One of the major components of HIV-suppressive activity as they can bind to CCR5 T-cells. Important in 
T-cell chemotaxis to inflamed areas. Causes the upregulation of activation markers and pro-inflammatory 





Has anti-HIV activity as it can bind to CCR5. Also involved in T-cell chemotaxis to inflamed tissues and the 
upregulation of inflammatory and activation markers. Causes IL-12 secretion from DCs, enhancing Th1 
immunity5,9.  
 TNF-α Activates NFκβ, which initiates the inflammatory cascade in HIV infection5. Is part of a feedback loop 




Induces chemotaxis in macrophages, DCs, NK cells and T-cells towards inflamed areas. Facilitates 
infection by stimulating HIV replication in macrophages and lymphocytes11. Has been associated with 
immunological treatment failure in individuals on HAART12.  
Adaptive IFN-γ Is the most well characterized antiviral cytokine. Critical for both innate and adaptive immunity. Is mostly 
produced by NK and NKT-cells in innate immunity and by Th1 effector cells as part of the antigen-specific 
immunity13. Is important for both self-activation and activation of nearby immune cells14. Is bifunctional, 
has both inhibitory and stimulatory effects on HIV. IFN-γ can suppress HIV replication but chronic 
exposure to IFN-γ has negative consequences on T-cell homeostasis and survival15.  
Regulatory IL-10 Is a Th2 cytokine and can modulate T-cell activation16. Depending on its concentration. Can have both 
inhibitory and inductive effects on HIV in-vitro. Inhibits replication in macrophages via the release of 
TNF-α and IL-6. Lower concentrations have been associated with enhanced replication in monocyte-




Hematopoietic IL-7 Is elevated in seropositive individuals17. Is crucial for T-cell development and maintenance of T-cell 
homeostasis18. Participates in CTL development19. However, may also induce HIV replication in chronic-
infected individuals20.  
 G-CSF Is both a hematopoietic growth factor and a mediator of anti-HIV and inflammatory responses. Is 
considered to be useful in immune reconstitution in patients on HAART21,22.  
1Kedzierska & Crowe, 2001; 2Boulware et al., 2011; 3Kaplanski et al., 2003; 4Gabay, 2006; 5reviewed by Alfano & Poli, 2005; 6Matsumoto et al., 
1993;7Narimatsu, Wolday & Patterson, 2005; 8Roux et al., 2000;9reviewed by Maurer & von Stebut, 2004 and Menten, Wuyts & Van Damme, 2002; 
10Leghmari et al., 2008; 11Lane et al., 2003; 12Stylianou et al., 2000; 13Schoenborn & Wilson, 2007; 14Schroder et al., 2004;15Catalfamo et al., 
2011;16Boulware et al., 2011; 17Boulassel et al., 2003; 18Fry & Mackall, 2001; 19Kim et al., 1997; 20Scripture-Adams et al., 2002; 21Hübel, Dale & Liles, 
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DESIGN	  AND	  OPTIMISATION	  OF	  THE	  POLYCHROMATIC	  FLOW	  CYTOMETRY	  
PANEL	  FOR	  EVALUATING	  THE	  QUALITY	  AND	  LEVEL	  OF	  ACTIVATION	  OF	  
BLOOD	  AND	  CERVICAL	  T-­‐CELLS	  
	  
To	   address	   the	   objectives	   of	   this	   study,	   a	   ten-­‐colour	   antibody	   panel	   was	  
optimized	  to	  measure	  the	  frequency	  of	  T-­‐cells	  (based	  on	  expression	  of	  CD3,	  CD4	  
and	  CD8),	  their	  memory	  phenotype	  (based	  on	  expression	  of	  CD45RO	  and	  CCR7)	  
and	   their	   level	   of	   activation	   (based	   on	   expression	   of	   CD38	   and	   HLA-­‐DR),	  
proliferation	  (based	  on	  expression	  of	  Ki67)	  and	  exhaustion	  (based	  on	  expression	  
of	   CD57).	   A	   viability	  marker,	   violet	   viability	   reactive	   dye	   (VIVID),	  was	   used	   to	  
identify	   live	   cells.	  A	  dump	   channel	  was	  used	   to	   exclude	  B-­‐cells	   and	  monocytes	  
(CD14	  and	  CD19)	  in	  order	  to	  improve	  the	  accuracy	  of	  the	  panel	  to	  identify	  T-­‐cell-­‐
specific	  markers.	  This	  chapter	  describes	  the	  steps	  involved	  in	  designing	  the	  10-­‐
colour	  antibody	  panel,	  and	  optimizing	  the	  staining	  protocol.	  	  
	  
A2.1 Configuration of the LSR Fortessa 
A	   BD	   FortessaTM	   flow	   cytometer	   was	   used	   for	   this	   study.	   The	   BD	   FortessaTM	  
cytometer	  used	  in	  this	  study	  had	  four	  lasers	  (a	  violet	  laser	  at	  405	  nm,	  a	  blue	  laser	  
at	  488nm,	  a	  green	  laser	  at	  544nm	  and	  a	  red	  laser	  at	  640nm),	  capable	  of	  detecting	  
≤18	  colours	  (figure	  A2.1).	  
	   	  




Figure	   A2.1.	   Configuration	   of	   the	   BD	   LSRFortessa	   used	   in	   this	   study,	   showing	   the	  
different	  lasers	  and	  the	  number	  of	  channels	  for	  each	  of	  them.	  	  
	  
A2.2 Selection of antibodies 
Antibody	  selection	  for	  this	  study	  was	  dependent	  on	  several	  factors	  including	  the	  
configuration	   of	   the	   Fortessa	   flow	   cytometer,	   the	   level	   of	   expression	   of	   each	  
phenotypic,	  memory	   or	   activation	  marker,	   the	   stain	   index	   of	   each	   antibody	   (a	  
measure	   of	   the	   effective	   brightness	   of	   the	   antibody-­‐fluorochrome	   conjugate,	  
which	   would	   impact	   on	   the	   overall	   level	   of	   background	   responses)	   and	   the	  
amount	   of	   spectral	   overlap	   from	   each	   fluorochrome	   (Maecker	   and	   Trotter,	  
2012).	   In	  general,	   the	  antibodies	  with	   the	  brighter	   fluorochromes	  are	  matched	  
with	  markers	  that	  are	  expressed	  at	  lower	  levels	  while	  the	  dimmer	  fluorochromes	  
can	   be	   used	   for	   the	   markers	   found	   at	   a	   higher	   frequency.	   For	   this	   panel,	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Fortessa	   (BD	  Biosciences,	  2012)	  were	  used	   for	  antigens	   like	  Ki67	  and	  CD57	  as	  
these	  are	  the	  markers	  that	  are	  expressed	  at	  a	  lower	  frequency	  on	  or	  inside	  cells,	  
compared	   to	   the	   other	   markers	   being	   measured.	   Furthermore,	   dimmer	  
fluorochromes	   such	   as	   APC-­‐Cy7,	   APC	   and	   Pacific	   Blue	   were	   then	   kept	   for	   the	  
more	  densely	  expressed	  markers	  such	  as	  HLA-­‐DR,	  CD3	  and	  Vivid	  (the	  dead	  cell	  
marker).	  	  
	  
Another	  factor	  to	  be	  considered	  for	  selection	  of	  fluorochromes	  was	  the	  amount	  
of	  spillover	  of	  one	  fluorochrome	  into	  the	  other	  channels.	  One	  of	  the	  ways	  to	  deal	  
with	   it	   is	   to	   use	   compensation	   beads	   (as	   described	   in	   section	   2.9).	   Spectral	  
compensation	   is	   important	   because	   it	   ensures	   that	   cells	   that	   fluoresce	   in	   one	  
channel	   will	   have	   no	   effect	   in	   other	   channels	   (Maecker	   and	   Trotter,	   2012).	  
However,	  in	  the	  case	  of	  some	  of	  the	  brightest	  fluorochromes,	  compensation	  does	  
not	  get	  rid	  of	  all	   the	  noise,	   leading	   to	  a	  decrease	   in	  resolution	  or	  sensitivity.	   In	  
this	   case,	   it	   is	   recommended	   that	   a	   dimmer	   antibody	   be	   used	   to	   minimize	  
spectral	  overlap.	  For	  example,	  in	  the	  panel	  designed	  for	  this	  study,	  PerCp-­‐Cy5.5	  
(used	  for	  the	  CD4	  marker)	  was	  included	  together	  with	  APC	  (for	  the	  CD3	  marker)	  
instead	  of	  other	  brighter	  markers,	  for	  example	  PE-­‐Cy5,	  as	  this	  would	  result	  in	  a	  
lower	  level	  of	  background	  fluorescence	  and	  higher	  resolution	  sensitivity	  for	  APC.	  	  
	  
A2.3 Titration of antibodies 
Titrations	  were	  carried	  out	  for	  all	  the	  fluorochromes	  in	  the	  panel	  to	  ensure	  that	  
the	   volumes	   used	   in	   each	   experiment	   allowed	   for	   optimal	   separation	   between	  
the	  positive	  and	  negative	  populations,	   and	  excluded	   the	  maximum	  background	  
fluorescence	   possible.	   Titration	   allowed	   the	   determination	   of	   each	   antibodies	  
saturation	  titre,	  defined	  as	  the	  volume	  of	  antibody	  (or	  the	  highest	  dilution	  factor)	  
that	  allows	  complete	  staining	  of	   the	  particular	  cellular	  marker	   in	  a	  sample.	  For	  
these	   experiments,	   6-­‐8	   fold	   serial	   dilutions	   were	   carried	   out	   for	   each	   of	   the	  
antibodies	   titrated.	  Surface	  and/or	   intracellular	  staining	  with	   the	  antibody	  was	  
carried	  out	  as	  described	  in	  section	  2.8.	  Pseudo-­‐colour	  plots	  and	  histograms	  were	  
generated	  to	  determine	  the	  degree	  of	  separation	  and	  the	  amount	  of	  background	  
fluorescence	  with	  each	  antibody	  volume.	  To	  confirm	  that	  the	  correct	  saturation	  
titre	  was	  chosen,	  signal-­‐to-­‐noise	  ratio	  plots	  were	  also	  generated	   from	  the	  data.	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This	  was	  obtained	  by	  plotting	  the	  ratio	  of	  the	  MFI	  of	  the	  positive	  population	  to	  
that	  of	  the	  negative	  population	  against	  the	  volume	  of	  antibody	  used	  in	  each	  case.	  
From	   the	  graphs,	   saturation	  occurs	   at	   the	  point	  where	   the	   curve	  plateaus.	  The	  
titration	   results	   for	   CD57	   (detected	   by	   surface	   staining	   in	   this	   study)	   and	  CD3	  
(detected	  by	  intracellular	  staining)	  are	  shown	  as	  examples	  (figure	  A2.2).	  Staining	  
for	  CD3	  was	  done	   intracellularly	  due	   to	   the	   internalization	  of	   the	  receptor	   that	  
may	  occur	  on	  activated	  cells	  (Schrum	  et	  al.,	  2003).	  For	  titration	  of	  CD57,	  the	  best	  
separation	   between	   the	   positive	   and	   negative	   populations	   was	   determined	   to	  
correspond	  with	  a	  volume	  of	  5μl	  of	  antibody	  (indicated	  by	  the	  red	  arrow;	  figure	  
A2.2A	  and	  B).	  The	  signal-­‐to-­‐noise	  ratio	  curve	  in	  figure	  A2.2C	  shows	  that	  this	  was	  
the	  optimal	  volume	  because	  difference	  in	  fluorescence	  between	  the	  positive	  and	  
the	  negative	  cell	  populations	  plateaus	  at	  a	  volume	  of	  5μl.	  For	  the	  CD3	  antibody	  
titration,	  the	  saturation	  point	  could	  not	  be	  easily	  determined	  from	  the	  signal-­‐to-­‐
noise	  ratio	  curve	  (figure	  A2.3C).	  Since	  the	  most	  distinct	  separation	  between	  the	  
positive	   and	   negative	   populations	   occurred	   with	   a	   volume	   of	   2.5μl,	   this	   was	  
chosen	  to	  be	  the	  optimal	  volume	  (as	  shown	  by	  the	  red	  arrow	  in	  figure	  A2.3A	  and	  
B).	  	   	  




Figure	  A2.2.	  CD57-­‐FITC	  antibody	  titration.	  A.	  Pseudo-­‐colour	  plots	  with	  gates	  showing	  
the	   position	   of	   the	   positive	   and	   negative	   populations	   and	   the	   degree	   of	   separation	  
between	  the	  two.	  The	  CD57+	  cells	  were	  obtained	  after	  first	  gating	  on	  live	  cells,	  singlets,	  
lymphocytes	  and	  then	  CD3+	  T-­‐cells.	  The	  volume	  of	  antibody	  used	  in	  each	  case	  is	  shown	  
on	  the	  upper	  right	  corner	  of	  each	  plot.	  B.	  Histograms	  showing	  the	  relative	  fluorescence	  
of	   the	  positive	  and	  negative	  populations.	  C.	  Graph	  of	   the	  signal-­‐to-­‐ratio	  comparing	   the	  
frequency	  of	  the	  positive	  events	  against	  the	  negative	  ones.	  





















































Figure	  A2.3.	  CD3-­‐APC	  antibody	   titration.	  A.	  Pseudo-­‐colour	  plots	  with	  gates	  showing	  
the	   position	   of	   the	   positive	   and	   negative	   populations	   and	   the	   separation	   between	   the	  
two.	   The	   CD3+	   cells	   were	   obtained	   after	   first	   gating	   on	   live	   cells,	   singlets	   and	   then	  
lymphocytes.	   The	   volume	   of	   antibody	   used	   in	   each	   case	   is	   shown	   on	   the	   upper	   right	  
corner	  of	  each	  plot.	  B.	  Histograms	  showing	  the	  relative	  fluorescence	  of	  the	  positive	  and	  
negative	   populations.	   C.	   Graph	   of	   the	   signal-­‐to-­‐ratio	   comparing	   the	   frequency	   of	   the	  
positive	  events	  against	  the	  negative	  ones.	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A2.4 Inclusion of a dump channel 
To	  improve	  the	  quality	  the	  data	  obtained	  through	  flow	  cytometric	  analysis	  and	  
to	  avoid	  non-­‐specific	  binding	  of	  antibodies	  to	  non-­‐T-­‐cells,	  antibodies	  for	  markers	  
specific	  for	  monocytes	  (CD14)	  and	  B-­‐cells	  (CD19)	  were	  also	  included	  as	  part	  of	  a	  
dump	   channel	   (figure	   A2.4).	   Antibodies	   included	   in	   the	   dump	   channel	   were	  
selected	   to	   use	   the	   same	   channel	   (Pacific	   Blue)	   as	   Vivid.	   In	   this	   way,	   a	   single	  
channel	  could	  be	  used	  to	  exclude	  all	  B-­‐cells,	  monocytes	  and	  dead	  cells,	   thereby	  
decreasing	  background	  responses	  and	  giving	  better	  data.	  	  
	  
	  
Figure	   A2.4.	   Gates	   showing	   only	   the	   CD3+	   T-­‐cells	   after	   the	   Pacific	   Blue	   channel	   was	  
used	  to	  exclude	  all	  dead	  cells,	  B-­‐cells	  and	  monocytes.	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A2.5 Overview of the antibody panel 
Table	  3.1	  provides	   a	   list	   of	   the	   antibodies	   that	  were	   included	   in	   the	  optimized	  
10-­‐colour	  polychromatic	  flow	  cytometry	  panel	  used	  in	  this	  study.	  
	  
Table	   A2.1.	   Antibody	   specificity	   and	   fluorochromes	   included	   in	   the	   flow	   cytometry	  
panel	  




CD3	   APC	   UCHT1	   eBioscience	   1.25	   Intracellular	  
CD8	   Qdot	  605	   3B5	   Invitrogen	  
5	  (1:10	  
dilution)	   Extracellular	  
CD4	   PerCP-­‐Cy5.5	   OKT4	   eBioscience	   1.0	   Extracellular	  
CCR7	   PE-­‐Cy7	   3D12	   BD	  Biosciences	   2.5	   Extracellular	  
CD45RO	   ECD	   UCHL1	   IO	  Test	   5.0	   Extracellular	  
CD38	   Alexa	  Fluor	  700	   HIT2	   eBioscience	   5.0	   Extracellular	  
HLA-­‐DR	   APC-­‐Cy7	   L243	   BD	  Biosciences	   3.0	   Extracellular	  
KI67	   PE	   20Raj1	   eBioscience	   1.0	   Intracellular	  
CD57	   FITC	   NK1	   BD	  Biosciences	   5.0	   Extracellular	  
CD14	   Pacific	  Blue	   M5E2	   BD	  Biosciences	   1.25	   Extracellular	  
CD19	   Pacific	  Blue	   MHCD1928	   Invitrogen	   2.5	   Extracellular	  
	  
The	   panel	   makes	   use	   of	   all	   the	   four	   lasers	   used	   by	   the	   Fortessa:	   the	  
fluorochromes	   Pacific	   Blue	   and	   Qdot	   605	   are	   excited	   by	   the	   violet	   laser,	   ECD,	  
FITC	  and	  PerCP-­‐Cy5.5	  by	   the	  blue	   laser,	  PE	  and	  PE-­‐Cy7	  by	   the	  green	   laser	  and	  
Alexa	  Fluor	  700,	  APC	  and	  APC-­‐Cy7	  by	  the	  red	  laser.	  	  
	  
A2.6 Fluorescence Minus One (FMO) controls 
FMO	  controls	  were	  included	  in	  each	  experiment	  in	  order	  to	  allow	  more	  accurate	  
gating	   and	   determine	   the	   presence	   of	   false	   positives	   or	   background	   responses	  
(potentially	  due	  to	  degradation	  of	  conjugated	  antibody-­‐fluorochrome	  molecules,	  
to	  spillover	  or	  antibody	  reactions	  especially	  when	  large	  panels	  are	  used).	  In	  each	  
staining	   experiment,	   aliquots	   of	   1x106	  PBMCs	  were	   stained	  with	   the	   full	   panel	  
excluding	   one	   individual	   antibody	   in	   each	   case.	   This	   way,	   fluorescence	   from	  
secondary	  channels	   is	  visible,	  as	   the	  main	  antibody	  has	  been	   left	  out	  as	  shown	  
for	   each	   antibody	   in	   figure	   A2.5.	   Using	   FMOs	   is	   crucial	   especially	   for	  markers	  
that	  are	  usually	  expressed	  at	  low	  levels.	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For	  the	  panel	  optimized	  for	  this	  study,	  very	  low	  levels	  of	  background	  noise	  in	  all	  
the	  different	   channels	  was	  noted.	  The	  highest	   level	  of	  background	  was	   seen	   in	  
the	  Pacific	  Blue	   (0.107;	   figure	  A2.5A),	  PE-­‐Cy7	   (0.101;	   figure	  A2.5B)	  and	   the	  PE	  
Texas	   Red	   (0.118;	   figure	   A2.5C)	   channels.	   Since	   these	   fluorochromes	   are	  
conjugated	  to	  highly	  expressed	  markers,	  the	  level	  of	  background	  responses	  could	  
be	   considered	   negligible	   compared	   to	   the	   level	   of	   fluorescence	   emitted	   by	   the	  
primary	   fluorochrome.	   The	   frequency	   of	   the	   background	   responses	   for	   each	  
parameter	  were	   recorded	   and	   subtracted	   from	   analyses	   carried	   out	   on	   all	   the	  




Figure	   A2.5.	   FMO	   controls	   for	   the	   full	   10-­‐colour	   antibody	   panel.	  The	   title	  of	  each	  
individual	  set	  of	  plots	  indicates	  which	  antibody	  has	  been	  excluded	  in	  each	  case.	  All	  plots	  
were	   first	   gated	   on	   live	   cells,	   singlets,	   lymphocytes	   and	   CD3+	   T-­‐cells	   except	   for	   the	  
Pacific	  Blue	  channel	  that	  shows	  the	  events	  gated	  from	  singlets.	  Below	  each	  FMO	  plot	  is	  
the	   corresponding	   pseudo-­‐colour	   plot	   that	   had	   been	   gated	   on	   a	   fully	   stained	   PBMC	  
sample.	  FM:	  Fluorescence	  minus.	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A2.7 Time gates 
Before	  gating	  for	  the	  different	  phenotypic	  and	  functional	  markers	  included	  in	  the	  
panel,	  the	  cells	  were	  first	  gated	  based	  on	  time	  (figure	  A2.6).	  This	  gating	  strategy	  
allows	  exclusion	  of	  artefacts	  from	  acquisition	  like	  bubbles	  or	  small	  blockages	  in	  
the	   fluidic	   system	  of	   the	  apparatus	  or	  other	   issues	   that	  went	  unnoticed	  during	  
the	   acquisition	   process.	   Including	   time	   gates	   in	   the	   gating	   strategy	   provided	   a	  
good	  method	  for	  identifying	  and	  excluding	  irregularities	  in	  the	  flow	  cytometer’s	  
pressure	  and	  laser	  output.	  The	  time	  gates	  were	  drawn	  in	  such	  a	  way	  as	  to	  only	  
include	   the	   part	   where	   the	   event	   rate	   and	   fluorescence	   signals	   were	   constant	  
over	  time.	  	  
	  
	  
Figure	  A2.6.	  Time	  gates	  drawn	  for	  each	  of	  the	  four	  lasers	  used	  by	  the	  LSR	  Fortessa.	  	  
	  
A2.8 Gating strategy 
After	  all	  the	  optimization	  steps,	  a	  gating	  strategy	  was	  then	  designed	  to	  determine	  
the	   level	   of	   expression	   of	   the	   different	   markers	   for	   each	   sample.	   Figure	   A2.7	  
shows	   the	   final	   gating	   strategy	   that	   was	   used	   for	   the	   analysis	   of	   all	   the	   flow	  
cytometry	  data	   for	   the	  study.	  The	   total	  number	  of	  events	  recorded	  on	   the	   flow	  
cytometer	   were	   first	   analysed	   according	   to	   event	   size	   (forward	   scatter	   (FSC)-­‐
height	  against	  FSC-­‐area)	  to	  select	  for	  singlets	  only	  and	  exclude	  doublets	  or	  larger	  
cellular	  aggregates.	  The	  Pacific	  Blue	  channel	  was	  used	  to	  gate	  on	  the	  live	  T-­‐cells,	  
while	  eliminating	  all	  dead	  cells,	  B-­‐cells	  and	  monocytes.	  Lymphocytes	  were	  gated	  
on	  according	  to	  their	  size	  and	  level	  of	  granularity	  (side	  scatter-­‐area	  against	  FSC-­‐
area).	  CD3+	  T-­‐cells	  were	  gated	  on,	   followed	  by	  the	  CD4+	  and	  CD8+	  T-­‐cells	  while	  
making	   sure	   the	  double	  positive	   cells	  were	  not	   included.	  Gates	   specific	   for	   the	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DR),	   the	   proliferation	  marker	   (Ki67)	   and	   the	   senescence	  marker	   (CD57)	  were	  
then	  drawn	  for	  both	  the	  CD4+	  and	  the	  CD8+	  T-­‐cells.	  	  
	  




















Figure	  A2.7.	   Final	   gating	   strategy	  using	   the	   optimized	  panel.	  The	  memory	  and	  functional	  markers	  were	  gated	  on	  CD4+	  and	  CD8+	  T-­‐cells.	  The	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A2.9 Discussion 
The	   aim	   of	   this	   Chapter	   was	   to	   develop	   and	   optimize	   a	   polychromatic	   flow	  
cytometry	   panel	   to	   accurately	   measure	   specific	   markers	   on	   CD3+CD4+	   and	  
CD3+CD8+	   T-­‐cells	   in	   both	   peripheral	   blood	   and	   cervical	   cytobrush	   samples	   of	  
HIV-­‐positive	  women.	  Cellular	  markers	  were	  selected	  to	  differentiate	  between	  the	  
different	  memory	  subsets	  (using	  CCR7	  and	  CD45RO)	  and	  to	  quantify	  the	  degree	  
of	   immune	   activation	   (based	   on	   the	   level	   of	   expression	   of	   CD38	   and	  HLA-­‐DR),	  
proliferation	   (Ki67)	   and	   senescence	   (CD57).	   All	   the	   optimization	   experiments	  
were	  carried	  out	  on	  PBMC	  samples	  from	  HIV-­‐negative	  individuals,	  before	  testing	  
the	  final	  panel	  on	  PBMCs	  from	  HIV-­‐positive	  individuals.	  The	  antibody	  panel	  used	  
was	  designed	  and	  optimized	  by	  (1)	  identifying	  the	  relevant	  markers	  that	  would	  
give	   the	   most	   comprehensive	   data	   relevant	   to	   the	   study	   and	   choosing	   the	  
appropriate	   fluorochrome	   conjugates;	   (2)	   titrating	   the	   reagents	   for	   optimal	  
results;	  and	  (3)	  determining	  the	  level	  of	  background	  noise/false	  positive	  events	  
and	  correcting	  for	  it	  (using	  FMOs).	  
	  
Polychromatic	  flow	  cytometry	  is	  especially	  useful	  when	  the	  samples	  are	  difficult	  
to	  obtain	  or	  when	  the	  cells	  being	  analysed	  are	  rare.	  This	  is	  relevant	  in	  this	  study	  
using	  cervical	   cytobrush	  samples	   that	  are	  known	   to	  contain	  a	   relatively	   few	  T-­‐
lymphocytes	  (Bere	  et	  al.,	  2010).	  This	  technique	  allows	  for	  analysis	  of	  specific	  cell	  
populations	  with	  a	  higher	  degree	  of	  accuracy	  and	  a	  large	  volume	  of	  information	  
can	   be	   obtained	   from	   a	   single	   sample.	   Overall,	   an	   optimized	   10-­‐colour	   flow	  
cytometry	  panel	  was	  developed	  that	  reliably	  generated	  information	  about	  the	  T-­‐
cell	  phenotype	  and	  its	  functions	  in	  HIV-­‐positive	  women	  included	  in	  this	  study.	  	  
	  
	  
